Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Behavioral & Substance Use Disorder Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:carbocyclic antibiotic
go back to main search page
Accession:CHEBI:49319 term browser browse the term
Synonyms:related_synonym: carbocyclic antibiotics


show annotations for term's descendants           Sort by:
fusidic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 decreases activity
multiple interactions 		EXP
ISO 		Fusidic Acid results in decreased activity of ABCB11 protein
Fusidic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] 		CTD PMID:12106615 PMID:20829430 PMID:23956101 PMID:24014644 PMID:27676153 NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581 		JBrowse link
G Abcb1a ATP binding cassette subfamily B member 1A multiple interactions ISO Fusidic Acid inhibits the reaction [ABCB1 protein results in increased export of Digoxin] CTD PMID:26888941 NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135 		JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 multiple interactions EXP Fusidic Acid results in decreased expression of and results in decreased activity of ABCC2 protein CTD PMID:12106615 NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions ISO Fusidic Acid inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam] CTD PMID:26888941 NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857 		JBrowse link
G Slc10a1 solute carrier family 10 member 1 multiple interactions ISO Fusidic Acid inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid] CTD PMID:27676153 NCBI chr 6:106,344,319...106,357,944
Ensembl chr 6:106,344,319...106,357,944 		JBrowse link
G Slco1a4 solute carrier organic anion transporter family, member 1a4 multiple interactions EXP Fusidic Acid inhibits the reaction [SLCO1A4 protein results in increased uptake of Rosuvastatin Calcium] CTD PMID:26888941 NCBI chr 4:176,441,104...176,495,846
Ensembl chr 4:176,441,104...176,495,816 		JBrowse link
G Slco1b2 solute carrier organic anion transporter family member 1B2 multiple interactions
decreases activity 		EXP
ISO 		Fusidic Acid inhibits the reaction [SLCO1B2 protein results in increased uptake of Rosuvastatin Calcium]
Fusidic Acid inhibits the reaction [SLCO1B3 protein results in increased uptake of Rosuvastatin Calcium]
Fusidic Acid results in decreased activity of SLCO1B3 protein 		CTD PMID:26888941 PMID:27676153 NCBI chr 4:176,282,577...176,355,557
Ensembl chr 4:176,282,584...176,351,083 		JBrowse link
G Ugt1a1 UDP glucuronosyltransferase family 1 member A1 multiple interactions ISO Fusidic Acid inhibits the reaction [UGT1A1 protein results in increased glucuronidation of Estradiol] CTD PMID:27676153 NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:96,144,786...96,256,264 		JBrowse link
trichostatin A term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G 9330159F19Rikl RIKEN cDNA 9330159F19 gene like increases expression ISO trichostatin A results in increased expression of KIAA0408 mRNA CTD PMID:24935251 NCBI chr 1:30,444,202...30,469,195
Ensembl chr 1:30,444,208...30,453,155 		JBrowse link
G A2m alpha-2-macroglobulin increases expression ISO trichostatin A results in increased expression of A2M mRNA CTD PMID:24935251 NCBI chr 4:156,570,163...156,619,870
Ensembl chr 4:156,569,860...156,619,868 		JBrowse link
G A2ml1 alpha-2-macroglobulin-like 1 decreases expression ISO trichostatin A results in decreased expression of OVOS2P mRNA CTD PMID:26272509 NCBI chr 4:163,501,210...163,543,419
Ensembl chr 4:163,501,585...163,543,506 		JBrowse link
G Aak1 AP2 associated kinase 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of AAK1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AAK1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:120,845,012...121,009,170
Ensembl chr 4:120,858,557...121,004,236 		JBrowse link
G Aamdc adipogenesis associated, Mth938 domain containing increases expression ISO trichostatin A results in increased expression of AAMDC mRNA CTD PMID:28542535 NCBI chr 1:161,273,205...161,303,253
Ensembl chr 1:161,262,347...161,299,340 		JBrowse link
G Abat 4-aminobutyrate aminotransferase increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ABAT mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABAT mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:7,503,351...7,599,474
Ensembl chr10:7,492,022...7,599,474 		JBrowse link
G Abca1 ATP binding cassette subfamily A member 1 decreases expression ISO trichostatin A results in decreased expression of ABCA1 mRNA CTD PMID:24935251 NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:72,473,676...72,596,473 		JBrowse link
G Abca13 ATP binding cassette subfamily A member 13 increases expression ISO trichostatin A results in increased expression of ABCA13 mRNA CTD PMID:24935251 NCBI chr14:88,087,146...88,589,868
Ensembl chr14:88,087,801...88,589,392 		JBrowse link
G Abca5 ATP binding cassette subfamily A member 5 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of ABCA5 mRNA
trichostatin A results in decreased expression of ABCA5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABCA5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:95,739,610...95,808,633
Ensembl chr10:95,739,610...95,808,424 		JBrowse link
G Abca7 ATP binding cassette subfamily A member 7 affects expression ISO trichostatin A affects the expression of ABCA7 mRNA CTD PMID:28542535 NCBI chr 7:10,342,092...10,362,094
Ensembl chr 7:10,342,092...10,361,989 		JBrowse link
G Abcb1a ATP binding cassette subfamily B member 1A multiple interactions
increases expression 		ISO [[decitabine co-treated with trichostatin A] affects the methylation of ABCB1 gene] which affects the expression of ABCB1 mRNA; [trichostatin A affects the methylation of ABCB1 gene] which affects the expression of ABCB1 mRNA; decitabine promotes the reaction [trichostatin A results in increased expression of ABCB1 mRNA] CTD PMID:18673531 PMID:24935251 PMID:27570640 NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135 		JBrowse link
G Abcc10 ATP binding cassette subfamily C member 10 increases expression ISO trichostatin A results in increased expression of ABCC10 mRNA CTD PMID:12566991 NCBI chr 9:22,154,811...22,174,743
Ensembl chr 9:22,154,804...22,174,743 		JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 decreases expression ISO trichostatin A results in decreased expression of ABCC2 mRNA; trichostatin A results in decreased expression of ABCC2 protein CTD PMID:10691972 NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471 		JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 decreases expression ISO trichostatin A results in decreased expression of ABCC3 mRNA CTD PMID:10691972 NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,793,583...79,839,494 		JBrowse link
G Abcc6 ATP binding cassette subfamily C member 6 decreases expression ISO trichostatin A results in decreased expression of ABCC6 mRNA CTD PMID:24935251 NCBI chr 1:105,583,681...105,637,895
Ensembl chr 1:105,583,682...105,637,895 		JBrowse link
G Abcd3 ATP binding cassette subfamily D member 3 increases expression ISO trichostatin A results in increased expression of ABCD3 mRNA CTD PMID:27188386 NCBI chr 2:212,536,791...212,590,379
Ensembl chr 2:212,536,791...212,590,504 		JBrowse link
G Abcg1 ATP binding cassette subfamily G member 1 decreases expression ISO trichostatin A results in decreased expression of ABCG1 mRNA CTD PMID:26705709 NCBI chr20:9,128,056...9,184,312
Ensembl chr20:9,127,803...9,186,563 		JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ABCG2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABCG2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493 		JBrowse link
G Abhd13 abhydrolase domain containing 13 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ABHD13 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABHD13 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:86,203,851...86,218,843
Ensembl chr16:86,201,794...86,290,906 		JBrowse link
G Abhd15 abhydrolase domain containing 15 increases expression ISO trichostatin A results in increased expression of ABHD15 mRNA CTD PMID:24935251 NCBI chr10:62,861,335...62,866,726
Ensembl chr10:62,861,317...62,868,540 		JBrowse link
G Abhd17a abhydrolase domain containing 17A, depalmitoylase affects expression ISO trichostatin A affects the expression of ABHD17A mRNA CTD PMID:28542535 NCBI chr 7:9,775,016...9,781,447 JBrowse link
G Abhd17b abhydrolase domain containing 17B, depalmitoylase decreases expression
affects expression 		ISO trichostatin A results in decreased expression of ABHD17B mRNA
trichostatin A affects the expression of ABHD17B mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 1:228,624,821...228,659,254
Ensembl chr 1:228,624,499...228,658,948 		JBrowse link
G Abhd2 abhydrolase domain containing 2, acylglycerol lipase affects expression ISO trichostatin A affects the expression of ABHD2 mRNA CTD PMID:28542535 NCBI chr 1:142,626,748...142,707,892
Ensembl chr 1:142,626,732...142,712,674 		JBrowse link
G Abhd3 abhydrolase domain containing 3, phospholipase increases expression ISO trichostatin A results in increased expression of ABHD3 mRNA CTD PMID:24935251 NCBI chr18:1,996,010...2,051,311
Ensembl chr18:1,993,525...2,075,492 		JBrowse link
G Abhd6 abhydrolase domain containing 6, acylglycerol lipase increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of ABHD6 mRNA
trichostatin A results in decreased expression of ABHD6 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABHD6 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr15:19,289,967...19,337,500
Ensembl chr15:19,289,969...19,337,193 		JBrowse link
G Abi3bp ABI family member 3 binding protein decreases expression
increases expression 		ISO trichostatin A results in decreased expression of ABI3BP mRNA
trichostatin A results in increased expression of ABI3BP mRNA 		CTD PMID:24935251 PMID:26705709 NCBI chr11:57,381,282...57,597,989
Ensembl chr11:57,381,422...57,598,120 		JBrowse link
G Abl1 ABL proto-oncogene 1, non-receptor tyrosine kinase decreases expression ISO trichostatin A results in decreased expression of ABL1 mRNA CTD PMID:19606018 PMID:23770000 NCBI chr 3:35,377,587...35,480,843
Ensembl chr 3:35,377,391...35,480,846 		JBrowse link
G Abraxas1 abraxas 1, BRCA1 A complex subunit decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of ABRAXAS1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABRAXAS1 mRNA
trichostatin A affects the expression of ABRAXAS1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr14:9,100,650...9,115,012
Ensembl chr14:9,100,671...9,115,011 		JBrowse link
G Abtb3 ankyrin repeat and BTB domain containing 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ABTB3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABTB3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:19,922,883...20,199,740
Ensembl chr 7:19,923,814...20,198,110 		JBrowse link
G Acad11 acyl-CoA dehydrogenase family, member 11 increases expression ISO trichostatin A results in increased expression of ACAD11 mRNA CTD PMID:24935251 PMID:26272509 NCBI chr 8:113,560,142...113,625,346
Ensembl chr 8:113,560,196...113,625,352 		JBrowse link
G Acadsb acyl-CoA dehydrogenase, short/branched chain affects expression ISO trichostatin A affects the expression of ACADSB mRNA CTD PMID:28542535 NCBI chr 1:195,619,088...195,660,564
Ensembl chr 1:195,619,038...195,660,561 		JBrowse link
G Acbd7 acyl-CoA binding domain containing 7 affects expression ISO trichostatin A affects the expression of ACBD7 mRNA CTD PMID:28542535 NCBI chr17:79,813,106...79,821,254
Ensembl chr17:79,813,106...79,818,448 		JBrowse link
G Acer3 alkaline ceramidase 3 affects expression ISO trichostatin A affects the expression of ACER3 mRNA CTD PMID:28542535 NCBI chr 1:161,915,397...162,017,802
Ensembl chr 1:161,915,397...162,017,912 		JBrowse link
G Ackr3 atypical chemokine receptor 3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ACKR3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACKR3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 9:98,247,300...98,258,877
Ensembl chr 9:98,246,605...98,260,214 		JBrowse link
G Aco1 aconitase 1 affects expression ISO trichostatin A affects the expression of ACO1 mRNA CTD PMID:28542535 NCBI chr 5:60,055,895...60,111,920
Ensembl chr 5:60,055,866...60,112,600 		JBrowse link
G Acox1 acyl-CoA oxidase 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ACOX1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACOX1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:101,905,083...101,930,136
Ensembl chr10:101,905,083...101,930,136 		JBrowse link
G Acp3 acid phosphatase 3 increases expression ISO trichostatin A results in increased expression of ACP3 mRNA CTD PMID:24935251 NCBI chr 8:113,784,372...113,833,033
Ensembl chr 8:113,785,032...113,833,033 		JBrowse link
G Acsf2 acyl-CoA synthetase family member 2 increases expression ISO trichostatin A results in increased expression of ACSF2 mRNA CTD PMID:24935251 NCBI chr10:80,001,389...80,043,796
Ensembl chr10:80,001,389...80,045,050 		JBrowse link
G Acsl1 acyl-CoA synthetase long-chain family member 1 increases expression ISO trichostatin A results in increased expression of ACSL1 mRNA CTD PMID:24935251 NCBI chr16:52,487,870...52,554,110
Ensembl chr16:52,487,870...52,554,023 		JBrowse link
G Acsl3 acyl-CoA synthetase long-chain family member 3 increases expression
affects expression 		ISO trichostatin A results in increased expression of ACSL3 mRNA
trichostatin A affects the expression of ACSL3 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 9:87,563,601...87,613,078
Ensembl chr 9:87,563,601...87,613,097 		JBrowse link
G Acsl4 acyl-CoA synthetase long-chain family member 4 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ACSL4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSL4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:110,739,633...110,803,416
Ensembl chr  X:110,739,648...110,803,261 		JBrowse link
G Acsm3 acyl-CoA synthetase medium-chain family member 3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ACSM3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSM3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:183,564,652...183,591,328
Ensembl chr 1:183,564,635...183,591,437 		JBrowse link
G Acta2 actin alpha 2, smooth muscle increases expression
multiple interactions
decreases expression 		ISO
EXP 		trichostatin A results in increased expression of ACTA2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACTA2 mRNA
trichostatin A inhibits the reaction [Folic Acid results in increased expression of ACTA2 mRNA]; trichostatin A inhibits the reaction [Folic Acid results in increased expression of ACTA2 protein]; trichostatin A inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]
trichostatin A results in decreased expression of ACTA2 protein 		CTD PMID:12445420 PMID:26272509 PMID:27188386 PMID:27396813 PMID:39617304 NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503 		JBrowse link
G Actc1 actin, alpha, cardiac muscle 1 decreases expression ISO trichostatin A results in decreased expression of ACTC1 mRNA CTD PMID:24935251 NCBI chr 3:121,266,291...121,271,827
Ensembl chr 3:121,266,291...121,271,827 		JBrowse link
G Actn3 actinin alpha 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ACTN3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ACTN3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:211,588,473...211,604,401
Ensembl chr 1:211,588,474...211,604,401 		JBrowse link
G Actr2 actin related protein 2 increases expression
decreases expression 		ISO
EXP 		trichostatin A results in increased expression of ACTR2 mRNA
trichostatin A results in decreased expression of ACTR2 protein 		CTD PMID:12445420 PMID:24935251 NCBI chr14:98,500,119...98,535,092
Ensembl chr14:98,500,138...98,541,998 		JBrowse link
G Actr3 actin related protein 3 decreases expression EXP trichostatin A results in decreased expression of ACTR3 mRNA; trichostatin A results in decreased expression of ACTR3 protein CTD PMID:12445420 NCBI chr13:39,353,413...39,396,509
Ensembl chr13:39,353,079...39,396,711 		JBrowse link
G Acvr1c activin A receptor type 1C increases expression ISO trichostatin A results in increased expression of ACVR1C mRNA CTD PMID:24935251 NCBI chr 3:63,224,322...63,301,252
Ensembl chr 3:63,227,559...63,301,205 		JBrowse link
G Ada adenosine deaminase decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ADA mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:172,818,174...172,842,283
Ensembl chr 3:172,818,176...172,842,293 		JBrowse link
G Adam12 ADAM metallopeptidase domain 12 decreases expression
increases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ADAM12 mRNA
trichostatin A results in increased expression of ADAM12 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] affects the expression of ADAM12 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:198,116,968...198,443,680
Ensembl chr 1:198,116,975...198,447,552 		JBrowse link
G Adam22 ADAM metallopeptidase domain 22 decreases expression ISO trichostatin A results in decreased expression of ADAM22 mRNA CTD PMID:26272509 NCBI chr 4:26,670,984...26,925,843
Ensembl chr 4:26,671,112...26,925,843 		JBrowse link
G Adam28 ADAM metallopeptidase domain 28 increases expression ISO trichostatin A results in increased expression of ADAM28 mRNA CTD PMID:24935251 NCBI chr15:50,184,286...50,250,605
Ensembl chr15:50,127,516...50,250,526 		JBrowse link
G Adamts1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ADAMTS1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr11:38,418,565...38,427,384
Ensembl chr11:38,418,101...38,427,390 		JBrowse link
G Adamts15 ADAM metallopeptidase with thrombospondin type 1 motif, 15 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ADAMTS15 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS15 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:37,566,064...37,589,446
Ensembl chr 8:37,566,065...37,589,446 		JBrowse link
G Adamts17 ADAM metallopeptidase with thrombospondin type 1 motif, 17 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ADAMTS17 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS17 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:129,856,062...130,178,430
Ensembl chr 1:129,856,074...130,176,844 		JBrowse link
G Adamts19 ADAM metallopeptidase with thrombospondin type 1 motif, 19 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ADAMTS19 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS19 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr18:54,545,357...54,729,184
Ensembl chr18:54,545,357...54,729,181 		JBrowse link
G Adamts20 ADAM metallopeptidase with thrombospondin type 1 motif, 20 decreases expression ISO trichostatin A results in decreased expression of ADAMTS20 mRNA CTD PMID:24935251 NCBI chr 7:127,275,538...127,407,325
Ensembl chr 7:127,275,538...127,407,296 		JBrowse link
G Adamts3 ADAM metallopeptidase with thrombospondin type 1, motif 3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ADAMTS3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr14:18,515,249...18,721,887
Ensembl chr14:18,515,249...18,721,887 		JBrowse link
G Adamts5 ADAM metallopeptidase with thrombospondin type 1 motif, 5 increases expression ISO trichostatin A results in increased expression of ADAMTS5 mRNA CTD PMID:24935251 NCBI chr11:38,486,945...38,533,516
Ensembl chr11:38,486,955...38,533,516 		JBrowse link
G Adamts6 ADAM metallopeptidase with thrombospondin type 1 motif, 6 increases expression ISO trichostatin A results in increased expression of ADAMTS6 mRNA CTD PMID:24935251 PMID:27188386 NCBI chr 2:37,155,260...37,367,077
Ensembl chr 2:37,155,288...37,367,070 		JBrowse link
G Adamts9 ADAM metallopeptidase with thrombospondin type 1 motif, 9 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ADAMTS9 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAMTS9 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:126,847,726...127,019,924
Ensembl chr 4:126,847,729...127,019,876 		JBrowse link
G Adarb1 adenosine deaminase, RNA-specific, B1 decreases expression
affects expression 		ISO trichostatin A results in decreased expression of ADARB1 mRNA
trichostatin A affects the expression of ADARB1 mRNA 		CTD PMID:27188386 PMID:28542535 NCBI chr20:11,222,171...11,350,416
Ensembl chr20:11,222,164...11,350,415 		JBrowse link
G Adat2 adenosine deaminase, tRNA-specific 2 affects expression ISO trichostatin A affects the expression of ADAT2 mRNA CTD PMID:28542535 NCBI chr 1:9,774,680...9,795,376
Ensembl chr 1:9,774,680...9,795,376 		JBrowse link
G Adck2 aarF domain containing kinase 2 increases expression ISO trichostatin A results in increased expression of ADCK2 mRNA CTD PMID:24935251 NCBI chr 4:69,315,633...69,328,535
Ensembl chr 4:69,315,635...69,329,502 		JBrowse link
G Adcy1 adenylate cyclase 1 decreases expression ISO trichostatin A results in decreased expression of ADCY1 mRNA CTD PMID:24935251 NCBI chr14:86,125,119...86,234,459
Ensembl chr14:86,124,850...86,261,075 		JBrowse link
G Adcy7 adenylate cyclase 7 increases expression ISO trichostatin A results in increased expression of ADCY7 mRNA CTD PMID:24935251 NCBI chr19:34,913,154...34,972,366
Ensembl chr19:34,914,322...34,936,743 		JBrowse link
G Adcy9 adenylate cyclase 9 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ADCY9 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCY9 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:11,645,373...11,768,462
Ensembl chr10:11,645,282...11,765,792 		JBrowse link
G Adcyap1r1 ADCYAP receptor type I increases expression ISO trichostatin A results in increased expression of ADCYAP1R1 mRNA CTD PMID:24935251 NCBI chr 4:85,924,171...85,972,973
Ensembl chr 4:85,924,100...85,972,973 		JBrowse link
G Add2 adducin 2 decreases expression ISO trichostatin A results in decreased expression of ADD2 mRNA CTD PMID:24935251 NCBI chr 4:120,001,977...120,101,090
Ensembl chr 4:120,002,054...120,101,091 		JBrowse link
G Add3 adducin 3 increases expression EXP trichostatin A results in increased expression of ADD3 mRNA CTD PMID:12445420 NCBI chr 1:262,152,722...262,260,504
Ensembl chr 1:262,154,996...262,260,504 		JBrowse link
G Adgrb3 adhesion G protein-coupled receptor B3 increases expression ISO trichostatin A results in increased expression of ADGRB3 mRNA CTD PMID:24935251 NCBI chr 9:34,917,474...35,645,350
Ensembl chr 9:34,917,474...35,644,811 		JBrowse link
G Adgrd1 adhesion G protein-coupled receptor D1 increases expression ISO trichostatin A results in increased expression of ADGRD1 mRNA CTD PMID:26705709 NCBI chr12:33,124,981...33,239,778
Ensembl chr12:33,125,915...33,272,509 		JBrowse link
G Adgrf5 adhesion G protein-coupled receptor F5 decreases expression ISO trichostatin A results in decreased expression of ADGRF5 mRNA CTD PMID:26705709 NCBI chr 9:25,014,861...25,128,045
Ensembl chr 9:25,018,277...25,121,237 		JBrowse link
G Adgrg6 adhesion G protein-coupled receptor G6 multiple interactions
increases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADGRG6 mRNA
trichostatin A results in increased expression of ADGRG6 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:10,633,004...10,774,685
Ensembl chr 1:10,631,829...10,774,023 		JBrowse link
G Adgrl3 adhesion G protein-coupled receptor L3 multiple interactions
decreases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA
trichostatin A results in decreased expression of ADGRL3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr14:26,690,891...27,458,132
Ensembl chr14:26,722,194...27,280,418 		JBrowse link
G Adgrl4 adhesion G protein-coupled receptor L4 increases expression ISO trichostatin A results in increased expression of ADGRL4 mRNA CTD PMID:24935251 NCBI chr 2:243,014,927...243,117,226
Ensembl chr 2:243,014,796...243,117,222 		JBrowse link
G Adipor2 adiponectin receptor 2 affects expression ISO trichostatin A affects the expression of ADIPOR2 mRNA CTD PMID:28542535 NCBI chr 4:154,195,440...154,261,141
Ensembl chr 4:154,172,567...154,231,666 		JBrowse link
G Adk adenosine kinase multiple interactions
increases expression 		ISO trichostatin A inhibits the reaction [Nickel affects the expression of ADK mRNA]
trichostatin A results in increased expression of ADK mRNA 		CTD PMID:14575637 PMID:24935251 NCBI chr15:2,912,543...3,295,745
Ensembl chr15:2,912,544...3,295,745 		JBrowse link
G Adm adrenomedullin increases expression ISO trichostatin A results in increased expression of ADM mRNA CTD PMID:24935251 NCBI chr 1:174,164,178...174,182,372
Ensembl chr 1:174,178,773...174,182,371 		JBrowse link
G Adnp activity-dependent neuroprotector homeobox affects expression ISO trichostatin A affects the expression of ADNP mRNA CTD PMID:28542535 NCBI chr 3:177,310,258...177,340,379
Ensembl chr 3:177,310,258...177,336,188 		JBrowse link
G Adora1 adenosine A1 receptor decreases expression ISO trichostatin A results in decreased expression of ADORA1 mRNA CTD PMID:24935251 NCBI chr13:48,210,922...48,247,826
Ensembl chr13:48,213,273...48,247,190 		JBrowse link
G Adpgk ADP-dependent glucokinase affects expression ISO trichostatin A affects the expression of ADPGK mRNA CTD PMID:28542535 NCBI chr 8:68,595,194...68,623,179
Ensembl chr 8:68,595,248...68,623,178 		JBrowse link
G Adra2a adrenoceptor alpha 2A increases expression ISO trichostatin A results in increased expression of ADRA2A mRNA CTD PMID:24935251 NCBI chr 1:263,066,780...263,069,580
Ensembl chr 1:263,065,278...263,069,871 		JBrowse link
G Adrb1 adrenoceptor beta 1 increases expression ISO trichostatin A results in increased expression of ADRB1 mRNA CTD PMID:24935251 NCBI chr 1:265,777,103...265,780,114
Ensembl chr 1:265,766,079...265,849,237 		JBrowse link
G Adrb2 adrenoceptor beta 2 increases expression
affects expression 		ISO trichostatin A results in increased expression of ADRB2 mRNA
trichostatin A affects the expression of ADRB2 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr18:57,912,760...57,914,802
Ensembl chr18:57,911,348...57,914,803 		JBrowse link
G Adss2 adenylosuccinate synthase 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ADSS2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADSS2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr13:92,301,302...92,331,638
Ensembl chr13:92,301,302...92,331,638 		JBrowse link
G Aebp2 AE binding protein 2 affects expression ISO trichostatin A affects the expression of AEBP2 mRNA CTD PMID:28542535 NCBI chr 4:175,258,286...175,297,149
Ensembl chr 4:175,258,887...175,326,422 		JBrowse link
G Aen apoptosis enhancing nuclease affects expression ISO trichostatin A affects the expression of AEN mRNA CTD PMID:28542535 NCBI chr 1:142,224,499...142,233,902
Ensembl chr 1:142,224,493...142,233,898 		JBrowse link
G Afap1 actin filament associated protein 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of AFAP1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AFAP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:78,967,961...79,081,032
Ensembl chr14:78,967,961...79,080,939 		JBrowse link
G Afap1l1 actin filament associated protein 1-like 1 increases expression ISO trichostatin A results in increased expression of AFAP1L1 mRNA CTD PMID:24935251 PMID:26272509 NCBI chr18:57,454,120...57,514,584
Ensembl chr18:57,454,121...57,514,480 		JBrowse link
G Afap1l2 actin filament associated protein 1-like 2 increases expression ISO trichostatin A results in increased expression of AFAP1L2 mRNA CTD PMID:24935251 NCBI chr 1:265,969,368...266,065,951
Ensembl chr 1:265,969,368...266,065,943 		JBrowse link
G Afdn afadin, adherens junction formation factor decreases expression
multiple interactions
increases expression 		ISO trichostatin A results in decreased expression of AFDN mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AFDN mRNA
trichostatin A results in increased expression of AFDN mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 1:58,041,065...58,170,505
Ensembl chr 1:58,041,641...58,170,505 		JBrowse link
G Aff3 ALF transcription elongation factor 3 increases expression ISO trichostatin A results in increased expression of AFF3 mRNA CTD PMID:24935251 NCBI chr 9:47,894,903...48,352,380
Ensembl chr 9:47,894,903...48,353,000 		JBrowse link
G Aff4 ALF transcription elongation factor 4 increases expression
affects expression
multiple interactions 		ISO trichostatin A results in increased expression of AFF4 mRNA
trichostatin A affects the expression of AFF4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AFF4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr10:37,998,319...38,080,580
Ensembl chr10:37,999,579...38,080,580 		JBrowse link
G Afg3l2 AFG3 like matrix AAA peptidase subunit 2 increases expression ISO trichostatin A results in increased expression of AFG3L2 mRNA CTD PMID:24935251 NCBI chr18:63,224,163...63,269,000
Ensembl chr18:63,224,163...63,269,000 		JBrowse link
G Agbl1 AGBL carboxypeptidase 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of AGBL1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AGBL1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:139,453,667...140,360,473
Ensembl chr 1:139,453,867...140,360,629 		JBrowse link
G Agbl2 AGBL carboxypeptidase 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of AGBL2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AGBL2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:97,220,654...97,255,905
Ensembl chr 3:97,220,781...97,255,904 		JBrowse link
G Agbl3 AGBL carboxypeptidase 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of AGBL3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AGBL3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:64,416,139...64,498,987
Ensembl chr 4:64,421,397...64,498,985 		JBrowse link
G Agfg1 ArfGAP with FG repeats 1 decreases expression ISO trichostatin A results in decreased expression of AGFG1 mRNA CTD PMID:24935251 PMID:26272509 NCBI chr 9:91,572,962...91,630,688
Ensembl chr 9:91,573,157...91,626,910 		JBrowse link
G Agfg2 ArfGAP with FG repeats 2 affects expression ISO trichostatin A affects the expression of AGFG2 mRNA CTD PMID:28542535 NCBI chr12:24,649,008...24,692,069
Ensembl chr12:24,649,038...24,685,197 		JBrowse link
G Agpat3 1-acylglycerol-3-phosphate O-acyltransferase 3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of AGPAT3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AGPAT3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr20:10,330,650...10,415,026
Ensembl chr20:10,394,465...10,410,632 		JBrowse link
G Agrn agrin affects expression ISO trichostatin A affects the expression of AGRN mRNA CTD PMID:28542535 NCBI chr 5:172,031,528...172,064,429
Ensembl chr 5:172,031,528...172,064,539 		JBrowse link
G Agtr2 angiotensin II receptor, type 2 multiple interactions EXP trichostatin A inhibits the reaction [Dexamethasone results in decreased expression of AGTR2 mRNA] CTD PMID:32791177 NCBI chr  X:116,914,320...116,918,504
Ensembl chr  X:116,913,656...116,918,745 		JBrowse link
G Ahi1 Abelson helper integration site 1 increases expression ISO trichostatin A results in increased expression of AHI1 mRNA CTD PMID:24935251 NCBI chr 1:17,580,859...17,711,775
Ensembl chr 1:17,582,006...17,711,774 		JBrowse link
G Ahnak AHNAK nucleoprotein increases expression
multiple interactions 		ISO trichostatin A results in increased expression of AHNAK mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AHNAK mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:215,311,289...215,400,010
Ensembl chr 1:215,321,931...215,400,675 		JBrowse link
G Ahnak2 AHNAK nucleoprotein 2 decreases expression ISO trichostatin A results in decreased expression of AHNAK2 mRNA CTD PMID:27188386 NCBI chr 6:137,648,867...137,697,580
Ensembl chr 6:137,652,537...137,675,546 		JBrowse link
G Ahr aryl hydrocarbon receptor increases expression
affects expression
multiple interactions 		ISO trichostatin A results in increased expression of AHR mRNA; trichostatin A results in increased expression of AHR protein
trichostatin A affects the expression of AHR mRNA
[Tetrachlorodibenzodioxin co-treated with trichostatin A] results in increased expression of AHR mRNA 		CTD PMID:12927368 PMID:28542535 PMID:37217010 NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901 		JBrowse link
G Ahsa2 activator of HSP90 ATPase homolog 2 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of AHSA2P mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AHSA2P mRNA
trichostatin A affects the expression of AHSA2P mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr14:101,677,447...101,688,706
Ensembl chr14:101,677,447...101,686,923 		JBrowse link
G Aifm1 apoptosis inducing factor, mitochondria associated 1 multiple interactions ISO [perifosine co-treated with trichostatin A] results in increased secretion of AIFM1 protein; [vorinostat co-treated with trichostatin A] affects the localization of AIFM1 protein CTD PMID:15781658 PMID:16026644 NCBI chr  X:132,528,107...132,567,237
Ensembl chr  X:132,528,107...132,567,237 		JBrowse link
G Aifm3 AIF family member 3 decreases expression ISO trichostatin A results in decreased expression of AIFM3 mRNA CTD PMID:24935251 NCBI chr11:97,009,100...97,030,601
Ensembl chr11:97,008,426...97,023,334 		JBrowse link
G Aig1 androgen-induced 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of AIG1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AIG1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:9,866,546...10,089,454
Ensembl chr 1:9,866,548...10,089,155 		JBrowse link
G Aip aryl-hydrocarbon receptor-interacting protein affects expression ISO trichostatin A affects the expression of AIP mRNA CTD PMID:28542535 NCBI chr 1:210,837,473...210,848,691
Ensembl chr 1:210,836,755...210,848,634 		JBrowse link
G Ajap1 adherens junctions associated protein 1 increases expression ISO trichostatin A results in increased expression of AJAP1 mRNA CTD PMID:24935251 NCBI chr 5:169,190,477...169,302,938
Ensembl chr 5:169,190,477...169,304,515 		JBrowse link
G Ajuba ajuba LIM protein decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of AJUBA mRNA; trichostatin A results in decreased expression of JUB mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AJUBA mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:31,989,796...32,000,042
Ensembl chr15:31,989,799...32,000,042 		JBrowse link
G Ak2 adenylate kinase 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of AK2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AK2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:146,609,469...146,649,008
Ensembl chr 5:146,630,445...146,650,610 		JBrowse link
G Ak4 adenylate kinase 4 increases expression ISO trichostatin A results in increased expression of AK4 mRNA CTD PMID:24935251 NCBI chr 5:121,154,565...121,214,403
Ensembl chr 5:121,154,572...121,214,401 		JBrowse link
G Ak5 adenylate kinase 5 decreases expression ISO trichostatin A results in decreased expression of AK5 mRNA CTD PMID:24935251 NCBI chr 2:244,057,240...244,241,372
Ensembl chr 2:244,057,240...244,241,366 		JBrowse link
G Ak7 adenylate kinase 7 increases expression ISO trichostatin A results in increased expression of AK7 mRNA CTD PMID:24935251 NCBI chr 6:130,376,499...130,444,674
Ensembl chr 6:130,376,550...130,444,677 		JBrowse link
G Ak8 adenylate kinase 8 affects expression ISO trichostatin A affects the expression of AK8 mRNA CTD PMID:28542535 NCBI chr 3:32,426,892...32,542,432
Ensembl chr 3:32,426,421...32,542,431 		JBrowse link
G Akap1 A-kinase anchoring protein 1 decreases expression ISO trichostatin A results in decreased expression of AKAP1 mRNA CTD PMID:24935251 NCBI chr10:74,118,232...74,151,366
Ensembl chr10:74,119,124...74,138,190 		JBrowse link
G Akap10 A-kinase anchoring protein 10 increases expression ISO trichostatin A results in increased expression of AKAP10 mRNA CTD PMID:24935251 NCBI chr10:47,044,819...47,108,153
Ensembl chr10:47,044,819...47,108,203 		JBrowse link
G Akap12 A-kinase anchoring protein 12 multiple interactions
decreases expression
increases expression 		ISO
EXP 		[[Decitabine co-treated with trichostatin A] affects the methylation of AKAP12 promoter] which affects the expression of AKAP12 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AKAP12 mRNA
trichostatin A results in decreased expression of AKAP12 mRNA
trichostatin A results in increased expression of AKAP12 mRNA 		CTD PMID:12445420 PMID:18803327 PMID:24935251 PMID:26272509 PMID:26705709 More... NCBI chr 1:43,135,515...43,225,245
Ensembl chr 1:43,199,008...43,225,557 		JBrowse link
G Akap8 A-kinase anchoring protein 8 decreases expression ISO trichostatin A results in decreased expression of AKAP8 mRNA CTD PMID:24935251 PMID:28542535 NCBI chr 7:11,966,769...11,983,056
Ensembl chr 7:11,966,772...11,982,900 		JBrowse link
G Akap8l A-kinase anchoring protein 8 like decreases expression ISO trichostatin A results in decreased expression of AKAP8L mRNA CTD PMID:24935251 NCBI chr 7:11,983,215...12,012,843
Ensembl chr 7:11,982,721...12,012,811 		JBrowse link
G Akap9 A-kinase anchoring protein 9 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of AKAP9 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AKAP9 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:31,011,475...31,147,338
Ensembl chr 4:31,011,475...31,147,338 		JBrowse link
G Akip1 A-kinase interacting protein 1 decreases expression ISO trichostatin A results in decreased expression of AKIP1 mRNA CTD PMID:24935251 NCBI chr 1:173,169,520...173,178,445
Ensembl chr 1:173,169,458...173,178,445 		JBrowse link
G Akr1c1 aldo-keto reductase family 1, member C1 multiple interactions
increases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1C1 mRNA
trichostatin A results in increased expression of AKR1C1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr17:70,720,397...70,747,285
Ensembl chr17:70,720,398...70,747,247 		JBrowse link
G Akr1c2 aldo-keto reductase family 1, member C2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of AKR1C2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1C2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr17:70,669,684...70,717,935
Ensembl chr17:70,669,710...70,685,686 		JBrowse link
G Akr1c3 aldo-keto reductase family 1, member C3 increases expression ISO trichostatin A results in increased expression of AKR1C3 mRNA CTD PMID:24935251 PMID:26705709 NCBI chr17:71,020,884...71,037,779
Ensembl chr17:70,970,900...71,048,438 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO [perifosine co-treated with trichostatin A] results in decreased activity of AKT1 protein; AKT1 protein modified form inhibits the reaction [trichostatin A inhibits the reaction [Oxygen deficiency results in increased expression of MMP2 mRNA]]; AKT1 protein modified form inhibits the reaction [trichostatin A inhibits the reaction [Oxygen deficiency results in increased expression of MMP9 mRNA]]; AKT1 protein modified form results in decreased activity of [perifosine co-treated with trichostatin A]; trichostatin A inhibits the reaction [Oxygen deficiency results in increased phosphorylation of AKT1 protein] CTD PMID:15781658 PMID:26509796 NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610 		JBrowse link
G Akt3 AKT serine/threonine kinase 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of AKT3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AKT3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr13:91,475,839...91,758,060
Ensembl chr13:91,475,839...91,748,020 		JBrowse link
G Alad aminolevulinate dehydratase decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of ALAD mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ALAD mRNA
trichostatin A affects the expression of ALAD mRNA 		CTD PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 5:80,977,562...80,987,901
Ensembl chr 5:80,977,562...80,988,041 		JBrowse link
G Alas1 5'-aminolevulinate synthase 1 affects expression ISO trichostatin A affects the expression of ALAS1 mRNA CTD PMID:28542535 NCBI chr 8:115,755,238...115,768,642
Ensembl chr 8:115,755,238...115,768,642 		JBrowse link
G Alb albumin increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ALB mRNA
trichostatin A inhibits the reaction [Folic Acid results in decreased expression of ALB protein] 		CTD PMID:25084468 PMID:39617304 NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865 		JBrowse link
G Alcam activated leukocyte cell adhesion molecule increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ALCAM mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALCAM mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr11:61,804,932...62,005,250
Ensembl chr11:61,805,049...62,006,876 		JBrowse link
G Aldh1a2 aldehyde dehydrogenase 1 family, member A2 decreases expression ISO trichostatin A results in decreased expression of ALDH1A2 mRNA CTD PMID:24935251 PMID:26705709 NCBI chr 8:80,758,641...80,837,891
Ensembl chr 8:80,758,142...80,837,883 		JBrowse link
G Aldh1a3 aldehyde dehydrogenase 1 family, member A3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ALDH1A3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1A3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:129,392,516...129,436,552
Ensembl chr 1:129,392,516...129,427,777 		JBrowse link
G Aldh1l2 aldehyde dehydrogenase 1 family, member L2 increases expression ISO trichostatin A results in increased expression of ALDH1L2 mRNA CTD PMID:24935251 NCBI chr 7:22,141,872...22,193,403
Ensembl chr 7:22,141,842...22,193,398 		JBrowse link
G Aldh2 aldehyde dehydrogenase 2 family member decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ALDH2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ALDH2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr12:40,610,244...40,643,220
Ensembl chr12:40,610,224...40,643,219 		JBrowse link
G Aldh3a2 aldehyde dehydrogenase 3 family, member A2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ALDH3A2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ALDH3A2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:46,427,789...46,448,449
Ensembl chr10:46,407,993...46,448,648 		JBrowse link
G Aldoa aldolase, fructose-bisphosphate A increases expression
decreases expression 		ISO trichostatin A results in increased expression of ALDOA mRNA
trichostatin A results in decreased expression of ALDOA mRNA 		CTD PMID:24935251 PMID:27188386 NCBI chr 1:190,832,820...190,838,021
Ensembl chr 1:190,832,820...190,838,211 		JBrowse link
G Alg10 ALG10, alpha-1,2-glucosyltransferase affects expression ISO trichostatin A affects the expression of ALG10 mRNA CTD PMID:28542535 NCBI chr 7:123,214,636...123,225,104
Ensembl chr 7:123,214,636...123,225,104 		JBrowse link
G Alg6 ALG6, alpha-1,3-glucosyltransferase affects expression ISO trichostatin A affects the expression of ALG6 mRNA CTD PMID:28542535 NCBI chr 5:119,520,415...119,606,365
Ensembl chr 5:119,520,430...119,606,659 		JBrowse link
G Alkal2 ALK and LTK ligand 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ALKAL2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALKAL2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:53,223,204...53,232,794
Ensembl chr 6:53,223,341...53,233,011 		JBrowse link
G Alpk2 alpha-kinase 2 increases expression ISO trichostatin A results in increased expression of ALPK2 mRNA CTD PMID:24935251 PMID:26705709 NCBI chr18:61,045,717...61,161,703
Ensembl chr18:61,045,380...61,175,985 		JBrowse link
G Alpk3 alpha-kinase 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ALPK3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ALPK3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:144,423,690...144,471,534
Ensembl chr 1:144,423,726...144,490,309 		JBrowse link
G Als2 alsin Rho guanine nucleotide exchange factor ALS2 affects expression ISO trichostatin A affects the expression of ALS2 mRNA CTD PMID:28542535 NCBI chr 9:68,107,310...68,180,192
Ensembl chr 9:68,107,528...68,179,660 		JBrowse link
G Alx1 ALX homeobox 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ALX1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALX1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:40,044,185...40,063,778
Ensembl chr 7:40,033,676...40,063,778 		JBrowse link
G Amacr alpha-methylacyl-CoA racemase decreases expression ISO trichostatin A results in decreased expression of AMACR mRNA CTD PMID:24935251 NCBI chr 2:61,673,291...61,685,381
Ensembl chr 2:61,670,475...61,685,379 		JBrowse link
G Amdhd1 amidohydrolase domain containing 1 decreases expression ISO trichostatin A results in decreased expression of AMDHD1 mRNA CTD PMID:24935251 PMID:26272509 NCBI chr 7:29,930,966...29,946,199
Ensembl chr 7:29,929,965...29,959,683 		JBrowse link
G Amer2 APC membrane recruitment protein 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMER2 mRNA
trichostatin A results in increased expression of AMER2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:38,701,509...38,711,817
Ensembl chr15:38,701,657...38,705,633 		JBrowse link
G Amfr autocrine motility factor receptor decreases expression ISO trichostatin A results in decreased expression of AMFR mRNA CTD PMID:24935251 NCBI chr19:11,002,451...11,038,182
Ensembl chr19:11,002,101...11,038,364 		JBrowse link
G Amigo1 adhesion molecule with Ig like domain 1 decreases expression ISO trichostatin A results in decreased expression of AMIGO1 mRNA CTD PMID:24935251 NCBI chr 2:198,511,285...198,516,744
Ensembl chr 2:198,511,039...198,521,146 		JBrowse link
G Amigo2 adhesion molecule with Ig like domain 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of AMIGO2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMIGO2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:130,270,639...130,273,735
Ensembl chr 7:130,270,554...130,282,218 		JBrowse link
G Amn1 antagonist of mitotic exit network 1 homolog increases expression ISO trichostatin A results in increased expression of AMN1 mRNA CTD PMID:24935251 NCBI chr 4:183,886,469...183,913,411
Ensembl chr 4:183,886,474...183,913,411 		JBrowse link
G Amot angiomotin increases expression ISO trichostatin A results in increased expression of AMOT mRNA CTD PMID:24935251 NCBI chr  X:113,778,990...113,837,846
Ensembl chr  X:113,781,526...113,837,482 		JBrowse link
G Ampd3 adenosine monophosphate deaminase 3 multiple interactions ISO trichostatin A inhibits the reaction [Dexamethasone results in increased expression of AMPD3 mRNA] CTD PMID:23946490 NCBI chr 1:174,319,526...174,364,605
Ensembl chr 1:174,294,867...174,364,608 		JBrowse link
G Amph amphiphysin increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of AMPH mRNA
trichostatin A results in decreased expression of AMPH mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AMPH mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr17:50,435,018...50,678,583
Ensembl chr17:50,435,018...50,678,501 		JBrowse link
G Anapc13 anaphase promoting complex subunit 13 affects expression ISO trichostatin A affects the expression of ANAPC13 mRNA CTD PMID:28542535 NCBI chr 8:112,084,405...112,092,821
Ensembl chr 8:112,084,405...112,092,821 		JBrowse link
G Ang angiogenin increases expression
affects expression 		ISO trichostatin A results in increased expression of ANG mRNA
trichostatin A affects the expression of ANG mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr15:26,786,233...26,796,883
Ensembl chr15:26,786,065...26,801,106 		JBrowse link
G Angpt1 angiopoietin 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ANGPT1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:75,415,959...75,668,696
Ensembl chr 7:75,418,218...75,668,696 		JBrowse link
G Angpt2 angiopoietin 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ANGPT2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:77,790,760...77,841,241
Ensembl chr16:77,790,563...77,841,239 		JBrowse link
G Angptl1 angiopoietin-like 1 decreases expression ISO trichostatin A results in decreased expression of ANGPTL1 mRNA CTD PMID:26705709 NCBI chr13:71,463,913...71,531,810
Ensembl chr13:71,511,727...71,531,818 		JBrowse link
G Angptl4 angiopoietin-like 4 multiple interactions ISO
EXP 		[decitabine co-treated with trichostatin A] results in increased expression of ANGPTL4 mRNA
[decitabine co-treated with trichostatin A] inhibits the reaction [[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased methylation of ANGPTL4 promoter] which results in decreased expression of ANGPTL4 mRNA] 		CTD PMID:21489049 NCBI chr 7:15,252,450...15,259,971
Ensembl chr 7:15,252,473...15,258,681 		JBrowse link
G Ank2 ankyrin 2 decreases expression
increases expression 		ISO trichostatin A results in decreased expression of ANK2 mRNA
trichostatin A results in increased expression of ANK2 mRNA 		CTD PMID:24935251 NCBI chr 2:218,052,555...218,628,414
Ensembl chr 2:218,052,555...218,537,259 		JBrowse link
G Ank3 ankyrin 3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ANK3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANK3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr20:18,601,307...19,224,790
Ensembl chr20:18,601,826...19,084,879 		JBrowse link
G Ankdd1a ankyrin repeat and death domain containing 1A increases expression ISO trichostatin A results in increased expression of ANKDD1A mRNA CTD PMID:24935251 NCBI chr 8:74,912,707...74,938,870
Ensembl chr 8:74,916,011...74,937,863 		JBrowse link
G Ankh ANKH inorganic pyrophosphate transport regulator increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ANKH mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKH mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:79,883,350...80,011,222
Ensembl chr 2:79,883,544...80,011,699 		JBrowse link
G Ankle1 ankyrin repeat and LEM domain containing 1 increases expression ISO trichostatin A results in increased expression of ANKLE1 mRNA CTD PMID:24935251 NCBI chr16:18,109,865...18,116,999
Ensembl chr16:18,110,476...18,114,244 		JBrowse link
G Ankmy2 ankyrin repeat and MYND domain containing 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ANKMY2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKMY2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:58,616,251...58,657,634
Ensembl chr 6:58,615,243...58,657,685 		JBrowse link
G Ankrd1 ankyrin repeat domain 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ANKRD1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:26705709 PMID:27188386 NCBI chr 1:243,228,460...243,237,014
Ensembl chr 1:243,228,448...243,263,751 		JBrowse link
G Ankrd12 ankyrin repeat domain 12 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of ANKRD12 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKRD12 mRNA
trichostatin A affects the expression of ANKRD12 mRNA 		CTD PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 9:113,030,127...113,134,816
Ensembl chr 9:113,030,919...113,134,762 		JBrowse link
G Ankrd13a ankyrin repeat domain 13a affects expression ISO trichostatin A affects the expression of ANKRD13A mRNA CTD PMID:28542535 NCBI chr12:47,458,828...47,488,959
Ensembl chr12:47,458,831...47,489,312 		JBrowse link
G Ankrd13c ankyrin repeat domain 13C decreases expression ISO trichostatin A results in decreased expression of ANKRD13C mRNA CTD PMID:24935251 NCBI chr 2:249,679,752...249,729,272
Ensembl chr 2:249,681,872...249,729,272 		JBrowse link
G Ankrd22 ankyrin repeat domain 22 increases expression ISO trichostatin A results in increased expression of ANKRD22 mRNA CTD PMID:24935251 NCBI chr 1:241,052,235...241,083,737
Ensembl chr 1:241,052,237...241,105,559 		JBrowse link
G Ankrd27 ankyrin repeat domain 27 affects expression ISO trichostatin A affects the expression of ANKRD27 mRNA CTD PMID:28542535 NCBI chr 1:97,387,997...97,440,501
Ensembl chr 1:97,388,099...97,440,501 		JBrowse link
G Ankrd28 ankyrin repeat domain 28 increases expression ISO trichostatin A results in increased expression of ANKRD28 mRNA CTD PMID:24935251 PMID:26705709 NCBI chr16:6,924,868...7,056,593
Ensembl chr16:6,924,882...7,056,593 		JBrowse link
G Ankrd29 ankyrin repeat domain 29 increases expression ISO trichostatin A results in increased expression of ANKRD29 mRNA CTD PMID:24935251 NCBI chr18:3,711,052...3,768,997
Ensembl chr18:3,711,059...3,769,098 		JBrowse link
G Ankrd35 ankyrin repeat domain 35 decreases expression
affects expression 		ISO trichostatin A results in decreased expression of ANKRD35 mRNA
trichostatin A affects the expression of ANKRD35 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 2:186,895,896...186,915,903
Ensembl chr 2:186,895,945...186,915,902 		JBrowse link
G Ankrd46 ankyrin repeat domain 46 increases expression ISO trichostatin A results in increased expression of ANKRD46 mRNA CTD PMID:24935251 NCBI chr 7:69,532,303...69,553,311
Ensembl chr 7:69,532,304...69,545,421 		JBrowse link
G Ankrd50 ankyrin repeat domain containing 50 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ANKRD50 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKRD50 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:123,394,311...123,428,788
Ensembl chr 2:123,396,606...123,427,340 		JBrowse link
G Ankrd6 ankyrin repeat domain 6 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of ANKRD6 mRNA
trichostatin A results in decreased expression of ANKRD6 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKRD6 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:51,999,225...52,139,623
Ensembl chr 5:51,999,221...52,139,594 		JBrowse link
G Ano3 anoctamin 3 increases expression ISO trichostatin A results in increased expression of ANO3 mRNA CTD PMID:24935251 NCBI chr 3:117,690,242...118,004,695
Ensembl chr 3:117,692,103...118,004,675 		JBrowse link
G Ano4 anoctamin 4 increases expression ISO trichostatin A results in increased expression of ANO4 mRNA CTD PMID:24935251 NCBI chr 7:25,216,389...25,625,811
Ensembl chr 7:25,216,389...25,625,746 		JBrowse link
G Ano5 anoctamin 5 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of ANO5 mRNA
trichostatin A results in decreased expression of ANO5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANO5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:110,222,411...110,323,505
Ensembl chr 1:110,222,446...110,323,501 		JBrowse link
G Anp32b acidic nuclear phosphoprotein 32 family member B affects expression ISO trichostatin A affects the expression of ANP32B mRNA CTD PMID:28542535 NCBI chr 5:65,538,872...65,561,305
Ensembl chr 5:65,538,535...65,561,437 		JBrowse link
G Antxr1 ANTXR cell adhesion molecule 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ANTXR1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANTXR1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:121,148,102...121,335,549
Ensembl chr 4:121,148,103...121,336,892 		JBrowse link
G Antxr2 ANTXR cell adhesion molecule 2 increases expression ISO trichostatin A results in increased expression of ANTXR2 mRNA CTD PMID:24935251 NCBI chr14:11,845,774...11,986,166
Ensembl chr14:11,845,700...11,986,168 		JBrowse link
G Anxa1 annexin A1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ANXA1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:227,287,713...227,306,739
Ensembl chr 1:227,287,717...227,306,831 		JBrowse link
G Anxa11 annexin A11 increases expression ISO trichostatin A results in increased expression of ANXA11 mRNA CTD PMID:24935251 NCBI chr16:1,419,627...1,464,590
Ensembl chr16:1,418,351...1,464,839 		JBrowse link
G Anxa2 annexin A2 multiple interactions
increases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2 mRNA; [trichostatin A co-treated with Decitabine] results in increased expression of ANXA2 protein
trichostatin A results in increased expression of ANXA2 mRNA; trichostatin A results in increased expression of ANXA2 protein 		CTD PMID:19294695 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 8:78,986,252...79,022,638
Ensembl chr 8:78,986,242...79,022,631 		JBrowse link
G Anxa3 annexin A3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ANXA3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr14:13,031,675...13,085,678
Ensembl chr14:13,023,762...13,085,849 		JBrowse link
G Anxa4 annexin A4 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ANXA4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:120,741,750...120,798,534
Ensembl chr 4:120,741,750...120,798,513 		JBrowse link
G Anxa9 annexin A9 increases expression ISO trichostatin A results in increased expression of ANXA9 mRNA CTD PMID:24935251 NCBI chr 2:185,562,174...185,572,560
Ensembl chr 2:185,562,174...185,572,560 		JBrowse link
G Aoah acyloxyacyl hydrolase decreases expression ISO trichostatin A results in decreased expression of AOAH mRNA CTD PMID:24935251 NCBI chr17:48,503,812...48,745,161
Ensembl chr17:48,503,812...48,745,146 		JBrowse link
G Aopep aminopeptidase O increases expression
multiple interactions 		ISO trichostatin A results in increased expression of AOPEP mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AOPEP mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr17:1,817,001...2,133,008
Ensembl chr17:1,817,001...2,133,104 		JBrowse link
G Aox1 aldehyde oxidase 1 decreases expression ISO trichostatin A results in decreased expression of AOX1 mRNA CTD PMID:24935251 NCBI chr 9:67,073,831...67,152,980
Ensembl chr 9:67,073,821...67,152,980 		JBrowse link
G Ap1m2 adaptor related protein complex 1 subunit mu 2 increases expression ISO trichostatin A results in increased expression of AP1M2 mRNA CTD PMID:24935251 NCBI chr 8:28,114,748...28,132,767
Ensembl chr 8:28,114,748...28,132,642 		JBrowse link
G Ap1s2 adaptor related protein complex 1 subunit sigma 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of AP1S2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AP1S2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr  X:34,204,601...34,230,819
Ensembl chr  X:34,204,603...34,228,529 		JBrowse link
G Ap1s3 adaptor related protein complex 1 subunit sigma 3 affects expression ISO trichostatin A affects the expression of AP1S3 mRNA CTD PMID:28542535 NCBI chr 9:88,399,109...88,458,396
Ensembl chr 9:88,399,109...88,488,089 		JBrowse link
G Ap2b1 adaptor related protein complex 2 subunit beta 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of AP2B1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AP2B1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:68,596,925...68,702,547
Ensembl chr10:68,597,093...68,702,539 		JBrowse link
G Ap4s1 adaptor related protein complex 4 subunit sigma 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of AP4S1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AP4S1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:74,863,742...74,916,907
Ensembl chr 6:74,868,558...74,912,406 		JBrowse link
G Ap5m1 adaptor related protein complex 5 subunit mu 1 decreases expression ISO trichostatin A results in decreased expression of AP5M1 mRNA CTD PMID:24935251 PMID:26272509 NCBI chr15:24,835,122...24,864,854
Ensembl chr15:24,835,100...24,862,606 		JBrowse link
G Ap5s1 adaptor related protein complex 5 subunit sigma 1 affects expression
decreases expression 		ISO trichostatin A affects the expression of AP5S1 mRNA
trichostatin A results in decreased expression of AP5S1 mRNA 		CTD PMID:28542535 PMID:33770205 NCBI chr 3:138,882,634...138,885,940
Ensembl chr 3:138,882,634...138,888,899 		JBrowse link
G Apaf1 apoptotic peptidase activating factor 1 multiple interactions
increases activity 		ISO [trichostatin A results in increased activity of APAF1 protein] which results in increased susceptibility to Cisplatin CTD PMID:20925046 NCBI chr 7:27,381,392...27,466,772
Ensembl chr 7:27,381,855...27,466,772 		JBrowse link
G Apba1 amyloid beta precursor protein binding family A member 1 decreases expression
increases expression 		ISO trichostatin A results in decreased expression of APBA1 mRNA
trichostatin A results in increased expression of APBA1 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 1:230,790,297...230,995,986
Ensembl chr 1:230,790,297...230,995,986 		JBrowse link
G Apbb2 amyloid beta precursor protein binding family B member 2 increases expression ISO trichostatin A results in increased expression of APBB2 mRNA CTD PMID:24935251 NCBI chr14:41,849,638...42,232,930
Ensembl chr14:41,911,785...42,232,280 		JBrowse link
G Apbb3 amyloid beta precursor protein binding family B member 3 affects expression ISO trichostatin A affects the expression of APBB3 mRNA CTD PMID:28542535 NCBI chr18:28,547,205...28,554,383
Ensembl chr18:28,547,205...28,554,383 		JBrowse link
G Apc APC regulator of WNT signaling pathway increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of APC mRNA
trichostatin A results in decreased expression of APC mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of APC mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr18:26,138,382...26,196,021
Ensembl chr18:26,102,679...26,197,022 		JBrowse link
G Apcdd1 APC down-regulated 1 increases expression ISO trichostatin A results in increased expression of APCDD1 mRNA CTD PMID:24935251 NCBI chr18:58,655,696...58,686,359
Ensembl chr18:58,655,919...58,686,356 		JBrowse link
G Apela apelin receptor early endogenous ligand increases expression ISO trichostatin A results in increased expression of APELA mRNA CTD PMID:26272509 PMID:26705709 NCBI chr16:29,460,855...29,469,962
Ensembl chr16:29,460,812...29,469,955 		JBrowse link
G Apex1 apurinic/apyrimidinic endodeoxyribonuclease 1 multiple interactions
increases acetylation 		ISO trichostatin A promotes the reaction [EP300 protein binds to APEX1 protein]
trichostatin A results in increased acetylation of APEX1 protein 		CTD PMID:20856196 NCBI chr15:26,618,146...26,620,330
Ensembl chr15:26,618,224...26,620,329 		JBrowse link
G Aplf aprataxin and PNKP like factor increases expression
affects expression 		ISO trichostatin A results in increased expression of APLF mRNA
trichostatin A affects the expression of APLF mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 4:121,627,800...121,679,980
Ensembl chr 4:121,627,800...121,679,961 		JBrowse link
G Aplp2 amyloid beta precursor like protein 2 affects expression ISO trichostatin A affects the expression of APLP2 mRNA CTD PMID:28542535 NCBI chr 8:37,857,407...37,920,487
Ensembl chr 8:37,857,407...37,920,031 		JBrowse link
G Apod apolipoprotein D multiple interactions ISO [decitabine co-treated with trichostatin A] affects the expression of APOD mRNA CTD PMID:16865689 NCBI chr11:82,936,216...82,957,264
Ensembl chr11:82,936,038...82,957,263 		JBrowse link
G Apol2 apolipoprotein L2 decreases expression ISO trichostatin A results in decreased expression of APOL2 mRNA CTD PMID:28542535 NCBI chr 7:111,211,944...111,219,209
Ensembl chr 7:111,211,893...111,217,223 		JBrowse link
G Appbp2 amyloid beta precursor protein binding protein 2 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of APPBP2 mRNA
trichostatin A results in decreased expression of APPBP2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of APPBP2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:70,555,212...70,597,267
Ensembl chr10:70,555,212...70,597,193 		JBrowse link
G Appl2 adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of APPL2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of APPL2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:22,019,480...22,072,386
Ensembl chr 7:22,022,963...22,072,385 		JBrowse link
G Aqp4 aquaporin 4 increases expression ISO trichostatin A results in increased expression of AQP4 mRNA CTD PMID:24935251 NCBI chr18:6,782,389...6,799,034
Ensembl chr18:6,782,389...6,799,098 		JBrowse link
G Ar androgen receptor multiple interactions
decreases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AR mRNA; [trichostatin A co-treated with Decitabine] results in increased expression of AR mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [trichostatin A results in decreased expression of AR protein]
trichostatin A results in decreased expression of AR mRNA; trichostatin A results in decreased expression of AR protein 		CTD PMID:18092350 PMID:19805354 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr  X:67,135,317...67,304,476
Ensembl chr  X:67,135,317...67,304,467 		JBrowse link
G Arap2 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ARAP2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARAP2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr14:50,921,323...51,120,972
Ensembl chr14:50,921,713...51,120,962 		JBrowse link
G Arb2a ARB2 cotranscriptional regulator A decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ARB2A mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARB2A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:9,289,694...9,753,991
Ensembl chr 2:9,289,699...9,753,989 		JBrowse link
G Areg amphiregulin increases expression ISO trichostatin A results in increased expression of AREG mRNA CTD PMID:24935251 NCBI chr14:17,256,384...17,265,641
Ensembl chr14:17,256,384...17,265,641 		JBrowse link
G Arf1 ARF GTPase 1 increases expression ISO trichostatin A results in increased expression of ARF1 mRNA CTD PMID:24935251 NCBI chr10:44,497,543...44,513,994 JBrowse link
G Arfgap2 ARF GTPase activating protein 2 affects expression ISO trichostatin A affects the expression of ARFGAP2 mRNA CTD PMID:28542535 NCBI chr 3:97,692,105...97,704,246
Ensembl chr 3:97,692,110...97,704,247 		JBrowse link
G Arfgap3 ARF GTPase activating protein 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ARFGAP3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARFGAP3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:116,312,996...116,359,300
Ensembl chr 7:116,313,001...116,359,592 		JBrowse link
G Arfgef1 ARF guanine nucleotide exchange factor 1 multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of ARFGEF1 mRNA] CTD PMID:14575637 NCBI chr 5:13,764,507...13,859,237
Ensembl chr 5:13,764,975...13,859,237 		JBrowse link
G Arfgef3 ARFGEF family member 3 decreases expression ISO trichostatin A results in decreased expression of ARFGEF3 mRNA CTD PMID:24935251 NCBI chr 1:15,058,574...15,223,742
Ensembl chr 1:15,058,579...15,223,742 		JBrowse link
G Arfip1 ARF interacting protein 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ARFIP1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARFIP1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:172,141,862...172,224,464
Ensembl chr 2:172,141,859...172,221,280 		JBrowse link
G Arg2 arginase 2 decreases expression
multiple interactions
increases expression 		ISO trichostatin A results in decreased expression of ARG2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARG2 mRNA
trichostatin A results in increased expression of ARG2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 6:103,669,001...103,694,375
Ensembl chr 6:103,668,988...103,694,375 		JBrowse link
G Arglu1 arginine and glutamate rich 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ARGLU1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARGLU1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr16:87,455,097...87,479,148
Ensembl chr16:87,455,113...87,479,148 		JBrowse link
G Arhgap11a Rho GTPase activating protein 11A affects expression ISO trichostatin A affects the expression of ARHGAP11A mRNA CTD PMID:28542535 NCBI chr 3:121,045,187...121,071,985
Ensembl chr 3:121,045,187...121,061,468 		JBrowse link
G Arhgap15 Rho GTPase activating protein 15 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ARHGAP15 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGAP15 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:48,382,945...49,002,213
Ensembl chr 3:48,382,904...49,011,378 		JBrowse link
G Arhgap18 Rho GTPase activating protein 18 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ARHGAP18 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP18 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:20,222,948...20,456,827
Ensembl chr 1:20,222,954...20,456,670 		JBrowse link
G Arhgap19 Rho GTPase activating protein 19 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ARHGAP19 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGAP19 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:250,519,703...250,566,705
Ensembl chr 1:250,530,214...250,580,190 		JBrowse link
G Arhgap24 Rho GTPase activating protein 24 increases expression
decreases expression 		ISO trichostatin A results in increased expression of ARHGAP24 mRNA
trichostatin A results in decreased expression of ARHGAP24 mRNA 		CTD PMID:24935251 NCBI chr14:7,105,200...7,488,437
Ensembl chr14:7,105,200...7,528,950 		JBrowse link
G Arhgap26 Rho GTPase activating protein 26 increases expression
affects expression 		ISO trichostatin A results in increased expression of ARHGAP26 mRNA
trichostatin A affects the expression of ARHGAP26 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr18:30,702,602...31,489,047
Ensembl chr18:31,089,787...31,489,047 		JBrowse link
G Arhgap27 Rho GTPase activating protein 27 multiple interactions ISO [[decitabine co-treated with trichostatin A] affects the methylation of ARHGAP27 promoter] which affects the expression of ARHGAP27 mRNA CTD PMID:18803327 NCBI chr10:88,780,527...88,813,275
Ensembl chr10:88,780,527...88,814,616 		JBrowse link
G Arhgap28 Rho GTPase activating protein 28 increases expression ISO trichostatin A results in increased expression of ARHGAP28 mRNA CTD PMID:24935251 NCBI chr 9:115,277,849...115,444,789
Ensembl chr 9:115,279,734...115,445,008 		JBrowse link
G Arhgap29 Rho GTPase activating protein 29 increases expression ISO trichostatin A results in increased expression of ARHGAP29 mRNA CTD PMID:24935251 NCBI chr 2:212,744,626...212,816,710
Ensembl chr 2:212,755,803...212,986,729 		JBrowse link
G Arhgap35 Rho GTPase activating protein 35 decreases expression ISO trichostatin A results in decreased expression of ARHGAP35 mRNA CTD PMID:24935251 NCBI chr 1:86,330,566...86,447,414
Ensembl chr 1:86,330,566...86,447,414 		JBrowse link
G Arhgap45 Rho GTPase activating protein 45 increases expression ISO trichostatin A results in increased expression of ARHGAP45 mRNA CTD PMID:19096014 NCBI chr 7:10,325,515...10,340,955
Ensembl chr 7:10,325,539...10,341,890 		JBrowse link
G Arhgap5 Rho GTPase activating protein 5 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ARHGAP5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGAP5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:75,711,199...75,774,636
Ensembl chr 6:75,711,515...75,774,636 		JBrowse link
G Arhgap6 Rho GTPase activating protein 6 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ARHGAP6 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP6 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr  X:28,525,912...29,062,344
Ensembl chr  X:28,525,917...29,061,244 		JBrowse link
G Arhgap8 Rho GTPase activating protein 8 increases expression ISO trichostatin A results in increased expression of ARHGAP8 mRNA CTD PMID:24935251 NCBI chr 7:117,723,512...117,782,031
Ensembl chr 7:117,730,578...117,782,030 		JBrowse link
G Arhgef12 Rho guanine nucleotide exchange factor 12 affects expression ISO trichostatin A affects the expression of ARHGEF12 mRNA CTD PMID:28542535 NCBI chr 8:52,247,047...52,373,158
Ensembl chr 8:52,247,047...52,372,376 		JBrowse link
G Arhgef16 Rho guanine nucleotide exchange factor 16 multiple interactions ISO [[decitabine co-treated with trichostatin A] affects the methylation of ARHGEF16 promoter] which affects the expression of ARHGEF16 mRNA CTD PMID:18803327 NCBI chr 5:170,126,573...170,148,624
Ensembl chr 5:170,126,575...170,148,624 		JBrowse link
G Arhgef3 Rho guanine nucleotide exchange factor 3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ARHGEF3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGEF3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr16:2,308,311...2,588,634
Ensembl chr16:2,308,400...2,588,819 		JBrowse link
G Arhgef37 Rho guanine nucleotide exchange factor 37 increases expression ISO trichostatin A results in increased expression of ARHGEF37 mRNA CTD PMID:24935251 NCBI chr18:57,205,621...57,271,284
Ensembl chr18:57,230,117...57,271,031 		JBrowse link
G Arhgef39 Rho guanine nucleotide exchange factor 39 affects expression ISO trichostatin A affects the expression of ARHGEF39 mRNA CTD PMID:28542535 NCBI chr 5:62,548,300...62,551,870
Ensembl chr 5:62,548,303...62,551,870 		JBrowse link
G Arhgef4 Rho guanine nucleotide exchange factor 4 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ARHGEF4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGEF4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 9:44,357,716...44,500,959
Ensembl chr 9:44,357,736...44,501,550 		JBrowse link
G Arhgef7 Rho guanine nucleotide exchange factor 7 decreases expression ISO trichostatin A results in decreased expression of ARHGEF7 mRNA CTD PMID:24935251 NCBI chr16:84,373,123...84,484,759
Ensembl chr16:84,373,123...84,484,597 		JBrowse link
G Arid1a AT-rich interaction domain 1A affects expression ISO trichostatin A affects the expression of ARID1A mRNA CTD PMID:28542535 NCBI chr 5:151,192,014...151,269,291
Ensembl chr 5:151,192,014...151,265,386 		JBrowse link
G Arid1b AT-rich interaction domain 1B affects expression ISO trichostatin A affects the expression of ARID1B mRNA CTD PMID:28542535 NCBI chr 1:47,973,199...48,328,793
Ensembl chr 1:47,973,997...48,328,793 		JBrowse link
G Arid2 AT-rich interaction domain 2 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of ARID2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARID2 mRNA
trichostatin A affects the expression of ARID2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 7:129,326,371...129,443,813
Ensembl chr 7:129,324,137...129,443,187 		JBrowse link
G Arid5b AT-rich interaction domain 5B increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ARID5B mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARID5B mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr20:20,305,693...20,489,689
Ensembl chr20:20,306,712...20,489,686 		JBrowse link
G Arl13b ARF like GTPase 13B affects expression ISO trichostatin A affects the expression of ARL13B mRNA CTD PMID:28542535 NCBI chr11:13,597,538...13,663,681
Ensembl chr11:13,597,538...13,663,546 		JBrowse link
G Arl3 ARF like GTPase 3 affects expression ISO trichostatin A affects the expression of ARL3 mRNA CTD PMID:28542535 NCBI chr 1:255,342,078...255,388,087
Ensembl chr 1:255,342,076...255,388,279 		JBrowse link
G Arl4c ARF like GTPase 4C decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ARL4C mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARL4C mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:96,748,075...96,751,510
Ensembl chr 9:96,745,069...96,752,772 		JBrowse link
G Arl4d ARF like GTPase 4D affects expression ISO trichostatin A affects the expression of ARL4D mRNA CTD PMID:28542535 NCBI chr10:87,092,276...87,103,079
Ensembl chr10:87,077,523...87,106,199 		JBrowse link
G Arl5b ARF like GTPase 5B affects expression ISO trichostatin A affects the expression of ARL5B mRNA CTD PMID:28542535 NCBI chr17:82,864,315...82,888,458
Ensembl chr17:82,864,287...82,890,646 		JBrowse link
G Arl6 ARF like GTPase 6 increases expression ISO trichostatin A results in increased expression of ARL6 mRNA CTD PMID:24935251 NCBI chr11:54,180,271...54,207,136
Ensembl chr11:54,181,241...54,210,813 		JBrowse link
G Arl6ip1 ARL6 interacting reticulophagy regulator 1 affects expression ISO trichostatin A affects the expression of ARL6IP1 mRNA CTD PMID:28542535 NCBI chr 1:181,864,717...181,874,232
Ensembl chr 1:181,864,746...181,874,232 		JBrowse link
G Armc8 armadillo repeat containing 8 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of ARMC8 mRNA
trichostatin A results in decreased expression of ARMC8 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARMC8 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 8:108,916,274...109,010,877
Ensembl chr 8:108,916,274...109,010,717 		JBrowse link
G Armc9 armadillo repeat containing 9 affects expression ISO trichostatin A affects the expression of ARMC9 mRNA CTD PMID:28542535 NCBI chr 9:94,250,492...94,376,589
Ensembl chr 9:94,250,859...94,376,589 		JBrowse link
G Armh3 armadillo-like helical domain containing 3 decreases expression ISO trichostatin A results in decreased expression of ARMH3 mRNA CTD PMID:24935251 NCBI chr 1:254,615,274...254,797,673
Ensembl chr 1:254,615,274...254,781,315 		JBrowse link
G Armh4 armadillo-like helical domain containing 4 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ARMH4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARMH4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:25,455,478...25,556,569
Ensembl chr15:25,455,297...25,556,534 		JBrowse link
G Arnt2 aryl hydrocarbon receptor nuclear translocator 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ARNT2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARNT2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:147,645,354...147,801,986
Ensembl chr 1:147,599,058...147,801,997 		JBrowse link
G Arpc1b actin related protein 2/3 complex, subunit 1B increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ARPC1B mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARPC1B mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr12:14,595,939...14,609,501
Ensembl chr12:14,595,678...14,609,504 		JBrowse link
G Arpp21 cAMP regulated phosphoprotein 21 increases expression ISO trichostatin A results in increased expression of ARPP21 mRNA CTD PMID:24204683 NCBI chr 8:120,912,964...121,077,586
Ensembl chr 8:120,912,970...121,031,357 		JBrowse link
G Arrb1 arrestin, beta 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ARRB1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARRB1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:163,249,654...163,321,711
Ensembl chr 1:163,250,157...163,340,859 		JBrowse link
G Arrdc4 arrestin domain containing 4 increases expression ISO trichostatin A results in increased expression of ARRDC4 mRNA CTD PMID:24935251 NCBI chr 1:131,779,436...131,793,438
Ensembl chr 1:131,779,437...131,793,565 		JBrowse link
G Arsg arylsulfatase G decreases expression ISO trichostatin A results in decreased expression of ARSG mRNA CTD PMID:24935251 PMID:26272509 NCBI chr10:94,912,094...95,063,021
Ensembl chr10:94,913,152...95,042,447 		JBrowse link
G Arsj arylsulfatase family, member J increases expression ISO trichostatin A results in increased expression of ARSJ mRNA CTD PMID:24935251 NCBI chr 2:217,449,147...217,529,142
Ensembl chr 2:217,449,147...217,529,142 		JBrowse link
G Arsk arylsulfatase family, member K affects expression ISO trichostatin A affects the expression of ARSK mRNA CTD PMID:28542535 NCBI chr 2:7,306,181...7,363,311
Ensembl chr 2:7,306,181...7,363,311 		JBrowse link
G Arx aristaless related homeobox decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ARX mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARX mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr  X:62,010,097...62,022,009
Ensembl chr  X:62,010,097...62,022,002 		JBrowse link
G Asap1 ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ASAP1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASAP1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:97,675,354...97,982,523
Ensembl chr 7:97,675,354...97,982,024 		JBrowse link
G Asap2 ArfGAP with SH3 domain, ankyrin repeat and PH domain 2 increases expression ISO trichostatin A results in increased expression of ASAP2 mRNA CTD PMID:24935251 NCBI chr 6:46,386,605...46,549,669
Ensembl chr 6:46,386,605...46,549,669 		JBrowse link
G Asb1 ankyrin repeat and SOCS box-containing 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ASB1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASB1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 9:99,566,852...99,588,321
Ensembl chr 9:99,567,867...99,583,907 		JBrowse link
G Asb2 ankyrin repeat and SOCS box-containing 2 increases expression ISO trichostatin A results in increased expression of ASB2 mRNA CTD PMID:24935251 NCBI chr 6:128,239,550...128,275,833
Ensembl chr 6:128,239,552...128,266,321 		JBrowse link
G Asb9 ankyrin repeat and SOCS box-containing 9 increases expression ISO trichostatin A results in increased expression of ASB9 mRNA CTD PMID:24935251 NCBI chr  X:33,588,484...33,633,285
Ensembl chr  X:33,588,484...33,624,397 		JBrowse link
G Ascl1 achaete-scute family bHLH transcription factor 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ASCL1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASCL1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:23,790,642...23,793,509
Ensembl chr 7:23,790,360...23,798,231 		JBrowse link
G Ascl2 achaete-scute family bHLH transcription factor 2 multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of ASCL2 mRNA] CTD PMID:14575637 NCBI chr 1:207,578,447...207,665,126
Ensembl chr 1:207,578,449...207,580,856 		JBrowse link
G Asf1b anti-silencing function 1B histone chaperone affects expression ISO trichostatin A affects the expression of ASF1B mRNA CTD PMID:28542535 NCBI chr19:41,085,786...41,100,352
Ensembl chr19:41,086,114...41,100,352 		JBrowse link
G Asgr1 asialoglycoprotein receptor 1 decreases expression ISO trichostatin A results in decreased expression of ASGR1 mRNA CTD PMID:27188386 NCBI chr10:55,274,299...55,278,323
Ensembl chr10:55,274,706...55,278,322 		JBrowse link
G Asic5 acid sensing ion channel subunit family member 5 multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of ASIC5 mRNA] CTD PMID:14575637 NCBI chr 2:169,606,059...169,634,885
Ensembl chr 2:169,606,059...169,634,885 		JBrowse link
G Asmtl acetylserotonin O-methyltransferase-like increases expression ISO trichostatin A results in increased expression of ASMTL mRNA CTD PMID:28542535 NCBI chr12:21,429,119...21,431,847
Ensembl chr12:21,429,171...21,431,847 		JBrowse link
G Asns asparagine synthetase (glutamine-hydrolyzing) increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ASNS mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASNS mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:36,752,061...36,769,970
Ensembl chr 4:36,751,802...36,776,050 		JBrowse link
G Asph aspartate-beta-hydroxylase decreases expression ISO trichostatin A results in decreased expression of ASPH mRNA CTD PMID:24935251 NCBI chr 5:27,398,933...27,611,519
Ensembl chr 5:27,398,949...27,611,215 		JBrowse link
G Asphd2 aspartate beta-hydroxylase domain containing 2 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of ASPHD2 mRNA
trichostatin A results in decreased expression of ASPHD2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASPHD2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr12:49,908,539...49,919,060
Ensembl chr12:49,908,241...49,925,254 		JBrowse link
G Aspm assembly factor for spindle microtubules decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ASPM mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASPM mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:53,625,584...53,674,489
Ensembl chr13:53,625,584...53,674,489 		JBrowse link
G Ass1 argininosuccinate synthase 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ASS1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASS1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:35,144,765...35,194,632
Ensembl chr 3:35,144,999...35,194,627 		JBrowse link
G Astn1 astrotactin 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ASTN1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASTN1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr13:73,070,754...73,388,902
Ensembl chr13:73,071,267...73,388,895 		JBrowse link
G Astn2 astrotactin 2 increases expression ISO trichostatin A results in increased expression of ASTN2 mRNA CTD PMID:24935251 NCBI chr 5:83,772,988...84,759,439
Ensembl chr 5:83,773,633...84,759,485 		JBrowse link
G Asxl1 ASXL transcriptional regulator 1 increases expression ISO trichostatin A results in increased expression of ASXL1 mRNA CTD PMID:24935251 NCBI chr 3:162,273,828...162,341,742
Ensembl chr 3:162,273,828...162,341,742 		JBrowse link
G Asxl2 ASXL transcriptional regulator 2 increases expression ISO trichostatin A results in increased expression of ASXL2 mRNA CTD PMID:24935251 NCBI chr 6:32,090,497...32,234,487
Ensembl chr 6:32,145,607...32,227,851 		JBrowse link
G Asxl3 ASXL transcriptional regulator 3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ASXL3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASXL3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr18:13,868,223...14,040,867
Ensembl chr18:13,868,674...14,037,373 		JBrowse link
G Atad2 ATPase family, AAA domain containing 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ATAD2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATAD2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:91,523,626...91,566,238
Ensembl chr 7:91,523,626...91,566,238 		JBrowse link
G Atad2b ATPase family, AAA domain containing 2B affects expression ISO trichostatin A affects the expression of ATAD2B mRNA CTD PMID:28542535 NCBI chr 6:33,646,075...33,789,532
Ensembl chr 6:33,646,075...33,789,532 		JBrowse link
G Atad5 ATPase family, AAA domain containing 5 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ATAD5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATAD5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:65,568,569...65,616,379
Ensembl chr10:65,568,591...65,616,376 		JBrowse link
G Atf1 activating transcription factor 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ATF1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATF1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:133,240,774...133,283,488
Ensembl chr 7:133,241,197...133,283,485 		JBrowse link
G Atf2 activating transcription factor 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ATF2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATF2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:79,125,814...79,202,896
Ensembl chr 3:79,126,705...79,202,745 		JBrowse link
G Atf3 activating transcription factor 3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ATF3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATF3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:105,274,103...105,331,653
Ensembl chr13:105,282,440...105,295,750 		JBrowse link
G Atf5 activating transcription factor 5 decreases expression
affects expression 		ISO trichostatin A results in decreased expression of ATF5 mRNA
trichostatin A affects the expression of ATF5 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 1:104,432,094...104,437,611
Ensembl chr 1:104,432,094...104,436,183 		JBrowse link
G Atf7 activating transcription factor 7 decreases expression ISO trichostatin A results in decreased expression of ATF7 mRNA CTD PMID:24935251 NCBI chr 7:135,537,351...135,649,188
Ensembl chr 7:135,542,111...135,599,899 		JBrowse link
G Atf7ip activating transcription factor 7 interacting protein increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ATF7IP mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATF7IP mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:171,117,122...171,202,871
Ensembl chr 4:171,117,122...171,202,867 		JBrowse link
G Atf7ip2 activating transcription factor 7 interacting protein 2 increases expression ISO trichostatin A results in increased expression of ATF7IP2 mRNA CTD PMID:24935251 NCBI chr10:5,909,898...5,952,844
Ensembl chr10:5,909,658...5,952,995 		JBrowse link
G Atg101 autophagy related 101 affects expression ISO trichostatin A affects the expression of ATG101 mRNA CTD PMID:28542535 NCBI chr 7:134,277,223...134,286,387
Ensembl chr 7:134,272,847...134,286,379 		JBrowse link
G Atg2a autophagy related 2A affects expression ISO trichostatin A affects the expression of ATG2A mRNA CTD PMID:28542535 NCBI chr 1:212,971,822...212,991,505
Ensembl chr 1:212,971,844...212,991,528 		JBrowse link
G Atg7 autophagy related 7 decreases response to substance
multiple interactions 		ISO ATG7 gene mutant form results in decreased susceptibility to trichostatin A
ATG7 gene mutant form inhibits the reaction [trichostatin A inhibits the reaction [Cisplatin results in increased activity of CASP3 protein]]; ATG7 gene mutant form inhibits the reaction [trichostatin A inhibits the reaction [Cisplatin results in increased expression of CASP3 protein modified form]]; ATG7 gene mutant form inhibits the reaction [trichostatin A promotes the reaction [Cisplatin results in increased expression of MAP1LC3B protein modified form]]; ATG7 gene mutant form inhibits the reaction [trichostatin A results in increased expression of MAP1LC3B protein modified form] 		CTD PMID:29476062 NCBI chr 4:149,390,000...149,597,534
Ensembl chr 4:149,391,390...149,598,319 		JBrowse link
G Atl1 atlastin GTPase 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ATL1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATL1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:94,113,149...94,210,955
Ensembl chr 6:94,112,877...94,211,219 		JBrowse link
G Atm ATM serine/threonine kinase increases expression ISO trichostatin A results in increased expression of ATM mRNA CTD PMID:24935251 NCBI chr 8:62,724,939...62,829,040
Ensembl chr 8:62,727,291...62,828,629 		JBrowse link
G Atoh7 atonal bHLH transcription factor 7 decreases expression ISO trichostatin A results in decreased expression of ATOH7 mRNA CTD PMID:24935251 NCBI chr20:25,529,528...25,529,977
Ensembl chr20:25,528,906...25,530,368 		JBrowse link
G Atosa atos homolog A affects expression ISO trichostatin A affects the expression of ATOSA mRNA CTD PMID:28542535 NCBI chr 8:84,575,360...84,653,103
Ensembl chr 8:84,575,370...84,653,091 		JBrowse link
G Atosb atos homolog B decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ATOSB mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATOSB mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:62,056,654...62,070,338
Ensembl chr 5:62,056,654...62,064,613 		JBrowse link
G Atp10b ATPase phospholipid transporting 10B increases expression ISO trichostatin A results in increased expression of ATP10B mRNA CTD PMID:24935251 NCBI chr10:27,996,729...28,252,801
Ensembl chr10:27,910,295...28,251,450 		JBrowse link
G Atp10d ATPase phospholipid transporting 10D (putative) increases expression ISO trichostatin A results in increased expression of ATP10D mRNA CTD PMID:24935251 NCBI chr14:36,265,696...36,366,460
Ensembl chr14:36,265,696...36,366,460 		JBrowse link
G Atp13a4 ATPase 13A4 increases expression ISO trichostatin A results in increased expression of ATP13A4 mRNA CTD PMID:24935251 NCBI chr11:84,727,014...84,864,747
Ensembl chr11:84,731,041...84,864,747 		JBrowse link
G Atp1a2 ATPase Na+/K+ transporting subunit alpha 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ATP1A2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP1A2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr13:87,261,964...87,286,911
Ensembl chr13:87,261,968...87,286,911 		JBrowse link
G Atp1b2 ATPase Na+/K+ transporting subunit beta 2 multiple interactions ISO [decitabine co-treated with trichostatin A] affects the expression of ATP1B2 mRNA
[[decitabine co-treated with trichostatin A] affects the methylation of ATP1B2 promoter] which affects the expression of ATP1B2 mRNA 		CTD PMID:16865689 PMID:18836996 NCBI chr10:54,817,473...54,823,708
Ensembl chr10:54,817,476...54,823,708 		JBrowse link
G Atp23 ATP23 metallopeptidase and ATP synthase assembly factor homolog increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ATP23 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP23 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:64,600,100...64,615,240
Ensembl chr 7:64,600,100...64,615,392 		JBrowse link
G Atp2a3 ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3 multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of ATP2A3 mRNA] CTD PMID:14575637 NCBI chr10:58,079,710...58,111,279
Ensembl chr10:58,079,852...58,111,278 		JBrowse link
G Atp2b1 ATPase plasma membrane Ca2+ transporting 1 decreases expression ISO trichostatin A results in decreased expression of ATP2B1 mRNA CTD PMID:24935251 NCBI chr 7:35,622,267...35,731,904
Ensembl chr 7:35,622,461...35,731,904 		JBrowse link
G Atp2b4 ATPase plasma membrane Ca2+ transporting 4 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ATP2B4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP2B4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr13:47,708,157...47,807,389
Ensembl chr13:47,711,121...47,758,876 		JBrowse link
G Atp2c2 ATPase secretory pathway Ca2+ transporting 2 increases expression ISO trichostatin A results in increased expression of ATP2C2 mRNA CTD PMID:24935251 NCBI chr19:64,662,729...64,719,998
Ensembl chr19:64,662,715...64,719,996 		JBrowse link
G Atp5f1b ATP synthase F1 subunit beta multiple interactions
affects expression 		ISO [trichostatin A co-treated with decitabine] results in increased expression of ATP5F1B protein
trichostatin A affects the expression of ATP5F1B protein 		CTD PMID:19294695 NCBI chr 7:1,100,058...1,106,461
Ensembl chr 7:1,099,860...1,106,462 		JBrowse link
G Atp6ap1l ATPase H+ transporting accessory protein 1 like decreases expression ISO trichostatin A results in decreased expression of ATP6AP1L mRNA CTD PMID:24935251 NCBI chr 2:23,772,724...23,814,913
Ensembl chr 2:23,772,745...23,814,618 		JBrowse link
G Atp6ap2 ATPase H+ transporting accessory protein 2 affects expression ISO trichostatin A affects the expression of ATP6AP2 mRNA CTD PMID:28542535 NCBI chr  X:12,856,708...12,883,670
Ensembl chr  X:12,855,859...12,905,875 		JBrowse link
G Atp6v0a4 ATPase H+ transporting V0 subunit a4 increases expression ISO trichostatin A results in increased expression of ATP6V0A4 mRNA CTD PMID:24935251 NCBI chr 4:67,727,145...67,809,092
Ensembl chr 4:67,727,145...67,809,092 		JBrowse link
G Atp6v0d1 ATPase H+ transporting V0 subunit D1 affects expression ISO trichostatin A affects the expression of ATP6V0D1 mRNA CTD PMID:28542535 NCBI chr19:50,313,268...50,357,248
Ensembl chr19:50,313,273...50,357,395 		JBrowse link
G Atp6v0d2 ATPase H+ transporting V0 subunit D2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ATP6V0D2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP6V0D2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:38,133,151...38,182,245
Ensembl chr 5:38,133,158...38,182,245 		JBrowse link
G Atp6v1a ATPase H+ transporting V1 subunit A affects expression ISO trichostatin A affects the expression of ATP6V1A mRNA CTD PMID:28542535 NCBI chr11:70,066,800...70,120,603
Ensembl chr11:70,035,134...70,120,603 		JBrowse link
G Atp6v1b2 ATPase H+ transporting V1 subunit B2 affects expression ISO trichostatin A affects the expression of ATP6V1B2 mRNA CTD PMID:28542535 NCBI chr16:25,384,254...25,408,388
Ensembl chr16:25,384,257...25,408,839 		JBrowse link
G Atp6v1c1 ATPase H+ transporting V1 subunit C1 affects expression ISO trichostatin A affects the expression of ATP6V1C1 mRNA CTD PMID:28542535 NCBI chr 7:71,719,326...71,757,191
Ensembl chr 7:71,719,404...71,757,184 		JBrowse link
G Atp6v1d ATPase H+ transporting V1 subunit D affects expression ISO trichostatin A affects the expression of ATP6V1D mRNA CTD PMID:28542535 NCBI chr 6:103,389,778...103,405,346
Ensembl chr 6:103,389,783...103,405,346 		JBrowse link
G Atp6v1h ATPase H+ transporting V1 subunit H increases expression ISO trichostatin A results in increased expression of ATP6V1H mRNA CTD PMID:24935251 NCBI chr 5:19,176,849...19,282,516
Ensembl chr 5:19,176,849...19,282,516 		JBrowse link
G Atp7a ATPase copper transporting alpha increases expression ISO trichostatin A results in increased expression of ATP7A mRNA CTD PMID:28542535 NCBI chr  X:75,159,635...75,267,094
Ensembl chr  X:75,159,782...75,267,093 		JBrowse link
G Atp8a1 ATPase phospholipid transporting 8A1 decreases expression
increases expression
affects expression 		ISO trichostatin A results in decreased expression of ATP8A1 mRNA
trichostatin A results in increased expression of ATP8A1 mRNA
trichostatin A affects the expression of ATP8A1 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr14:40,668,932...40,911,465
Ensembl chr14:40,731,846...40,911,463 		JBrowse link
G Atp8a2 ATPase phospholipid transporting 8A2 decreases expression ISO trichostatin A results in decreased expression of ATP8A2 mRNA CTD PMID:24935251 NCBI chr15:37,993,507...38,526,408
Ensembl chr15:38,002,305...38,526,212 		JBrowse link
G Atp8b1 ATPase phospholipid transporting 8B1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ATP8B1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:26705709 PMID:27188386 NCBI chr18:60,286,605...60,427,862
Ensembl chr18:60,288,464...60,427,027 		JBrowse link
G Atp9a ATPase phospholipid transporting 9A (putative) decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ATP9A mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP9A mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:177,779,203...177,886,431
Ensembl chr 3:177,779,203...178,023,661 		JBrowse link
G Atrnl1 attractin like 1 increases expression ISO trichostatin A results in increased expression of ATRNL1 mRNA CTD PMID:24935251 PMID:28542535 NCBI chr 1:266,676,051...267,216,847
Ensembl chr 1:266,675,852...267,216,842 		JBrowse link
G Atrx ATRX, chromatin remodeler decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ATRX mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATRX mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr  X:74,916,548...75,062,880
Ensembl chr  X:74,916,548...75,062,880 		JBrowse link
G Atxn1 ataxin 1 increases expression ISO trichostatin A results in increased expression of ATXN1 mRNA CTD PMID:24935251 NCBI chr17:18,943,397...19,354,751
Ensembl chr17:19,208,200...19,356,790 		JBrowse link
G Atxn2l ataxin 2-like affects expression ISO trichostatin A affects the expression of ATXN2L mRNA CTD PMID:28542535 NCBI chr 1:190,508,878...190,526,263
Ensembl chr 1:190,508,878...190,520,579 		JBrowse link
G Atxn7 ataxin 7 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ATXN7 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATXN7 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:13,547,859...13,693,311
Ensembl chr15:13,547,862...13,693,526 		JBrowse link
G Atxn7l1 ataxin 7-like 1 decreases expression ISO trichostatin A results in decreased expression of ATXN7L1 mRNA CTD PMID:24935251 NCBI chr 6:55,487,309...55,709,751
Ensembl chr 6:55,649,362...55,701,996 		JBrowse link
G Atxn7l2 ataxin 7-like 2 affects expression ISO trichostatin A affects the expression of ATXN7L2 mRNA CTD PMID:28542535 NCBI chr 2:198,527,066...198,535,899
Ensembl chr 2:198,527,066...198,534,062 		JBrowse link
G Aurka aurora kinase A decreases expression
affects expression 		ISO trichostatin A results in decreased expression of AURKA mRNA
trichostatin A affects the expression of AURKA mRNA 		CTD PMID:19606018 PMID:28542535 NCBI chr 3:181,546,742...181,562,890
Ensembl chr 3:181,546,742...181,562,771 		JBrowse link
G Aurkb aurora kinase B decreases expression ISO trichostatin A results in decreased expression of AURKB mRNA CTD PMID:19606018 NCBI chr10:54,243,116...54,249,675
Ensembl chr10:54,242,850...54,252,285 		JBrowse link
G Auts2 activator of transcription and developmental regulator AUTS2 decreases expression ISO trichostatin A results in decreased expression of AUTS2 mRNA CTD PMID:24935251 NCBI chr12:29,739,138...30,830,386
Ensembl chr12:29,740,523...30,830,386 		JBrowse link
G Axin2 axin 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of AXIN2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AXIN2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:94,393,379...94,426,579
Ensembl chr10:94,395,909...94,426,575 		JBrowse link
G Azgp1 alpha-2-glycoprotein 1, zinc-binding multiple interactions
increases expression 		ISO decitabine inhibits the reaction [trichostatin A results in increased expression of AZGP1 mRNA] CTD PMID:18978557 NCBI chr12:22,044,685...22,051,248
Ensembl chr12:22,044,751...22,053,020 		JBrowse link
G Azi2 5-azacytidine induced 2 multiple interactions ISO [decitabine co-treated with trichostatin A] results in decreased expression of AZI2 mRNA CTD PMID:17891453 NCBI chr 8:126,651,268...126,674,795
Ensembl chr 8:126,651,206...126,676,182 		JBrowse link
G Azin2 antizyme inhibitor 2 affects expression ISO trichostatin A affects the expression of AZIN2 mRNA CTD PMID:28542535 NCBI chr 5:146,568,187...146,594,777
Ensembl chr 5:146,565,437...146,594,777 		JBrowse link
G B2m beta-2 microglobulin increases expression
multiple interactions 		ISO trichostatin A results in increased expression of B2M mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of B2M mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:129,549,236...129,555,354
Ensembl chr 3:129,549,318...129,555,356 		JBrowse link
G B3galnt1 beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside blood group) decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of B3GALNT1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of B3GALNT1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:156,157,234...156,187,037
Ensembl chr 2:156,156,265...156,188,404 		JBrowse link
G B3galnt2 beta-1,3-N-acetylgalactosaminyltransferase 2 increases expression ISO trichostatin A results in increased expression of B3GALNT2 mRNA CTD PMID:24935251 NCBI chr17:56,030,409...56,072,952
Ensembl chr17:56,030,409...56,072,952 		JBrowse link
G B3gat1 beta-1,3-glucuronyltransferase 1 decreases expression ISO trichostatin A results in decreased expression of B3GAT1 mRNA CTD PMID:24935251 NCBI chr 8:33,362,791...33,390,446
Ensembl chr 8:33,363,048...33,390,443 		JBrowse link
G B3gat2 beta-1,3-glucuronyltransferase 2 decreases expression
increases expression 		ISO trichostatin A results in decreased expression of B3GAT2 mRNA
trichostatin A results in increased expression of B3GAT2 mRNA 		CTD PMID:24935251 NCBI chr 9:33,663,482...33,746,466
Ensembl chr 9:33,663,482...33,746,466 		JBrowse link
G B3gnt2 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of B3GNT2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of B3GNT2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:101,009,682...101,034,507
Ensembl chr14:100,967,131...101,043,412 		JBrowse link
G B3gnt5 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5 decreases expression ISO trichostatin A results in decreased expression of B3GNT5 mRNA CTD PMID:24935251 NCBI chr11:94,645,480...94,657,584
Ensembl chr11:94,645,480...94,660,514 		JBrowse link
G B4galt4 beta-1,4-galactosyltransferase 4 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of B4GALT4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of B4GALT4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr11:75,501,358...75,527,291
Ensembl chr11:75,501,366...75,527,177 		JBrowse link
G B4galt6 beta-1,4-galactosyltransferase 6 decreases expression ISO trichostatin A results in decreased expression of B4GALT6 mRNA CTD PMID:24935251 NCBI chr18:12,233,350...12,290,204
Ensembl chr18:12,233,351...12,290,204 		JBrowse link
G Baalc BAALC binder of MAP3K1 and KLF4 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of BAALC mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BAALC mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:71,803,640...71,877,608
Ensembl chr 7:71,774,898...71,879,261 		JBrowse link
G Bace2 beta-secretase 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of BACE2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BACE2 mRNA 		CTD PMID:24935251 PMID:27188386 NCBI chr11:50,176,852...50,258,948
Ensembl chr11:50,176,621...50,259,008 		JBrowse link
G Bach2 BTB domain and CNC homolog 2 decreases expression ISO trichostatin A results in decreased expression of BACH2 mRNA CTD PMID:24935251 NCBI chr 5:51,428,802...51,779,030
Ensembl chr 5:51,434,870...51,774,234 		JBrowse link
G Bag2 BAG cochaperone 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of BAG2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 9:43,465,993...43,476,637
Ensembl chr 9:43,465,995...43,476,752 		JBrowse link
G Baiap2 BAR/IMD domain containing adaptor protein 2 affects expression ISO trichostatin A affects the expression of BAIAP2 mRNA CTD PMID:28542535 NCBI chr10:105,721,371...105,788,549
Ensembl chr10:105,721,417...105,788,549 		JBrowse link
G Baiap3 BAI1-associated protein 3 affects expression ISO trichostatin A affects the expression of BAIAP3 mRNA CTD PMID:28542535 NCBI chr10:14,764,768...14,777,516
Ensembl chr10:14,756,693...14,777,516 		JBrowse link
G Bak1 BCL2-antagonist/killer 1 multiple interactions
decreases expression 		ISO
EXP 		[perifosine co-treated with trichostatin A] results in decreased expression of BAK1 protein
trichostatin A results in decreased expression of BAK1 mRNA 		CTD PMID:15781658 PMID:23558232 NCBI chr20:5,102,334...5,111,615
Ensembl chr20:5,102,335...5,110,974 		JBrowse link
G Bambi BMP and activin membrane-bound inhibitor increases expression
multiple interactions 		ISO trichostatin A results in increased expression of BAMBI mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAMBI mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr17:58,816,438...58,821,003
Ensembl chr17:58,816,442...58,821,247 		JBrowse link
G Bank1 B-cell scaffold protein with ankyrin repeats 1 increases expression ISO trichostatin A results in increased expression of BANK1 mRNA CTD PMID:24935251 NCBI chr 2:227,203,998...227,474,008
Ensembl chr 2:227,203,998...227,474,037 		JBrowse link
G Barhl1 BarH-like homeobox 1 decreases expression ISO trichostatin A results in decreased expression of BARHL1 mRNA CTD PMID:24935251 NCBI chr 3:32,639,283...32,646,605
Ensembl chr 3:32,638,644...32,646,605 		JBrowse link
G Basp1 brain abundant, membrane attached signal protein 1 multiple interactions ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BASP1 mRNA CTD PMID:27188386 NCBI chr 2:77,546,628...77,594,297
Ensembl chr 2:77,546,092...77,597,178 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions
increases expression 		ISO [perifosine co-treated with trichostatin A] results in increased activity of BAX protein; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [SLC39A6 mutant form inhibits the reaction [trichostatin A results in increased expression of BAX protein]]; SLC39A6 mutant form inhibits the reaction [trichostatin A results in increased expression of BAX protein]; Zinc inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [SLC39A6 mutant form inhibits the reaction [trichostatin A results in increased expression of BAX protein]]]
trichostatin A inhibits the reaction [Folic Acid results in increased expression of BAX mRNA] 		CTD PMID:15781658 PMID:16010430 PMID:19887557 PMID:39617304 NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429 		JBrowse link
G Baz1a bromodomain adjacent to zinc finger domain, 1A increases expression
multiple interactions 		ISO trichostatin A results in increased expression of BAZ1A mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAZ1A mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:78,124,872...78,247,672
Ensembl chr 6:78,124,872...78,247,648 		JBrowse link
G Bbc3 Bcl-2 binding component 3 multiple interactions
increases expression 		ISO Etoposide promotes the reaction [trichostatin A results in increased expression of BBC3 protein]; trichostatin A promotes the reaction [Etoposide results in increased expression of BBC3 protein]
trichostatin A results in increased expression of BBC3 mRNA; trichostatin A results in increased expression of BBC3 protein 		CTD PMID:21527555 PMID:25699604 NCBI chr 1:86,141,450...86,150,666
Ensembl chr 1:86,141,603...86,150,666 		JBrowse link
G Bbip1 BBSome interacting protein 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of BBIP1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BBIP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:262,950,459...262,964,410
Ensembl chr 1:262,950,462...262,964,394 		JBrowse link
G Bbs10 Bardet-Biedl syndrome 10 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of BBS10 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BBS10 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:48,637,324...48,640,395
Ensembl chr 7:48,637,356...48,640,391 		JBrowse link
G Bbs12 Bardet-Biedl syndrome 12 affects expression ISO trichostatin A affects the expression of BBS12 mRNA CTD PMID:28542535 NCBI chr 2:122,131,550...122,149,152
Ensembl chr 2:122,137,856...122,149,153 		JBrowse link
G Bbs7 Bardet-Biedl syndrome 7 increases expression
affects expression 		ISO trichostatin A results in increased expression of BBS7 mRNA
trichostatin A affects the expression of BBS7 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 2:121,362,884...121,402,473
Ensembl chr 2:121,362,885...121,402,473 		JBrowse link
G Bbs9 Bardet-Biedl syndrome 9 affects expression ISO trichostatin A affects the expression of BBS9 mRNA CTD PMID:28542535 NCBI chr 8:29,288,846...29,713,889
Ensembl chr 8:29,289,997...29,713,880 		JBrowse link
G Bbx BBX high mobility group box domain containing increases expression
multiple interactions 		ISO trichostatin A results in increased expression of BBX mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BBX mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr11:63,850,034...64,097,700
Ensembl chr11:63,850,018...64,093,265 		JBrowse link
G Bcar3 BCAR3 adaptor protein, NSP family member multiple interactions
increases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCAR3 mRNA
trichostatin A results in increased expression of BCAR3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:213,209,907...213,323,305
Ensembl chr 2:213,209,893...213,323,302 		JBrowse link
G Bcdin3d BCDIN3 domain containing RNA methyltransferase increases expression ISO trichostatin A results in increased expression of BCDIN3D mRNA CTD PMID:24935251 NCBI chr 7:132,484,404...132,488,998
Ensembl chr 7:132,484,431...132,488,998 		JBrowse link
G Bche butyrylcholinesterase increases expression
multiple interactions 		ISO trichostatin A results in increased expression of BCHE mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCHE mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:160,607,289...160,699,760
Ensembl chr 2:160,606,288...160,699,760 		JBrowse link
G Bcl11a BCL11 transcription factor A increases expression
multiple interactions 		ISO trichostatin A results in increased expression of BCL11A mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCL11A mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr14:102,230,147...102,325,289
Ensembl chr14:102,231,113...102,325,623 		JBrowse link
G Bcl11b BCL11 transcription factor B decreases expression
increases expression 		ISO trichostatin A results in decreased expression of BCL11B protein
trichostatin A results in increased expression of BCL11B mRNA 		CTD PMID:24204683 PMID:24935251 NCBI chr 6:132,598,968...132,692,123
Ensembl chr 6:132,598,968...132,691,301 		JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases response to substance
multiple interactions
decreases expression
increases expression 		ISO
EXP 		BCL2 protein results in decreased susceptibility to trichostatin A
[Plant Extracts co-treated with trichostatin A] results in decreased expression of BCL2 protein; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [SLC39A6 mutant form inhibits the reaction [trichostatin A results in decreased expression of BCL2 protein]]; SLC39A6 mutant form inhibits the reaction [trichostatin A results in decreased expression of BCL2 protein]; Zinc inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [SLC39A6 mutant form inhibits the reaction [trichostatin A results in decreased expression of BCL2 protein]]]
trichostatin A results in decreased expression of BCL2 mRNA; trichostatin A results in decreased expression of BCL2 protein
trichostatin A inhibits the reaction [Benzene results in decreased expression of BCL2 mRNA]
trichostatin A results in increased expression of BCL2 mRNA 		CTD PMID:16010430 PMID:18709356 PMID:19887557 PMID:21143203 PMID:21527555 More... NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900 		JBrowse link
G Bcl2a1 BCL2-related protein A1 multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of BCL2A1A mRNA] CTD PMID:14575637 NCBI chr 8:98,596,806...98,604,890
Ensembl chr 8:98,596,650...98,604,890 		JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions
decreases response to substance
decreases expression
affects expression 		ISO
EXP 		BCL2L1 protein results in decreased susceptibility to [Bortezomib co-treated with trichostatin A]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [SLC39A6 mutant form inhibits the reaction [trichostatin A results in decreased expression of BCL2L1 protein]]; SLC39A6 mutant form inhibits the reaction [trichostatin A results in decreased expression of BCL2L1 protein]; trichostatin A promotes the reaction [Bortezomib results in decreased expression of BCL2L1 mRNA]; trichostatin A promotes the reaction [Bortezomib results in decreased expression of BCL2L1 protein]; Zinc inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [SLC39A6 mutant form inhibits the reaction [trichostatin A results in decreased expression of BCL2L1 protein]]]
BCL2L1 protein results in decreased susceptibility to trichostatin A
BCL2L1 gene mutant form results in decreased susceptibility to trichostatin A
trichostatin A results in decreased expression of BCL2L1 mRNA
trichostatin A affects the expression of BCL2L1 mRNA 		CTD PMID:10970895 PMID:15781649 PMID:16009488 PMID:16904634 PMID:19887557 More... NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907
Ensembl chr 1:161,745,540...161,764,907 		JBrowse link
G Bcl2l11 Bcl2-like 11 multiple interactions
increases expression
decreases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA; trichostatin A inhibits the reaction [Nickel affects the expression of BCL2L11 mRNA]
trichostatin A results in increased expression of BCL2L11 mRNA
trichostatin A results in decreased expression of BCL2L11 mRNA 		CTD PMID:14575637 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:135,820,042...135,857,330
Ensembl chr 3:135,817,562...135,960,695 		JBrowse link
G Bcl2l12 Bcl2 like 12 affects expression ISO trichostatin A affects the expression of BCL2L12 mRNA CTD PMID:28542535 NCBI chr 1:104,608,753...104,617,472
Ensembl chr 1:104,608,753...104,617,472 		JBrowse link
G Bcl6 BCL6, transcription repressor affects expression ISO trichostatin A affects the expression of BCL6 mRNA CTD PMID:28542535 NCBI chr11:90,358,753...90,382,049
Ensembl chr11:90,358,753...90,382,047 		JBrowse link
G Bclaf1 BCL2-associated transcription factor 1 decreases expression ISO trichostatin A results in decreased expression of BCLAF1 mRNA CTD PMID:24935251 PMID:28542535 NCBI chr 1:16,904,572...16,937,106
Ensembl chr 1:16,914,118...16,936,801 		JBrowse link
G Bco1 beta-carotene oxygenase 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCO1 mRNA
trichostatin A results in decreased expression of BCO1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr19:62,058,061...62,094,923
Ensembl chr19:62,058,089...62,094,917 		JBrowse link
G Bcor BCL6 co-repressor decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of BCOR mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCOR mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:13,282,431...13,402,254
Ensembl chr  X:13,360,376...13,402,254 		JBrowse link
G Bcr BCR activator of RhoGEF and GTPase decreases expression ISO trichostatin A results in decreased expression of BCR mRNA CTD PMID:24935251 NCBI chr20:13,468,732...13,596,333
Ensembl chr20:13,468,732...13,596,333 		JBrowse link
G Bdnf brain-derived neurotrophic factor increases expression
multiple interactions
decreases expression 		EXP
ISO 		trichostatin A results in increased expression of BDNF mRNA
[trichostatin A co-treated with Serotonin] results in increased expression of BDNF mRNA
trichostatin A inhibits the reaction [BDNF protein results in increased expression of NAB2 protein]; trichostatin A inhibits the reaction [BDNF protein results in increased expression of PPP1R1B protein]
trichostatin A results in decreased expression of BDNF mRNA 		CTD PMID:19360904 PMID:19476549 PMID:24204683 PMID:24935251 NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:116,619,633...116,670,657 		JBrowse link
G Bdp1 BDP1 general transcription factor IIIB subunit decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of BDP1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BDP1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:33,112,518...33,204,270
Ensembl chr 2:33,112,518...33,204,241 		JBrowse link
G Bean1 brain expressed, associated with NEDD4, 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of BEAN1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BEAN1 mRNA 		CTD PMID:26705709 PMID:27188386 NCBI chr19:745,993...792,853
Ensembl chr19:745,993...793,039 		JBrowse link
G Bend4 BEN domain containing 4 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of BEND4 mRNA
trichostatin A results in decreased expression of BEND4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEND4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr14:41,106,206...41,142,572
Ensembl chr14:41,106,763...41,136,979 		JBrowse link
G Bend5 BEN domain containing 5 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of BEND5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEND5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:131,519,214...131,565,228
Ensembl chr 5:131,519,214...131,762,906 		JBrowse link
G Bend6 BEN domain containing 6 increases expression ISO trichostatin A results in increased expression of BEND6 mRNA CTD PMID:27188386 NCBI chr 9:43,576,982...43,631,437
Ensembl chr 9:43,576,982...43,631,194 		JBrowse link
G Bend7 BEN domain containing 7 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of BEND7 mRNA
trichostatin A results in decreased expression of BEND7 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEND7 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr17:78,392,489...78,475,459
Ensembl chr17:78,393,601...78,475,223 		JBrowse link
G Best4 bestrophin 4 decreases expression ISO trichostatin A results in decreased expression of BEST4 mRNA CTD PMID:24935251 NCBI chr 5:135,858,774...135,865,624
Ensembl chr 5:135,860,018...135,863,707 		JBrowse link
G Bex1 brain expressed X-linked 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEX2 mRNA
trichostatin A results in decreased expression of BEX2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:104,010,639...104,012,143
Ensembl chr  X:104,010,371...104,011,236 		JBrowse link
G Bgn biglycan increases expression
multiple interactions 		ISO trichostatin A results in increased expression of BGN mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BGN mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr  X:156,348,633...156,360,797
Ensembl chr  X:156,348,615...156,360,799 		JBrowse link
G Bhlhe40 basic helix-loop-helix family, member e40 increases expression
multiple interactions
affects expression 		ISO trichostatin A results in increased expression of BHLHE40 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BHLHE40 mRNA
trichostatin A affects the expression of BHLHE40 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 4:143,174,450...143,180,150
Ensembl chr 4:143,174,048...143,180,783 		JBrowse link
G Bhmt betaine-homocysteine S-methyltransferase increases expression ISO trichostatin A results in increased expression of BHMT mRNA CTD PMID:24935251 NCBI chr 2:26,594,852...26,614,429
Ensembl chr 2:26,594,854...26,614,715 		JBrowse link
G Bicd1 BICD cargo adaptor 1 decreases expression ISO trichostatin A results in decreased expression of BICD1 mRNA CTD PMID:24935251 NCBI chr 4:184,208,891...184,362,840
Ensembl chr 4:184,210,363...184,357,391 		JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions
increases expression
affects expression 		ISO trichostatin A promotes the reaction [CASP9 protein affects the localization of BID protein]
trichostatin A results in increased expression of BID mRNA
trichostatin A affects the expression of BID mRNA 		CTD PMID:12556448 PMID:24935251 PMID:28542535 NCBI chr 4:155,785,366...155,808,775
Ensembl chr 4:155,785,377...155,808,275 		JBrowse link
G Bik BCL2-interacting killer increases expression ISO trichostatin A results in increased expression of BIK mRNA CTD PMID:24935251 NCBI chr 7:116,552,303...116,571,317
Ensembl chr 7:116,552,303...116,571,317 		JBrowse link
G Birc3 baculoviral IAP repeat-containing 3 increases expression
multiple interactions
affects expression 		ISO trichostatin A results in increased expression of BIRC3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BIRC3 mRNA
trichostatin A affects the expression of BIRC3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 8:13,285,702...13,313,329
Ensembl chr 8:13,285,703...13,298,590 		JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions
decreases expression 		ISO decitabine inhibits the reaction [trichostatin A results in decreased expression of BIRC5 mRNA]
trichostatin A results in decreased expression of BIRC5 mRNA; trichostatin A results in decreased expression of BIRC5 protein 		CTD PMID:18718068 PMID:19606018 PMID:23770000 NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155 		JBrowse link
G Bivm basic, immunoglobulin-like variable motif containing increases expression
multiple interactions 		ISO trichostatin A results in increased expression of BIVM mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BIVM mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:53,760,885...53,797,125
Ensembl chr 9:53,761,331...53,797,118 		JBrowse link
G Blacat1 BLACAT1 overlapping LEMD1 locus decreases expression ISO trichostatin A results in decreased expression of BLACAT1 mRNA CTD PMID:26272509 NCBI chr13:46,189,091...46,202,506
Ensembl chr13:46,197,208...46,197,306 		JBrowse link
G Blcap BLCAP, apoptosis inducing factor decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of BLCAP mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BLCAP mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:166,642,676...166,656,924
Ensembl chr 3:166,642,677...166,652,829 		JBrowse link
G Bltp1 bridge-like lipid transfer protein family member 1 affects expression ISO trichostatin A affects the expression of BLTP1 mRNA CTD PMID:28542535 NCBI chr 2:121,636,181...121,852,802
Ensembl chr 2:121,636,323...121,852,802 		JBrowse link
G Blvra biliverdin reductase A decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of BLVRA mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BLVRA mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:134,793,397...134,819,367
Ensembl chr 3:134,794,203...134,819,785 		JBrowse link
G Bmal2 basic helix-loop-helix ARNT like 2 decreases expression ISO trichostatin A results in decreased expression of BMAL2 mRNA CTD PMID:24935251 NCBI chr 4:181,429,097...181,478,384
Ensembl chr 4:181,430,159...181,478,382 		JBrowse link
G Bmerb1 bMERB domain containing 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of BMERB1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BMERB1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:2,286,999...2,453,890
Ensembl chr10:2,287,000...2,453,728 		JBrowse link
G Bmf Bcl2 modifying factor affects expression ISO trichostatin A affects the expression of BMF mRNA CTD PMID:28542535 NCBI chr 3:125,953,466...125,974,087
Ensembl chr 3:125,953,466...125,974,258 		JBrowse link
G Bmi1 BMI1 proto-oncogene, polycomb ring finger multiple interactions
affects expression 		ISO [Decitabine co-treated with trichostatin A] results in increased expression of BMI1 mRNA; [Decitabine co-treated with trichostatin A] results in increased expression of BMI1 protein
trichostatin A affects the expression of BMI1 mRNA 		CTD PMID:17185465 PMID:28542535 NCBI chr17:86,240,683...86,250,044
Ensembl chr17:86,243,491...86,250,024 		JBrowse link
G Bmp2 bone morphogenetic protein 2 increases expression
multiple interactions 		ISO
EXP 		trichostatin A results in increased expression of BMP2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP2 mRNA
trichostatin A results in increased expression of BMP2 mRNA; trichostatin A results in increased expression of BMP2 protein 		CTD PMID:23562654 PMID:26272509 PMID:27188386 NCBI chr 3:141,264,648...141,275,416
Ensembl chr 3:141,264,646...141,274,760 		JBrowse link
G Bmp4 bone morphogenetic protein 4 increases expression
multiple interactions 		ISO
EXP 		trichostatin A results in increased expression of BMP4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP4 mRNA 		CTD PMID:23562654 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:22,098,191...22,113,145
Ensembl chr15:22,098,470...22,105,172 		JBrowse link
G Bmp5 bone morphogenetic protein 5 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of BMP5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 8:85,397,629...85,520,374
Ensembl chr 8:85,396,925...85,520,189 		JBrowse link
G Bmp6 bone morphogenetic protein 6 affects expression ISO trichostatin A affects the expression of BMP6 mRNA CTD PMID:28542535 NCBI chr17:26,523,704...26,785,558
Ensembl chr17:26,523,704...26,675,261 		JBrowse link
G Bmp7 bone morphogenetic protein 7 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of BMP7 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP7 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:182,059,318...182,135,273
Ensembl chr 3:182,052,337...182,135,137 		JBrowse link
G Bmper BMP-binding endothelial regulator increases expression
multiple interactions 		ISO trichostatin A results in increased expression of BMPER mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMPER mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 8:30,008,049...30,253,201
Ensembl chr 8:30,008,148...30,434,359 		JBrowse link
G Bmpr1b bone morphogenetic protein receptor type 1B increases expression
decreases expression 		ISO trichostatin A results in increased expression of BMPR1B mRNA
trichostatin A results in decreased expression of BMPR1B mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 2:233,211,525...233,544,344
Ensembl chr 2:233,211,525...233,544,311 		JBrowse link
G Bnc1 basonuclin zinc finger protein 1 increases expression ISO trichostatin A results in increased expression of BNC1 mRNA CTD PMID:24935251 NCBI chr 1:145,326,881...145,352,534
Ensembl chr 1:145,326,892...145,353,510 		JBrowse link
G Bnc2 basonuclin zinc finger protein 2 increases expression ISO trichostatin A results in increased expression of BNC2 mRNA CTD PMID:24935251 NCBI chr 5:103,724,934...104,061,890
Ensembl chr 5:103,724,934...104,125,428 		JBrowse link
G Bnip3 BCL2 interacting protein 3 increases expression ISO trichostatin A results in increased expression of BNIP3 mRNA CTD PMID:24935251 NCBI chr 1:203,137,778...203,154,962
Ensembl chr 1:203,137,778...203,154,962 		JBrowse link
G Bnipl BCL2 interacting protein like increases expression
multiple interactions 		ISO trichostatin A results in increased expression of BNIPL mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNIPL mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:185,507,591...185,519,415
Ensembl chr 2:185,507,593...185,517,582 		JBrowse link
G Boc BOC cell adhesion associated, oncogene regulated increases expression ISO trichostatin A results in increased expression of BOC mRNA CTD PMID:24935251 NCBI chr11:69,628,703...69,704,009
Ensembl chr11:69,628,660...69,704,004 		JBrowse link
G Bok BCL2 family apoptosis regulator BOK increases expression ISO trichostatin A results in increased expression of BOK mRNA CTD PMID:24935251 NCBI chr 9:101,670,729...101,681,834
Ensembl chr 9:101,670,625...101,681,833 		JBrowse link
G Borcs7 BLOC-1 related complex subunit 7 affects expression ISO trichostatin A affects the expression of BORCS7 mRNA CTD PMID:28542535 NCBI chr 1:255,505,745...255,519,579
Ensembl chr 1:255,505,745...255,518,815 		JBrowse link
G Bphl biphenyl hydrolase like affects expression ISO trichostatin A affects the expression of BPHL mRNA CTD PMID:28542535 NCBI chr17:31,006,283...31,042,631
Ensembl chr17:31,004,972...31,042,632 		JBrowse link
G Bptf bromodomain PHD finger transcription factor decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of BPTF mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BPTF mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:92,480,007...92,582,485
Ensembl chr10:92,480,007...92,582,413 		JBrowse link
G Braf B-Raf proto-oncogene, serine/threonine kinase decreases expression ISO trichostatin A results in decreased expression of BRAF mRNA CTD PMID:24935251 NCBI chr 4:69,329,772...69,476,931
Ensembl chr 4:69,342,813...69,476,931 		JBrowse link
G Brca1 BRCA1, DNA repair associated decreases expression ISO trichostatin A results in decreased expression of BRCA1 mRNA CTD PMID:23770000 NCBI chr10:86,917,693...86,978,012
Ensembl chr10:86,917,693...86,977,763 		JBrowse link
G Brca2 BRCA2, DNA repair associated decreases expression ISO trichostatin A results in decreased expression of BRCA2 mRNA CTD PMID:23770000 NCBI chr12:4,895,092...4,939,340
Ensembl chr12:4,895,447...4,936,194 		JBrowse link
G Brd2 bromodomain containing 2 multiple interactions
affects localization 		ISO trichostatin A inhibits the reaction [IL3 protein promotes the reaction [BRD2 protein binds to CISH promoter]]
trichostatin A affects the localization of BRD2 protein 		CTD PMID:25769527 NCBI chr20:4,728,282...4,737,286
Ensembl chr20:4,728,951...4,737,290 		JBrowse link
G Bri3bp Bri3 binding protein increases expression ISO trichostatin A results in increased expression of BRI3BP mRNA CTD PMID:24935251 PMID:26272509 NCBI chr12:36,838,098...36,849,919
Ensembl chr12:36,838,098...36,849,919 		JBrowse link
G Brinp1 BMP/retinoic acid inducible neural specific 1 multiple interactions
increases expression 		ISO [decitabine co-treated with trichostatin A] inhibits the reaction [sodium arsenite affects the methylation of BRINP1 promoter]
trichostatin A results in increased expression of BRINP1 mRNA 		CTD PMID:18448484 PMID:24935251 NCBI chr 5:87,363,621...87,565,580
Ensembl chr 5:87,364,050...87,508,256 		JBrowse link
G Brix1 biogenesis of ribosomes BRX1 multiple interactions
affects expression 		ISO trichostatin A inhibits the reaction [Nickel affects the expression of BRIX1 mRNA]
trichostatin A affects the expression of BRIX1 mRNA 		CTD PMID:14575637 PMID:28542535 NCBI chr 2:61,177,769...61,188,647
Ensembl chr 2:61,177,771...61,188,647 		JBrowse link
G Brms1 BRMS1, transcriptional repressor and anoikis regulator affects expression ISO trichostatin A affects the expression of BRMS1 mRNA CTD PMID:28542535 NCBI chr 1:211,775,142...211,784,411
Ensembl chr 1:211,775,095...211,784,410 		JBrowse link
G Bsg basigin affects expression ISO trichostatin A affects the expression of BSG mRNA CTD PMID:28542535 NCBI chr 7:10,643,788...10,651,005
Ensembl chr 7:10,643,789...10,651,005 		JBrowse link
G Bspry B-box and SPRY domain containing increases expression ISO trichostatin A results in increased expression of BSPRY mRNA CTD PMID:24935251 NCBI chr 5:80,942,974...80,965,157
Ensembl chr 5:80,942,979...80,988,154 		JBrowse link
G Btbd17 BTB domain containing 17 decreases expression ISO trichostatin A results in decreased expression of BTBD17 mRNA CTD PMID:24935251 NCBI chr10:100,325,177...100,331,669
Ensembl chr10:100,325,177...100,331,771 		JBrowse link
G Btbd8 BTB domain containing 8 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of BTBD8 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BTBD8 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr14:2,410,093...2,483,114
Ensembl chr14:2,410,093...2,479,202 		JBrowse link
G Btd biotinidase multiple interactions
increases expression 		ISO trichostatin A inhibits the reaction [chromium hexavalent ion results in decreased expression of BTD protein]
trichostatin A results in increased expression of BTD protein 		CTD PMID:21641978 NCBI chr16:6,869,448...6,900,711
Ensembl chr16:6,869,291...6,901,410 		JBrowse link
G Btf3l4 basic transcription factor 3-like 4 affects expression ISO trichostatin A affects the expression of BTF3L4 mRNA CTD PMID:28542535 NCBI chr 5:128,796,594...128,816,219
Ensembl chr 5:128,796,594...128,816,602 		JBrowse link
G Btg2 BTG anti-proliferation factor 2 affects expression ISO trichostatin A affects the expression of BTG2 mRNA CTD PMID:28542535 NCBI chr13:48,083,931...48,087,690
Ensembl chr13:48,083,931...48,087,690 		JBrowse link
G Btg3 BTG anti-proliferation factor 3 increases expression ISO trichostatin A results in increased expression of BTG3 mRNA CTD PMID:24935251 NCBI chr11:30,517,068...30,532,981
Ensembl chr11:30,517,072...30,533,082 		JBrowse link
G Btn2a2 butyrophilin, subfamily 2, member A2 affects expression ISO trichostatin A affects the expression of BTN2A2 mRNA CTD PMID:28542535 NCBI chr17:42,048,842...42,060,650
Ensembl chr17:42,048,842...42,060,650 		JBrowse link
G Btrc beta-transducin repeat containing E3 ubiquitin protein ligase affects expression ISO trichostatin A affects the expression of BTRC mRNA CTD PMID:28542535 NCBI chr 1:254,159,085...254,324,819
Ensembl chr 1:254,159,124...254,328,357 		JBrowse link
G Bub1 BUB1 mitotic checkpoint serine/threonine kinase decreases expression ISO trichostatin A results in decreased expression of BUB1 mRNA CTD PMID:24935251 NCBI chr 3:135,473,525...135,504,921
Ensembl chr 3:135,472,582...135,504,921 		JBrowse link
G Bud31 BUD31 homolog affects expression ISO trichostatin A affects the expression of BUD31 mRNA CTD PMID:28542535 NCBI chr12:14,576,602...14,584,132
Ensembl chr12:14,576,605...14,584,039 		JBrowse link
G C10h17orf100 similar to human chromosome 17 open reading frame 100 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of C17ORF100 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C17ORF100 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:57,339,186...57,342,233
Ensembl chr10:57,337,035...57,341,474 		JBrowse link
G C10h5orf47 similar to human chromosome 5 open reading frame 47 increases expression ISO trichostatin A results in increased expression of C5ORF47 mRNA CTD PMID:24935251 NCBI chr10:16,184,999...16,198,515
Ensembl chr10:16,184,999...16,198,419 		JBrowse link
G C11h22orf39 similar to human chromosome 22 open reading frame 39 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of C22ORF39 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C22ORF39 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr11:95,660,135...95,665,750
Ensembl chr11:95,663,881...95,664,588 		JBrowse link
G C11h3orf38 similar to human chromosome 3 open reading frame 38 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of C3ORF38 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C3ORF38 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:15,930,504...15,935,152
Ensembl chr11:15,783,138...15,935,152 		JBrowse link
G C11h3orf52 similar to human chromosome 3 open reading frame 52 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of C3ORF52 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C3ORF52 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr11:68,629,570...68,654,874
Ensembl chr11:68,629,570...68,654,868 		JBrowse link
G C11h3orf70 similar to human chromosome 3 open reading frame 70 increases expression ISO trichostatin A results in increased expression of C3ORF70 mRNA CTD PMID:24935251 NCBI chr11:92,850,327...92,900,608
Ensembl chr11:92,850,327...92,900,608 		JBrowse link
G C12h12orf76 similar to human chromosome 12 open reading frame 76 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of C12ORF76 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C12ORF76 mRNA 		CTD PMID:24935251 PMID:27188386 NCBI chr12:47,452,148...47,456,832
Ensembl chr12:47,452,016...47,456,829 		JBrowse link
G C13h1orf21 similar to human chromosome 1 open reading frame 21 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of C1ORF21 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1ORF21 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr13:66,540,245...66,749,631
Ensembl chr13:66,540,245...66,659,684 		JBrowse link
G C13h1orf226 similar to human chromosome 1 open reading frame 226 multiple interactions
decreases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1ORF226 mRNA
trichostatin A results in decreased expression of C1ORF226 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr13:85,063,350...85,071,435
Ensembl chr13:85,063,350...85,353,741 		JBrowse link
G C13h1orf53 similar to human chromosome 1 open reading frame 53 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of C1ORF53 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1ORF53 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr13:52,965,244...52,970,432
Ensembl chr13:52,965,244...52,970,607 		JBrowse link
G C15h8orf58 similar to human chromosome 8 open reading frame 58 decreases expression ISO trichostatin A results in decreased expression of C8ORF58 mRNA CTD PMID:24935251 NCBI chr15:51,638,336...51,645,141
Ensembl chr15:51,638,350...51,642,974 		JBrowse link
G C17h5orf24 similar to human chromosome 5 open reading frame 24 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of C5ORF24 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C5ORF24 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:8,928,209...8,938,126
Ensembl chr17:8,929,936...8,932,379 		JBrowse link
G C18h5orf46 similar to human chromosome 5 open reading frame 46 increases expression ISO trichostatin A results in increased expression of C5ORF46 mRNA CTD PMID:26705709 NCBI chr18:36,199,309...36,220,409
Ensembl chr18:36,199,309...36,220,409 		JBrowse link
G C19h16orf87 similar to human chromosome 16 open reading frame 87 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of C16ORF87 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C16ORF87 mRNA
trichostatin A affects the expression of C16ORF87 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr19:37,800,187...37,827,091
Ensembl chr19:37,799,799...37,827,452 		JBrowse link
G C1galt1 core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase, 1 increases expression ISO trichostatin A results in increased expression of C1GALT1 mRNA CTD PMID:24935251 NCBI chr 4:36,894,440...36,932,434
Ensembl chr 4:36,894,488...36,932,441 		JBrowse link
G C1galt1c1 C1GALT1-specific chaperone 1 decreases expression ISO trichostatin A results in decreased expression of C1GALT1C1 mRNA CTD PMID:24935251 NCBI chr  X:122,243,736...122,248,217
Ensembl chr  X:122,234,454...122,248,422 		JBrowse link
G C1h9orf40 similar to human chromosome 9 open reading frame 40 increases expression ISO trichostatin A results in increased expression of C9ORF40 mRNA CTD PMID:24935251 NCBI chr 1:225,555,300...225,559,509
Ensembl chr 1:225,555,280...225,559,693 		JBrowse link
G C1qtnf2 C1q and TNF related 2 increases expression ISO trichostatin A results in increased expression of C1QTNF2 mRNA CTD PMID:24935251 NCBI chr10:28,443,326...28,460,400
Ensembl chr10:28,443,425...28,460,395 		JBrowse link
G C1qtnf4 C1q and TNF related 4 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of C1QTNF4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1QTNF4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:97,310,220...97,328,818
Ensembl chr 3:97,327,670...97,342,587 		JBrowse link
G C1qtnf6 C1q and TNF related 6 multiple interactions ISO [decitabine co-treated with trichostatin A] inhibits the reaction [sodium arsenite affects the methylation of C1QTNF6 promoter] CTD PMID:18448484 NCBI chr 7:111,958,348...111,964,948
Ensembl chr 7:111,958,350...111,966,871 		JBrowse link
G C1rl complement C1r subcomponent like increases expression ISO trichostatin A results in increased expression of C1RL mRNA CTD PMID:24935251 NCBI chr 4:159,080,495...159,097,066
Ensembl chr 4:159,080,495...159,097,066 		JBrowse link
G C2cd2 C2 calcium-dependent domain containing 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of C2CD2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2CD2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr11:50,694,680...50,759,096
Ensembl chr11:50,694,563...50,759,016 		JBrowse link
G C2h3orf33 similar to human chromosome 3 open reading frame 33 decreases expression ISO trichostatin A results in decreased expression of C3ORF33 mRNA CTD PMID:26272509 NCBI chr 2:150,522,758...150,554,007
Ensembl chr 2:150,530,231...150,554,055 		JBrowse link
G C2h4orf33 similar to human chromosome 4 open reading frame 33 increases expression ISO trichostatin A results in increased expression of C4ORF33 mRNA CTD PMID:24935251 NCBI chr 2:126,692,176...126,769,183
Ensembl chr 2:126,697,854...126,746,878 		JBrowse link
G C2h5orf22 similar to human chromosome 5 open reading frame 22 decreases expression ISO trichostatin A results in decreased expression of C5ORF22 mRNA CTD PMID:24935251 NCBI chr 2:63,576,348...63,591,764
Ensembl chr 2:63,576,348...63,591,585 		JBrowse link
G C3h11orf96 similar to human chromosome 11 open reading frame 96 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of C11ORF96 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF96 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:100,375,474...100,376,717
Ensembl chr 3:100,351,199...100,378,346 		JBrowse link
G C4h12orf60 similar to human chromosome 12 open reading frame 60 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of C12ORF60 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C12ORF60 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:171,450,603...171,462,735
Ensembl chr 4:171,425,040...171,484,498 		JBrowse link
G C4h2orf68 similar to human chromosome 2 open reading frame 68 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of C2ORF68 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2ORF68 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:105,960,543...105,966,509
Ensembl chr 4:105,960,751...105,966,508 		JBrowse link
G C5h6orf163 similar to human chromosome 6 open reading frame 163 increases expression ISO trichostatin A results in increased expression of C6ORF163 mRNA CTD PMID:24935251 NCBI chr 5:54,113,073...54,132,787
Ensembl chr 5:54,112,859...54,126,074 		JBrowse link
G C5h8orf34 similar to human chromosome 8 open reading frame 34 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of C8ORF34 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C8ORF34 mRNA 		CTD PMID:24935251 PMID:27188386 NCBI chr 5:12,021,000...12,560,212
Ensembl chr 5:12,021,007...12,559,772 		JBrowse link
G C5h8orf88 similar to human chromosome 8 open reading frame 88 increases expression ISO trichostatin A results in increased expression of C8ORF88 mRNA CTD PMID:27188386 NCBI chr 5:33,127,385...33,152,914
Ensembl chr 5:33,126,632...33,174,768 		JBrowse link
G C6h14orf132 similar to human chromosome 14 open reading frame 132 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of C14ORF132 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C14ORF132 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:130,130,176...130,163,153
Ensembl chr 6:130,130,794...130,158,762 		JBrowse link
G C7h12orf56 similar to human chromosome 12 open reading frame 56 multiple interactions
increases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C12ORF56 mRNA
trichostatin A results in increased expression of C12ORF56 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:59,055,283...59,106,900
Ensembl chr 7:59,056,310...59,106,407 		JBrowse link
G C7h12orf75 similar to human chromosome 12 open reading frame 75 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of C12ORF75 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C12ORF75 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:21,902,745...21,945,704
Ensembl chr 7:21,902,745...21,945,748 		JBrowse link
G C7h8orf76 similar to human chromosome 8 open reading frame 76 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of C8ORF76 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C8ORF76 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:91,448,422...91,459,284
Ensembl chr 7:91,443,270...91,462,404 		JBrowse link
G C8h11orf52 similar to human chromosome 11 open reading frame 52 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of C11ORF52 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF52 mRNA 		CTD PMID:24935251 PMID:27188386 NCBI chr 8:59,977,717...59,984,706
Ensembl chr 8:59,976,623...59,990,901 		JBrowse link
G C8h11orf87 similar to human chromosome 11 open reading frame 87 increases expression ISO trichostatin A results in increased expression of C11ORF87 mRNA CTD PMID:24935251 NCBI chr 8:61,958,626...61,966,119
Ensembl chr 8:61,957,676...61,968,365 		JBrowse link
G C8h15orf61 similar to human chromosome 15 open reading frame 61 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of C15ORF61 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C15ORF61 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:72,763,513...72,768,248
Ensembl chr 8:72,757,256...72,768,748 		JBrowse link
G C9h6orf141 similar to human chromosome 6 open reading frame 141 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of C6ORF141 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C6ORF141 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 9:27,521,466...27,525,644
Ensembl chr 9:27,521,466...27,525,644 		JBrowse link
G Ca11 carbonic anhydrase 11 decreases expression ISO trichostatin A results in decreased expression of CA11 mRNA CTD PMID:24935251 NCBI chr 1:105,306,347...105,311,651
Ensembl chr 1:105,302,289...105,311,832 		JBrowse link
G Ca12 carbonic anhydrase 12 increases expression ISO trichostatin A results in increased expression of CA12 mRNA CTD PMID:24935251 NCBI chr 8:76,169,723...76,225,465
Ensembl chr 8:76,169,815...76,225,465 		JBrowse link
G Ca13 carbonic anhydrase 13 increases expression ISO trichostatin A results in increased expression of CA13 mRNA CTD PMID:24935251 NCBI chr 2:88,649,643...88,680,763
Ensembl chr 2:88,649,625...88,680,763 		JBrowse link
G Ca3 carbonic anhydrase 3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CA3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:88,491,666...88,501,299
Ensembl chr 2:88,491,670...88,500,524 		JBrowse link
G Ca4 carbonic anhydrase 4 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CA4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CA4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:70,325,102...70,333,916
Ensembl chr10:70,325,358...70,333,916 		JBrowse link
G Ca8 carbonic anhydrase 8 increases expression ISO trichostatin A results in increased expression of CA8 mRNA CTD PMID:24935251 NCBI chr 5:26,102,767...26,199,819
Ensembl chr 5:26,102,813...26,199,796 		JBrowse link
G Cab39l calcium binding protein 39-like decreases expression ISO trichostatin A results in decreased expression of CAB39L mRNA CTD PMID:24935251 NCBI chr15:37,782,778...37,885,191
Ensembl chr15:37,782,870...37,919,742 		JBrowse link
G Cabp7 calcium binding protein 7 increases expression ISO trichostatin A results in increased expression of CABP7 mRNA CTD PMID:24935251 NCBI chr14:83,822,322...83,832,667
Ensembl chr14:83,822,327...83,832,735 		JBrowse link
G Cachd1 cache domain containing 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CACHD1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACHD1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:120,527,224...120,752,685
Ensembl chr 5:120,526,770...120,772,877 		JBrowse link
G Cacna1a calcium voltage-gated channel subunit alpha1 A increases expression ISO trichostatin A results in increased expression of CACNA1A mRNA CTD PMID:24935251 NCBI chr19:40,425,560...40,724,810
Ensembl chr19:40,425,560...40,724,599 		JBrowse link
G Cacna1b calcium voltage-gated channel subunit alpha1 B increases expression ISO trichostatin A results in increased expression of CACNA1B mRNA CTD PMID:24935251 NCBI chr 3:27,779,133...27,944,292
Ensembl chr 3:27,779,166...27,944,285 		JBrowse link
G Cacna1g calcium voltage-gated channel subunit alpha1 G increases expression ISO trichostatin A results in increased expression of CACNA1G mRNA CTD PMID:24935251 PMID:28542535 NCBI chr10:79,851,886...79,919,926
Ensembl chr10:79,851,896...79,919,634 		JBrowse link
G Cacna2d1 calcium voltage-gated channel auxiliary subunit alpha2delta 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CACNA2D1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CACNA2D1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:19,902,324...20,330,287
Ensembl chr 4:19,905,764...20,330,147 		JBrowse link
G Cacna2d3 calcium voltage-gated channel auxiliary subunit alpha2delta 3 increases expression ISO trichostatin A results in increased expression of CACNA2D3 mRNA CTD PMID:24935251 NCBI chr16:4,105,048...4,919,037
Ensembl chr16:4,105,048...4,919,098 		JBrowse link
G Cacna2d4 calcium voltage-gated channel auxiliary subunit alpha2delta 4 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CACNA2D4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNA2D4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:154,080,877...154,197,369
Ensembl chr 4:154,080,877...154,193,778 		JBrowse link
G Cacnb3 calcium voltage-gated channel auxiliary subunit beta 3 affects expression ISO trichostatin A affects the expression of CACNB3 mRNA CTD PMID:28542535 NCBI chr 7:131,663,810...131,676,085
Ensembl chr 7:131,662,545...131,676,085 		JBrowse link
G Cacybp calcyclin binding protein increases expression
affects expression 		ISO trichostatin A results in increased expression of CACYBP mRNA
trichostatin A affects the expression of CACYBP mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr13:74,970,917...74,981,298
Ensembl chr13:74,970,923...74,981,505 		JBrowse link
G Cad carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase decreases expression ISO trichostatin A results in decreased expression of CAD mRNA CTD PMID:19606018 NCBI chr 6:31,012,091...31,035,098
Ensembl chr 6:31,012,091...31,035,297 		JBrowse link
G Cadm1 cell adhesion molecule 1 increases expression ISO trichostatin A results in increased expression of CADM1 mRNA CTD PMID:26272509 NCBI chr 8:56,744,374...57,075,264
Ensembl chr 8:56,744,372...57,080,192 		JBrowse link
G Cadm2 cell adhesion molecule 2 increases expression ISO trichostatin A results in increased expression of CADM2 mRNA CTD PMID:27188386 NCBI chr11:17,994,856...18,971,895
Ensembl chr11:17,994,856...18,971,448 		JBrowse link
G Cadm3 cell adhesion molecule 3 decreases expression ISO trichostatin A results in decreased expression of CADM3 mRNA CTD PMID:24935251 NCBI chr13:88,317,124...88,349,718
Ensembl chr13:88,317,124...88,350,114 		JBrowse link
G Cadm4 cell adhesion molecule 4 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of CADM4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CADM4 mRNA
trichostatin A affects the expression of CADM4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 1:89,203,089...89,225,345
Ensembl chr 1:89,202,554...89,225,345 		JBrowse link
G Cadps calcium dependent secretion activator decreases expression
increases expression 		ISO trichostatin A results in decreased expression of CADPS mRNA
trichostatin A results in increased expression of CADPS mRNA 		CTD PMID:24935251 PMID:26272509 NCBI chr15:14,719,078...15,173,218
Ensembl chr15:14,720,726...15,173,211 		JBrowse link
G Cadps2 calcium dependent secretion activator 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CADPS2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CADPS2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:52,746,054...53,275,252
Ensembl chr 4:52,746,065...53,275,004 		JBrowse link
G Cage1 cancer antigen 1 multiple interactions ISO [decitabine co-treated with trichostatin A] results in increased expression of CAGE1 mRNA CTD PMID:17891453 NCBI chr17:26,995,671...27,033,740
Ensembl chr17:26,995,078...27,033,754 		JBrowse link
G Calb1 calbindin 1 decreases expression ISO trichostatin A results in decreased expression of CALB1 mRNA CTD PMID:24935251 NCBI chr 5:34,172,612...34,199,555
Ensembl chr 5:34,172,664...34,200,160 		JBrowse link
G Calb2 calbindin 2 increases expression ISO trichostatin A results in increased expression of CALB2 mRNA CTD PMID:24935251 NCBI chr19:55,023,849...55,050,858
Ensembl chr19:55,023,838...55,057,952 		JBrowse link
G Calca calcitonin-related polypeptide alpha increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CALCA mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CALCA mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:178,312,636...178,317,588
Ensembl chr 1:178,312,638...178,317,529 		JBrowse link
G Calcb calcitonin-related polypeptide, beta increases expression ISO trichostatin A results in increased expression of CALCB mRNA CTD PMID:24935251 NCBI chr 1:178,399,634...178,404,654
Ensembl chr 1:178,399,785...178,404,654 		JBrowse link
G Calcoco1 calcium binding and coiled coil domain 1 affects expression ISO trichostatin A affects the expression of CALCOCO1 mRNA CTD PMID:28542535 NCBI chr 7:135,713,208...135,728,044
Ensembl chr 7:135,713,208...135,727,928 		JBrowse link
G Calcoco2 calcium binding and coiled-coil domain 2 decreases expression
affects expression 		ISO trichostatin A results in decreased expression of CALCOCO2 mRNA
trichostatin A affects the expression of CALCOCO2 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr10:81,552,084...81,568,266 JBrowse link
G Calcrl calcitonin receptor like receptor increases expression ISO trichostatin A results in increased expression of CALCRL mRNA CTD PMID:24935251 PMID:27188386 NCBI chr 3:89,835,071...89,932,616
Ensembl chr 3:89,835,077...89,887,350 		JBrowse link
G Cald1 caldesmon 1 increases expression ISO trichostatin A results in increased expression of CALD1 mRNA CTD PMID:24935251 PMID:26705709 NCBI chr 4:64,232,906...64,414,085
Ensembl chr 4:64,233,171...64,414,085 		JBrowse link
G Calu calumenin increases expression ISO trichostatin A results in increased expression of CALU mRNA CTD PMID:24935251 NCBI chr 4:58,914,456...58,941,957
Ensembl chr 4:58,914,421...58,941,956 		JBrowse link
G Camk1d calcium/calmodulin-dependent protein kinase ID decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CAMK1D mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAMK1D mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:77,491,191...77,892,018
Ensembl chr17:77,491,220...77,892,012 		JBrowse link
G Camk2a calcium/calmodulin-dependent protein kinase II alpha decreases expression
multiple interactions 		EXP trichostatin A results in decreased expression of CAMK2A mRNA
trichostatin A inhibits the reaction [Cisplatin results in decreased expression of CAMK2A mRNA] 		CTD PMID:23558232 NCBI chr18:56,648,779...56,711,505
Ensembl chr18:56,649,025...56,711,504 		JBrowse link
G Camk2b calcium/calmodulin-dependent protein kinase II beta multiple interactions EXP trichostatin A inhibits the reaction [Cisplatin results in decreased expression of CAMK2B mRNA] CTD PMID:23558232 NCBI chr14:85,059,166...85,148,121
Ensembl chr14:85,059,191...85,148,485 		JBrowse link
G Camk2n1 calcium/calmodulin-dependent protein kinase II inhibitor 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CAMK2N1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAMK2N1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:155,958,116...155,959,897
Ensembl chr 5:155,957,878...155,961,058 		JBrowse link
G Camk4 calcium/calmodulin-dependent protein kinase IV increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of CAMK4 mRNA
trichostatin A results in decreased expression of CAMK4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAMK4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr18:24,857,152...25,076,054
Ensembl chr18:24,857,146...25,077,193 		JBrowse link
G Camsap3 calmodulin regulated spectrin-associated protein family, member 3 decreases expression
affects expression 		ISO trichostatin A results in decreased expression of CAMSAP3 mRNA
trichostatin A affects the expression of CAMSAP3 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr12:6,440,959...6,464,582
Ensembl chr12:6,441,152...6,464,582 		JBrowse link
G Camta1 calmodulin binding transcription activator 1 increases expression ISO trichostatin A results in increased expression of CAMTA1 mRNA CTD PMID:24935251 NCBI chr 5:166,791,639...167,639,502
Ensembl chr 5:166,793,101...167,639,733 		JBrowse link
G Capn1 calpain 1 decreases expression EXP trichostatin A results in decreased expression of CAPN1 mRNA CTD PMID:23558232 NCBI chr 1:212,705,219...212,736,134
Ensembl chr 1:212,705,222...212,729,445 		JBrowse link
G Capn11 calpain 11 increases expression ISO trichostatin A results in increased expression of CAPN11 mRNA CTD PMID:28542535 NCBI chr 9:22,841,500...22,863,042
Ensembl chr 9:22,841,522...22,863,032 		JBrowse link
G Capn2 calpain 2 decreases expression EXP trichostatin A results in decreased expression of CAPN2 mRNA CTD PMID:23558232 NCBI chr13:96,681,902...96,732,625
Ensembl chr13:96,681,848...96,732,625 		JBrowse link
G Capn6 calpain 6 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CAPN6 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAPN6 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr  X:112,177,467...112,202,178
Ensembl chr  X:112,177,467...112,202,178 		JBrowse link
G Caprin1 cell cycle associated protein 1 affects expression ISO trichostatin A affects the expression of CAPRIN1 mRNA CTD PMID:28542535 NCBI chr 3:110,606,489...110,685,408
Ensembl chr 3:110,606,489...110,685,562 		JBrowse link
G Caps2 calcyphosine 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CAPS2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAPS2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:49,467,320...49,525,465
Ensembl chr 7:49,464,885...49,525,465 		JBrowse link
G Carf calcium responsive transcription factor decreases expression ISO trichostatin A results in decreased expression of CARF mRNA CTD PMID:24935251 NCBI chr 9:68,996,419...69,046,480
Ensembl chr 9:68,996,250...69,046,479 		JBrowse link
G Carhsp1 calcium regulated heat stable protein 1 affects expression ISO trichostatin A affects the expression of CARHSP1 mRNA CTD PMID:28542535 NCBI chr10:7,453,602...7,467,218
Ensembl chr10:7,452,978...7,467,770 		JBrowse link
G Carmn cardiac mesoderm enhancer-associated non-coding RNA increases expression ISO trichostatin A results in increased expression of CARMN mRNA CTD PMID:26705709 NCBI chr18:57,368,191...57,389,112
Ensembl chr18:57,360,134...57,389,921 		JBrowse link
G Cars1 cysteinyl-tRNA synthetase 1 decreases expression ISO trichostatin A results in decreased expression of CARS1 mRNA CTD PMID:24935251 NCBI chr 1:208,183,092...208,225,425
Ensembl chr 1:208,182,788...208,225,407 		JBrowse link
G Casd1 CAS1 domain containing 1 decreases expression
affects expression 		ISO trichostatin A results in decreased expression of CASD1 mRNA
trichostatin A affects the expression of CASD1 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 4:33,613,805...33,705,821
Ensembl chr 4:33,613,450...33,705,821 		JBrowse link
G Casp12 caspase 12 decreases expression EXP trichostatin A results in decreased expression of CASP12 mRNA CTD PMID:23558232 NCBI chr 8:10,927,188...10,954,442
Ensembl chr 8:10,926,994...10,954,442 		JBrowse link
G Casp3 caspase 3 multiple interactions
increases expression
increases cleavage
increases activity 		ISO
EXP 		[Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP3 protein; [Decitabine co-treated with trichostatin A] results in increased activity of CASP3 protein; [Genistein co-treated with trichostatin A] results in increased activity of CASP3 protein; [perifosine co-treated with trichostatin A] results in increased activity of CASP3 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP3 protein; EP300 protein affects the reaction [Quercetin promotes the reaction [trichostatin A results in increased activity of CASP3 protein]]; EP300 protein affects the reaction [trichostatin A results in increased activity of CASP3 protein]; Genistein promotes the reaction [trichostatin A results in increased activity of CASP3 protein]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [SLC39A6 mutant form inhibits the reaction [trichostatin A results in increased cleavage of CASP3 protein]]; NR4A1 protein promotes the reaction [trichostatin A results in increased cleavage of CASP3 protein]; Quercetin promotes the reaction [trichostatin A results in increased activity of CASP3 protein]; SLC39A6 mutant form inhibits the reaction [trichostatin A results in increased cleavage of CASP3 protein]; trichostatin A results in increased cleavage of and results in increased activity of CASP3 protein; Zinc inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [SLC39A6 mutant form inhibits the reaction [trichostatin A results in increased cleavage of CASP3 protein]]]
trichostatin A results in increased expression of CASP3 mRNA; trichostatin A results in increased expression of CASP3 protein modified form
ATG7 gene mutant form inhibits the reaction [trichostatin A inhibits the reaction [Cisplatin results in increased activity of CASP3 protein]]; ATG7 gene mutant form inhibits the reaction [trichostatin A inhibits the reaction [Cisplatin results in increased expression of CASP3 protein modified form]]; Chloroquine inhibits the reaction [trichostatin A inhibits the reaction [Cisplatin results in increased expression of CASP3 protein modified form]]; trichostatin A inhibits the reaction [Cisplatin results in increased activity of CASP3 protein]; trichostatin A inhibits the reaction [Cisplatin results in increased expression of CASP3 protein modified form]
Chloroquine inhibits the reaction [trichostatin A inhibits the reaction [Cisplatin results in increased activity of CASP3 protein]]; trichostatin A inhibits the reaction [Cisplatin results in increased activity of CASP3 protein] 		CTD PMID:15781658 PMID:16009488 PMID:16010430 PMID:16865256 PMID:16904634 More... NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732 		JBrowse link
G Casp4 caspase 4 decreases expression EXP trichostatin A results in decreased expression of CASP4 mRNA CTD PMID:23558232 NCBI chr 8:10,883,817...10,919,978
Ensembl chr 8:10,883,769...10,920,727 		JBrowse link
G Casp7 caspase 7 multiple interactions
decreases expression
increases expression 		ISO
EXP 		[Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP7 protein
trichostatin A results in decreased expression of CASP7 mRNA
trichostatin A results in increased expression of CASP7 mRNA 		CTD PMID:16904634 PMID:23558232 PMID:24935251 NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:265,442,676...265,482,512 		JBrowse link
G Casp8 caspase 8 multiple interactions
increases expression 		ISO [[Decitabine co-treated with trichostatin A] affects the methylation of CASP8 promoter] which affects the expression of CASP8 mRNA; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP8 protein; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CASP8 mRNA; [perifosine co-treated with trichostatin A] results in increased activity of CASP8 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP8 protein
trichostatin A results in increased expression of CASP8 mRNA 		CTD PMID:15781658 PMID:16904634 PMID:18819746 PMID:21345073 PMID:24935251 More... NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699 		JBrowse link
G Casp9 caspase 9 multiple interactions
affects expression 		ISO [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP9 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP9 protein; trichostatin A promotes the reaction [CASP9 protein affects the localization of BID protein]; trichostatin A results in increased cleavage of and results in increased activity of CASP9 protein
trichostatin A affects the expression of CASP9 mRNA 		CTD PMID:12556448 PMID:16010430 PMID:16904634 PMID:21345073 PMID:28542535 Ensembl chr 5:159,391,188...159,409,648 JBrowse link
G Cast calpastatin increases expression ISO trichostatin A results in increased expression of CAST mRNA CTD PMID:24935251 NCBI chr 2:5,707,633...5,817,213
Ensembl chr 2:5,707,640...5,817,180 		JBrowse link
G Castor1 cytosolic arginine sensor for mTORC1 subunit 1 affects expression ISO trichostatin A affects the expression of CASTOR1 mRNA CTD PMID:28542535 NCBI chr14:83,309,710...83,314,123
Ensembl chr14:83,309,504...83,314,127 		JBrowse link
G Castor2 cytosolic arginine sensor for mTORC1 subunit 2 affects expression ISO trichostatin A affects the expression of CASTOR2 mRNA CTD PMID:28542535 NCBI chr12:28,213,927...28,256,593
Ensembl chr12:28,213,935...28,256,593 		JBrowse link
G Casz1 castor zinc finger 1 increases expression ISO trichostatin A results in increased expression of CASZ1 mRNA CTD PMID:17940511 PMID:24935251 NCBI chr 5:164,527,083...164,677,037
Ensembl chr 5:164,527,112...164,677,014 		JBrowse link
G Cat catalase multiple interactions ISO CAT protein affects the reaction [trichostatin A promotes the reaction [SOD2 protein results in increased expression of MMP1 mRNA]] CTD PMID:24973648 NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526 		JBrowse link
G Cav1 caveolin 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CAV1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAV1 mRNA 		CTD PMID:24935251 PMID:26238599 PMID:26272509 PMID:27188386 NCBI chr 4:46,606,538...46,639,616
Ensembl chr 4:46,600,738...46,639,740 		JBrowse link
G Cav2 caveolin 2 increases expression ISO trichostatin A results in increased expression of CAV2 mRNA CTD PMID:24935251 NCBI chr 4:46,582,681...46,590,058
Ensembl chr 4:46,582,096...46,591,425 		JBrowse link
G Cavin2 caveolae associated protein 2 increases expression ISO trichostatin A results in increased expression of CAVIN2 mRNA CTD PMID:24935251 NCBI chr 9:57,794,007...57,806,024
Ensembl chr 9:57,794,019...57,806,024 		JBrowse link
G Cavin3 caveolae associated protein 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CAVIN3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAVIN3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:169,238,384...169,239,973
Ensembl chr 1:169,238,384...169,239,981 		JBrowse link
G Cbfb core-binding factor subunit beta affects expression ISO trichostatin A affects the expression of CBFB mRNA CTD PMID:28542535 NCBI chr19:49,955,133...50,002,661
Ensembl chr19:49,959,096...50,002,657 		JBrowse link
G Cblb Cbl proto-oncogene B decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CBLB mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CBLB mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr11:62,058,829...62,225,904
Ensembl chr11:62,061,653...62,225,778 		JBrowse link
G Cbln1 cerebellin 1 precursor increases expression ISO trichostatin A results in increased expression of CBLN1 mRNA CTD PMID:24935251 NCBI chr19:35,782,151...35,785,960
Ensembl chr19:35,781,952...35,785,960 		JBrowse link
G Cbr4 carbonyl reductase 4 increases expression ISO trichostatin A results in increased expression of CBR4 mRNA CTD PMID:24935251 NCBI chr16:33,625,734...33,695,067
Ensembl chr16:33,617,399...33,656,832 		JBrowse link
G Cbs cystathionine beta synthase increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CBS mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CBS mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr20:9,709,394...9,733,925
Ensembl chr20:9,709,395...9,734,066 		JBrowse link
G Cbx2 chromobox 2 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of CBX2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CBX2 mRNA
trichostatin A affects the expression of CBX2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr10:104,777,054...104,785,922
Ensembl chr10:104,777,056...104,785,926 		JBrowse link
G Cbx5 chromobox 5 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CBX5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CBX5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:136,203,827...136,254,575
Ensembl chr 7:136,211,649...136,229,118 		JBrowse link
G Cbx6 chromobox 6 affects expression ISO trichostatin A affects the expression of CBX6 mRNA CTD PMID:28542535 NCBI chr 7:113,253,364...113,263,413
Ensembl chr 7:113,253,364...113,263,413 		JBrowse link
G Cbx7 chromobox 7 increases expression ISO trichostatin A results in increased expression of CBX7 mRNA CTD PMID:24935251 NCBI chr 7:113,341,030...113,358,716
Ensembl chr 7:113,341,030...113,358,346 		JBrowse link
G Ccbe1 collagen and calcium binding EGF domains 1 increases expression ISO trichostatin A results in increased expression of CCBE1 mRNA CTD PMID:24935251 NCBI chr18:61,849,821...62,093,876
Ensembl chr18:61,853,149...62,094,075 		JBrowse link
G Ccdc110 coiled-coil domain containing 110 increases expression
decreases expression 		ISO trichostatin A results in increased expression of CCDC110 mRNA
trichostatin A results in decreased expression of CCDC110 mRNA 		CTD PMID:24935251 NCBI chr16:53,048,305...53,069,606
Ensembl chr16:53,047,965...53,069,777 		JBrowse link
G Ccdc12 coiled-coil domain containing 12 affects expression ISO trichostatin A affects the expression of CCDC12 mRNA CTD PMID:28542535 NCBI chr 8:119,513,007...119,564,802
Ensembl chr 8:119,514,094...119,564,802 		JBrowse link
G Ccdc126 coiled-coil domain containing 126 affects expression ISO trichostatin A affects the expression of CCDC126 mRNA CTD PMID:28542535 NCBI chr 4:79,628,483...79,649,513
Ensembl chr 4:79,628,412...79,649,508 		JBrowse link
G Ccdc136 coiled-coil domain containing 136 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CCDC136 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC136 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:58,963,196...58,992,962
Ensembl chr 4:58,962,908...58,992,975 		JBrowse link
G Ccdc148 coiled-coil domain containing 148 affects expression ISO trichostatin A affects the expression of CCDC148 mRNA CTD PMID:28542535 NCBI chr 3:63,765,656...64,040,802
Ensembl chr 3:63,765,668...64,040,757 		JBrowse link
G Ccdc149 coiled-coil domain containing 149 affects expression ISO trichostatin A affects the expression of CCDC149 mRNA CTD PMID:28542535 NCBI chr14:62,722,567...62,817,778
Ensembl chr14:62,722,600...62,817,777 		JBrowse link
G Ccdc15 coiled-coil domain containing 15 increases expression ISO trichostatin A results in increased expression of CCDC15 mRNA CTD PMID:24935251 NCBI chr 8:45,165,297...45,257,641
Ensembl chr 8:45,134,596...45,277,989 		JBrowse link
G Ccdc157 coiled-coil domain containing 157 affects expression ISO trichostatin A affects the expression of CCDC157 mRNA CTD PMID:28542535 NCBI chr14:83,236,010...83,255,012
Ensembl chr14:83,237,956...83,267,666 		JBrowse link
G Ccdc171 coiled-coil domain containing 171 decreases expression ISO trichostatin A results in decreased expression of CCDC171 mRNA CTD PMID:24935251 NCBI chr 5:102,965,763...103,449,740
Ensembl chr 5:102,965,911...103,533,290 		JBrowse link
G Ccdc172 coiled-coil domain containing 172 increases expression ISO trichostatin A results in increased expression of CCDC172 mRNA CTD PMID:24935251 NCBI chr 1:267,615,341...267,661,568
Ensembl chr 1:267,615,349...267,662,269 		JBrowse link
G Ccdc177 coiled-coil domain containing 177 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CCDC177 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC177 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:106,135,827...106,142,413
Ensembl chr 6:106,134,333...106,144,441 		JBrowse link
G Ccdc18 coiled-coil domain containing 18 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of CCDC18 mRNA
trichostatin A results in decreased expression of CCDC18 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC18 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr14:1,646,725...1,752,581
Ensembl chr14:1,646,809...1,750,470 		JBrowse link
G Ccdc181 coiled-coil domain containing 181 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CCDC181 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC181 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:79,157,708...79,171,365
Ensembl chr13:79,157,697...79,171,364 		JBrowse link
G Ccdc186 coiled-coil domain containing 186 decreases expression ISO trichostatin A results in decreased expression of CCDC186 mRNA CTD PMID:26272509 NCBI chr 1:265,840,429...265,878,082
Ensembl chr 1:265,843,039...265,877,131 		JBrowse link
G Ccdc22 coiled-coil domain containing 22 affects expression ISO trichostatin A affects the expression of CCDC22 mRNA CTD PMID:28542535 NCBI chr  X:17,570,184...17,582,130
Ensembl chr  X:17,535,659...17,582,130 		JBrowse link
G Ccdc28b coiled coil domain containing 28B decreases expression ISO trichostatin A results in decreased expression of CCDC28B mRNA CTD PMID:24935251 NCBI chr 5:147,246,627...147,251,629
Ensembl chr 5:147,246,628...147,251,629 		JBrowse link
G Ccdc3 coiled-coil domain containing 3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CCDC3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr17:77,941,148...78,044,820
Ensembl chr17:77,944,977...78,044,470 		JBrowse link
G Ccdc39 coiled-coil domain 39 molecular ruler complex subunit increases expression ISO trichostatin A results in increased expression of CCDC39 mRNA CTD PMID:24935251 NCBI chr 2:118,593,881...118,631,584
Ensembl chr 2:118,593,881...118,631,647 		JBrowse link
G Ccdc50 coiled-coil domain containing 50 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CCDC50 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC50 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr11:86,837,624...86,900,164
Ensembl chr11:86,837,624...86,899,980 		JBrowse link
G Ccdc68 coiled-coil domain containing 68 increases expression ISO trichostatin A results in increased expression of CCDC68 mRNA CTD PMID:24935251 NCBI chr18:65,817,232...65,859,529
Ensembl chr18:65,786,926...65,859,526 		JBrowse link
G Ccdc69 coiled-coil domain containing 69 increases expression ISO trichostatin A results in increased expression of CCDC69 mRNA CTD PMID:24935251 NCBI chr10:39,673,984...39,701,080
Ensembl chr10:39,673,985...39,700,579 		JBrowse link
G Ccdc80 coiled-coil domain containing 80 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CCDC80 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC80 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr11:69,191,188...69,224,844
Ensembl chr11:69,191,189...69,224,844 		JBrowse link
G Ccdc81 coiled-coil domain containing 81 increases expression ISO trichostatin A results in increased expression of CCDC81 mRNA CTD PMID:26705709 NCBI chr 1:153,152,032...153,203,586
Ensembl chr 1:153,152,034...153,203,984 		JBrowse link
G Ccdc82 coiled-coil domain containing 82 increases expression
affects expression 		ISO trichostatin A results in increased expression of CCDC82 mRNA
trichostatin A affects the expression of CCDC82 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 8:18,509,293...18,665,008
Ensembl chr 8:18,509,382...18,550,529 		JBrowse link
G Ccdc85a coiled-coil domain containing 85A increases expression ISO trichostatin A results in increased expression of CCDC85A mRNA CTD PMID:24935251 NCBI chr14:106,327,580...106,560,205
Ensembl chr14:106,327,580...106,560,165 		JBrowse link
G Ccdc88a coiled coil domain containing 88A decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CCDC88A mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC88A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:107,304,654...107,456,104
Ensembl chr14:107,305,199...107,453,285 		JBrowse link
G Ccdc90b coiled-coil domain containing 90B increases expression ISO trichostatin A results in increased expression of CCDC90B mRNA CTD PMID:24935251 NCBI chr 1:156,045,192...156,058,750
Ensembl chr 1:156,045,138...156,061,403 		JBrowse link
G Ccdc91 coiled-coil domain containing 91 multiple interactions
increases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC91 mRNA
trichostatin A results in increased expression of CCDC91 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:182,132,931...182,304,948
Ensembl chr 4:182,132,942...182,304,948 		JBrowse link
G Cck cholecystokinin decreases expression ISO trichostatin A results in decreased expression of CCK mRNA CTD PMID:24935251 NCBI chr 8:130,031,012...130,037,702
Ensembl chr 8:130,031,013...130,037,686 		JBrowse link
G Cckbr cholecystokinin B receptor decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CCKBR mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCKBR mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:169,183,578...169,193,583
Ensembl chr 1:169,183,194...169,193,745 		JBrowse link
G Ccl11 C-C motif chemokine ligand 11 multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of CCL11 mRNA] CTD PMID:14575637 NCBI chr10:67,525,975...67,530,576
Ensembl chr10:67,525,862...67,530,575 		JBrowse link
G Ccl26 C-C motif chemokine ligand 26 increases expression ISO trichostatin A results in increased expression of CCL26 mRNA CTD PMID:24935251 NCBI chr12:26,745,972...26,750,924 JBrowse link
G Ccm2l CCM2 like scaffold protein increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CCM2L mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCM2L mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:161,993,717...162,009,372
Ensembl chr 3:161,859,312...162,009,371 		JBrowse link
G Ccn1 cellular communication network factor 1 increases expression ISO trichostatin A results in increased expression of CCN1 mRNA CTD PMID:26705709 NCBI chr 2:237,222,730...237,225,689
Ensembl chr 2:237,222,432...237,225,883 		JBrowse link
G Ccn2 cellular communication network factor 2 increases expression ISO trichostatin A results in increased expression of CCN2 mRNA; trichostatin A results in increased expression of CTGF mRNA CTD PMID:19606018 PMID:26705709 NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:22,621,501...22,624,976 		JBrowse link
G Ccn3 cellular communication network factor 3 increases expression ISO trichostatin A results in increased expression of CCN3 mRNA CTD PMID:24935251 NCBI chr 7:87,983,788...87,990,810
Ensembl chr 7:87,982,216...87,994,581 		JBrowse link
G Ccna1 cyclin A1 multiple interactions
decreases expression
increases expression 		ISO trichostatin A inhibits the reaction [MECP2 protein binds to CCNA1 promoter]; trichostatin A promotes the reaction [H3-4 protein modified form binds to CCNA1 promoter]; trichostatin A promotes the reaction [H4C16 protein modified form binds to CCNA1 promoter]
trichostatin A results in decreased expression of CCNA1 mRNA
trichostatin A results in increased expression of CCNA1 mRNA 		CTD PMID:17698632 PMID:24935251 NCBI chr 2:141,383,352...141,428,205
Ensembl chr 2:141,382,468...141,393,300 		JBrowse link
G Ccna2 cyclin A2 decreases expression
affects expression 		ISO trichostatin A results in decreased expression of CCNA2 protein
trichostatin A affects the expression of CCNA2 mRNA 		CTD PMID:15179185 PMID:28542535 NCBI chr 2:121,355,363...121,361,762
Ensembl chr 2:121,355,363...121,361,701 		JBrowse link
G Ccnb1 cyclin B1 decreases expression ISO trichostatin A results in decreased expression of CCNB1 mRNA; trichostatin A results in decreased expression of CCNB1 protein CTD PMID:16009488 PMID:19606018 PMID:23770000 NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225 		JBrowse link
G Ccnb2 cyclin B2 decreases expression ISO trichostatin A results in decreased expression of CCNB2 mRNA CTD PMID:23770000 NCBI chr 8:79,968,459...79,981,717
Ensembl chr 8:79,968,465...79,981,682 		JBrowse link
G Ccnd1 cyclin D1 multiple interactions
decreases expression
increases expression 		ISO [3-deazaneplanocin co-treated with trichostatin A] affects the expression of CCND1 protein; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCND1 mRNA
trichostatin A results in decreased expression of CCND1 mRNA; trichostatin A results in decreased expression of CCND1 protein
trichostatin A results in increased expression of CCND1 mRNA
trichostatin A affects the reaction [Folic Acid affects the expression of CCND1 mRNA] 		CTD PMID:15179185 PMID:17431121 PMID:18538736 PMID:23770000 PMID:24935251 More... NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810 		JBrowse link
G Ccnd2 cyclin D2 increases expression
decreases expression 		ISO trichostatin A results in increased expression of CCND2 protein
trichostatin A results in decreased expression of CCND2 mRNA 		CTD PMID:16009488 PMID:26272509 PMID:26559563 NCBI chr 4:161,653,048...161,675,422
Ensembl chr 4:161,653,048...161,680,301
Ensembl chr 4:161,653,048...161,680,301 		JBrowse link
G Ccnd3 cyclin D3 multiple interactions ISO trichostatin A results in increased expression of and results in increased stability of CCND3 protein CTD PMID:15179185 NCBI chr 9:20,891,696...20,987,199
Ensembl chr 9:20,891,704...20,987,033 		JBrowse link
G Ccne1 cyclin E1 increases expression ISO trichostatin A results in increased expression of CCNE1 mRNA; trichostatin A results in increased expression of CCNE1 protein CTD PMID:15179185 PMID:24935251 NCBI chr 1:99,918,672...99,927,986
Ensembl chr 1:99,918,674...99,927,822 		JBrowse link
G Ccne2 cyclin E2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CCNE2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNE2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:29,082,169...29,094,879
Ensembl chr 5:29,082,703...29,094,882 		JBrowse link
G Ccng1 cyclin G1 affects expression ISO trichostatin A affects the expression of CCNG1 mRNA CTD PMID:28542535 NCBI chr10:25,678,503...25,684,876
Ensembl chr10:25,677,885...25,683,766 		JBrowse link
G Ccng2 cyclin G2 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of CCNG2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNG2 mRNA
trichostatin A affects the expression of CCNG2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr14:15,088,694...15,097,190
Ensembl chr14:15,088,695...15,096,206 		JBrowse link
G Ccnh cyclin H increases expression ISO trichostatin A results in increased expression of CCNH mRNA CTD PMID:23770000 NCBI chr 2:17,570,449...17,591,078
Ensembl chr 2:17,570,263...17,614,860 		JBrowse link
G Ccnj cyclin J affects expression ISO trichostatin A affects the expression of CCNJ mRNA CTD PMID:28542535 NCBI chr 1:249,608,991...249,626,798
Ensembl chr 1:249,608,969...249,626,794 		JBrowse link
G Ccnt1 cyclin T1 decreases expression ISO trichostatin A results in decreased expression of CCNT1 mRNA CTD PMID:24935251 NCBI chr 7:131,566,176...131,596,988
Ensembl chr 7:131,566,176...131,596,938 		JBrowse link
G Ccnt2 cyclin T2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CCNT2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNT2 mRNA 		CTD PMID:23770000 PMID:26272509 PMID:27188386 NCBI chr13:41,804,007...41,845,641
Ensembl chr13:41,804,046...41,844,488 		JBrowse link
G Ccnyl1 cyclin Y-like 1 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of CCNYL1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNYL1 mRNA
trichostatin A affects the expression of CCNYL1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 9:73,565,484...73,601,926
Ensembl chr 9:73,565,402...73,601,922 		JBrowse link
G Ccpg1 cell cycle progression 1 increases expression ISO trichostatin A results in increased expression of CCPG1 mRNA CTD PMID:24935251 NCBI chr 8:82,600,677...82,633,082
Ensembl chr 8:82,600,536...82,660,246 		JBrowse link
G Ccr2 C-C motif chemokine receptor 2 multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of CCR2 mRNA] CTD PMID:14575637 NCBI chr 8:132,611,883...132,619,106
Ensembl chr 8:132,611,410...132,620,059 		JBrowse link
G Ccr5 C-C motif chemokine receptor 5 multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of CCR5 mRNA] CTD PMID:14575637 NCBI chr 8:132,629,097...132,660,980
Ensembl chr 8:132,629,683...132,637,594 		JBrowse link
G Ccr6 C-C motif chemokine receptor 6 multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of CCR6 mRNA] CTD PMID:14575637 NCBI chr 1:55,022,037...55,055,857
Ensembl chr 1:55,021,833...55,046,059 		JBrowse link
G Ccs copper chaperone for superoxide dismutase affects expression ISO trichostatin A affects the expression of CCS mRNA CTD PMID:28542535 NCBI chr 1:211,543,192...211,564,354
Ensembl chr 1:211,542,701...211,564,260 		JBrowse link
G Ccser1 coiled-coil serine-rich protein 1 increases expression ISO trichostatin A results in increased expression of CCSER1 mRNA CTD PMID:24935251 NCBI chr 4:91,483,896...92,720,439
Ensembl chr 4:91,483,770...92,718,789 		JBrowse link
G Cd109 CD109 molecule increases expression ISO trichostatin A results in increased expression of CD109 mRNA CTD PMID:24935251 NCBI chr 8:88,334,736...88,449,463
Ensembl chr 8:88,334,736...88,449,462 		JBrowse link
G Cd14 CD14 molecule multiple interactions
increases expression 		ISO decitabine promotes the reaction [trichostatin A results in increased expression of CD14 mRNA] CTD PMID:18718068 NCBI chr18:28,609,558...28,611,409
Ensembl chr18:28,608,883...28,611,292 		JBrowse link
G Cd1d1 CD1d1 molecule increases expression ISO trichostatin A results in increased expression of CD1D mRNA CTD PMID:24935251 NCBI chr 2:174,721,522...174,725,029
Ensembl chr 2:174,721,522...174,725,029 		JBrowse link
G Cd24 CD24 molecule increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CD24 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD24 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr20:48,655,549...48,661,786
Ensembl chr20:48,655,805...48,661,785 		JBrowse link
G Cd274 CD274 molecule increases expression ISO trichostatin A results in increased expression of CD274 mRNA CTD PMID:26705709 NCBI chr 1:236,526,215...236,549,956
Ensembl chr 1:236,496,463...236,549,951 		JBrowse link
G Cd302 CD302 molecule increases expression ISO trichostatin A results in increased expression of CD302 mRNA CTD PMID:24935251 NCBI chr 3:65,131,017...65,164,737
Ensembl chr 3:65,113,102...65,164,737 		JBrowse link
G Cd36 CD36 molecule multiple interactions ISO trichostatin A inhibits the reaction [[bisphenol A affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of CD36 mRNA] CTD PMID:29718165 NCBI chr 4:18,209,088...18,302,142 JBrowse link
G Cd44 CD44 molecule multiple interactions
increases expression 		ISO [3-deazaneplanocin co-treated with trichostatin A] affects the expression of CD44 protein; trichostatin A inhibits the reaction [Nickel affects the expression of CD44 mRNA]
trichostatin A results in increased expression of CD44 mRNA 		CTD PMID:14575637 PMID:18538736 PMID:24935251 NCBI chr 3:109,610,824...109,699,776
Ensembl chr 3:109,612,054...109,699,424 		JBrowse link
G Cd46 CD46 molecule multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of CD46 mRNA] CTD PMID:14575637 NCBI chr13:109,104,122...109,134,903 JBrowse link
G Cd47 Cd47 molecule increases expression ISO trichostatin A results in increased expression of CD47 mRNA CTD PMID:24935251 NCBI chr11:64,374,816...64,438,763
Ensembl chr11:64,377,926...64,438,272 		JBrowse link
G Cd69 Cd69 molecule multiple interactions ISO trichostatin A inhibits the reaction [enterotoxin B, staphylococcal results in increased expression of CD69 protein] CTD PMID:24200994 NCBI chr 4:164,411,485...164,419,403
Ensembl chr 4:164,411,485...164,419,509 		JBrowse link
G Cd74 CD74 molecule increases expression ISO trichostatin A results in increased expression of CD74 mRNA CTD PMID:24935251 PMID:27188386 NCBI chr18:56,527,071...56,536,406
Ensembl chr18:56,527,132...56,536,410 		JBrowse link
G Cd83 CD83 molecule increases expression ISO trichostatin A results in increased expression of CD83 mRNA CTD PMID:24935251 NCBI chr17:21,093,281...21,113,223
Ensembl chr17:21,093,281...21,113,047 		JBrowse link
G Cd9 CD9 molecule increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CD9 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD9 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:26705709 PMID:27188386 NCBI chr 4:159,942,553...159,975,463
Ensembl chr 4:159,942,560...159,975,444 		JBrowse link
G Cd99 CD99 molecule (Xg blood group) increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CD99 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD99 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr20:56,000,494...56,005,140 JBrowse link
G Cdc14a cell division cycle 14A decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CDC14A mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDC14A mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:206,910,475...207,070,537
Ensembl chr 2:206,910,475...207,091,722 		JBrowse link
G Cdc14b cell division cycle 14B increases expression ISO trichostatin A results in increased expression of CDC14B mRNA CTD PMID:24935251 NCBI chr17:850,272...938,972
Ensembl chr17:850,390...971,164 		JBrowse link
G Cdc20 cell division cycle 20 decreases expression ISO trichostatin A results in decreased expression of CDC20 mRNA CTD PMID:23770000 NCBI chr 5:137,251,596...137,255,799
Ensembl chr 5:137,251,596...137,255,799 		JBrowse link
G Cdc25b cell division cycle 25B decreases expression ISO trichostatin A results in decreased expression of CDC25B mRNA CTD PMID:19606018 NCBI chr 3:138,860,148...138,870,287
Ensembl chr 3:138,860,130...138,870,492 		JBrowse link
G Cdc25c cell division cycle 25C decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CDC25C mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDC25C mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr18:26,608,483...26,630,292
Ensembl chr18:26,609,959...26,630,292 		JBrowse link
G Cdc27 cell division cycle 27 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CDC27 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDC27 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:89,900,676...89,949,770
Ensembl chr10:89,900,684...89,949,770 		JBrowse link
G Cdc40 cell division cycle 40 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CDC40 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDC40 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr20:45,855,739...45,908,239
Ensembl chr20:45,855,739...45,907,978 		JBrowse link
G Cdc42ep2 CDC42 effector protein 2 affects expression ISO trichostatin A affects the expression of CDC42EP2 mRNA CTD PMID:28542535 NCBI chr 1:212,631,317...212,640,231
Ensembl chr 1:212,629,881...212,640,234 		JBrowse link
G Cdc42ep3 CDC42 effector protein 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CDC42EP3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDC42EP3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:21,463,081...21,483,553
Ensembl chr 6:21,461,762...21,508,540 		JBrowse link
G Cdc42ep5 CDC42 effector protein 5 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CDC42EP5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDC42EP5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:79,108,036...79,110,550 JBrowse link
G Cdc42se1 CDC42 small effector 1 increases expression ISO trichostatin A results in increased expression of CDC42SE1 mRNA CTD PMID:24935251 NCBI chr 2:185,494,692...185,502,519
Ensembl chr 2:185,496,547...185,502,514 		JBrowse link
G Cdc5l cell division cycle 5-like decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CDC5L mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDC5L mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 9:23,062,397...23,100,901
Ensembl chr 9:23,062,205...23,100,899 		JBrowse link
G Cdc6 cell division cycle 6 affects expression ISO trichostatin A affects the expression of CDC6 mRNA CTD PMID:28542535 NCBI chr10:84,360,361...84,374,239
Ensembl chr10:84,360,381...84,374,241 		JBrowse link
G Cdc7 cell division cycle 7 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of CDC7 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDC7 mRNA
trichostatin A affects the expression of CDC7 mRNA 		CTD PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr14:2,949,538...2,969,656
Ensembl chr14:2,949,539...2,969,656 		JBrowse link
G Cdca2 cell division cycle associated 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CDCA2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDCA2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:46,071,360...46,117,524
Ensembl chr15:46,071,360...46,116,639 		JBrowse link
G Cdca7 cell division cycle associated 7 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CDCA7 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDCA7 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:77,730,315...77,740,950
Ensembl chr 3:77,729,970...77,740,947 		JBrowse link
G Cdca7l cell division cycle associated 7 like increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CDCA7L mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDCA7L mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:144,936,885...144,982,844
Ensembl chr 6:144,908,171...144,982,843 		JBrowse link
G Cdh1 cadherin 1 multiple interactions
increases expression 		ISO [[Decitabine co-treated with trichostatin A] affects the acetylation of H3-4 protein] which affects the expression of CDH1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH1 mRNA; [trichostatin A affects the acetylation of H3-4 protein] which affects the expression of CDH1 mRNA; trichostatin A inhibits the reaction [chromium hexavalent ion results in decreased expression of CDH1 protein]
trichostatin A results in increased expression of CDH1 mRNA; trichostatin A results in increased expression of CDH1 protein
trichostatin A inhibits the reaction [Folic Acid results in decreased expression of CDH1 mRNA]; trichostatin A inhibits the reaction [Folic Acid results in decreased expression of CDH1 protein] 		CTD PMID:18025290 PMID:18584348 PMID:23518002 PMID:24935251 PMID:26272509 More... NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565 		JBrowse link
G Cdh10 cadherin 10 increases expression ISO trichostatin A results in increased expression of CDH10 mRNA CTD PMID:24935251 NCBI chr 2:70,355,521...70,577,880
Ensembl chr 2:70,357,217...70,578,332 		JBrowse link
G Cdh11 cadherin 11 increases expression
decreases expression 		ISO trichostatin A results in increased expression of CDH11 mRNA
trichostatin A results in decreased expression of CDH11 mRNA; trichostatin A results in decreased expression of CDH11 protein 		CTD PMID:18025290 PMID:24935251 PMID:26272509 NCBI chr19:2,152,961...2,312,140
Ensembl chr19:2,154,840...2,312,140 		JBrowse link
G Cdh13 cadherin 13 multiple interactions ISO [trichostatin A affects the acetylation of CDH13 gene] which affects the expression of CDH13 mRNA CTD PMID:18553387 NCBI chr19:63,258,251...64,296,122
Ensembl chr19:63,258,122...64,296,119 		JBrowse link
G Cdh15 cadherin 15 affects expression ISO trichostatin A affects the expression of CDH15 mRNA CTD PMID:28542535 NCBI chr19:67,812,169...67,834,986
Ensembl chr19:67,812,164...67,834,985 		JBrowse link
G Cdh18 cadherin 18 increases expression ISO trichostatin A results in increased expression of CDH18 mRNA CTD PMID:24935251 NCBI chr 2:74,548,681...75,550,720
Ensembl chr 2:75,075,595...75,550,720 		JBrowse link
G Cdh19 cadherin 19 increases expression ISO trichostatin A results in increased expression of CDH19 mRNA CTD PMID:24935251 NCBI chr13:28,450,361...28,561,932
Ensembl chr13:28,451,283...28,533,753 		JBrowse link
G Cdh2 cadherin 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CDH2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr18:8,051,097...8,265,288
Ensembl chr18:8,051,097...8,265,288 		JBrowse link
G Cdh23 cadherin-related 23 increases expression ISO trichostatin A results in increased expression of CDH23 mRNA CTD PMID:24935251 NCBI chr20:28,783,124...29,165,624
Ensembl chr20:28,783,564...29,165,332 		JBrowse link
G Cdh3 cadherin 3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CDH3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr19:51,303,414...51,353,900
Ensembl chr19:51,300,083...51,354,257 		JBrowse link
G Cdh4 cadherin 4 decreases expression ISO trichostatin A results in decreased expression of CDH4 mRNA CTD PMID:24935251 NCBI chr 3:186,902,763...187,381,020
Ensembl chr 3:186,902,751...187,381,020 		JBrowse link
G Cdh6 cadherin 6 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CDH6 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH6 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:63,801,630...63,952,309
Ensembl chr 2:63,806,135...63,952,287 		JBrowse link
G Cdh7 cadherin 7 decreases expression ISO trichostatin A results in decreased expression of CDH7 mRNA CTD PMID:24935251 NCBI chr13:27,186,223...27,336,076
Ensembl chr13:27,187,257...27,336,023 		JBrowse link
G Cdh8 cadherin 8 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CDH8 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH8 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:26705709 PMID:27188386 NCBI chr19:5,494,552...5,901,950
Ensembl chr19:5,500,221...5,902,627 		JBrowse link
G Cdh9 cadherin 9 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CDH9 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH9 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:67,954,708...68,094,371
Ensembl chr 2:67,955,166...68,094,365 		JBrowse link
G Cdk1 cyclin-dependent kinase 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CDK1 mRNA
trichostatin A inhibits the reaction [Estradiol results in increased expression of CDK1 mRNA]; trichostatin A inhibits the reaction [Raloxifene Hydrochloride promotes the reaction [Estradiol results in increased expression of CDK1 mRNA]] 		CTD PMID:19606018 PMID:22476901 PMID:23770000 PMID:24935251 NCBI chr20:19,265,252...19,280,456
Ensembl chr20:19,265,289...19,280,455 		JBrowse link
G Cdk10 cyclin-dependent kinase 10 affects expression ISO trichostatin A affects the expression of CDK10 mRNA CTD PMID:28542535 NCBI chr19:68,168,040...68,184,923
Ensembl chr19:68,169,874...68,177,599 		JBrowse link
G Cdk14 cyclin-dependent kinase 14 decreases expression ISO trichostatin A results in decreased expression of CDK14 mRNA CTD PMID:26272509 NCBI chr 4:29,619,237...30,213,651
Ensembl chr 4:29,621,217...30,213,651 		JBrowse link
G Cdk19 cyclin-dependent kinase 19 decreases expression
multiple interactions
increases expression 		ISO trichostatin A results in decreased expression of CDK19 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDK19 mRNA
trichostatin A results in increased expression of CDK19 mRNA 		CTD PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr20:45,324,911...45,465,121
Ensembl chr20:45,324,862...45,465,121 		JBrowse link
G Cdk4 cyclin-dependent kinase 4 decreases expression ISO trichostatin A results in decreased expression of CDK4 mRNA CTD PMID:19606018 PMID:23770000 NCBI chr 7:64,771,453...64,774,891
Ensembl chr 7:64,771,147...64,775,163 		JBrowse link
G Cdk5r1 cyclin-dependent kinase 5 regulatory subunit 1 increases expression
multiple interactions
decreases expression 		ISO trichostatin A results in increased expression of CDK5R1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDK5R1 mRNA
trichostatin A results in decreased expression of CDK5R1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:33770205 NCBI chr10:65,981,692...65,985,831
Ensembl chr10:65,978,911...65,989,272 		JBrowse link
G Cdk6 cyclin-dependent kinase 6 decreases expression
increases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CDK6 mRNA
trichostatin A results in increased expression of CDK6 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDK6 mRNA 		CTD PMID:23770000 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:31,592,384...31,784,732
Ensembl chr 4:31,601,192...31,781,701 		JBrowse link
G Cdk7 cyclin-dependent kinase 7 affects expression ISO trichostatin A affects the expression of CDK7 mRNA CTD PMID:28542535 NCBI chr 2:33,574,623...33,599,485
Ensembl chr 2:33,574,623...33,599,485 		JBrowse link
G Cdk8 cyclin-dependent kinase 8 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CDK8 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDK8 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr12:13,851,024...13,919,017
Ensembl chr12:13,851,024...13,917,992 		JBrowse link
G Cdkl5 cyclin-dependent kinase-like 5 affects expression ISO trichostatin A affects the expression of CDKL5 mRNA CTD PMID:28542535 NCBI chr  X:37,566,320...37,796,766
Ensembl chr  X:37,566,378...37,796,760 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions
affects expression
increases expression 		ISO
EXP 		[decitabine co-treated with trichostatin A] affects the expression of CDKN1A mRNA; [decitabine co-treated with trichostatin A] results in increased expression of CDKN1A protein; [trichostatin A co-treated with Bortezomib] results in increased expression of CDKN1A mRNA; [trichostatin A co-treated with Bortezomib] results in increased expression of CDKN1A protein; Etoposide promotes the reaction [trichostatin A results in increased expression of CDKN1A protein]; Hydroxyurea inhibits the reaction [trichostatin A results in increased expression of CDKN1A protein]; MIR106B mRNA affects the reaction [trichostatin A affects the expression of CDKN1A protein]; MIR106B mRNA inhibits the reaction [trichostatin A results in increased expression of CDKN1A mRNA]; Tretinoin promotes the reaction [trichostatin A results in increased expression of CDKN1A mRNA]; Tretinoin promotes the reaction [trichostatin A results in increased expression of CDKN1A protein]; trichostatin A promotes the reaction [decitabine results in increased expression of CDKN1A mRNA]; trichostatin A promotes the reaction [decitabine results in increased expression of CDKN1A protein]; trichostatin A promotes the reaction [Etoposide results in increased expression of CDKN1A protein]
[trichostatin A affects the expression of DNMT3B protein] which affects the expression of CDKN1A mRNA; trichostatin A affects the expression of CDKN1A protein
trichostatin A inhibits the reaction [potassium bromate results in increased expression of CDKN1A protein]
trichostatin A results in increased expression of CDKN1A mRNA; trichostatin A results in increased expression of CDKN1A protein 		CTD PMID:15179185 PMID:16009488 PMID:16043219 PMID:16051188 PMID:16865256 More... NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969 		JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions
affects expression
increases expression 		ISO [decitabine co-treated with trichostatin A] results in increased expression of CDKN1B mRNA; Tretinoin promotes the reaction [trichostatin A results in increased expression of CDKN1B mRNA]; Tretinoin promotes the reaction [trichostatin A results in increased expression of CDKN1B protein]
[trichostatin A affects the expression of DNMT3B protein] which affects the expression of CDKN1B mRNA
trichostatin A results in increased expression of CDKN1B mRNA; trichostatin A results in increased expression of CDKN1B protein 		CTD PMID:17185465 PMID:17431121 PMID:18544619 PMID:23770000 NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:169,490,876...169,496,498 		JBrowse link
G Cdkn1c cyclin-dependent kinase inhibitor 1C increases expression
multiple interactions
decreases expression 		ISO trichostatin A results in increased expression of CDKN1C mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDKN1C mRNA
trichostatin A results in decreased expression of CDKN1C mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:208,084,801...208,087,680
Ensembl chr 1:208,084,787...208,087,498 		JBrowse link
G Cdkn2a cyclin-dependent kinase inhibitor 2A multiple interactions
decreases expression
increases expression 		ISO [[decitabine co-treated with trichostatin A] affects the methylation of CDKN2A promoter] which affects the expression of CDKN2A mRNA; [decitabine co-treated with trichostatin A] affects the expression of CDKN2A protein; [decitabine co-treated with trichostatin A] affects the methylation of CDKN2A promoter
trichostatin A results in decreased expression of CDKN2A mRNA
trichostatin A results in increased expression of CDKN2A mRNA; trichostatin A results in increased expression of CDKN2A protein 		CTD PMID:17019711 PMID:18069755 PMID:18813790 PMID:19606018 PMID:23770000 NCBI chr 5:109,100,763...109,114,448
Ensembl chr 5:109,100,772...109,119,248 		JBrowse link
G Cdkn2b cyclin-dependent kinase inhibitor 2B multiple interactions
increases expression 		ISO decitabine promotes the reaction [trichostatin A results in increased expression of CDKN2B mRNA] CTD PMID:18718068 NCBI chr 5:109,123,308...109,134,906
Ensembl chr 5:109,114,322...109,134,855 		JBrowse link
G Cdkn3 cyclin-dependent kinase inhibitor 3 increases expression ISO trichostatin A results in increased expression of CDKN3 mRNA CTD PMID:27188386 NCBI chr15:22,502,299...22,513,725
Ensembl chr15:22,502,382...22,513,722 		JBrowse link
G Cdon cell adhesion associated, oncogene regulated increases expression
multiple interactions
affects expression 		ISO trichostatin A results in increased expression of CDON mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDON mRNA
trichostatin A affects the expression of CDON mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 8:42,032,921...42,119,451
Ensembl chr 8:42,033,042...42,119,345 		JBrowse link
G Cds1 CDP-diacylglycerol synthase 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CDS1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDS1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr14:8,126,678...8,187,243
Ensembl chr14:8,124,838...8,187,218 		JBrowse link
G Cdv3 carnitine deficiency-associated gene expressed in ventricle 3 affects expression ISO trichostatin A affects the expression of CDV3 mRNA CTD PMID:28542535 NCBI chr 8:112,812,898...112,826,073
Ensembl chr 8:112,813,952...112,826,056 		JBrowse link
G Cdx2 caudal type homeo box 2 multiple interactions ISO trichostatin A promotes the reaction [decitabine results in increased expression of CDX2 mRNA] CTD PMID:16990345 NCBI chr12:12,762,769...12,769,246
Ensembl chr12:12,762,904...12,769,246 		JBrowse link
G Cdx4 caudal type homeo box 4 multiple interactions
increases expression 		ISO trichostatin A inhibits the reaction [Nickel affects the expression of CDX4 mRNA]
trichostatin A results in increased expression of CDX4 mRNA 		CTD PMID:14575637 PMID:27188386 NCBI chr  X:72,392,653...72,401,239
Ensembl chr  X:72,392,653...72,401,239 		JBrowse link
G Ceacam1 CEA cell adhesion molecule 1 increases expression ISO trichostatin A results in increased expression of CEACAM1 mRNA CTD PMID:24935251 NCBI chr 1:90,171,401...90,187,810
Ensembl chr 1:90,171,401...90,187,798 		JBrowse link
G Cebpb CCAAT/enhancer binding protein beta multiple interactions
increases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPB mRNA; trichostatin A inhibits the reaction [Lipopolysaccharides results in increased expression of CEBPB mRNA]
trichostatin A results in increased expression of CEBPB mRNA 		CTD PMID:21911040 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:176,816,859...176,838,072 		JBrowse link
G Cebpd CCAAT/enhancer binding protein delta multiple interactions
decreases expression
increases expression 		EXP
ISO 		Cisplatin inhibits the reaction [trichostatin A results in decreased expression of CEBPD mRNA]
trichostatin A results in increased expression of CEBPD mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPD mRNA 		CTD PMID:23558232 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr11:98,268,856...98,269,994
Ensembl chr11:98,265,651...98,280,824 		JBrowse link
G Cecr2 CECR2, histone acetyl-lysine reader decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CECR2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CECR2 mRNA 		CTD PMID:24935251 PMID:27188386 NCBI chr 4:155,562,576...155,670,253
Ensembl chr 4:155,562,727...155,666,741 		JBrowse link
G Celf2 CUGBP, Elav-like family member 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CELF2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CELF2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:75,813,928...76,639,300
Ensembl chr17:75,813,704...76,636,362 		JBrowse link
G Celf5 CUGBP, Elav-like family member 5 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of CELF5 mRNA
trichostatin A results in decreased expression of CELF5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CELF5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:8,876,551...8,901,078
Ensembl chr 7:8,876,564...8,901,069 		JBrowse link
G Celsr1 cadherin, EGF LAG seven-pass G-type receptor 1 decreases expression ISO trichostatin A results in decreased expression of CELSR1 mRNA CTD PMID:28542535 NCBI chr 7:118,867,450...119,004,859
Ensembl chr 7:118,867,450...119,004,856 		JBrowse link
G Celsr3 cadherin, EGF LAG seven-pass G-type receptor 3 increases expression ISO trichostatin A results in increased expression of CELSR3 mRNA CTD PMID:26705709 NCBI chr 8:118,409,136...118,438,593
Ensembl chr 8:118,409,136...118,436,847 		JBrowse link
G Cemip2 cell migration inducing hyaluronidase 2 decreases expression
multiple interactions
increases expression 		ISO trichostatin A results in decreased expression of CEMIP2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CEMIP2 mRNA
trichostatin A results in increased expression of CEMIP2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:33770205 NCBI chr 1:228,756,826...228,834,313
Ensembl chr 1:228,757,466...228,832,906 		JBrowse link
G Cenpb centromere protein B affects expression ISO trichostatin A affects the expression of CENPB mRNA CTD PMID:28542535 NCBI chr 3:138,850,003...138,852,796
Ensembl chr 3:138,841,679...138,854,372 		JBrowse link
G Cenph centromere protein H multiple interactions ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CENPH mRNA CTD PMID:27188386 NCBI chr 2:33,630,738...33,644,258
Ensembl chr 2:33,630,738...33,644,242 		JBrowse link
G Cenpi centromere protein I affects expression ISO trichostatin A affects the expression of CENPI mRNA CTD PMID:28542535 NCBI chr  X:101,809,192...101,860,935
Ensembl chr  X:101,809,659...101,860,934 		JBrowse link
G Cenpq centromere protein Q decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CENPQ mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CENPQ mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:27,454,339...27,469,371
Ensembl chr 9:27,454,252...27,469,366 		JBrowse link
G Cenpu centromere protein U decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CENPU mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CENPU mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:52,448,446...52,471,662
Ensembl chr16:52,425,096...52,471,662 		JBrowse link
G Cenpv centromere protein V decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CENPV mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CENPV mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:47,713,778...47,746,800
Ensembl chr10:47,713,778...47,727,679 		JBrowse link
G Cep112 centrosomal protein 112 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CEP112 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CEP112 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:93,865,630...94,332,679
Ensembl chr10:93,865,699...94,332,680 		JBrowse link
G Cep126 centrosomal protein 126 multiple interactions
increases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP126 mRNA
trichostatin A results in increased expression of CEP126 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 8:13,485,211...13,552,711
Ensembl chr 8:13,490,685...13,552,221 		JBrowse link
G Cep15 centrosomal protein 15 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CEP15 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP15 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:15,247,627...15,265,560
Ensembl chr15:15,247,932...15,265,475 		JBrowse link
G Cep19 centrosomal protein 19 affects expression ISO trichostatin A affects the expression of CEP19 mRNA CTD PMID:28542535 NCBI chr11:82,182,868...82,192,134
Ensembl chr11:82,182,868...82,192,032 		JBrowse link
G Cep350 centrosomal protein 350 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CEP350 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CEP350 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:70,573,597...70,714,673
Ensembl chr13:70,573,597...70,714,673 		JBrowse link
G Cep55 centrosomal protein 55 affects expression ISO trichostatin A affects the expression of CEP55 mRNA CTD PMID:28542535 NCBI chr 1:245,245,272...245,260,835
Ensembl chr 1:245,245,306...245,260,890 		JBrowse link
G Cep57 centrosomal protein 57 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CEP57 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CEP57 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:18,951,179...18,971,205
Ensembl chr 8:18,932,808...18,970,890 		JBrowse link
G Cep68 centrosomal protein 68 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of CEP68 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CEP68 mRNA
trichostatin A affects the expression of CEP68 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr14:98,649,993...98,671,892
Ensembl chr14:98,649,993...98,671,868 		JBrowse link
G Cep70 centrosomal protein 70 decreases expression
multiple interactions
increases expression 		ISO trichostatin A results in decreased expression of CEP70 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CEP70 mRNA
trichostatin A results in increased expression of CEP70 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 8:108,689,562...108,742,620
Ensembl chr 8:108,689,671...108,742,617 		JBrowse link
G Cep76 centrosomal protein 76 affects expression ISO trichostatin A affects the expression of CEP76 mRNA CTD PMID:28542535 NCBI chr18:63,444,389...63,478,358
Ensembl chr18:63,443,746...63,478,358 		JBrowse link
G Cep85l centrosomal protein 85-like increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CEP85L mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP85L mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:33,111,114...33,282,182
Ensembl chr20:33,115,438...33,282,238 		JBrowse link
G Cep89 centrosomal protein 89 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CEP89 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CEP89 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:97,195,116...97,237,015
Ensembl chr 1:97,195,135...97,237,016 		JBrowse link
G Cept1 choline/ethanolamine phosphotransferase 1 increases expression ISO trichostatin A results in increased expression of CEPT1 mRNA CTD PMID:24935251 NCBI chr 2:196,682,455...196,724,430
Ensembl chr 2:196,681,681...196,723,812 		JBrowse link
G Cerk ceramide kinase decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CERK mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CERK mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:119,105,674...119,149,885
Ensembl chr 7:119,105,674...119,148,570 		JBrowse link
G Cers6 ceramide synthase 6 decreases expression ISO trichostatin A results in decreased expression of LASS6 mRNA CTD PMID:24935251 NCBI chr 3:74,038,520...74,287,544
Ensembl chr 3:74,038,851...74,287,544 		JBrowse link
G Cetn2 centrin 2 affects expression ISO trichostatin A affects the expression of CETN2 mRNA CTD PMID:28542535 NCBI chr  X:155,812,212...155,817,186
Ensembl chr  X:155,812,003...155,817,744 		JBrowse link
G Cfap184 cilia and flagella associated protein 184 affects expression ISO trichostatin A affects the expression of CFAP184 mRNA CTD PMID:28542535 NCBI chr14:78,501,256...78,503,715
Ensembl chr14:78,486,414...78,507,808 		JBrowse link
G Cfap20dc CFAP20 domain containing increases expression ISO trichostatin A results in increased expression of CFAP20DC mRNA CTD PMID:24935251 PMID:27188386 NCBI chr15:18,661,562...18,907,226
Ensembl chr15:18,661,508...18,907,225 		JBrowse link
G Cfap210 cilia and flagella associated protein 210 affects expression ISO trichostatin A affects the expression of CFAP210 mRNA CTD PMID:28542535 NCBI chr 3:74,928,368...74,962,508
Ensembl chr 3:74,927,880...74,962,497 		JBrowse link
G Cfap263 cilia and flagella associated protein 263 increases expression
decreases expression 		ISO trichostatin A results in increased expression of CFAP263 mRNA
trichostatin A results in decreased expression of CFAP263 mRNA 		CTD PMID:24935251 NCBI chr19:9,503,062...9,522,957
Ensembl chr19:9,503,066...9,522,957 		JBrowse link
G Cfap300 cilia and flagella associated protein 300 increases expression ISO trichostatin A results in increased expression of CFAP300 mRNA CTD PMID:24935251 NCBI chr 8:13,465,016...13,483,679
Ensembl chr 8:13,464,984...13,483,839 		JBrowse link
G Cfap44 cilia and flagella associated protein 44 increases expression ISO trichostatin A results in increased expression of CFAP44 mRNA CTD PMID:24935251 NCBI chr11:69,704,997...69,789,998
Ensembl chr11:69,705,719...69,789,905 		JBrowse link
G Cfap91 cilia and flagella associated protein 91 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CFAP91 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP91 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:75,919,129...75,962,786
Ensembl chr11:75,919,142...75,962,785 		JBrowse link
G Cfap95 cilia and flagella associated protein 95 increases expression ISO trichostatin A results in increased expression of CFAP95 mRNA CTD PMID:24935251 NCBI chr 1:230,558,329...230,669,479
Ensembl chr 1:230,558,331...230,669,479 		JBrowse link
G Cfap96 cilia and flagella associated protein 96 increases expression ISO trichostatin A results in increased expression of CFAP96 mRNA CTD PMID:24935251 NCBI chr16:53,023,623...53,048,176
Ensembl chr16:53,023,878...53,048,965 		JBrowse link
G Cfap97 cilia and flagella associated protein 97 decreases expression ISO trichostatin A results in decreased expression of CFAP97 mRNA CTD PMID:24935251 NCBI chr16:52,818,693...52,867,775
Ensembl chr16:52,818,697...52,868,061 		JBrowse link
G Cfdp1 craniofacial development protein 1 increases expression ISO trichostatin A results in increased expression of CFDP1 mRNA CTD PMID:24935251 NCBI chr19:56,627,596...56,733,099
Ensembl chr19:56,626,963...56,733,098 		JBrowse link
G Cfh complement factor H increases expression ISO trichostatin A results in increased expression of CFH mRNA CTD PMID:24935251 NCBI chr13:54,063,079...54,164,523
Ensembl chr13:54,062,531...54,164,532 		JBrowse link
G Cfl2 cofilin 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CFL2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFL2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:78,090,843...78,094,888
Ensembl chr 6:78,090,843...78,094,888 		JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator decreases expression ISO trichostatin A results in decreased expression of CFLAR mRNA CTD PMID:28542535 NCBI chr 9:67,679,502...67,747,226
Ensembl chr 9:67,679,559...67,726,434 		JBrowse link
G Cftr CF transmembrane conductance regulator increases expression ISO trichostatin A results in increased expression of CFTR mRNA CTD PMID:24935251 NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:47,526,735...47,694,643 		JBrowse link
G Cga glycoprotein hormones, alpha polypeptide increases expression ISO trichostatin A results in increased expression of CGA mRNA CTD PMID:24935251 NCBI chr 5:54,283,109...54,295,464
Ensembl chr 5:54,235,019...54,295,464 		JBrowse link
G Cgnl1 cingulin-like 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CGNL1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CGNL1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 8:81,154,169...81,305,598
Ensembl chr 8:81,140,091...81,305,747 		JBrowse link
G Cgrrf1 cell growth regulator with ring finger domain 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CGRRF1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CGRRF1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:22,560,902...22,588,815
Ensembl chr15:22,568,332...22,588,811 		JBrowse link
G Chac1 ChaC glutathione-specific gamma-glutamylcyclotransferase 1 affects expression ISO trichostatin A affects the expression of CHAC1 mRNA CTD PMID:28542535 NCBI chr 3:126,796,131...126,799,352
Ensembl chr 3:126,796,024...126,799,361 		JBrowse link
G Chchd2 coiled-coil-helix-coiled-coil-helix domain containing 2 increases expression ISO trichostatin A results in increased expression of CHCHD2 mRNA CTD PMID:24935251 NCBI chr12:32,464,847...32,470,871
Ensembl chr12:32,464,824...32,470,871 		JBrowse link
G Chchd4 coiled-coil-helix-coiled-coil-helix domain containing 4 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CHCHD4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHCHD4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:125,525,428...125,534,562
Ensembl chr 4:125,525,429...125,534,562
Ensembl chr 1:125,525,429...125,534,562 		JBrowse link
G Chchd7 coiled-coil-helix-coiled-coil-helix domain containing 7 increases expression ISO trichostatin A results in increased expression of CHCHD7 mRNA CTD PMID:24935251 NCBI chr 5:21,754,719...21,759,274
Ensembl chr 5:21,754,719...21,759,274 		JBrowse link
G Chd1l chromodomain helicase DNA binding protein 1-like increases expression
affects expression 		ISO trichostatin A results in increased expression of CHD1L mRNA
trichostatin A affects the expression of CHD1L mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 2:187,819,869...187,906,359
Ensembl chr 2:187,811,954...187,890,477 		JBrowse link
G Chd2 chromodomain helicase DNA binding protein 2 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of CHD2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CHD2 mRNA
trichostatin A affects the expression of CHD2 mRNA 		CTD PMID:24935251 PMID:27188386 PMID:28542535 NCBI chr 1:136,597,993...136,726,874
Ensembl chr 1:136,599,900...136,710,335 		JBrowse link
G Chd6 chromodomain helicase DNA binding protein 6 decreases expression ISO trichostatin A results in decreased expression of CHD6 mRNA CTD PMID:24935251 NCBI chr 3:170,016,204...170,177,480
Ensembl chr 3:170,016,204...170,177,558 		JBrowse link
G Chd9 chromodomain helicase DNA binding protein 9 increases expression ISO trichostatin A results in increased expression of CHD9 mRNA CTD PMID:24935251 NCBI chr19:32,114,379...32,337,488
Ensembl chr19:32,115,920...32,319,042 		JBrowse link
G Chek1 checkpoint kinase 1 decreases expression ISO trichostatin A results in decreased expression of CHEK1 mRNA CTD PMID:23770000 NCBI chr 8:44,609,417...44,629,867
Ensembl chr 8:44,609,417...44,629,359 		JBrowse link
G Chek2 checkpoint kinase 2 decreases expression ISO trichostatin A results in decreased expression of CHEK2 mRNA CTD PMID:23770000 NCBI chr12:51,448,838...51,481,159
Ensembl chr12:51,449,140...51,480,667 		JBrowse link
G Chgb chromogranin B increases expression ISO trichostatin A results in increased expression of CHGB mRNA CTD PMID:24935251 NCBI chr 3:140,496,712...140,510,057
Ensembl chr 3:140,495,951...140,510,054 		JBrowse link
G Chi3l1 chitinase 3 like 1 decreases expression ISO trichostatin A results in decreased expression of CHI3L1 mRNA CTD PMID:24935251 PMID:26272509 NCBI chr13:48,193,839...48,201,822
Ensembl chr13:48,193,800...48,201,825 		JBrowse link
G Chka choline kinase alpha affects expression ISO trichostatin A affects the expression of CHKA mRNA CTD PMID:28542535 NCBI chr 1:210,506,069...210,554,753
Ensembl chr 1:210,506,056...210,554,752 		JBrowse link
G Chl1 cell adhesion molecule L1-like multiple interactions
increases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHL1 mRNA; trichostatin A inhibits the reaction [Nickel affects the expression of CHL1 mRNA]
trichostatin A results in increased expression of CHL1 mRNA 		CTD PMID:14575637 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:137,847,648...138,062,077
Ensembl chr 4:137,847,895...138,062,077 		JBrowse link
G Chm CHM Rab escort protein increases expression ISO trichostatin A results in increased expression of CHM mRNA CTD PMID:24935251 NCBI chr  X:82,395,463...82,554,249
Ensembl chr  X:82,396,816...82,568,642 		JBrowse link
G Chmp1b charged multivesicular body protein 1B affects expression ISO trichostatin A affects the expression of CHMP1B mRNA CTD PMID:28542535 NCBI chr18:63,010,270...63,012,800
Ensembl chr18:63,010,251...63,011,415 		JBrowse link
G Chmp3 charged multivesicular body protein 3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CHMP3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHMP3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:105,134,860...105,180,862
Ensembl chr 4:105,134,755...105,182,262 		JBrowse link
G Chn1 chimerin 1 decreases expression ISO trichostatin A results in decreased expression of CHN1 mRNA CTD PMID:24935251 NCBI chr 3:78,917,329...79,084,040
Ensembl chr 3:78,917,329...79,084,197 		JBrowse link
G Chn2 chimerin 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHN2 mRNA
trichostatin A results in increased expression of CHN2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:84,478,989...84,738,068
Ensembl chr 4:84,704,862...84,738,068 		JBrowse link
G Chodl chondrolectin decreases expression ISO trichostatin A results in decreased expression of CHODL mRNA CTD PMID:26705709 NCBI chr11:31,141,030...31,163,342
Ensembl chr11:31,141,021...31,163,334 		JBrowse link
G Chp1 calcineurin-like EF-hand protein 1 affects expression ISO trichostatin A affects the expression of CHP1 mRNA CTD PMID:28542535 NCBI chr 3:126,989,800...127,025,071
Ensembl chr 3:126,989,579...127,042,443 		JBrowse link
G Chpt1 choline phosphotransferase 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CHPT1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHPT1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:24,753,880...24,802,529
Ensembl chr 7:24,750,343...24,802,521 		JBrowse link
G Chrac1 chromatin accessibility complex subunit 1 affects expression ISO trichostatin A affects the expression of CHRAC1 mRNA CTD PMID:28542535 NCBI chr 7:106,901,841...106,905,441 JBrowse link
G Chrdl1 chordin-like 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CHRDL1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CHRDL1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:111,685,864...111,789,684
Ensembl chr  X:111,685,866...111,789,661 		JBrowse link
G Chrm3 cholinergic receptor, muscarinic 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRM3 mRNA
trichostatin A results in increased expression of CHRM3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr17:64,696,549...65,158,622
Ensembl chr17:64,696,066...65,173,304 		JBrowse link
G Chrm4 cholinergic receptor, muscarinic 4 multiple interactions
affects expression 		ISO trichostatin A inhibits the reaction [Nickel affects the expression of CHRM4 mRNA]
trichostatin A affects the expression of CHRM4 mRNA 		CTD PMID:14575637 PMID:28542535 NCBI chr 3:98,349,080...98,356,821
Ensembl chr 3:98,348,650...98,358,771 		JBrowse link
G Chrna3 cholinergic receptor nicotinic alpha 3 subunit increases expression ISO trichostatin A results in increased expression of CHRNA3 mRNA CTD PMID:24935251 NCBI chr 8:64,297,755...64,311,251
Ensembl chr 8:64,297,755...64,311,412 		JBrowse link
G Chrna5 cholinergic receptor nicotinic alpha 5 subunit decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CHRNA5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CHRNA5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:64,265,879...64,294,233
Ensembl chr 8:64,265,879...64,294,233 		JBrowse link
G Chrna9 cholinergic receptor nicotinic alpha 9 subunit increases expression ISO trichostatin A results in increased expression of CHRNA9 mRNA CTD PMID:24935251 NCBI chr14:42,588,948...42,595,669
Ensembl chr14:42,588,948...42,595,669 		JBrowse link
G Chst15 carbohydrate sulfotransferase 15 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CHST15 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHST15 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:196,458,978...196,540,088
Ensembl chr 1:196,460,425...196,491,444 		JBrowse link
G Chst3 carbohydrate sulfotransferase 3 increases expression ISO trichostatin A results in increased expression of CHST3 mRNA CTD PMID:24935251 NCBI chr20:28,657,308...28,694,976
Ensembl chr20:28,657,308...28,694,526 		JBrowse link
G Chst4 carbohydrate sulfotransferase 4 increases expression ISO trichostatin A results in increased expression of CHST4 mRNA CTD PMID:24935251 NCBI chr19:54,900,914...54,911,735
Ensembl chr19:54,882,719...54,916,648 		JBrowse link
G Chst6 carbohydrate sulfotransferase 6 increases expression ISO trichostatin A results in increased expression of CHST6 mRNA CTD PMID:24935251 NCBI chr19:56,769,991...56,790,276
Ensembl chr19:56,769,967...56,790,306 		JBrowse link
G Chst9 carbohydrate sulfotransferase 9 increases expression ISO trichostatin A results in increased expression of CHST9 mRNA CTD PMID:24935251 NCBI chr18:6,850,874...7,125,222
Ensembl chr18:6,851,831...7,125,161 		JBrowse link
G Chsy1 chondroitin sulfate synthase 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CHSY1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHSY1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:129,100,088...129,161,167
Ensembl chr 1:129,100,041...129,161,081 		JBrowse link
G Chsy3 chondroitin sulfate synthase 3 increases expression ISO trichostatin A results in increased expression of CHSY3 mRNA CTD PMID:24935251 NCBI chr18:54,842,260...55,096,008
Ensembl chr18:54,842,180...55,095,981 		JBrowse link
G Cish cytokine inducible SH2-containing protein multiple interactions ISO trichostatin A inhibits the reaction [IL3 protein promotes the reaction [BRD2 protein binds to CISH promoter]]; trichostatin A inhibits the reaction [IL3 protein results in increased expression of CISH mRNA]; trichostatin A inhibits the reaction [STAT5A gene mutant form results in increased expression of CISH mRNA] CTD PMID:25769527 NCBI chr 8:116,850,969...116,855,917
Ensembl chr 8:116,850,773...116,855,986 		JBrowse link
G Ckb creatine kinase B decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CKB mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CKB mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:136,550,583...136,553,464
Ensembl chr 6:136,549,844...136,553,478 		JBrowse link
G Cks1b CDC28 protein kinase regulatory subunit 1B decreases expression ISO trichostatin A results in decreased expression of CKS1B mRNA CTD PMID:23770000 NCBI chr 2:177,130,751...177,135,333
Ensembl chr 2:177,130,777...177,135,365 		JBrowse link
G Clasp2 cytoplasmic linker associated protein 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CLASP2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLASP2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 8:122,555,532...122,736,934
Ensembl chr 8:122,555,524...122,737,587 		JBrowse link
G Clcn2 chloride voltage-gated channel 2 decreases expression ISO trichostatin A results in decreased expression of CLCN2 mRNA CTD PMID:24935251 NCBI chr11:93,702,382...93,716,059
Ensembl chr11:93,702,360...93,716,059 		JBrowse link
G Clcn3 chloride voltage-gated channel 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CLCN3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLCN3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:34,138,004...34,210,984
Ensembl chr16:34,137,952...34,210,984 		JBrowse link
G Clcn4 chloride voltage-gated channel 4 increases expression ISO trichostatin A results in increased expression of CLCN4 mRNA CTD PMID:24935251 NCBI chr  X:27,290,769...27,356,967
Ensembl chr  X:27,290,868...27,356,939 		JBrowse link
G Clcn5 chloride voltage-gated channel 5 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CLCN5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLCN5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr  X:17,857,260...18,011,844
Ensembl chr  X:17,857,260...18,011,844 		JBrowse link
G Cldn1 claudin 1 decreases expression
increases expression 		ISO trichostatin A results in decreased expression of CLDN1 mRNA
trichostatin A results in increased expression of CLDN1 mRNA 		CTD PMID:24935251 PMID:26705709 NCBI chr11:87,926,376...87,941,533
Ensembl chr11:87,926,337...87,941,529 		JBrowse link
G Cldn10 claudin 10 increases expression ISO trichostatin A results in increased expression of CLDN10 mRNA CTD PMID:24935251 PMID:27188386 NCBI chr15:102,269,858...102,361,589
Ensembl chr15:102,269,858...102,361,589 		JBrowse link
G Cldn11 claudin 11 increases expression ISO trichostatin A results in increased expression of CLDN11 mRNA CTD PMID:24935251 NCBI chr 2:114,136,234...114,149,539
Ensembl chr 2:114,136,234...114,149,539 		JBrowse link
G Cldn23 claudin 23 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CLDN23 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN23 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr16:63,117,045...63,118,769
Ensembl chr16:63,116,781...63,118,957 		JBrowse link
G Cldn3 claudin 3 multiple interactions ISO [decitabine co-treated with trichostatin A] inhibits the reaction [MBD2 protein binds to CLDN3 promoter]; [decitabine co-treated with trichostatin A] promotes the reaction [SP1 protein binds to CLDN3 promoter]; [decitabine co-treated with trichostatin A] promotes the reaction [SP3 protein binds to CLDN3 promoter]; trichostatin A inhibits the reaction [Nickel affects the expression of CLDN3 mRNA]; trichostatin A promotes the reaction [decitabine results in increased expression of CLDN3 mRNA]; trichostatin A promotes the reaction [decitabine results in increased expression of CLDN3 protein] CTD PMID:14575637 PMID:17986852 NCBI chr12:27,345,075...27,346,547
Ensembl chr12:27,345,076...27,348,841 		JBrowse link
G Cldn4 claudin 4 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CLDN4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr12:27,388,160...27,389,958
Ensembl chr12:27,387,981...27,389,958 		JBrowse link
G Cldn5 claudin 5 multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of CLDN5 mRNA] CTD PMID:14575637 NCBI chr11:95,717,172...95,718,598
Ensembl chr11:95,717,176...95,719,322 		JBrowse link
G Cldn6 claudin 6 decreases methylation
multiple interactions
increases expression 		ISO trichostatin A results in decreased methylation of CLDN6 promoter
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN6 mRNA; [trichostatin A co-treated with Azacitidine] results in decreased methylation of CLDN6 promoter
trichostatin A results in increased expression of CLDN6 mRNA 		CTD PMID:18661270 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:13,213,837...13,218,578
Ensembl chr10:13,213,956...13,218,581 		JBrowse link
G Cldn7 claudin 7 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CLDN7 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN7 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:55,188,670...55,190,871
Ensembl chr10:55,188,684...55,190,905 		JBrowse link
G Cldn8 claudin 8 increases expression ISO trichostatin A results in increased expression of CLDN8 mRNA CTD PMID:18661270 NCBI chr11:41,362,081...41,364,330 JBrowse link
G Cldn9 claudin 9 multiple interactions
decreases methylation
increases expression 		ISO [trichostatin A co-treated with Azacitidine] results in decreased methylation of CLDN9 promoter
trichostatin A results in decreased methylation of CLDN9 promoter
trichostatin A results in increased expression of CLDN9 mRNA 		CTD PMID:18661270 NCBI chr10:13,218,728...13,220,159
Ensembl chr10:13,218,729...13,220,178 		JBrowse link
G Cldnd1 claudin domain containing 1 affects expression ISO trichostatin A affects the expression of CLDND1 mRNA CTD PMID:28542535 NCBI chr11:55,352,321...55,358,779
Ensembl chr11:55,352,321...55,358,907 		JBrowse link
G Clec11a C-type lectin domain containing 11A increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CLEC11A mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLEC11A mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:103,938,029...103,941,170
Ensembl chr 1:103,935,185...103,946,784 		JBrowse link
G Clec16a C-type lectin domain containing 16A affects expression ISO trichostatin A affects the expression of CLEC16A mRNA CTD PMID:28542535 NCBI chr10:5,434,725...5,631,246
Ensembl chr10:5,434,725...5,630,619 		JBrowse link
G Clec18a C-type lectin domain family 18, member A decreases expression ISO trichostatin A results in decreased expression of CLEC18A mRNA CTD PMID:24935251 NCBI chr19:55,947,625...55,964,505
Ensembl chr19:55,947,223...55,965,323 		JBrowse link
G Clgn calmegin increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of CLGN mRNA
trichostatin A results in decreased expression of CLGN mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLGN mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr19:41,601,568...41,633,207
Ensembl chr19:41,601,568...41,633,325 		JBrowse link
G Clic1 chloride intracellular channel 1 decreases expression ISO trichostatin A results in decreased expression of CLIC1 protein CTD PMID:19294695 NCBI chr20:3,769,522...3,778,367
Ensembl chr20:3,769,527...3,778,367 		JBrowse link
G Clic4 chloride intracellular channel 4 affects expression ISO trichostatin A affects the expression of CLIC4 mRNA CTD PMID:28542535 NCBI chr 5:152,737,371...152,797,118
Ensembl chr 5:152,737,371...152,797,118 		JBrowse link
G Clic5 chloride intracellular channel 5 increases expression ISO trichostatin A results in increased expression of CLIC5 mRNA CTD PMID:24935251 NCBI chr 9:24,208,455...24,310,964
Ensembl chr 9:24,208,456...24,358,780 		JBrowse link
G Clic6 chloride intracellular channel 6 multiple interactions
increases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLIC6 mRNA
trichostatin A results in increased expression of CLIC6 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr11:45,223,715...45,266,261
Ensembl chr11:45,223,669...45,267,344 		JBrowse link
G Clip1 CAP-GLY domain containing linker protein 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CLIP1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLIP1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr12:38,571,533...38,678,779
Ensembl chr12:38,571,834...38,678,779 		JBrowse link
G Clip2 CAP-GLY domain containing linker protein 2 affects expression ISO trichostatin A affects the expression of CLIP2 mRNA CTD PMID:28542535 NCBI chr12:27,798,289...27,863,486
Ensembl chr12:27,799,524...27,863,484 		JBrowse link
G Clip3 CAP-GLY domain containing linker protein 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CLIP3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLIP3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:94,674,492...94,690,643
Ensembl chr 1:94,674,661...94,690,642 		JBrowse link
G Clmn calmin increases expression
affects expression 		ISO trichostatin A results in increased expression of CLMN mRNA
trichostatin A affects the expression of CLMN mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 6:129,470,613...129,572,079
Ensembl chr 6:129,478,149...129,572,027 		JBrowse link
G Cln5 CLN5, intracellular trafficking protein decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CLN5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLN5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:86,308,286...86,321,679
Ensembl chr 2:67,620,667...67,622,952
Ensembl chr15:67,620,667...67,622,952 		JBrowse link
G Clp1 cleavage factor polyribonucleotide kinase subunit 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CLP1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLP1 mRNA 		CTD PMID:24935251 PMID:27188386 NCBI chr 3:90,213,461...90,217,165
Ensembl chr 3:90,213,465...90,217,538 		JBrowse link
G Clpp caseinolytic mitochondrial matrix peptidase proteolytic subunit affects expression ISO trichostatin A affects the expression of CLPP mRNA CTD PMID:28542535 NCBI chr 9:1,917,305...1,924,706
Ensembl chr 9:1,918,682...1,924,705 		JBrowse link
G Clpx caseinolytic mitochondrial matrix peptidase chaperone subunit X affects expression ISO trichostatin A affects the expression of CLPX mRNA CTD PMID:28542535 NCBI chr 8:74,700,602...74,740,244
Ensembl chr 8:74,700,662...74,744,762 		JBrowse link
G Clstn2 calsyntenin 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CLSTN2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLSTN2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:106,899,894...107,516,402
Ensembl chr 8:106,899,894...107,040,053 		JBrowse link
G Cltrn collectrin, amino acid transport regulator decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CLTRN mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLTRN mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr  X:33,993,825...34,027,124
Ensembl chr  X:33,993,825...34,027,181 		JBrowse link
G Clu clusterin increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CLU mRNA; trichostatin A results in increased expression of CLU protein
trichostatin A inhibits the reaction [Nickel affects the expression of CLU mRNA] 		CTD PMID:14575637 PMID:19234609 PMID:24935251 NCBI chr15:44,336,619...44,375,861
Ensembl chr15:44,359,914...44,375,860 		JBrowse link
G Clybl citramalyl-CoA lyase increases expression ISO trichostatin A results in increased expression of CLYBL mRNA CTD PMID:24935251 NCBI chr15:105,690,283...105,912,347
Ensembl chr15:105,690,295...105,912,345 		JBrowse link
G Cmah cytidine monophospho-N-acetylneuraminic acid hydroxylase increases expression ISO trichostatin A results in increased expression of CMAHP mRNA CTD PMID:26705709 NCBI chr17:40,985,129...41,070,317
Ensembl chr17:41,011,641...41,070,252 		JBrowse link
G Cmtm7 CKLF-like MARVEL transmembrane domain containing 7 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CMTM7 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CMTM7 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 8:123,326,233...123,353,148
Ensembl chr 8:123,325,975...123,353,148 		JBrowse link
G Cnih4 cornichon family member 4 decreases expression ISO trichostatin A results in decreased expression of CNIH4 mRNA CTD PMID:24935251 NCBI chr13:95,442,054...95,458,163
Ensembl chr13:95,442,054...95,459,590 		JBrowse link
G Cnksr2 connector enhancer of kinase suppressor of Ras 2 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of CNKSR2 mRNA
trichostatin A results in decreased expression of CNKSR2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNKSR2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr  X:40,722,843...40,971,730
Ensembl chr  X:40,722,996...40,965,604 		JBrowse link
G Cnksr3 Cnksr family member 3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CNKSR3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNKSR3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:45,904,581...45,996,921
Ensembl chr 1:45,904,581...45,996,921 		JBrowse link
G Cnmd chondromodulin increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CNMD mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNMD mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:61,450,617...61,475,382
Ensembl chr15:61,450,450...61,475,350 		JBrowse link
G Cnn1 calponin 1 affects expression ISO trichostatin A affects the expression of CNN1 mRNA CTD PMID:28542535 NCBI chr 8:28,908,437...28,917,099
Ensembl chr 8:28,908,330...28,919,482 		JBrowse link
G Cnn3 calponin 3 decreases expression ISO trichostatin A results in decreased expression of CNN3 mRNA CTD PMID:24935251 NCBI chr 2:212,203,661...212,234,772
Ensembl chr 2:212,226,640...212,234,815 		JBrowse link
G Cnnm2 cyclin and CBS domain divalent metal cation transport mediator 2 affects expression ISO trichostatin A affects the expression of CNNM2 mRNA CTD PMID:28542535 NCBI chr 1:255,585,063...255,709,455
Ensembl chr 1:255,585,095...255,704,849 		JBrowse link
G Cnot2 CCR4-NOT transcription complex, subunit 2 decreases expression
affects expression 		ISO trichostatin A results in decreased expression of CNOT2 mRNA
trichostatin A affects the expression of CNOT2 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 7:54,016,447...54,117,511
Ensembl chr 7:54,016,447...54,107,960 		JBrowse link
G Cnot3 CCR4-NOT transcription complex, subunit 3 decreases expression ISO trichostatin A results in decreased expression of CNOT3 mRNA CTD PMID:24935251 NCBI chr 1:74,471,284...74,487,527
Ensembl chr 1:74,470,566...74,487,527 		JBrowse link
G Cnot4 CCR4-NOT transcription complex, subunit 4 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CNOT4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNOT4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:64,679,903...64,781,432
Ensembl chr 4:64,679,904...64,738,083 		JBrowse link
G Cnot6l CCR4-NOT transcription complex, subunit 6-like increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CNOT6L mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNOT6L mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr14:13,714,475...13,806,481
Ensembl chr14:13,714,475...13,806,481 		JBrowse link
G Cnot7 CCR4-NOT transcription complex, subunit 7 increases expression ISO trichostatin A results in increased expression of CNOT7 mRNA CTD PMID:24935251 NCBI chr16:58,478,882...58,498,046
Ensembl chr16:58,478,900...58,498,046 		JBrowse link
G Cnot9 CCR4-NOT transcription complex subunit 9 affects expression ISO trichostatin A affects the expression of CNOT9 mRNA CTD PMID:28542535 NCBI chr 9:83,533,369...83,558,207
Ensembl chr 9:83,533,369...83,558,197 		JBrowse link
G Cnpy1 canopy FGF signaling regulator 1 decreases expression ISO trichostatin A results in decreased expression of CNPY1 mRNA CTD PMID:24935251 NCBI chr 4:7,870,403...7,925,266
Ensembl chr 4:7,869,829...7,925,266 		JBrowse link
G Cnpy2 canopy FGF signaling regulator 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CNPY2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNPY2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:1,332,293...1,338,081
Ensembl chr 7:1,334,335...1,340,333 		JBrowse link
G Cnr1 cannabinoid receptor 1 increases expression ISO trichostatin A results in increased expression of CNR1 mRNA CTD PMID:24935251 NCBI chr 5:53,204,867...53,230,396
Ensembl chr 5:53,204,260...53,239,252 		JBrowse link
G Cnr2 cannabinoid receptor 2 increases expression ISO trichostatin A results in increased expression of CNR2 mRNA CTD PMID:22262103 NCBI chr 5:153,408,968...153,435,092
Ensembl chr 5:153,409,147...153,435,961 		JBrowse link
G Cnrip1 cannabinoid receptor interacting protein 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CNRIP1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNRIP1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr14:95,664,435...95,707,062
Ensembl chr14:95,664,774...95,694,371 		JBrowse link
G Cntf ciliary neurotrophic factor affects expression ISO trichostatin A affects the expression of CNTF mRNA CTD PMID:28542535 NCBI chr 1:219,312,512...219,314,535
Ensembl chr 1:219,312,512...219,314,488 		JBrowse link
G Cntln centlein increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CNTLN mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNTLN mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:104,340,801...104,622,491
Ensembl chr 5:104,342,173...104,630,976 		JBrowse link
G Cntn1 contactin 1 increases expression ISO trichostatin A results in increased expression of CNTN1 mRNA CTD PMID:24935251 NCBI chr 7:125,142,638...125,440,397
Ensembl chr 7:125,142,696...125,440,391 		JBrowse link
G Cntn2 contactin 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CNTN2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTN2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr13:46,497,269...46,528,112
Ensembl chr13:46,499,396...46,528,027 		JBrowse link
G Cntn3 contactin 3 increases expression ISO trichostatin A results in increased expression of CNTN3 mRNA CTD PMID:24935251 NCBI chr 4:136,397,575...136,770,765
Ensembl chr 4:136,398,572...136,770,717 		JBrowse link
G Cntn6 contactin 6 decreases expression ISO trichostatin A results in decreased expression of CNTN6 mRNA CTD PMID:24935251 NCBI chr 4:138,911,090...139,307,339
Ensembl chr 4:138,911,380...139,311,816 		JBrowse link
G Cntnap2 contactin associated protein 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CNTNAP2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTNAP2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:75,109,358...77,366,258
Ensembl chr 4:75,109,858...77,366,258 		JBrowse link
G Cntnap3 contactin associated protein family member 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CNTNAP3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTNAP3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr17:273,137...461,233
Ensembl chr17:273,137...461,233 		JBrowse link
G Cntrl centriolin decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CNTRL mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTRL mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:38,825,575...38,897,835
Ensembl chr 3:38,825,624...38,897,833 		JBrowse link
G Coa7 cytochrome c oxidase assembly factor 7 affects expression ISO trichostatin A affects the expression of COA7 mRNA CTD PMID:28542535 NCBI chr 5:128,298,084...128,308,935
Ensembl chr 5:128,298,093...128,309,664 		JBrowse link
G Cobl cordon-bleu WH2 repeat protein increases expression
multiple interactions 		ISO trichostatin A results in increased expression of COBL mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COBL mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr14:91,041,721...91,274,272
Ensembl chr14:91,041,721...91,274,257 		JBrowse link
G Cobll1 cordon-bleu WH2 repeat protein-like 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of COBLL1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COBLL1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:70,161,369...70,324,844
Ensembl chr 3:70,161,372...70,323,460 		JBrowse link
G Coch cochlin decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of COCH mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COCH mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:74,766,485...74,780,504
Ensembl chr 6:74,766,419...74,780,502 		JBrowse link
G Cog8 component of oligomeric golgi complex 8 multiple interactions ISO [decitabine co-treated with trichostatin A] results in decreased expression of COG8 mRNA CTD PMID:17524140 NCBI chr19:51,861,376...51,872,126
Ensembl chr19:51,861,376...51,872,129 		JBrowse link
G Coil coilin decreases expression
affects expression 		ISO trichostatin A results in decreased expression of COIL mRNA
trichostatin A affects the expression of COIL mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr10:74,286,279...74,307,597
Ensembl chr10:74,286,840...74,307,595 		JBrowse link
G Col11a1 collagen type XI alpha 1 chain increases expression ISO trichostatin A results in increased expression of COL11A1 mRNA CTD PMID:24935251 PMID:27188386 NCBI chr 2:204,509,136...204,702,264
Ensembl chr 2:204,509,136...204,702,264 		JBrowse link
G Col11a2 collagen type XI alpha 2 chain increases expression
multiple interactions 		ISO trichostatin A results in increased expression of COL11A2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL11A2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr20:4,788,829...4,818,492
Ensembl chr20:4,788,829...4,817,648 		JBrowse link
G Col13a1 collagen type XIII alpha 1 chain increases expression
multiple interactions 		ISO trichostatin A results in increased expression of COL13A1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL13A1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr20:30,326,744...30,466,800
Ensembl chr20:30,326,744...30,466,800 		JBrowse link
G Col14a1 collagen type XIV alpha 1 chain increases expression ISO trichostatin A results in increased expression of COL14A1 mRNA CTD PMID:24935251 NCBI chr 7:88,611,827...88,826,939
Ensembl chr 7:88,611,828...88,826,938 		JBrowse link
G Col1a1 collagen type I alpha 1 chain increases expression
multiple interactions
affects expression 		ISO trichostatin A results in increased expression of COL1A1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A1 mRNA
trichostatin A inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein]
trichostatin A affects the expression of COL1A1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:27396813 PMID:28542535 NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460 		JBrowse link
G Col1a2 collagen type I alpha 2 chain increases expression
multiple interactions 		ISO trichostatin A results in increased expression of COL1A2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:33,518,557...33,553,484
Ensembl chr 4:33,518,420...33,553,995 		JBrowse link
G Col23a1 collagen type XXIII alpha 1 chain increases expression
multiple interactions 		ISO trichostatin A results in increased expression of COL23A1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL23A1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:36,050,327...36,337,279
Ensembl chr10:36,050,259...36,337,897 		JBrowse link
G Col27a1 collagen type XXVII alpha 1 chain increases expression
multiple interactions 		ISO trichostatin A results in increased expression of COL27A1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL27A1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:81,662,822...81,781,502
Ensembl chr 5:81,661,685...81,781,502 		JBrowse link
G Col2a1 collagen type II alpha 1 chain increases expression ISO trichostatin A results in increased expression of COL2A1 mRNA CTD PMID:24935251 NCBI chr 7:130,977,561...131,006,627
Ensembl chr 7:130,977,561...131,006,627 		JBrowse link
G Col3a1 collagen type III alpha 1 chain increases expression ISO trichostatin A results in increased expression of COL3A1 mRNA CTD PMID:23463510 NCBI chr 9:54,866,646...54,902,578
Ensembl chr 9:54,866,632...54,903,232 		JBrowse link
G Col4a1 collagen type IV alpha 1 chain increases expression ISO trichostatin A results in increased expression of COL4A1 mRNA CTD PMID:23463510 NCBI chr16:84,885,597...84,996,482
Ensembl chr16:84,885,597...84,996,482 		JBrowse link
G Col4a3 collagen type IV alpha 3 chain increases expression ISO trichostatin A results in increased expression of COL4A3 mRNA CTD PMID:24935251 NCBI chr 9:91,323,990...91,453,088
Ensembl chr 9:91,323,990...91,453,077 		JBrowse link
G Col4a4 collagen type IV alpha 4 chain increases expression ISO trichostatin A results in increased expression of COL4A4 mRNA CTD PMID:24935251 NCBI chr 9:91,281,324...91,323,577
Ensembl chr 9:91,203,670...91,323,577 		JBrowse link
G Col4a6 collagen type IV alpha 6 chain decreases expression
increases expression 		ISO trichostatin A results in decreased expression of COL4A6 mRNA
trichostatin A results in increased expression of COL4A6 mRNA 		CTD PMID:24935251 PMID:26705709 NCBI chr  X:109,554,945...109,905,987
Ensembl chr  X:109,552,651...109,905,944 		JBrowse link
G Col5a1 collagen type V alpha 1 chain increases expression
multiple interactions 		ISO trichostatin A results in increased expression of COL5A1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL5A1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:31,606,475...31,755,097
Ensembl chr 3:31,606,486...31,753,020 		JBrowse link
G Col5a2 collagen type V alpha 2 chain increases expression
multiple interactions 		ISO trichostatin A results in increased expression of COL5A2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL5A2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 9:54,940,768...55,090,151
Ensembl chr 9:54,940,764...55,090,150 		JBrowse link
G Col5a3 collagen type V alpha 3 chain increases expression
multiple interactions 		ISO trichostatin A results in increased expression of COL5A3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL5A3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:26705709 PMID:27188386 NCBI chr 8:27,580,768...27,626,002
Ensembl chr 8:27,580,768...27,626,122 		JBrowse link
G Col6a1 collagen type VI alpha 1 chain increases expression
multiple interactions 		ISO trichostatin A results in increased expression of COL6A1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr20:11,905,690...11,924,111
Ensembl chr20:11,905,457...11,924,107 		JBrowse link
G Col6a3 collagen type VI alpha 3 chain increases expression
multiple interactions 		ISO trichostatin A results in increased expression of COL6A3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:98,809,171...98,887,060
Ensembl chr 9:98,809,171...98,886,990 		JBrowse link
G Col9a3 collagen type IX alpha 3 chain increases expression ISO trichostatin A results in increased expression of COL9A3 mRNA CTD PMID:24935251 NCBI chr 3:188,089,337...188,112,034
Ensembl chr 3:188,089,403...188,112,270 		JBrowse link
G Colec12 collectin sub-family member 12 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of COLEC12 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COLEC12 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr18:1,005,787...1,193,455
Ensembl chr18:1,005,741...1,195,297 		JBrowse link
G Colgalt2 collagen beta(1-O)galactosyltransferase 2 decreases expression ISO trichostatin A results in decreased expression of COLGALT2 mRNA CTD PMID:24935251 NCBI chr13:67,073,551...67,178,194
Ensembl chr13:67,073,551...67,178,194 		JBrowse link
G Commd6 COMM domain containing 6 affects expression ISO trichostatin A affects the expression of COMMD6 mRNA CTD PMID:28542535 NCBI chr15:84,882,069...84,889,124
Ensembl chr15:84,882,548...84,889,194 		JBrowse link
G Comt catechol-O-methyltransferase multiple interactions ISO trichostatin A inhibits the reaction [Estradiol results in decreased expression of COMT mRNA] CTD PMID:30684530 NCBI chr11:96,072,371...96,091,956
Ensembl chr11:96,072,489...96,092,533 		JBrowse link
G Cops8 COP9 signalosome subunit 8 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of COPS8 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COPS8 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:98,655,031...98,664,861
Ensembl chr 9:98,654,870...98,665,381 		JBrowse link
G Coq7 coenzyme Q7, hydroxylase decreases expression ISO trichostatin A results in decreased expression of COQ7 mRNA CTD PMID:24935251 PMID:28542535 NCBI chr 1:182,270,570...182,285,959
Ensembl chr 1:182,269,399...182,285,508 		JBrowse link
G Coro2a coronin 2A increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CORO2A mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CORO2A mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:65,623,820...65,677,483
Ensembl chr 5:65,623,823...65,654,602 		JBrowse link
G Cotl1 coactosin-like F-actin binding protein 1 affects expression ISO trichostatin A affects the expression of COTL1 mRNA CTD PMID:28542535 NCBI chr19:64,780,309...64,814,629
Ensembl chr19:64,780,322...64,814,840 		JBrowse link
G Cox11 cytochrome c oxidase copper chaperone COX11 decreases expression ISO trichostatin A results in decreased expression of COX11 mRNA CTD PMID:24935251 NCBI chr10:75,955,825...75,962,398
Ensembl chr10:75,955,783...75,963,489 		JBrowse link
G Cox5b cytochrome c oxidase subunit 5B increases expression ISO trichostatin A results in increased expression of COX5B protein CTD PMID:19294695 NCBI chr 9:46,417,735...46,419,664
Ensembl chr 9:46,417,838...46,420,403 		JBrowse link
G Cox6b2 cytochrome c oxidase subunit 6B2 affects expression ISO trichostatin A affects the expression of COX6B2 mRNA CTD PMID:28542535 NCBI chr 1:78,122,871...78,124,096
Ensembl chr 1:78,122,453...78,124,094 		JBrowse link
G Cpap centrosome assembly and centriole elongation protein decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CPAP mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CPAP mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:34,742,838...34,806,020
Ensembl chr15:34,742,838...34,802,421 		JBrowse link
G Cpd carboxypeptidase D decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CPD mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CPD mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:62,121,681...62,185,638
Ensembl chr10:62,121,679...62,185,638 		JBrowse link
G Cpe carboxypeptidase E increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CPE mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPE mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr16:29,796,707...29,908,647
Ensembl chr16:29,796,689...29,909,524 		JBrowse link
G Cpeb1 cytoplasmic polyadenylation element binding protein 1 increases expression ISO trichostatin A results in increased expression of CPEB1 mRNA CTD PMID:24935251 NCBI chr 1:144,709,278...144,817,388
Ensembl chr 1:144,709,691...144,815,880 		JBrowse link
G Cpeb2 cytoplasmic polyadenylation element binding protein 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CPEB2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPEB2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:71,999,958...72,056,012
Ensembl chr14:72,002,072...72,052,263 		JBrowse link
G Cpeb4 cytoplasmic polyadenylation element binding protein 4 affects expression ISO trichostatin A affects the expression of CPEB4 mRNA CTD PMID:28542535 NCBI chr10:16,222,271...16,284,248
Ensembl chr10:16,225,672...16,283,787 		JBrowse link
G Cped1 cadherin-like and PC-esterase domain containing 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CPED1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPED1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:51,482,497...51,755,440
Ensembl chr 4:51,482,545...51,755,442 		JBrowse link
G Cpm carboxypeptidase M increases expression ISO trichostatin A results in increased expression of CPM mRNA CTD PMID:24935251 PMID:28542535 NCBI chr 7:55,111,599...55,172,114
Ensembl chr 7:55,111,599...55,172,114 		JBrowse link
G Cpne2 copine 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CPNE2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CPNE2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr19:10,440,245...10,477,783
Ensembl chr19:10,434,647...10,477,783 		JBrowse link
G Cpne3 copine 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CPNE3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CPNE3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:37,811,566...37,860,840
Ensembl chr 5:37,811,566...37,861,062 		JBrowse link
G Cpne4 copine 4 increases expression ISO trichostatin A results in increased expression of CPNE4 mRNA CTD PMID:24935251 NCBI chr 8:114,056,152...114,531,855
Ensembl chr 8:113,993,703...114,531,855 		JBrowse link
G Cpsf2 cleavage and polyadenylation specific factor 2 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of CPSF2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CPSF2 mRNA
trichostatin A affects the expression of CPSF2 mRNA 		CTD PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 6:126,885,417...126,917,634
Ensembl chr 6:126,885,476...126,917,632 		JBrowse link
G Cpt1b carnitine palmitoyltransferase 1B decreases expression ISO trichostatin A results in decreased expression of CPT1B mRNA CTD PMID:26272509 NCBI chr 7:122,370,974...122,380,473
Ensembl chr 7:122,370,444...122,380,036 		JBrowse link
G Cpt1c carnitine palmitoyltransferase 1c decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of CPT1C mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CPT1C mRNA
trichostatin A affects the expression of CPT1C mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 1:104,579,297...104,593,824
Ensembl chr 1:104,579,298...104,593,763 		JBrowse link
G Cpvl carboxypeptidase, vitellogenic-like multiple interactions
increases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPVL mRNA
trichostatin A results in increased expression of CPVL mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:84,311,853...84,422,098
Ensembl chr 4:84,311,854...84,416,033 		JBrowse link
G Cpxm2 carboxypeptidase X (M14 family), member 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CPXM2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPXM2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:196,266,930...196,377,350
Ensembl chr 1:196,266,930...196,377,347 		JBrowse link
G Cr1l complement C3b/C4b receptor 1 like increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CR1L mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CR1L mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr13:109,138,132...109,189,068
Ensembl chr13:109,103,235...109,188,869 		JBrowse link
G Crabp1 cellular retinoic acid binding protein 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CRABP1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRABP1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 8:64,047,431...64,055,469
Ensembl chr 8:64,047,060...64,055,470 		JBrowse link
G Crabp2 cellular retinoic acid binding protein 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CRABP2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRABP2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:175,714,862...175,719,208
Ensembl chr 2:175,707,312...175,728,385 		JBrowse link
G Cracd capping protein inhibiting regulator of actin dynamics increases expression ISO trichostatin A results in increased expression of CRACD mRNA CTD PMID:24935251 NCBI chr14:31,638,328...31,874,391
Ensembl chr14:31,638,328...31,683,987 		JBrowse link
G Crb2 crumbs cell polarity complex component 2 decreases expression ISO trichostatin A results in decreased expression of CRB2 mRNA CTD PMID:24935251 NCBI chr 3:41,946,694...41,974,629
Ensembl chr 3:41,947,325...41,974,629 		JBrowse link
G Creb3l2 cAMP responsive element binding protein 3-like 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CREB3L2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CREB3L2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:66,874,623...66,990,962
Ensembl chr 4:66,387,126...66,990,832 		JBrowse link
G Crebbp CREB binding protein multiple interactions ISO trichostatin A promotes the reaction [CREBBP protein binds to PDK4 promoter] CTD PMID:16757381 NCBI chr10:11,842,307...11,968,266
Ensembl chr10:11,822,620...11,968,266 		JBrowse link
G Crebzf CREB/ATF bZIP transcription factor decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CREBZF mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CREBZF mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:153,829,544...153,836,073
Ensembl chr 1:153,829,448...153,845,122 		JBrowse link
G Creld1 cysteine-rich with EGF-like domains 1 decreases expression ISO trichostatin A results in decreased expression of CRELD1 mRNA CTD PMID:24935251 NCBI chr 4:148,187,510...148,197,120
Ensembl chr 4:148,187,265...148,197,116 		JBrowse link
G Crem cAMP responsive element modulator multiple interactions
decreases expression
increases expression
affects expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CREM mRNA; trichostatin A inhibits the reaction [Nickel affects the expression of CREM mRNA]
trichostatin A results in decreased expression of CREM mRNA
trichostatin A results in increased expression of CREM mRNA
trichostatin A affects the expression of CREM mRNA 		CTD PMID:14575637 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr17:58,932,011...59,001,160
Ensembl chr17:58,934,147...59,001,160 		JBrowse link
G Crim1 cysteine rich transmembrane BMP regulator 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CRIM1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRIM1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:22,447,983...22,622,459
Ensembl chr 6:22,449,948...22,622,416 		JBrowse link
G Crip1 cysteine rich protein 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CRIP1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRIP1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:138,047,801...138,055,672
Ensembl chr 6:138,047,801...138,055,672 		JBrowse link
G Cripto cripto, EGF-CFC family member increases expression ISO trichostatin A results in increased expression of CRIPTO mRNA CTD PMID:26272509 NCBI chr 8:119,803,182...119,808,714
Ensembl chr 8:119,803,220...119,808,948 		JBrowse link
G Crispld1 cysteine-rich secretory protein LCCL domain containing 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CRISPLD1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRISPLD1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:6,050,970...6,098,265
Ensembl chr 5:6,051,891...6,098,265 		JBrowse link
G Crispld2 cysteine-rich secretory protein LCCL domain containing 2 increases expression
affects expression 		ISO trichostatin A results in increased expression of CRISPLD2 mRNA
trichostatin A affects the expression of CRISPLD2 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr19:64,961,764...65,020,099
Ensembl chr19:64,961,771...65,020,349 		JBrowse link
G Crkl CRK like proto-oncogene, adaptor protein multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of CRKL mRNA] CTD PMID:14575637 NCBI chr11:97,033,033...97,067,457
Ensembl chr11:97,024,782...97,067,457 		JBrowse link
G Crls1 cardiolipin synthase 1 increases expression ISO trichostatin A results in increased expression of CRLS1 mRNA CTD PMID:26272509 NCBI chr 3:140,572,680...140,591,543
Ensembl chr 3:140,572,716...140,591,599 		JBrowse link
G Crot carnitine O-octanoyltransferase increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of CROT mRNA
trichostatin A results in decreased expression of CROT mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CROT mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:26,031,729...26,088,057
Ensembl chr 4:26,052,516...26,088,064 		JBrowse link
G Crtap cartilage associated protein increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CRTAP mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRTAP mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:122,926,117...122,945,843
Ensembl chr 8:122,926,117...122,945,843 		JBrowse link
G Cry1 cryptochrome circadian regulator 1 affects expression ISO trichostatin A affects the expression of CRY1 mRNA CTD PMID:28542535 NCBI chr 7:20,417,526...20,481,791
Ensembl chr 7:20,417,107...20,481,822 		JBrowse link
G Cry2 cryptochrome circadian regulator 2 affects expression ISO trichostatin A affects the expression of CRY2 mRNA CTD PMID:28542535 NCBI chr 3:98,830,479...98,860,437
Ensembl chr 3:98,830,483...98,860,447 		JBrowse link
G Cryab crystallin, alpha B increases expression ISO trichostatin A results in increased expression of CRYAB mRNA CTD PMID:26705709 NCBI chr 8:59,989,885...59,995,532
Ensembl chr 8:59,989,814...59,995,528 		JBrowse link
G Cryba1 crystallin, beta A1 decreases expression ISO trichostatin A results in decreased expression of CRYBA1 mRNA CTD PMID:24935251 NCBI chr10:63,106,465...63,113,020
Ensembl chr10:63,106,475...63,112,817 		JBrowse link
G Cryba4 crystallin, beta A4 decreases expression ISO trichostatin A results in decreased expression of CRYBA4 mRNA CTD PMID:24935251 NCBI chr12:50,039,148...50,053,636
Ensembl chr12:50,047,049...50,053,634 		JBrowse link
G Crybg1 crystallin beta-gamma domain containing 1 increases expression ISO trichostatin A results in increased expression of CRYBG1 mRNA CTD PMID:24935251 NCBI chr20:49,007,673...49,204,040
Ensembl chr20:49,007,929...49,204,047 		JBrowse link
G Crygs crystallin, gamma S increases expression ISO trichostatin A results in increased expression of CRYGS mRNA CTD PMID:24935251 NCBI chr11:91,711,755...91,716,858
Ensembl chr11:91,711,755...91,716,858 		JBrowse link
G Cse1l chromosome segregation 1 like affects expression ISO trichostatin A affects the expression of CSE1L mRNA CTD PMID:28542535 NCBI chr 3:176,060,183...176,097,909
Ensembl chr 3:176,060,215...176,108,734 		JBrowse link
G Csf2 colony stimulating factor 2 multiple interactions ISO [trichostatin A co-treated with Dexamethasone] inhibits the reaction [IL1B protein promotes the reaction [H4C16 protein modified form binds to CSF2 promoter]]; trichostatin A inhibits the reaction [[Theophylline co-treated with Dexamethasone] inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]]; trichostatin A inhibits the reaction [Dexamethasone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]] CTD PMID:12070353 NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,887,692...38,890,031 		JBrowse link
G Csf2ra colony stimulating factor 2 receptor subunit alpha increases expression ISO trichostatin A results in increased expression of CSF2RA mRNA CTD PMID:24935251 NCBI chr14:113,219...118,808
Ensembl chr14:113,225...118,117 		JBrowse link
G Csk C-terminal Src kinase affects expression ISO trichostatin A affects the expression of CSK mRNA CTD PMID:28542535 NCBI chr 8:66,925,650...66,944,861
Ensembl chr 8:66,925,651...66,930,274 		JBrowse link
G Csnk1d casein kinase 1, delta affects expression ISO trichostatin A affects the expression of CSNK1D mRNA CTD PMID:28542535 NCBI chr10:106,713,497...106,754,953
Ensembl chr10:106,694,279...106,754,953 		JBrowse link
G Csnk2a2 casein kinase 2 alpha 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CSNK2A2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSNK2A2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:9,562,340...9,602,136
Ensembl chr19:9,562,321...9,602,136 		JBrowse link
G Cspp1 centrosome and spindle pole associated protein 1 increases expression ISO trichostatin A results in increased expression of CSPP1 mRNA CTD PMID:24935251 NCBI chr 5:13,860,072...13,975,299
Ensembl chr 5:13,860,072...13,975,321 		JBrowse link
G Csrnp2 cysteine and serine rich nuclear protein 2 affects expression ISO trichostatin A affects the expression of CSRNP2 mRNA CTD PMID:28542535 NCBI chr 7:133,473,027...133,488,868
Ensembl chr 7:133,473,027...133,488,868 		JBrowse link
G Csrnp3 cysteine and serine rich nuclear protein 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CSRNP3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSRNP3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:70,906,587...71,102,596
Ensembl chr 3:70,906,380...71,094,009 		JBrowse link
G Csrp1 cysteine and glycine-rich protein 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CSRP1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CSRP1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr13:49,709,928...49,731,141
Ensembl chr13:49,709,914...49,731,139 		JBrowse link
G Csrp2 cysteine and glycine-rich protein 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CSRP2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSRP2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:48,235,415...48,254,049
Ensembl chr 7:48,235,383...48,266,238 		JBrowse link
G Cst6 cystatin E/M increases expression ISO trichostatin A results in increased expression of CST6 mRNA; trichostatin A results in increased expression of CST6 protein CTD PMID:19503093 NCBI chr 1:212,084,676...212,086,384
Ensembl chr 1:212,084,676...212,086,384 		JBrowse link
G Cstb cystatin B affects expression ISO trichostatin A affects the expression of CSTB mRNA CTD PMID:28542535 NCBI chr20:10,245,157...10,247,199
Ensembl chr20:10,245,158...10,247,199 		JBrowse link
G Cstf2t cleavage stimulation factor subunit 2, tau variant decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CSTF2T mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSTF2T mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:238,366,042...238,369,608
Ensembl chr 1:238,365,912...238,369,749 		JBrowse link
G Cstf3 cleavage stimulation factor subunit 3 increases expression ISO trichostatin A results in increased expression of CSTF3 mRNA CTD PMID:24935251 NCBI chr 3:111,421,291...111,492,539
Ensembl chr 3:111,421,234...111,497,046 		JBrowse link
G Ctbp1 C-terminal binding protein 1 affects expression ISO trichostatin A affects the expression of CTBP1 mRNA CTD PMID:28542535 NCBI chr14:81,679,956...81,707,331
Ensembl chr14:81,679,765...81,707,554 		JBrowse link
G Ctbp2 C-terminal binding protein 2 increases expression ISO trichostatin A results in increased expression of CTBP2 mRNA CTD PMID:24935251 NCBI chr 1:197,208,536...197,348,802
Ensembl chr 1:197,212,133...197,254,261 		JBrowse link
G Ctbs chitobiase increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of CTBS mRNA
trichostatin A results in decreased expression of CTBS mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTBS mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:238,000,800...238,015,368
Ensembl chr 2:238,000,842...238,015,475 		JBrowse link
G Ctdsp1 CTD small phosphatase 1 affects expression ISO trichostatin A affects the expression of CTDSP1 mRNA CTD PMID:28542535 NCBI chr 9:83,422,755...83,428,411
Ensembl chr 9:83,423,051...83,428,412 		JBrowse link
G Ctdspl CTD small phosphatase like increases expression ISO trichostatin A results in increased expression of CTDSPL mRNA CTD PMID:24935251 NCBI chr 8:127,520,478...127,644,999
Ensembl chr 8:127,520,499...127,644,999 		JBrowse link
G Ctdspl2 CTD small phosphatase like 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CTDSPL2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTDSPL2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:26705709 PMID:27188386 NCBI chr 3:129,365,709...129,424,232
Ensembl chr 3:129,368,938...129,424,232 		JBrowse link
G Cthrc1 collagen triple helix repeat containing 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CTHRC1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTHRC1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:72,007,372...72,017,654
Ensembl chr 7:72,007,372...72,017,654 		JBrowse link
G Ctla4 cytotoxic T-lymphocyte-associated protein 4 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CTLA4 protein
[trichostatin A co-treated with Arsenic] results in increased expression of CTLA4 protein 		CTD PMID:19545742 PMID:32735129 NCBI chr 9:69,812,859...69,819,959
Ensembl chr 9:69,813,265...69,819,973 		JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions
increases expression 		ISO [3-deazaneplanocin co-treated with trichostatin A] affects the expression of CTNNB1 protein; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTNNB1 mRNA; trichostatin A inhibits the reaction [butylbenzyl phthalate affects the localization of CTNNB1 protein]; trichostatin A inhibits the reaction [Dibutyl Phthalate affects the localization of CTNNB1 protein]
[estradiol dipropionate co-treated with trichostatin A] results in decreased expression of CTNNB1 protein
trichostatin A results in increased expression of CTNNB1 mRNA 		CTD PMID:15930180 PMID:18538736 PMID:22552774 PMID:24935251 PMID:26272509 More... NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662 		JBrowse link
G Ctnnd2 catenin delta 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CTNND2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:82,879,469...83,727,409
Ensembl chr 2:82,879,469...83,727,409 		JBrowse link
G Ctps1 CTP synthase 1 decreases expression ISO trichostatin A results in decreased expression of CTPS1 mRNA CTD PMID:19606018 PMID:28542535 NCBI chr 5:139,372,349...139,440,441
Ensembl chr 5:139,410,249...139,440,465 		JBrowse link
G Ctps2 CTP synthase 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CTPS2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTPS2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:35,277,658...35,418,505
Ensembl chr  X:35,277,658...35,418,505 		JBrowse link
G Ctsc cathepsin C increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CTSC mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTSC mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:151,440,860...151,472,430
Ensembl chr 1:151,441,032...151,474,082 		JBrowse link
G Ctsz cathepsin Z increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CTSZ mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTSZ mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:183,643,077...183,653,847
Ensembl chr 3:183,643,077...183,657,012 		JBrowse link
G Cttnbp2nl CTTNBP2 N-terminal like decreases expression
affects expression 		ISO trichostatin A results in decreased expression of CTTNBP2NL mRNA
trichostatin A affects the expression of CTTNBP2NL mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 2:195,196,318...195,244,792
Ensembl chr 2:195,196,318...195,243,181 		JBrowse link
G Cul1 cullin 1 affects expression ISO trichostatin A affects the expression of CUL1 mRNA CTD PMID:28542535 NCBI chr 4:77,551,781...77,634,210
Ensembl chr 4:77,551,787...77,621,760 		JBrowse link
G Cul3 cullin 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CUL3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUL3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 9:89,040,987...89,118,775
Ensembl chr 9:89,040,987...89,118,427 		JBrowse link
G Cul4b cullin 4B decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CUL4B mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUL4B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:122,154,332...122,192,299
Ensembl chr  X:122,154,332...122,192,299 		JBrowse link
G Cul5 cullin 5 affects expression ISO trichostatin A affects the expression of CUL5 mRNA CTD PMID:28542535 NCBI chr 8:62,909,150...62,974,641
Ensembl chr 8:62,912,193...62,965,463 		JBrowse link
G Cutc cutC copper transporter affects expression ISO trichostatin A affects the expression of CUTC mRNA CTD PMID:28542535 NCBI chr 1:252,571,489...252,586,269
Ensembl chr 1:252,571,521...252,597,272 		JBrowse link
G Cux1 cut-like homeobox 1 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of CUX1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUX1 mRNA
trichostatin A affects the expression of CUX1 mRNA 		CTD PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr12:25,728,393...26,062,497
Ensembl chr12:25,743,733...26,062,497 		JBrowse link
G Cux2 cut-like homeobox 2 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of CUX2 mRNA
trichostatin A results in decreased expression of CUX2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUX2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr12:40,168,402...40,368,303
Ensembl chr12:40,149,292...40,366,528 		JBrowse link
G Cuzd1 CUB and zona pellucida-like domains 1 decreases expression
increases expression 		ISO trichostatin A results in decreased expression of CUZD1 mRNA
trichostatin A results in increased expression of CUZD1 mRNA 		CTD PMID:24935251 NCBI chr 1:195,519,609...195,532,733
Ensembl chr 1:195,519,609...195,532,733 		JBrowse link
G Cwc22 CWC22 spliceosome associated protein decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CWC22 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CWC22 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:83,222,400...83,271,427
Ensembl chr 3:83,209,194...83,271,513 		JBrowse link
G Cx3cl1 C-X3-C motif chemokine ligand 1 multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of CX3CL1 mRNA] CTD PMID:14575637 NCBI chr19:10,233,326...10,244,856
Ensembl chr19:10,233,329...10,242,999 		JBrowse link
G Cxadr CXADR, Ig-like cell adhesion molecule multiple interactions
increases expression
decreases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CXADR mRNA; Decitabine promotes the reaction [trichostatin A results in increased expression of CXADR mRNA alternative form]; Decitabine promotes the reaction [trichostatin A results in increased expression of CXADR mRNA]
trichostatin A results in increased expression of CXADR mRNA; trichostatin A results in increased expression of CXADR mRNA alternative form
trichostatin A results in decreased expression of CXADR mRNA 		CTD PMID:18618240 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr11:30,469,778...30,516,990
Ensembl chr11:30,469,526...30,516,988 		JBrowse link
G Cxcl1 C-X-C motif chemokine ligand 1 increases expression ISO trichostatin A results in increased expression of CXCL1 mRNA CTD PMID:24935251 NCBI chr14:17,477,542...17,479,321
Ensembl chr14:17,477,549...17,479,811 		JBrowse link
G Cxcl12 C-X-C motif chemokine ligand 12 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CXCL12 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL12 mRNA 		CTD PMID:19289100 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:152,060,781...152,073,628
Ensembl chr 4:152,060,780...152,073,627 		JBrowse link
G Cxcl14 C-X-C motif chemokine ligand 14 decreases acetylation
increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in decreased acetylation of CXCL14 protein
trichostatin A results in increased expression of CXCL14 mRNA
trichostatin A results in decreased expression of CXCL14 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL14 mRNA 		CTD PMID:20562917 PMID:24935251 PMID:26272509 PMID:26705709 PMID:27188386 NCBI chr17:8,323,150...8,331,176
Ensembl chr17:8,323,143...8,331,172 		JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 increases expression ISO trichostatin A results in increased expression of CXCL2 mRNA CTD PMID:24935251 NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,465,242...17,467,255 		JBrowse link
G Cxcl3 C-X-C motif chemokine ligand 3 increases expression ISO trichostatin A results in increased expression of CXCL1 mRNA CTD PMID:24935251 NCBI chr14:17,571,900...17,573,624
Ensembl chr14:17,571,900...17,573,624 		JBrowse link
G Cxcl6 C-X-C motif chemokine ligand 6 increases expression ISO trichostatin A results in increased expression of CXCL6 mRNA CTD PMID:24935251 NCBI chr14:17,594,959...17,596,417
Ensembl chr14:17,594,959...17,596,417 		JBrowse link
G Cxcr4 C-X-C motif chemokine receptor 4 multiple interactions
increases expression
decreases expression 		ISO [Decitabine co-treated with trichostatin A] results in increased expression of CXCR4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CXCR4 mRNA
trichostatin A results in increased expression of CXCR4 mRNA
trichostatin A results in decreased expression of CXCR4 mRNA 		CTD PMID:17616702 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr13:42,630,383...42,634,288
Ensembl chr13:42,630,104...42,634,459 		JBrowse link
G Cxxc5 CXXC finger protein 5 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CXXC5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXXC5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr18:27,701,650...27,732,633
Ensembl chr18:27,701,188...27,732,635 		JBrowse link
G Cyb5a cytochrome b5 type A increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CYB5A mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYB5A mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr18:80,487,923...80,520,544
Ensembl chr18:14,453,966...14,455,094
Ensembl chr18:14,453,966...14,455,094 		JBrowse link
G Cyb5b cytochrome b5 type B decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CYB5B mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CYB5B mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr19:51,972,611...52,006,477
Ensembl chr19:51,972,547...52,026,980 		JBrowse link
G Cyb5r1 cytochrome b5 reductase 1 increases expression ISO trichostatin A results in increased expression of CYB5R1 mRNA CTD PMID:28542535 NCBI chr13:48,401,061...48,407,466
Ensembl chr13:48,399,106...48,407,465 		JBrowse link
G Cybrd1 cytochrome b reductase 1 decreases expression ISO trichostatin A results in decreased expression of CYBRD1 mRNA CTD PMID:24935251 NCBI chr 3:76,342,231...76,369,846
Ensembl chr 3:76,342,404...76,370,061 		JBrowse link
G Cycs cytochrome c, somatic multiple interactions ISO [perifosine co-treated with trichostatin A] affects the localization of CYCS protein CTD PMID:15781658 NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816
Ensembl chr18:80,982,668...80,984,816 		JBrowse link
G Cyfip2 cytoplasmic FMR1 interacting protein 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of CYFIP2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CYFIP2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:31,122,653...31,242,440
Ensembl chr10:31,122,653...31,242,440 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions
increases activity
increases expression 		ISO [trichostatin A co-treated with Tetrachlorodibenzodioxin] results in increased activity of CYP1A1 protein; Tetrachlorodibenzodioxin promotes the reaction [trichostatin A results in increased expression of CYP1A1 mRNA]; trichostatin A affects the reaction [Curcumin affects the reaction [6-formylindolo(3,2-b)carbazole results in increased expression of CYP1A1 mRNA]]; trichostatin A inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]; trichostatin A promotes the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CYP1A1 mRNA]; trichostatin A promotes the reaction [6-formylindolo(3,2-b)carbazole results in increased expression of CYP1A1 mRNA]; trichostatin A promotes the reaction [[Benzo(a)pyrene results in increased expression of CYP1A1 protein] which results in increased chemical synthesis of benzo(a)pyrene-DNA adduct]; trichostatin A promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]; trichostatin A promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]; trichostatin A promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]
trichostatin A results in increased activity of CYP1A1 protein 		CTD PMID:12927368 PMID:15713371 PMID:20116417 PMID:25116688 PMID:27041069 More... NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012 		JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 multiple interactions
increases expression 		ISO trichostatin A promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A2 mRNA]
trichostatin A results in increased expression of CYP1A2 mRNA
Tetrachlorodibenzodioxin inhibits the reaction [trichostatin A results in increased expression of CYP1A2 mRNA] 		CTD PMID:12927368 PMID:15252868 PMID:28357125 NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149 		JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1B1 mRNA; trichostatin A inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA]; trichostatin A inhibits the reaction [Nickel affects the expression of CYP1B1 mRNA]; trichostatin A promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]
trichostatin A results in increased expression of CYP1B1 mRNA 		CTD PMID:12927368 PMID:14575637 PMID:15713371 PMID:24935251 PMID:26272509 More... NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142 		JBrowse link
G Cyp24a1 cytochrome P450, family 24, subfamily a, polypeptide 1 multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of CYP24A1 mRNA]; trichostatin A promotes the reaction [Calcitriol results in increased expression of CYP24A1 mRNA]; trichostatin A promotes the reaction [Valproic Acid promotes the reaction [Calcitriol results in increased expression of CYP24A1 mRNA]] CTD PMID:14575637 PMID:20206692 PMID:21115105 NCBI chr 3:179,694,647...179,709,083
Ensembl chr 3:179,694,647...179,709,083 		JBrowse link
G Cyp26a1 cytochrome P450, family 26, subfamily a, polypeptide 1 decreases expression
increases expression 		ISO trichostatin A results in decreased expression of CYP26A1 mRNA
trichostatin A results in increased expression of CYP26A1 mRNA 		CTD PMID:24935251 NCBI chr 1:244,883,822...244,887,657
Ensembl chr 1:244,883,752...244,887,657 		JBrowse link
G Cyp26b1 cytochrome P450, family 26, subfamily b, polypeptide 1 increases expression ISO trichostatin A results in increased expression of CYP26B1 mRNA CTD PMID:24935251 NCBI chr 4:118,599,356...118,616,176
Ensembl chr 4:118,599,356...118,616,176 		JBrowse link
G Cyp2r1 cytochrome P450, family 2, subfamily r, polypeptide 1 increases expression ISO trichostatin A results in increased expression of CYP2R1 mRNA CTD PMID:24935251 NCBI chr 1:178,166,984...178,232,191
Ensembl chr 1:178,219,704...178,232,423 		JBrowse link
G Cyp2s1 cytochrome P450, family 2, subfamily s, polypeptide 1 multiple interactions ISO trichostatin A inhibits the reaction [Dexamethasone results in decreased expression of CYP2S1 mRNA] CTD PMID:22155357 NCBI chr 1:90,437,741...90,453,073
Ensembl chr 1:90,438,224...90,453,073 		JBrowse link
G Cyp2u1 cytochrome P450, family 2, subfamily u, polypeptide 1 increases expression ISO trichostatin A results in increased expression of CYP2U1 mRNA CTD PMID:24935251 NCBI chr 2:222,523,516...222,541,055
Ensembl chr 2:222,523,518...222,541,124 		JBrowse link
G Cyp39a1 cytochrome P450, family 39, subfamily a, polypeptide 1 decreases expression
increases expression 		ISO trichostatin A results in decreased expression of CYP39A1 mRNA
trichostatin A results in increased expression of CYP39A1 mRNA 		CTD PMID:24935251 PMID:27188386 NCBI chr 9:24,727,817...24,804,060
Ensembl chr 9:24,727,817...24,804,060 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions ISO trichostatin A affects the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; trichostatin A promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA] CTD PMID:31877331 NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857 		JBrowse link
G Cyp4v3 cytochrome P450, family 4, subfamily v, polypeptide 3 decreases expression ISO trichostatin A results in decreased expression of CYP4V2 mRNA CTD PMID:24935251 NCBI chr16:53,650,978...53,675,916
Ensembl chr16:53,650,569...53,676,746 		JBrowse link
G Cyp4x1 cytochrome P450, family 4, subfamily x, polypeptide 1 increases expression ISO trichostatin A results in increased expression of CYP4X1 mRNA CTD PMID:24935251 NCBI chr 5:133,888,439...133,923,254
Ensembl chr 5:133,888,439...133,919,642 		JBrowse link
G Cyria CYFIP related Rac1 interactor A increases expression ISO trichostatin A results in increased expression of CYRIA mRNA CTD PMID:24935251 NCBI chr 6:40,774,165...40,883,005
Ensembl chr 6:40,774,171...40,881,860 		JBrowse link
G Cys1 cystin 1 increases expression ISO trichostatin A results in increased expression of CYS1 mRNA CTD PMID:24935251 NCBI chr 6:47,029,440...47,046,671
Ensembl chr 6:47,028,461...47,046,671 		JBrowse link
G Cyth3 cytohesin 3 affects expression ISO trichostatin A affects the expression of CYTH3 mRNA CTD PMID:28542535 NCBI chr12:15,953,781...16,076,584
Ensembl chr12:15,953,791...16,047,506 		JBrowse link
G Cytl1 cytokine like 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of CYTL1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYTL1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr14:77,278,635...77,283,645
Ensembl chr14:77,278,636...77,283,645 		JBrowse link
G Daam1 dishevelled associated activator of morphogenesis 1 increases expression
affects expression 		ISO trichostatin A results in increased expression of DAAM1 mRNA
trichostatin A affects the expression of DAAM1 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 6:96,125,521...96,286,049
Ensembl chr 6:96,125,621...96,286,049 		JBrowse link
G Daam2 dishevelled associated activator of morphogenesis 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of DAAM2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DAAM2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 9:18,926,620...19,044,672
Ensembl chr 9:18,926,623...19,044,671 		JBrowse link
G Dab1 DAB adaptor protein 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of DAB1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAB1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:123,621,510...124,742,585
Ensembl chr 5:124,369,415...124,742,584 		JBrowse link
G Dab2 DAB adaptor protein 2 increases expression ISO trichostatin A results in increased expression of DAB2 mRNA CTD PMID:24935251 NCBI chr 2:57,241,947...57,294,893
Ensembl chr 2:57,242,064...57,294,888 		JBrowse link
G Dach1 dachshund family transcription factor 1 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of DACH1 mRNA
trichostatin A results in decreased expression of DACH1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DACH1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:80,936,063...81,317,746
Ensembl chr15:80,936,063...81,317,627 		JBrowse link
G Dach2 dachshund family transcription factor 2 increases expression ISO trichostatin A results in increased expression of DACH2 mRNA CTD PMID:24935251 NCBI chr  X:82,644,374...83,210,181
Ensembl chr  X:82,644,128...83,210,000 		JBrowse link
G Dact1 dishevelled-binding antagonist of beta-catenin 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of DACT1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DACT1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:95,526,645...95,538,625
Ensembl chr 6:95,526,690...95,551,053 		JBrowse link
G Dact3 dishevelled-binding antagonist of beta-catenin 3 multiple interactions
affects expression 		ISO [3-deazaneplanocin co-treated with trichostatin A] affects the expression of DACT3 mRNA; [3-deazaneplanocin co-treated with trichostatin A] affects the expression of DACT3 protein; [[3-deazaneplanocin co-treated with trichostatin A] affects the acetylation of and affects the methylation of H3-4 protein] which affects the expression of DACT3; [[3-deazaneplanocin co-treated with trichostatin A] affects the acetylation of and affects the methylation of H4C16 protein] which affects the expression of DACT3
trichostatin A affects the expression of DACT3 mRNA 		CTD PMID:18538736 NCBI chr 1:86,674,989...86,686,722
Ensembl chr 1:86,674,734...86,687,421 		JBrowse link
G Dag1 dystroglycan 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of DAG1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DAG1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:117,769,517...117,834,347
Ensembl chr 8:117,769,517...117,782,199 		JBrowse link
G Dapk1 death associated protein kinase 1 increases expression ISO trichostatin A results in increased expression of DAPK1 mRNA CTD PMID:16865256 NCBI chr17:3,935,826...4,096,858
Ensembl chr17:3,935,625...4,096,581 		JBrowse link
G Dapk2 death-associated protein kinase 2 increases expression ISO trichostatin A results in increased expression of DAPK2 mRNA CTD PMID:16865256 NCBI chr 8:75,601,621...75,720,619
Ensembl chr 8:75,601,634...75,720,617 		JBrowse link
G Dapk3 death-associated protein kinase 3 decreases expression ISO trichostatin A results in decreased expression of DAPK3 mRNA CTD PMID:24935251 NCBI chr 7:9,174,903...9,183,272
Ensembl chr 7:9,174,904...9,183,272 		JBrowse link
G Daxx death-domain associated protein affects expression ISO trichostatin A affects the expression of DAXX mRNA CTD PMID:28542535 NCBI chr20:4,971,973...4,978,062
Ensembl chr20:4,971,941...4,977,720 		JBrowse link
G Dazap2 DAZ associated protein 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of DAZAP2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAZAP2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:133,593,503...133,599,044
Ensembl chr 7:133,593,512...133,599,047 		JBrowse link
G Dazl deleted in azoospermia-like decreases expression ISO trichostatin A results in decreased expression of DAZL mRNA CTD PMID:24935251 NCBI chr 9:18,193,363...18,210,100
Ensembl chr 9:18,193,363...18,210,100 		JBrowse link
G Dbf4 DBF4-CDC7 kinase regulatory subunit affects expression ISO trichostatin A affects the expression of DBF4 mRNA CTD PMID:28542535 NCBI chr 4:26,631,491...26,656,080
Ensembl chr 4:26,631,514...26,656,562 		JBrowse link
G Dcaf10 DDB1 and CUL4 associated factor 10 increases expression ISO trichostatin A results in increased expression of DCAF10 mRNA CTD PMID:24935251 NCBI chr 5:64,402,307...64,442,839
Ensembl chr 5:64,403,451...64,440,614 		JBrowse link
G Dcaf12l1 DDB1 and CUL4 associated factor 12-like 1 increases expression ISO trichostatin A results in increased expression of DCAF12L1 mRNA CTD PMID:24935251 NCBI chr  X:128,572,969...128,576,588
Ensembl chr  X:128,572,811...128,577,222 		JBrowse link
G Dcaf16 DDB1 and CUL4 associated factor 16 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of DCAF16 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCAF16 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:69,662,173...69,662,557 JBrowse link
G Dcaf4 DDB1 and CUL4 associated factor 4 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of DCAF4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCAF4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:108,885,970...108,912,116
Ensembl chr 6:108,885,932...108,912,110 		JBrowse link
G Dcaf7 DDB1 and CUL4 associated factor 7 multiple interactions ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCAF7 mRNA CTD PMID:27188386 NCBI chr10:91,473,900...91,496,080
Ensembl chr10:91,473,900...91,496,080 		JBrowse link
G Dcbld1 discoidin, CUB and LCCL domain containing 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of DCBLD1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCBLD1 mRNA 		CTD PMID:24935251 PMID:27188386 NCBI chr20:32,161,241...32,254,391
Ensembl chr20:32,161,254...32,281,176 		JBrowse link
G Dcbld2 discoidin, CUB and LCCL domain containing 2 multiple interactions ISO [[Decitabine co-treated with trichostatin A] affects the methylation of DCBLD2 promoter] which affects the expression of DCBLD2 mRNA; [[Decitabine co-treated with trichostatin A] affects the methylation of DCBLD2 promoter] which affects the expression of DCBLD2 protein; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCBLD2 mRNA; [trichostatin A affects the methylation of DCBLD2 promoter] which affects the expression of DCBLD2 mRNA; [trichostatin A affects the methylation of DCBLD2 promoter] which affects the expression of DCBLD2 protein CTD PMID:18314483 PMID:27188386 NCBI chr11:55,594,691...55,649,113
Ensembl chr11:55,594,691...55,649,085 		JBrowse link
G Dcc DCC netrin 1 receptor multiple interactions
increases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCC mRNA; trichostatin A inhibits the reaction [Nickel affects the expression of DCC mRNA]
trichostatin A results in increased expression of DCC mRNA 		CTD PMID:14575637 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr18:67,144,272...68,248,159
Ensembl chr18:67,149,179...68,247,541 		JBrowse link
G Dck deoxycytidine kinase decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of DCK mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCK mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:19,589,298...19,610,326
Ensembl chr14:19,589,298...19,610,326 		JBrowse link
G Dclk1 doublecortin-like kinase 1 decreases expression
increases expression 		ISO trichostatin A results in decreased expression of DCLK1 mRNA
trichostatin A results in increased expression of DCLK1 mRNA 		CTD PMID:24935251 NCBI chr 2:141,567,215...141,861,088
Ensembl chr 2:141,571,983...141,861,090 		JBrowse link
G Dclk2 doublecortin-like kinase 2 decreases expression ISO trichostatin A results in decreased expression of DCLK2 mRNA CTD PMID:24935251 NCBI chr 2:174,506,660...174,636,353
Ensembl chr 2:174,506,660...174,636,192 		JBrowse link
G Dcp2 decapping mRNA 2 increases expression ISO trichostatin A results in increased expression of DCP2 mRNA CTD PMID:24935251 NCBI chr18:37,001,615...37,037,949
Ensembl chr18:37,001,615...37,049,939 		JBrowse link
G Dct dopachrome tautomerase multiple interactions ISO trichostatin A inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased expression of DCT mRNA]; trichostatin A inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased expression of DCT protein] CTD PMID:15892717 NCBI chr15:101,469,159...101,508,029
Ensembl chr15:101,469,159...101,508,029 		JBrowse link
G Dctd dCMP deaminase affects expression ISO trichostatin A affects the expression of DCTD mRNA CTD PMID:28542535 NCBI chr16:50,799,699...50,831,398
Ensembl chr16:50,787,875...50,831,186 		JBrowse link
G Dctn6 dynactin subunit 6 affects expression ISO trichostatin A affects the expression of DCTN6 mRNA CTD PMID:28542535 NCBI chr16:64,780,759...64,799,766
Ensembl chr16:64,780,735...64,801,060 		JBrowse link
G Dcun1d4 defective in cullin neddylation 1 domain containing 4 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of DCUN1D4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCUN1D4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr14:35,006,792...35,087,285
Ensembl chr14:35,006,792...35,088,520 		JBrowse link
G Dcx doublecortin increases expression ISO trichostatin A results in increased expression of DCX mRNA CTD PMID:24935251 NCBI chr  X:112,227,455...112,370,291
Ensembl chr  X:112,227,455...112,304,161 		JBrowse link
G Ddah1 dimethylarginine dimethylaminohydrolase 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of DDAH1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DDAH1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:237,327,812...237,460,624
Ensembl chr 2:237,327,766...237,460,626 		JBrowse link
G Ddah2 DDAH family member 2, ADMA-independent decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of DDAH2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DDAH2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr20:3,766,115...3,769,161
Ensembl chr20:3,766,120...3,769,183 		JBrowse link
G Ddb2 damage specific DNA binding protein 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of DDB2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DDB2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:97,640,923...97,667,617
Ensembl chr 3:97,640,579...97,664,066 		JBrowse link
G Ddhd1 DDHD domain containing 1 increases expression ISO trichostatin A results in increased expression of DDHD1 mRNA CTD PMID:24935251 NCBI chr15:21,304,053...21,370,608
Ensembl chr15:21,303,826...21,370,608 		JBrowse link
G Ddit4 DNA-damage-inducible transcript 4 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of DDIT4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DDIT4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr20:28,434,938...28,437,037
Ensembl chr20:28,434,944...28,437,037 		JBrowse link
G Ddit4l DNA-damage-inducible transcript 4-like decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of DDIT4L mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DDIT4L mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:228,800,831...228,804,478
Ensembl chr 2:228,801,705...228,806,225 		JBrowse link
G Ddn dendrin affects expression ISO trichostatin A affects the expression of DDN mRNA CTD PMID:28542535 NCBI chr 7:131,832,270...131,836,252
Ensembl chr 7:131,832,271...131,836,294 		JBrowse link
G Ddr1 discoidin domain receptor tyrosine kinase 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of DDR1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DDR1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:3,047,269...3,069,277
Ensembl chr20:3,050,375...3,069,276 		JBrowse link
G Ddx11 DEAD/H-box helicase 11 decreases expression ISO trichostatin A results in decreased expression of DDX11 mRNA CTD PMID:23770000 NCBI chr 9:113,204,886...113,309,692
Ensembl chr 9:113,276,985...113,316,152 		JBrowse link
G Ddx17 DEAD-box helicase 17 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of DDX17 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DDX17 mRNA
trichostatin A affects the expression of DDX17 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 7:112,971,522...112,989,747
Ensembl chr 7:112,971,523...112,989,747 		JBrowse link
G Ddx23 DEAD-box helicase 23 affects expression ISO trichostatin A affects the expression of DDX23 mRNA CTD PMID:28542535 NCBI chr 7:131,676,636...131,693,917
Ensembl chr 7:131,676,636...131,689,074 		JBrowse link
G Ddx25 DEAD-box helicase 25 decreases expression ISO trichostatin A results in decreased expression of DDX25 mRNA CTD PMID:24935251 NCBI chr 8:42,152,046...42,168,635
Ensembl chr 8:42,152,047...42,168,080 		JBrowse link
G Ddx39b DExD-box helicase 39B multiple interactions ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DDX39B mRNA CTD PMID:27188386 NCBI chr20:3,577,200...3,589,651
Ensembl chr20:3,576,734...3,589,651 		JBrowse link
G Ddx3x DEAD-box helicase 3, X-linked decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of DDX3X mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DDX3X mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:12,152,346...12,165,983
Ensembl chr  X:12,152,346...12,165,983 		JBrowse link
G Ddx5 DEAD-box helicase 5 decreases expression ISO trichostatin A results in decreased expression of DDX5 mRNA CTD PMID:24935251 NCBI chr10:92,224,393...92,231,928
Ensembl chr10:92,224,395...92,231,300 		JBrowse link
G Ddx50 DExD-box helicase 50 increases expression ISO trichostatin A results in increased expression of DDX50 mRNA CTD PMID:24935251 NCBI chr20:31,104,354...31,133,652
Ensembl chr20:31,104,354...31,133,652 		JBrowse link
G Ddx6 DEAD-box helicase 6 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of DDX6 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DDX6 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 8:53,827,661...53,864,538
Ensembl chr 8:53,827,835...53,860,977 		JBrowse link
G Ddx60 DEXD/H-box helicase 60 decreases expression ISO trichostatin A results in decreased expression of DDX60 mRNA CTD PMID:24935251 NCBI chr16:33,087,940...33,208,843
Ensembl chr16:33,087,988...33,208,839 		JBrowse link
G Decr1 2,4-dienoyl-CoA reductase 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of DECR1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DECR1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:34,208,195...34,236,074
Ensembl chr 5:34,208,195...34,236,033 		JBrowse link
G Dedd2 death effector domain containing 2 decreases expression ISO trichostatin A results in decreased expression of DEDD2 mRNA CTD PMID:24935251 NCBI chr 1:89,916,906...89,934,663
Ensembl chr 1:89,919,524...89,936,804 		JBrowse link
G Def6 DEF6 guanine nucleotide exchange factor increases expression
affects expression 		ISO trichostatin A results in increased expression of DEF6 mRNA
trichostatin A affects the expression of DEF6 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr20:6,270,323...6,291,724
Ensembl chr20:6,269,357...6,291,771 		JBrowse link
G Dek DEK proto-oncogene affects expression ISO trichostatin A affects the expression of DEK mRNA CTD PMID:28542535 NCBI chr17:17,786,989...17,809,096
Ensembl chr17:17,787,139...17,810,122 		JBrowse link
G Dennd10 DENN domain containing 10 affects expression ISO trichostatin A affects the expression of DENND10 mRNA CTD PMID:28542535 NCBI chr 1:269,937,023...269,960,506
Ensembl chr 1:269,936,895...269,962,853 		JBrowse link
G Dennd11 DENN domain containing 11 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of DENND11 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND11 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:70,163,869...70,232,731
Ensembl chr 4:70,163,869...70,195,800 		JBrowse link
G Dennd1a DENN domain containing 1A decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of DENND1A mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1A mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:41,974,502...42,461,816
Ensembl chr 3:41,974,502...42,461,886 		JBrowse link
G Dennd1b DENN domain containing 1B increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of DENND1B mRNA
trichostatin A results in decreased expression of DENND1B mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1B mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr13:53,096,717...53,324,372
Ensembl chr13:53,092,261...53,324,369 		JBrowse link
G Dennd2a DENN domain containing 2A decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of DENND2A mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND2A mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:69,199,814...69,299,128
Ensembl chr 4:69,199,814...69,298,984 		JBrowse link
G Dennd2c DENN domain containing 2C affects expression ISO trichostatin A affects the expression of DENND2C mRNA CTD PMID:28542535 NCBI chr 2:193,310,822...193,378,986
Ensembl chr 2:193,335,230...193,378,978 		JBrowse link
G Dennd4a DENN domain containing 4A increases expression ISO trichostatin A results in increased expression of DENND4A mRNA CTD PMID:24935251 NCBI chr 8:74,218,131...74,331,543
Ensembl chr 8:74,218,191...74,331,542 		JBrowse link
G Dennd4b DENN domain containing 4B increases expression ISO trichostatin A results in increased expression of DENND4B mRNA CTD PMID:24935251 NCBI chr 2:178,018,095...178,034,054
Ensembl chr 2:178,018,358...178,034,054 		JBrowse link
G Dennd5b DENN domain containing 5B increases expression ISO trichostatin A results in increased expression of DENND5B mRNA CTD PMID:24935251 NCBI chr 4:183,688,039...183,821,012
Ensembl chr 4:183,692,227...183,820,508 		JBrowse link
G Depdc1 DEP domain containing 1 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of DEPDC1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DEPDC1 mRNA
trichostatin A affects the expression of DEPDC1 mRNA 		CTD PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 2:251,343,250...251,376,709
Ensembl chr 2:251,343,281...251,376,709 		JBrowse link
G Depdc7 DEP domain containing 7 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of DEPDC7 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPDC7 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:111,554,701...111,575,979
Ensembl chr 3:111,554,706...111,575,979 		JBrowse link
G Deptor DEP domain containing MTOR-interacting protein increases expression ISO trichostatin A results in increased expression of DEPTOR mRNA CTD PMID:24935251 NCBI chr 7:88,404,745...88,574,065
Ensembl chr 7:88,404,620...88,574,041 		JBrowse link
G Des desmin decreases expression EXP trichostatin A results in decreased expression of DES protein CTD PMID:12445420 NCBI chr 9:84,299,626...84,307,344
Ensembl chr 9:84,298,447...84,307,347 		JBrowse link
G Desi2 desumoylating isopeptidase 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of DESI2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DESI2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:92,493,765...92,543,307
Ensembl chr13:92,493,989...92,564,981 		JBrowse link
G Det1 DET1 partner of COP1 E3 ubiquitin ligase increases expression ISO trichostatin A results in increased expression of DET1 mRNA CTD PMID:24935251 NCBI chr 1:142,159,120...142,175,366
Ensembl chr 1:142,127,876...142,175,336 		JBrowse link
G Dgat2 diacylglycerol O-acyltransferase 2 decreases expression ISO trichostatin A results in decreased expression of DGAT2 mRNA CTD PMID:24935251 NCBI chr 1:162,866,237...162,896,655
Ensembl chr 1:162,866,237...162,896,566 		JBrowse link
G Dgkb diacylglycerol kinase, beta decreases expression ISO trichostatin A results in decreased expression of DGKB mRNA CTD PMID:24935251 NCBI chr 6:60,368,101...61,124,420
Ensembl chr 6:60,368,519...61,124,420 		JBrowse link
G Dgke diacylglycerol kinase epsilon increases expression ISO trichostatin A results in increased expression of DGKE mRNA CTD PMID:24935251 NCBI chr10:74,348,931...74,374,509
Ensembl chr10:74,350,246...74,374,478 		JBrowse link
G Dgki diacylglycerol kinase, iota decreases expression
increases expression 		ISO trichostatin A results in decreased expression of DGKI mRNA
trichostatin A results in increased expression of DGKI mRNA 		CTD PMID:24935251 NCBI chr 4:66,377,897...66,839,790
Ensembl chr 4:66,387,126...66,990,832 		JBrowse link
G Dgkq diacylglycerol kinase, theta decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of DGKQ mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKQ mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:1,203,380...1,217,536
Ensembl chr14:1,203,565...1,218,024 		JBrowse link
G Dhrs2 dehydrogenase/reductase 2 increases expression ISO trichostatin A results in increased expression of DHRS2 mRNA CTD PMID:19606018 PMID:24935251 NCBI chr15:32,658,855...32,673,591
Ensembl chr15:32,659,223...32,673,588 		JBrowse link
G Dhrsx dehydrogenase/reductase X-linked decreases expression ISO trichostatin A results in decreased expression of DHRSX mRNA CTD PMID:24935251 NCBI chr12:21,413,563...21,418,319
Ensembl chr12:21,413,575...21,418,319 		JBrowse link
G Dhtkd1 dehydrogenase E1 and transketolase domain containing 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of DHTKD1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DHTKD1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr17:77,242,512...77,316,074
Ensembl chr17:77,264,514...77,316,071 		JBrowse link
G Dhx15 DEAH-box helicase 15 affects expression ISO trichostatin A affects the expression of DHX15 mRNA CTD PMID:28542535 NCBI chr14:62,999,886...63,037,829
Ensembl chr14:62,999,877...63,037,828 		JBrowse link
G Dhx30 DExH-box helicase 30 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of DHX30 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DHX30 mRNA
trichostatin A affects the expression of DHX30 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 8:118,943,186...118,975,319
Ensembl chr 8:118,943,187...118,975,592 		JBrowse link
G Dhx9 DExH-box helicase 9 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of DHX9 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DHX9 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:68,152,813...68,189,580
Ensembl chr13:68,152,813...68,189,546 		JBrowse link
G Diablo diablo, IAP-binding mitochondrial protein decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of DIABLO mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DIABLO mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr12:38,716,668...38,731,285
Ensembl chr12:38,716,668...38,731,265 		JBrowse link
G Dido1 death inducer-obliterator 1 decreases expression
affects expression 		ISO trichostatin A results in decreased expression of DIDO1 mRNA
trichostatin A affects the expression of DIDO1 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 3:188,150,100...188,203,445
Ensembl chr 3:188,150,100...188,194,823 		JBrowse link
G Dip2c disco-interacting protein 2 homolog C decreases expression ISO trichostatin A results in decreased expression of DIP2C mRNA CTD PMID:27188386 NCBI chr17:65,338,711...65,724,111
Ensembl chr17:65,338,711...65,723,344 		JBrowse link
G Dipk1a divergent protein kinase domain 1A decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of DIPK1A mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DIPK1A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:1,917,353...1,988,188
Ensembl chr14:1,917,324...1,988,678 		JBrowse link
G Dipk1c divergent protein kinase domain 1C decreases expression ISO trichostatin A results in decreased expression of DIPK1C mRNA CTD PMID:24935251 NCBI chr18:80,362,854...80,384,774
Ensembl chr18:80,362,982...80,386,551 		JBrowse link
G Diras3 DIRAS family GTPase 3 increases expression ISO trichostatin A results in increased expression of DIRAS3 mRNA CTD PMID:23770000 NCBI chr 6:136,346,157...136,347,371
Ensembl chr 6:136,346,154...136,348,376 		JBrowse link
G Dis3 DIS3 homolog, exosome endoribonuclease and 3'-5' exoribonuclease affects expression ISO trichostatin A affects the expression of DIS3 mRNA CTD PMID:28542535 NCBI chr15:82,231,922...82,258,299
Ensembl chr15:82,231,283...82,258,333 		JBrowse link
G Disc1 DISC1 scaffold protein increases expression ISO trichostatin A results in increased expression of DISC1 mRNA CTD PMID:24935251 NCBI chr19:69,911,548...70,120,970
Ensembl chr19:69,911,976...70,120,970 		JBrowse link
G Disp1 dispatched RND transporter family member 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of DISP1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DISP1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr13:97,252,574...97,398,329
Ensembl chr13:97,252,574...97,398,460 		JBrowse link
G Dixdc1 DIX domain containing 1 affects expression ISO trichostatin A affects the expression of DIXDC1 mRNA CTD PMID:28542535 NCBI chr 8:59,904,218...59,977,595
Ensembl chr 8:59,904,218...59,978,447 		JBrowse link
G Dkk1 dickkopf WNT signaling pathway inhibitor 1 decreases expression ISO trichostatin A results in decreased expression of DKK1 mRNA CTD PMID:24935251 NCBI chr 1:237,794,969...237,798,650
Ensembl chr 1:237,794,969...237,798,650 		JBrowse link
G Dkk2 dickkopf WNT signaling pathway inhibitor 2 increases expression ISO trichostatin A results in increased expression of DKK2 mRNA CTD PMID:24935251 NCBI chr 2:223,242,375...223,334,249
Ensembl chr 2:223,242,377...223,334,724 		JBrowse link
G Dlc1 DLC1 Rho GTPase activating protein increases expression
multiple interactions 		ISO trichostatin A results in increased expression of DLC1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLC1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr16:61,954,177...62,374,819
Ensembl chr16:61,995,001...62,374,819 		JBrowse link
G Dlg1 discs large MAGUK scaffold protein 1 increases expression ISO trichostatin A results in increased expression of DLG1 mRNA CTD PMID:24935251 PMID:26272509 NCBI chr11:82,416,853...82,607,797
Ensembl chr11:82,416,853...82,607,797 		JBrowse link
G Dlg3 discs large MAGUK scaffold protein 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of DLG3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLG3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr  X:69,899,694...69,951,928
Ensembl chr  X:69,900,003...69,950,696 		JBrowse link
G Dlg5 discs large MAGUK scaffold protein 5 affects expression ISO trichostatin A affects the expression of DLG5 mRNA CTD PMID:28542535 NCBI chr15:125,287...237,334
Ensembl chr15:125,290...237,332 		JBrowse link
G Dlgap1 DLG associated protein 1 increases expression
decreases expression 		ISO trichostatin A results in increased expression of DLGAP1 mRNA
trichostatin A results in decreased expression of DLGAP1 mRNA 		CTD PMID:24935251 NCBI chr 9:117,304,144...118,173,463
Ensembl chr 9:117,614,061...118,173,463 		JBrowse link
G Dlgap2 DLG associated protein 2 decreases expression ISO trichostatin A results in decreased expression of DLGAP2 mRNA CTD PMID:24935251 NCBI chr16:81,489,059...82,198,693
Ensembl chr16:81,494,649...82,198,684 		JBrowse link
G Dlk1 delta like non-canonical Notch ligand 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of DLK1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLK1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:134,192,491...134,199,779
Ensembl chr 6:134,192,518...134,200,529 		JBrowse link
G Dll1 delta like canonical Notch ligand 1 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of DLL1 mRNA
trichostatin A results in decreased expression of DLL1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLL1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:64,985,161...64,993,274
Ensembl chr 1:64,985,161...64,993,276 		JBrowse link
G Dlx1 distal-less homeobox 1 increases expression
affects expression 		ISO trichostatin A results in increased expression of DLX1 mRNA
trichostatin A affects the expression of DLX1 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 3:76,763,864...76,768,454
Ensembl chr 3:76,763,500...76,768,447 		JBrowse link
G Dlx2 distal-less homeobox 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of DLX2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:76,777,912...76,781,255
Ensembl chr 3:76,777,912...76,781,255 		JBrowse link
G Dlx3 distal-less homeobox 3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of DLX3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:80,561,335...80,566,730
Ensembl chr10:80,561,335...80,566,711 		JBrowse link
G Dlx4 distal-less homeobox 4 increases expression ISO trichostatin A results in increased expression of DLX4 mRNA CTD PMID:24935251 NCBI chr10:80,581,878...80,587,272
Ensembl chr10:80,582,303...80,587,294 		JBrowse link
G Dlx5 distal-less homeobox 5 increases expression ISO trichostatin A results in increased expression of DLX5 mRNA CTD PMID:24935251 NCBI chr 4:35,965,579...35,969,973
Ensembl chr 4:35,965,579...35,969,845 		JBrowse link
G Dlx6 distal-less homeobox 6 decreases expression ISO trichostatin A results in decreased expression of DLX6 mRNA CTD PMID:26705709 NCBI chr 4:35,951,005...35,956,354
Ensembl chr 4:35,951,005...35,956,354 		JBrowse link
G Dmac2l distal membrane arm assembly component 2 like decreases expression ISO trichostatin A results in decreased expression of DMAC2L mRNA CTD PMID:24935251 NCBI chr 6:93,941,605...93,959,932
Ensembl chr 6:93,941,690...93,960,662 		JBrowse link
G Dmd dystrophin increases expression ISO trichostatin A results in increased expression of DMD mRNA CTD PMID:24935251 NCBI chr  X:51,070,098...53,437,845
Ensembl chr  X:51,070,273...53,437,835 		JBrowse link
G Dmkn dermokine multiple interactions ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DMKN mRNA CTD PMID:27188386 NCBI chr 1:95,140,737...95,158,676
Ensembl chr 1:95,141,620...95,157,439 		JBrowse link
G Dmrt3 doublesex and mab-3 related transcription factor 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of DMRT3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DMRT3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:232,670,642...232,690,557
Ensembl chr 1:232,675,059...232,688,833 		JBrowse link
G Dmrta1 DMRT-like family A1 decreases expression ISO trichostatin A results in decreased expression of DMRTA1 mRNA CTD PMID:24935251 NCBI chr 5:109,531,704...109,538,244
Ensembl chr 5:109,531,586...109,538,246 		JBrowse link
G Dmxl1 Dmx-like 1 affects expression ISO trichostatin A affects the expression of DMXL1 mRNA CTD PMID:28542535 NCBI chr18:45,179,505...45,349,999
Ensembl chr18:45,179,551...45,356,406 		JBrowse link
G Dmxl2 Dmx-like 2 increases expression ISO trichostatin A results in increased expression of DMXL2 mRNA CTD PMID:24935251 NCBI chr 8:63,637,314...63,803,911
Ensembl chr 8:63,637,314...63,781,116 		JBrowse link
G Dnaaf11 dynein axonemal assembly factor 11 multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of DNAAF11 mRNA] CTD PMID:14575637 NCBI chr 7:100,033,843...100,134,979
Ensembl chr 7:100,034,202...100,135,179 		JBrowse link
G Dnaaf2 dynein, axonemal, assembly factor 2 affects expression ISO trichostatin A affects the expression of DNAAF2 mRNA CTD PMID:28542535 NCBI chr 6:93,397,157...93,406,323
Ensembl chr 6:93,397,164...93,406,323 		JBrowse link
G Dnaaf3 dynein, axonemal, assembly factor 3 affects expression ISO trichostatin A affects the expression of DNAAF3 mRNA CTD PMID:28542535 NCBI chr 1:78,333,985...78,342,034
Ensembl chr 1:78,333,971...78,342,685 		JBrowse link
G Dnaaf5 dynein, axonemal, assembly factor 5 affects expression ISO trichostatin A affects the expression of DNAAF5 mRNA CTD PMID:28542535 NCBI chr12:20,567,482...20,606,600
Ensembl chr12:20,531,267...20,607,607 		JBrowse link
G Dnai4 dynein axonemal intermediate chain 4 increases expression ISO trichostatin A results in increased expression of DNAI4 mRNA CTD PMID:24935251 NCBI chr 5:123,016,480...123,105,283
Ensembl chr 5:123,016,480...123,105,283 		JBrowse link
G Dnajb1 DnaJ heat shock protein family (Hsp40) member B1 increases expression ISO trichostatin A results in increased expression of DNAJB1 mRNA CTD PMID:19606018 NCBI chr19:41,427,453...41,431,141
Ensembl chr19:41,427,453...41,431,416 		JBrowse link
G Dnajb11 DnaJ heat shock protein family (Hsp40) member B11 affects expression ISO trichostatin A affects the expression of DNAJB11 mRNA CTD PMID:28542535 NCBI chr11:91,656,334...91,672,800
Ensembl chr11:91,656,335...91,672,800 		JBrowse link
G Dnajb12 DnaJ heat shock protein family (Hsp40) member B12 affects expression ISO trichostatin A affects the expression of DNAJB12 mRNA CTD PMID:28542535 NCBI chr20:28,371,180...28,389,390
Ensembl chr20:28,371,199...28,389,389 		JBrowse link
G Dnajb2 DnaJ heat shock protein family (Hsp40) member B2 increases expression ISO trichostatin A results in increased expression of DNAJB2 mRNA CTD PMID:24973648 NCBI chr 9:84,179,702...84,187,942
Ensembl chr 9:84,179,695...84,187,942 		JBrowse link
G Dnajb9 DnaJ heat shock protein family (Hsp40) member B9 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of DNAJB9 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DNAJB9 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:66,997,842...67,007,371
Ensembl chr 6:66,997,842...67,009,344 		JBrowse link
G Dnajc1 DnaJ heat shock protein family (Hsp40) member C1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of DNAJC1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNAJC1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr17:85,863,651...86,020,954
Ensembl chr17:85,863,651...86,020,432 		JBrowse link
G Dnajc11 DnaJ heat shock protein family (Hsp40) member C11 affects expression ISO trichostatin A affects the expression of DNAJC11 mRNA CTD PMID:28542535 NCBI chr 5:167,724,776...167,770,032
Ensembl chr 5:167,724,717...167,770,694 		JBrowse link
G Dnajc12 DnaJ heat shock protein family (Hsp40) member C12 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of DNAJC12 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNAJC12 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr20:25,245,475...25,266,238
Ensembl chr20:25,222,298...25,266,251 		JBrowse link
G Dnajc16 DnaJ heat shock protein family (Hsp40) member C16 affects expression ISO trichostatin A affects the expression of DNAJC16 mRNA CTD PMID:28542535 NCBI chr 5:159,355,279...159,389,267
Ensembl chr 5:159,361,314...159,389,298 		JBrowse link
G Dnajc17 DnaJ heat shock protein family (Hsp40) member C17 affects expression ISO trichostatin A affects the expression of DNAJC17 mRNA CTD PMID:28542535 NCBI chr 3:126,616,043...126,649,599
Ensembl chr 3:126,616,051...126,649,656 		JBrowse link
G Dnajc18 DnaJ heat shock protein family (Hsp40) member C18 decreases expression ISO trichostatin A results in decreased expression of DNAJC18 mRNA CTD PMID:24935251 NCBI chr18:27,543,438...27,577,535
Ensembl chr18:27,543,438...27,577,535 		JBrowse link
G Dnajc2 DnaJ heat shock protein family (Hsp40) member C2 affects expression ISO trichostatin A affects the expression of DNAJC2 mRNA CTD PMID:28542535 NCBI chr 4:14,162,490...14,189,662
Ensembl chr 4:14,163,838...14,192,846 		JBrowse link
G Dnajc24 DnaJ heat shock protein family (Hsp40) member C24 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of DNAJC24 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DNAJC24 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:112,905,369...112,940,741
Ensembl chr 3:112,904,769...112,940,640 		JBrowse link
G Dnajc6 DnaJ heat shock protein family (Hsp40) member C6 increases expression ISO trichostatin A results in increased expression of DNAJC6 mRNA CTD PMID:24935251 PMID:26705709 NCBI chr 5:121,232,532...121,398,775
Ensembl chr 5:121,235,425...121,398,775 		JBrowse link
G Dnajc7 DnaJ heat shock protein family (Hsp40) member C7 affects expression ISO trichostatin A affects the expression of DNAJC7 mRNA CTD PMID:28542535 NCBI chr10:86,018,977...86,055,419
Ensembl chr10:86,018,961...86,055,489 		JBrowse link
G Dnali1 dynein, axonemal, light intermediate chain 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of DNALI1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DNALI1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:142,603,132...142,611,970
Ensembl chr 5:142,603,134...142,611,993 		JBrowse link
G Dnase1l1 deoxyribonuclease 1-like 1 decreases expression ISO trichostatin A results in decreased expression of DNASE1L1 mRNA CTD PMID:24935251 NCBI chr  X:157,208,230...157,216,812
Ensembl chr  X:157,208,230...157,216,711 		JBrowse link
G Dner delta/notch-like EGF repeat containing increases expression
multiple interactions 		ISO trichostatin A results in increased expression of DNER mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNER mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 9:93,035,108...93,350,568
Ensembl chr 9:93,035,108...93,350,568 		JBrowse link
G Dnlz DNL-type zinc finger affects expression ISO trichostatin A affects the expression of DNLZ mRNA CTD PMID:28542535 NCBI chr 3:29,568,041...29,569,937
Ensembl chr 3:29,568,041...29,569,996 		JBrowse link
G Dnm2 dynamin 2 increases expression ISO trichostatin A results in increased expression of DNM2 mRNA CTD PMID:23770000 NCBI chr 8:28,254,344...28,336,297
Ensembl chr 8:28,254,529...28,336,295 		JBrowse link
G Dnm3 dynamin 3 increases expression
affects expression 		ISO trichostatin A results in increased expression of DNM3 mRNA
trichostatin A affects the expression of DNM3 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr13:76,892,381...77,371,346
Ensembl chr13:76,892,171...77,371,350 		JBrowse link
G Dnmt1 DNA methyltransferase 1 multiple interactions ISO trichostatin A inhibits the reaction [Folic Acid results in increased expression of DNMT1 mRNA] CTD PMID:39617304 NCBI chr 8:27,716,797...27,763,405
Ensembl chr 8:27,716,797...27,763,119 		JBrowse link
G Dnmt3a DNA methyltransferase 3 alpha multiple interactions ISO trichostatin A inhibits the reaction [Folic Acid results in increased expression of DNMT3A mRNA] CTD PMID:39617304 NCBI chr 6:32,507,316...32,621,678
Ensembl chr 6:32,512,070...32,614,970 		JBrowse link
G Dnmt3b DNA methyltransferase 3 beta affects expression
multiple interactions 		ISO [trichostatin A affects the expression of DNMT3B protein] which affects the expression of CDKN1A mRNA; [trichostatin A affects the expression of DNMT3B protein] which affects the expression of CDKN1B mRNA; [trichostatin A affects the expression of DNMT3B protein] which affects the expression of RB1 mRNA; trichostatin A affects the expression of DNMT3B mRNA
trichostatin A affects the reaction [hydroquinone affects the expression of DNMT3B mRNA]
trichostatin A inhibits the reaction [Folic Acid results in increased expression of DNMT3B mRNA] 		CTD PMID:18544619 PMID:31899212 PMID:39617304 NCBI chr 3:162,590,777...162,629,313
Ensembl chr 3:162,604,037...162,629,313 		JBrowse link
G Dock11 dedicator of cytokinesis 11 increases expression ISO trichostatin A results in increased expression of DOCK11 mRNA CTD PMID:24935251 NCBI chr  X:119,997,523...120,180,643
Ensembl chr  X:119,997,552...120,180,634 		JBrowse link
G Dock2 dedicator of cytokinesis 2 increases expression ISO trichostatin A results in increased expression of DOCK2 mRNA CTD PMID:24935251 NCBI chr10:19,331,412...19,748,987
Ensembl chr10:19,331,412...19,748,969 		JBrowse link
G Dock4 dedicator of cytokinesis 4 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of DOCK4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:63,240,050...63,629,772
Ensembl chr 6:63,240,136...63,629,772 		JBrowse link
G Dock8 dedicator of cytokinesis 8 decreases expression ISO trichostatin A results in decreased expression of DOCK8 mRNA CTD PMID:24935251 NCBI chr 1:232,075,468...232,268,830
Ensembl chr 1:232,075,588...232,268,833 		JBrowse link
G Dock9 dedicator of cytokinesis 9 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of DOCK9 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK9 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:105,018,341...105,289,799
Ensembl chr15:105,024,912...105,289,799 		JBrowse link
G Dok5 docking protein 5 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of DOK5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOK5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:179,934,419...180,071,334
Ensembl chr 3:179,934,552...180,071,333 		JBrowse link
G Dorip1 dopamine receptor interacting protein 1 increases expression ISO trichostatin A results in increased expression of DORIP1 mRNA CTD PMID:24935251 NCBI chr 6:88,701,651...88,710,204
Ensembl chr 6:88,701,818...88,708,820 		JBrowse link
G Dot1l DOT1 like histone lysine methyltransferase decreases expression ISO trichostatin A results in decreased expression of DOT1L mRNA CTD PMID:28542535 NCBI chr 7:9,569,439...9,607,095
Ensembl chr 7:9,569,439...9,607,095 		JBrowse link
G Dpf1 double PHD fingers 1 affects expression ISO trichostatin A affects the expression of DPF1 mRNA CTD PMID:28542535 NCBI chr 1:93,729,683...93,743,425
Ensembl chr 1:93,726,970...93,743,425 		JBrowse link
G Dpm1 dolichyl-phosphate mannosyltransferase subunit 1, catalytic affects expression ISO trichostatin A affects the expression of DPM1 mRNA CTD PMID:28542535 NCBI chr 3:177,338,855...177,358,398
Ensembl chr 3:177,338,855...177,358,412 		JBrowse link
G Dpm3 dolichyl-phosphate mannosyltransferase subunit 3, regulatory decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of DPM3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DPM3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:176,974,290...176,974,805
Ensembl chr15:52,612,418...52,612,696 		JBrowse link
G Dpp4 dipeptidylpeptidase 4 increases expression ISO trichostatin A results in increased expression of DPP4 mRNA CTD PMID:26238599 NCBI chr 3:67,370,794...67,452,422
Ensembl chr 3:67,370,804...67,452,422 		JBrowse link
G Dpp6 dipeptidyl peptidase like 6 decreases expression ISO trichostatin A results in decreased expression of DPP6 mRNA CTD PMID:24935251 NCBI chr 4:8,323,220...9,242,694
Ensembl chr 4:8,324,843...9,242,209 		JBrowse link
G Dppa2 developmental pluripotency-associated 2 multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of DPPA2 mRNA] CTD PMID:14575637 NCBI chr11:66,008,002...66,020,044
Ensembl chr11:66,011,628...66,020,994 		JBrowse link
G Dppa5 developmental pluripotency associated 5 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of DPPA5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPPA5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 8:88,095,627...88,097,936
Ensembl chr 1:14,260,684...14,261,146 		JBrowse link
G Dpy19l1 dpy-19 like C-mannosyltransferase 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of DPY19L1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPY19L1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:31,209,025...31,297,485
Ensembl chr 8:31,209,025...31,297,518 		JBrowse link
G Dpy19l2 dpy-19 like 2 increases expression ISO trichostatin A results in increased expression of DPY19L2 mRNA CTD PMID:24935251 NCBI chr 8:31,338,450...31,457,682
Ensembl chr 8:31,338,488...31,457,725 		JBrowse link
G Dpyd dihydropyrimidine dehydrogenase increases expression
multiple interactions 		ISO trichostatin A results in increased expression of DPYD mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPYD mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:209,293,902...210,159,777
Ensembl chr 2:209,293,929...210,159,778 		JBrowse link
G Dpysl2 dihydropyrimidinase-like 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of DPYSL2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DPYSL2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:45,181,041...45,287,065
Ensembl chr15:45,181,041...45,287,065 		JBrowse link
G Dpysl3 dihydropyrimidinase-like 3 decreases expression ISO trichostatin A results in decreased expression of DPYSL3 mRNA CTD PMID:24935251 PMID:26272509 NCBI chr18:35,625,357...35,731,152
Ensembl chr18:35,625,357...35,731,152 		JBrowse link
G Dpysl5 dihydropyrimidinase-like 5 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of DPYSL5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DPYSL5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:31,295,035...31,379,348
Ensembl chr 6:31,295,035...31,379,348 		JBrowse link
G Dram1 DNA-damage regulated autophagy modulator 1 increases expression ISO trichostatin A results in increased expression of DRAM1 mRNA CTD PMID:24935251 NCBI chr 7:24,630,233...24,665,270
Ensembl chr 7:24,630,238...24,664,354 		JBrowse link
G Drd2 dopamine receptor D2 increases expression
multiple interactions 		ISO
EXP 		trichostatin A results in increased expression of DRD2 mRNA
trichostatin A co-treated with 5-aza-2'-deoxycytidine increases expression of Drd2 mRNA in pituitary gland 		CTD
RGD		 PMID:24204683 PMID:26509893 RGD:11344152 NCBI chr 8:58,605,403...58,669,339
Ensembl chr 8:58,605,403...58,669,339 		JBrowse link
G Drd4 dopamine receptor D4 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of DRD4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DRD4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:205,825,937...205,829,124
Ensembl chr 1:205,826,049...205,830,458 		JBrowse link
G Dsc2 desmocollin 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of DSC2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DSC2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr18:11,725,466...11,757,591
Ensembl chr18:11,725,466...11,757,466 		JBrowse link
G Dsc3 desmocollin 3 increases expression ISO trichostatin A results in increased expression of DSC3 mRNA CTD PMID:24935251 NCBI chr18:11,654,833...11,688,871
Ensembl chr18:11,653,832...11,688,871 		JBrowse link
G Dsel dermatan sulfate epimerase-like increases expression ISO trichostatin A results in increased expression of DSEL mRNA CTD PMID:24935251 NCBI chr13:194,738...200,959
Ensembl chr13:179,618...200,993 		JBrowse link
G Dsg2 desmoglein 2 increases expression ISO trichostatin A results in increased expression of DSG2 mRNA CTD PMID:24935251 PMID:26705709 NCBI chr18:12,121,287...12,179,590
Ensembl chr18:12,121,181...12,179,590 		JBrowse link
G Dsp desmoplakin increases expression
multiple interactions 		ISO trichostatin A results in increased expression of DSP mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DSP mRNA 		CTD PMID:24935251 PMID:26272509 PMID:26705709 PMID:27188386 NCBI chr17:26,829,153...26,877,419
Ensembl chr17:26,829,153...26,877,121 		JBrowse link
G Dspp dentin sialophosphoprotein increases expression EXP trichostatin A results in increased expression of DSPP mRNA CTD PMID:23562654 NCBI chr14:5,870,232...5,876,339
Ensembl chr14:5,870,232...5,876,339 		JBrowse link
G Dst dystonin decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of DST mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DST mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 9:43,631,716...44,025,535
Ensembl chr 9:43,631,517...44,025,533 		JBrowse link
G Dtd2 D-aminoacyl-tRNA deacylase 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of DTD2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DTD2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:75,185,496...75,191,774
Ensembl chr 6:75,156,201...75,191,774 		JBrowse link
G Dtna dystrobrevin, alpha increases expression ISO trichostatin A results in increased expression of DTNA mRNA CTD PMID:24935251 NCBI chr18:14,862,801...15,218,993
Ensembl chr18:14,862,818...15,218,993 		JBrowse link
G Dtnbp1 dystrobrevin binding protein 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of DTNBP1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DTNBP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:19,891,313...19,982,770
Ensembl chr17:19,891,337...19,984,418 		JBrowse link
G Dtwd1 DTW domain containing 1 affects expression ISO trichostatin A affects the expression of DTWD1 mRNA CTD PMID:28542535 NCBI chr 3:133,845,768...133,859,965
Ensembl chr 3:133,841,935...133,860,316 		JBrowse link
G Dus3l dihydrouridine synthase 3-like affects expression ISO trichostatin A affects the expression of DUS3L mRNA CTD PMID:28542535 NCBI chr 9:1,680,619...1,685,784
Ensembl chr 9:1,675,819...1,686,367 		JBrowse link
G Dusp1 dual specificity phosphatase 1 multiple interactions
increases activity
increases expression 		ISO DUSP1 mutant form inhibits the reaction [trichostatin A inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]]; DUSP1 mutant form inhibits the reaction [trichostatin A inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]]; DUSP1 mutant form inhibits the reaction [trichostatin A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of JUN protein]]; DUSP1 mutant form inhibits the reaction [trichostatin A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK14 protein]]; DUSP1 mutant form inhibits the reaction [trichostatin A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK8 protein]]; DUSP1 mutant form inhibits the reaction [trichostatin A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK9 protein]]; trichostatin A promotes the reaction [arsenite results in increased expression of DUSP1 mRNA]
trichostatin A results in increased activity of DUSP1 protein
trichostatin A results in increased expression of DUSP1 mRNA 		CTD PMID:11689710 PMID:21911040 PMID:24935251 PMID:26272509 NCBI chr10:17,184,853...17,187,646
Ensembl chr10:17,184,823...17,187,644 		JBrowse link
G Dusp2 dual specificity phosphatase 2 multiple interactions ISO [[decitabine co-treated with trichostatin A] affects the methylation of DUSP2 promoter] which affects the expression of DUSP2 mRNA CTD PMID:18836996 NCBI chr 3:135,009,636...135,011,821
Ensembl chr 3:135,009,590...135,011,809 		JBrowse link
G Dusp4 dual specificity phosphatase 4 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of DUSP4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DUSP4 mRNA
trichostatin A affects the expression of DUSP4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr16:64,079,893...64,101,396
Ensembl chr16:64,079,893...64,093,700 		JBrowse link
G Dusp5 dual specificity phosphatase 5 increases expression
multiple interactions
affects expression 		ISO trichostatin A results in increased expression of DUSP5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP5 mRNA
trichostatin A affects the expression of DUSP5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 1:262,543,774...262,557,201
Ensembl chr 1:262,543,738...262,562,417 		JBrowse link
G Dusp6 dual specificity phosphatase 6 decreases expression ISO trichostatin A results in decreased expression of DUSP6 mRNA CTD PMID:26272509 NCBI chr 7:35,979,502...35,983,834
Ensembl chr 7:35,977,921...35,983,833 		JBrowse link
G Dvl1 dishevelled segment polarity protein 1 multiple interactions ISO [decitabine co-treated with trichostatin A] results in decreased expression of DVL1 mRNA CTD PMID:17891453 NCBI chr 5:171,738,911...171,750,967
Ensembl chr 5:171,739,133...171,750,966 		JBrowse link
G Dvl2 dishevelled segment polarity protein 2 multiple interactions ISO [3-deazaneplanocin co-treated with trichostatin A] affects the expression of DVL2 protein CTD PMID:18538736 NCBI chr10:55,222,245...55,231,506
Ensembl chr10:55,222,056...55,231,506 		JBrowse link
G Dync1i1 dynein cytoplasmic 1 intermediate chain 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of DYNC1I1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DYNC1I1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:34,819,313...35,132,647
Ensembl chr 4:34,819,430...35,142,319 		JBrowse link
G Dync1li1 dynein cytoplasmic 1 light intermediate chain 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of DYNC1LI1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DYNC1LI1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:123,254,823...123,288,496
Ensembl chr 8:123,254,859...123,289,167 		JBrowse link
G Dync2h1 dynein cytoplasmic 2 heavy chain 1 decreases expression ISO trichostatin A results in decreased expression of DYNC2H1 mRNA CTD PMID:24935251 NCBI chr 8:12,473,955...12,697,075
Ensembl chr 8:12,473,955...12,697,058 		JBrowse link
G Dynlt3 dynein light chain Tctex-type 3 affects expression ISO trichostatin A affects the expression of DYNLT3 mRNA CTD PMID:28542535 NCBI chr  X:16,000,425...16,009,632
Ensembl chr  X:16,000,395...16,009,627 		JBrowse link
G Dyrk1a dual specificity tyrosine phosphorylation regulated kinase 1A affects expression ISO trichostatin A affects the expression of DYRK1A mRNA CTD PMID:28542535 NCBI chr11:47,360,824...47,479,033
Ensembl chr11:47,360,850...47,479,033 		JBrowse link
G Dyrk3 dual specificity tyrosine phosphorylation regulated kinase 3 increases expression ISO trichostatin A results in increased expression of DYRK3 mRNA CTD PMID:28542535 NCBI chr13:45,146,383...45,157,082
Ensembl chr13:45,146,384...45,157,249 		JBrowse link
G Dzip3 DAZ interacting zinc finger protein 3 increases expression ISO trichostatin A results in increased expression of DZIP3 mRNA CTD PMID:24935251 NCBI chr11:65,286,190...65,356,314
Ensembl chr11:65,286,190...65,356,314 		JBrowse link
G E2f3 E2F transcription factor 3 affects expression ISO trichostatin A affects the expression of E2F3 mRNA CTD PMID:28542535 NCBI chr17:34,810,355...34,887,725
Ensembl chr17:34,809,998...34,887,725 		JBrowse link
G E2f8 E2F transcription factor 8 affects expression ISO trichostatin A affects the expression of E2F8 mRNA CTD PMID:28542535 NCBI chr 1:107,701,985...107,720,538
Ensembl chr 1:107,701,985...107,720,009 		JBrowse link
G Ebag9 estrogen receptor binding site associated antigen 9 affects expression ISO trichostatin A affects the expression of EBAG9 mRNA CTD PMID:28542535 NCBI chr 7:77,695,213...77,713,565
Ensembl chr 7:77,695,072...77,713,557 		JBrowse link
G Ebf1 EBF transcription factor 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of EBF1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EBF1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:29,597,221...29,990,571
Ensembl chr10:29,601,351...29,988,702 		JBrowse link
G Ece1 endothelin converting enzyme 1 affects expression ISO trichostatin A affects the expression of ECE1 mRNA CTD PMID:28542535 NCBI chr 5:155,361,031...155,462,723
Ensembl chr 5:155,360,639...155,462,719 		JBrowse link
G Echdc3 enoyl CoA hydratase domain containing 3 increases expression ISO trichostatin A results in increased expression of ECHDC3 mRNA CTD PMID:24935251 NCBI chr17:76,980,112...77,002,934
Ensembl chr17:76,980,083...77,002,934 		JBrowse link
G Eci2 enoyl-CoA delta isomerase 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ECI2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ECI2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr17:30,056,274...30,092,169
Ensembl chr17:30,076,524...30,092,161 		JBrowse link
G Ecpas Ecm29 proteasome adaptor and scaffold decreases expression
increases expression
affects expression 		ISO trichostatin A results in decreased expression of ECPAS mRNA
trichostatin A results in increased expression of ECPAS mRNA
trichostatin A affects the expression of ECPAS mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 5:78,398,449...78,509,077
Ensembl chr 5:78,398,718...78,512,908 		JBrowse link
G Ect2 epithelial cell transforming 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ECT2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ECT2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:111,904,522...111,966,786
Ensembl chr 2:111,904,522...111,966,626 		JBrowse link
G Edn1 endothelin 1 decreases expression
increases expression
multiple interactions 		ISO trichostatin A results in decreased expression of EDN1 mRNA
trichostatin A results in increased expression of EDN1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDN1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:26705709 PMID:27188386 NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687 		JBrowse link
G Ednra endothelin receptor type A increases expression
multiple interactions 		ISO trichostatin A results in increased expression of EDNRA mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRA mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr19:47,137,360...47,207,961
Ensembl chr19:47,137,771...47,201,284 		JBrowse link
G Ednrb endothelin receptor type B increases expression
multiple interactions 		ISO trichostatin A results in increased expression of EDNRB mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:87,055,490...87,086,765
Ensembl chr15:87,057,691...87,086,765 		JBrowse link
G Eea1 early endosome antigen 1 increases expression ISO trichostatin A results in increased expression of EEA1 mRNA CTD PMID:24935251 NCBI chr 7:32,441,281...32,608,808
Ensembl chr 7:32,441,272...32,608,476 		JBrowse link
G Eef1a1 eukaryotic translation elongation factor 1 alpha 1 decreases expression ISO trichostatin A results in decreased expression of EEF1A1 mRNA CTD PMID:28542535 NCBI chr 8:88,221,839...88,225,688
Ensembl chr 8:88,221,843...88,225,072 		JBrowse link
G Eef1akmt3 EEF1A lysine methyltransferase 3 affects expression ISO trichostatin A affects the expression of EEF1AKMT3 mRNA CTD PMID:28542535 NCBI chr 7:64,738,726...64,749,904
Ensembl chr 7:64,740,232...64,750,055 		JBrowse link
G Eef2k eukaryotic elongation factor-2 kinase increases expression
multiple interactions 		ISO trichostatin A results in increased expression of EEF2K mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EEF2K mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:184,824,420...184,888,048
Ensembl chr 1:184,824,420...184,888,048 		JBrowse link
G Eepd1 endonuclease/exonuclease/phosphatase family domain containing 1 affects expression ISO trichostatin A affects the expression of EEPD1 mRNA CTD PMID:28542535 NCBI chr 8:32,233,834...32,340,148
Ensembl chr 8:32,233,070...32,340,147 		JBrowse link
G Efcab3 EF-hand calcium binding domain 3 affects expression ISO trichostatin A affects the expression of EFCAB3 mRNA CTD PMID:28542535 NCBI chr10:90,084,495...90,577,145
Ensembl chr10:90,084,397...90,577,144 		JBrowse link
G Efemp1 EGF containing fibulin extracellular matrix protein 1 increases expression ISO trichostatin A results in increased expression of EFEMP1 mRNA CTD PMID:24935251 NCBI chr14:106,811,769...106,890,961
Ensembl chr14:106,802,304...106,892,808 		JBrowse link
G Efemp2 EGF containing fibulin extracellular matrix protein 2 decreases expression ISO trichostatin A results in decreased expression of EFEMP2 mRNA CTD PMID:24935251 NCBI chr 1:212,211,057...212,218,739
Ensembl chr 1:212,210,972...212,218,739 		JBrowse link
G Efhb EF hand domain family, member B decreases expression ISO trichostatin A results in decreased expression of EFHB mRNA CTD PMID:24935251 NCBI chr 9:6,608,791...6,680,104
Ensembl chr 9:6,608,794...6,678,827 		JBrowse link
G Efhc1 EF-hand domain containing 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of EFHC1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EFHC1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 9:30,872,238...30,910,703
Ensembl chr 9:30,871,565...30,910,703 		JBrowse link
G Efna1 ephrin A1 increases expression
multiple interactions
affects expression 		ISO trichostatin A results in increased expression of EFNA1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFNA1 mRNA
trichostatin A affects the expression of EFNA1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 2:176,979,434...176,988,675
Ensembl chr 2:176,979,434...176,988,726 		JBrowse link
G Efna3 ephrin A3 affects expression ISO trichostatin A affects the expression of EFNA3 mRNA CTD PMID:28542535 NCBI chr 2:177,026,928...177,035,838
Ensembl chr 2:177,026,933...177,044,843 		JBrowse link
G Efna5 ephrin A5 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of EFNA5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EFNA5 mRNA 		CTD PMID:22723015 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 9:109,763,786...110,042,396
Ensembl chr 9:109,767,252...110,042,348 		JBrowse link
G Efnb2 ephrin B2 increases expression ISO trichostatin A results in increased expression of EFNB2 mRNA CTD PMID:24935251 NCBI chr16:87,485,215...87,529,224
Ensembl chr16:87,485,198...87,529,208 		JBrowse link
G Efr3a EFR3 homolog A affects expression ISO trichostatin A affects the expression of EFR3A mRNA CTD PMID:28542535 NCBI chr 7:99,441,764...99,522,454
Ensembl chr 7:99,441,767...99,522,454 		JBrowse link
G Efr3b EFR3 homolog B decreases expression ISO trichostatin A results in decreased expression of EFR3B mRNA CTD PMID:24935251 NCBI chr 6:32,664,593...32,740,417
Ensembl chr 6:32,666,945...32,740,417 		JBrowse link
G Egf epidermal growth factor multiple interactions
decreases expression
increases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGF mRNA
trichostatin A results in decreased expression of EGF mRNA
trichostatin A results in increased expression of EGF mRNA 		CTD PMID:23463510 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297 		JBrowse link
G Egfl6 EGF-like-domain, multiple 6 increases expression ISO trichostatin A results in increased expression of EGFL6 mRNA CTD PMID:24935251 NCBI chr  X:31,515,752...31,573,699
Ensembl chr  X:31,515,767...31,574,632 		JBrowse link
G Egfl8 EGF-like-domain, multiple 8 increases expression ISO trichostatin A results in increased expression of EGFL8 mRNA CTD PMID:24935251 PMID:26272509 NCBI chr20:4,137,531...4,140,632
Ensembl chr20:4,138,053...4,141,681 		JBrowse link
G Egflam EGF-like, fibronectin type III and laminin G domains increases expression ISO trichostatin A results in increased expression of EGFLAM mRNA CTD PMID:24935251 NCBI chr 2:58,029,934...58,204,010
Ensembl chr 2:58,029,935...58,203,643 		JBrowse link
G Egfr epidermal growth factor receptor increases expression
multiple interactions 		ISO trichostatin A results in increased expression of EGFR mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGFR mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358 		JBrowse link
G Egln3 egl-9 family hypoxia-inducible factor 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of EGLN3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGLN3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:77,385,549...77,411,015
Ensembl chr 6:77,385,549...77,411,015 		JBrowse link
G Egr1 early growth response 1 multiple interactions
affects expression
decreases expression 		ISO [Doxorubicin co-treated with trichostatin A] results in increased expression of EGR1 mRNA; EGR1 protein affects the reaction [trichostatin A affects the expression of GDF15 mRNA]; EGR1 protein affects the susceptibility to [Doxorubicin co-treated with trichostatin A]; trichostatin A promotes the reaction [[EP300 protein co-treated with EGR1 protein] results in increased expression of PTEN mRNA]
trichostatin A affects the expression of EGR1 mRNA; trichostatin A affects the expression of EGR1 protein
trichostatin A results in decreased expression of EGR1 mRNA 		CTD PMID:17330857 PMID:18801729 PMID:24935251 NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,736,838...26,740,843 		JBrowse link
G Egr2 early growth response 2 decreases expression
increases expression
affects expression 		ISO trichostatin A results in decreased expression of EGR2 mRNA
trichostatin A results in increased expression of EGR2 mRNA
trichostatin A affects the expression of EGR2 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr20:21,050,149...21,055,201
Ensembl chr20:21,050,149...21,057,748 		JBrowse link
G Egr3 early growth response 3 increases expression
decreases expression 		ISO trichostatin A results in increased expression of EGR3 mRNA
trichostatin A results in decreased expression of EGR3 mRNA 		CTD PMID:24935251 PMID:26705709 NCBI chr15:51,560,482...51,565,778
Ensembl chr15:51,560,344...51,565,712 		JBrowse link
G Ehbp1 EH domain binding protein 1 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of EHBP1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EHBP1 mRNA
trichostatin A affects the expression of EHBP1 mRNA 		CTD PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr14:100,294,585...100,581,764
Ensembl chr14:100,294,585...100,546,579 		JBrowse link
G Ehd3 EH-domain containing 3 increases expression ISO trichostatin A results in increased expression of EHD3 mRNA CTD PMID:24935251 NCBI chr 6:27,392,709...27,417,445
Ensembl chr 6:27,392,709...27,417,445 		JBrowse link
G Ehhadh enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase increases expression ISO trichostatin A results in increased expression of EHHADH mRNA CTD PMID:24935251 NCBI chr11:92,746,409...92,779,647
Ensembl chr11:92,746,420...92,779,662 		JBrowse link
G Ehmt1 euchromatic histone lysine methyltransferase 1 decreases expression ISO trichostatin A results in decreased expression of EHMT1 mRNA CTD PMID:24935251 NCBI chr 3:27,978,888...28,127,178
Ensembl chr 3:27,978,888...28,127,349 		JBrowse link
G Eid2b EP300 interacting inhibitor of differentiation 2B decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of EID2B mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EID2B mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:92,673,119...92,674,899 JBrowse link
G Eid3 EP300 interacting inhibitor of differentiation 3 decreases expression ISO trichostatin A results in decreased expression of EID3 mRNA CTD PMID:24935251 NCBI chr 7:22,747,645...22,748,967
Ensembl chr 7:22,747,656...22,749,177 		JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 increases expression ISO trichostatin A results in increased expression of EIF2AK3 mRNA CTD PMID:24935251 NCBI chr 4:104,363,838...104,425,271
Ensembl chr 4:104,363,833...104,425,268 		JBrowse link
G Eif2ak4 eukaryotic translation initiation factor 2 alpha kinase 4 decreases expression ISO trichostatin A results in decreased expression of EIF2AK4 mRNA CTD PMID:24935251 NCBI chr 3:125,810,207...125,895,574
Ensembl chr 3:125,810,060...125,895,574 		JBrowse link
G Eif2s2 eukaryotic translation initiation factor 2 subunit beta affects expression ISO trichostatin A affects the expression of EIF2S2 mRNA CTD PMID:28542535 NCBI chr 3:163,834,846...163,855,733
Ensembl chr 3:163,834,851...163,855,570 		JBrowse link
G Eif3a eukaryotic translation initiation factor 3, subunit A affects expression ISO trichostatin A affects the expression of EIF3A mRNA CTD PMID:28542535 NCBI chr 1:269,888,730...269,925,785
Ensembl chr 1:269,888,615...269,919,025 		JBrowse link
G Eif3m eukaryotic translation initiation factor 3, subunit M increases expression ISO trichostatin A results in increased expression of EIF3M mRNA CTD PMID:24935251 NCBI chr 3:111,879,589...111,897,193
Ensembl chr 3:111,870,925...111,897,193 		JBrowse link
G Eif4a3 eukaryotic translation initiation factor 4A3 affects expression ISO trichostatin A affects the expression of EIF4A3 mRNA CTD PMID:28542535 NCBI chr10:105,047,567...105,057,561
Ensembl chr10:105,047,568...105,058,207 		JBrowse link
G Eif4e eukaryotic translation initiation factor 4E affects expression ISO trichostatin A affects the expression of EIF4E mRNA CTD PMID:28542535 NCBI chr 2:229,736,309...229,772,628
Ensembl chr 2:229,739,897...229,774,105 		JBrowse link
G Eif4e3 eukaryotic translation initiation factor 4E family member 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of EIF4E3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EIF4E3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:133,709,802...133,858,398
Ensembl chr 4:133,625,768...133,885,647 		JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EIF4EBP1 mRNA; [trichostatin A co-treated with Bortezomib] results in decreased phosphorylation of EIF4EBP1 protein
trichostatin A results in increased expression of EIF4EBP1 mRNA 		CTD PMID:21345073 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr16:71,495,457...71,508,845
Ensembl chr16:71,487,930...71,508,874 		JBrowse link
G Eif4g2 eukaryotic translation initiation factor 4, gamma 2 decreases expression ISO trichostatin A results in decreased expression of EIF4G2 mRNA CTD PMID:19606018 NCBI chr 1:174,616,102...174,628,252
Ensembl chr 1:174,616,103...174,628,252 		JBrowse link
G Eif4g3 eukaryotic translation initiation factor 4 gamma, 3 decreases expression ISO trichostatin A results in decreased expression of EIF4G3 mRNA CTD PMID:24935251 NCBI chr 5:155,481,378...155,702,194
Ensembl chr 5:155,481,378...155,702,194 		JBrowse link
G Eif5 eukaryotic translation initiation factor 5 decreases expression ISO trichostatin A results in decreased expression of EIF5 mRNA CTD PMID:24935251 NCBI chr 6:136,410,333...136,418,827
Ensembl chr 6:136,407,440...136,418,821 		JBrowse link
G Eif5a eukaryotic translation initiation factor 5A increases expression
multiple interactions 		ISO trichostatin A results in increased expression of EIF5A mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EIF5A mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:55,138,821...55,143,272
Ensembl chr10:55,138,823...55,143,330 		JBrowse link
G Eif5a2 eukaryotic translation initiation factor 5A2 affects expression ISO trichostatin A affects the expression of EIF5A2 mRNA CTD PMID:28542535 NCBI chr 2:113,656,748...113,674,598
Ensembl chr 2:113,657,797...113,674,594 		JBrowse link
G Elac1 elaC ribonuclease Z 1 increases expression ISO trichostatin A results in increased expression of ELAC1 mRNA CTD PMID:24935251 NCBI chr18:69,596,475...69,617,206
Ensembl chr18:69,598,827...69,616,175 		JBrowse link
G Elavl1 ELAV like RNA binding protein 1 multiple interactions
decreases expression 		ISO [Decitabine co-treated with trichostatin A] affects the localization of ELAVL1 protein; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELAVL1 mRNA
trichostatin A results in decreased expression of ELAVL1 mRNA 		CTD PMID:17891453 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr12:7,441,699...7,482,625
Ensembl chr12:7,441,699...7,482,631 		JBrowse link
G Elavl2 ELAV like RNA binding protein 2 decreases expression ISO trichostatin A results in decreased expression of ELAVL2 mRNA CTD PMID:24935251 NCBI chr 5:111,076,705...111,202,341
Ensembl chr 5:111,076,705...111,224,918 		JBrowse link
G Elavl3 ELAV like RNA binding protein 3 increases expression ISO trichostatin A results in increased expression of ELAVL3 mRNA CTD PMID:24935251 NCBI chr 8:28,823,120...28,859,395
Ensembl chr 8:28,825,707...28,859,659 		JBrowse link
G Elf1 E74 like ETS transcription factor 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ELF1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:61,354,026...61,395,762
Ensembl chr15:61,330,877...61,395,758 		JBrowse link
G Elf3 E74 like ETS transcription factor 3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ELF3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr13:49,242,265...49,247,102
Ensembl chr13:49,242,267...49,247,380 		JBrowse link
G Elf5 E74 like ETS transcription factor 5 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ELF5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:110,264,460...110,291,926
Ensembl chr 3:110,252,797...110,291,926 		JBrowse link
G Elk1 ETS transcription factor ELK1 multiple interactions
increases activity 		ISO U 0126 inhibits the reaction [trichostatin A results in increased activity of ELK1 protein] CTD PMID:15103026 NCBI chr  X:3,692,367...3,709,252
Ensembl chr  X:3,693,293...3,709,249 		JBrowse link
G Elk3 ETS transcription factor ELK3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ELK3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELK3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:29,655,676...29,718,163
Ensembl chr 7:29,655,693...29,691,661 		JBrowse link
G Elk4 ETS transcription factor ELK4 decreases expression ISO trichostatin A results in decreased expression of ELK4 mRNA CTD PMID:24935251 NCBI chr13:46,004,145...46,027,206
Ensembl chr13:46,004,182...46,027,199 		JBrowse link
G Ell2 elongation factor for RNA polymerase II 2 multiple interactions
decreases expression
increases expression 		ISO trichostatin A inhibits the reaction [Nickel affects the expression of ELL2 mRNA]
trichostatin A results in decreased expression of ELL2 mRNA
trichostatin A results in increased expression of ELL2 mRNA 		CTD PMID:14575637 PMID:24935251 PMID:26705709 PMID:27188386 NCBI chr 2:6,910,446...6,990,654
Ensembl chr 2:6,921,771...7,016,199 		JBrowse link
G Elmod1 ELMO domain containing 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ELMOD1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELMOD1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 8:63,194,539...63,251,526
Ensembl chr 8:63,137,295...63,251,322 		JBrowse link
G Elof1 elongation factor 1 affects expression ISO trichostatin A affects the expression of ELOF1 mRNA CTD PMID:28542535 NCBI chr 8:28,921,338...28,926,612
Ensembl chr 8:28,921,339...28,926,228 		JBrowse link
G Elovl1 ELOVL fatty acid elongase 1 increases expression ISO trichostatin A results in increased expression of ELOVL1 mRNA CTD PMID:24935251 NCBI chr 5:137,246,781...137,251,351
Ensembl chr 5:137,246,849...137,251,352 		JBrowse link
G Elovl2 ELOVL fatty acid elongase 2 decreases expression
multiple interactions
increases expression 		ISO trichostatin A results in decreased expression of ELOVL2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELOVL2 mRNA
trichostatin A results in increased expression of ELOVL2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr17:23,750,350...23,790,601
Ensembl chr17:23,750,350...23,790,601 		JBrowse link
G Elovl4 ELOVL fatty acid elongase 4 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ELOVL4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELOVL4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 8:93,582,930...93,609,479
Ensembl chr 8:93,582,930...93,609,678 		JBrowse link
G Elovl6 ELOVL fatty acid elongase 6 increases expression ISO trichostatin A results in increased expression of ELOVL6 mRNA CTD PMID:24935251 NCBI chr 2:220,738,095...220,845,528
Ensembl chr 2:220,738,064...220,845,549 		JBrowse link
G Elovl7 ELOVL fatty acid elongase 7 increases expression ISO trichostatin A results in increased expression of ELOVL7 mRNA CTD PMID:24935251 NCBI chr 2:41,522,695...41,592,021
Ensembl chr 2:41,522,738...41,592,020 		JBrowse link
G Elp4 elongator acetyltransferase complex subunit 4 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ELP4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELP4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:112,617,020...112,839,963
Ensembl chr 3:112,617,035...112,839,963 		JBrowse link
G Elp6 elongator acetyltransferase complex subunit 6 affects expression ISO trichostatin A affects the expression of ELP6 mRNA CTD PMID:28542535 NCBI chr 8:119,158,380...119,173,483
Ensembl chr 8:119,158,396...119,174,244 		JBrowse link
G Emb embigin multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of EMB mRNA] CTD PMID:14575637 NCBI chr 2:50,803,468...50,858,001
Ensembl chr 2:50,801,973...50,862,920 		JBrowse link
G Emcn endomucin decreases expression ISO trichostatin A results in decreased expression of EMCN mRNA CTD PMID:26705709 NCBI chr 2:228,564,445...228,644,370
Ensembl chr 2:228,564,430...228,645,155 		JBrowse link
G Emilin3 elastin microfibril interfacer 3 decreases expression ISO trichostatin A results in decreased expression of EMILIN3 mRNA CTD PMID:24935251 NCBI chr 3:169,978,488...169,984,718
Ensembl chr 3:169,978,672...169,984,488 		JBrowse link
G Eml4 EMAP like 4 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of EML4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EML4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:16,972,054...17,087,365
Ensembl chr 6:16,972,075...17,087,439 		JBrowse link
G Eml6 EMAP like 6 decreases expression
increases expression
affects expression 		ISO trichostatin A results in decreased expression of EML6 mRNA
trichostatin A results in increased expression of EML6 mRNA
trichostatin A affects the expression of EML6 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr14:107,651,893...108,006,792
Ensembl chr14:107,699,400...108,005,409 		JBrowse link
G Emp1 epithelial membrane protein 1 decreases expression
increases expression
multiple interactions 		ISO trichostatin A results in decreased expression of EMP1 mRNA
trichostatin A results in increased expression of EMP1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EMP1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:169,931,537...169,964,366
Ensembl chr 4:169,931,440...169,964,365 		JBrowse link
G Emp2 epithelial membrane protein 2 increases expression ISO trichostatin A results in increased expression of EMP2 mRNA CTD PMID:24935251 NCBI chr10:5,866,869...5,901,533
Ensembl chr10:5,866,922...5,901,532 		JBrowse link
G Emsy EMSY transcriptional repressor, BRCA2 interacting decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of EMSY mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EMSY mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:162,295,167...162,364,742
Ensembl chr 1:162,295,169...162,364,707 		JBrowse link
G Emx2 empty spiracles homeobox 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of EMX2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EMX2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:268,612,663...268,619,671
Ensembl chr 1:268,612,663...268,619,671 		JBrowse link
G Emx2os Emx2 opposite strand/antisense RNA multiple interactions
decreases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EMX2OS mRNA
trichostatin A results in decreased expression of EMX2OS mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:268,555,719...268,612,889 JBrowse link
G Enah ENAH, actin regulator decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ENAH mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ENAH mRNA 		CTD PMID:22723015 PMID:26272509 PMID:27188386 NCBI chr13:96,149,437...96,269,841
Ensembl chr13:96,149,437...96,269,796 		JBrowse link
G Enc1 ectodermal-neural cortex 1 multiple interactions
increases expression 		ISO [[Decitabine co-treated with trichostatin A] affects the methylation of ENC1 promoter] which affects the expression of ENC1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENC1 mRNA
trichostatin A results in increased expression of ENC1 mRNA 		CTD PMID:18803327 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:30,285,274...30,297,194
Ensembl chr 2:30,283,736...30,315,721 		JBrowse link
G Endod1 endonuclease domain containing 1 increases expression ISO trichostatin A results in increased expression of ENDOD1 mRNA CTD PMID:24935251 NCBI chr 8:19,490,615...19,520,007
Ensembl chr 8:19,490,615...19,520,007 		JBrowse link
G Endog endonuclease G increases expression ISO trichostatin A results in increased expression of ENDOG mRNA CTD PMID:24935251 NCBI chr 3:33,846,935...33,849,531
Ensembl chr 3:33,846,885...33,849,573 		JBrowse link
G Eno1 enolase 1 increases expression
multiple interactions
affects expression 		ISO trichostatin A results in increased expression of ENO1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENO1 mRNA
trichostatin A affects the expression of ENO1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 5:166,002,867...166,014,252
Ensembl chr 3:77,946,261...77,986,003
Ensembl chr 5:77,946,261...77,986,003 		JBrowse link
G Eno2 enolase 2 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of ENO2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ENO2 mRNA
trichostatin A affects the expression of ENO2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 4:159,258,371...159,267,220
Ensembl chr 4:159,258,371...159,267,220 		JBrowse link
G Eno3 enolase 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ENO3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ENO3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:55,868,880...55,876,099
Ensembl chr10:55,866,101...55,874,540 		JBrowse link
G Enosf1 enolase superfamily member 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENOSF1 mRNA
trichostatin A results in increased expression of ENOSF1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386
G Enox1 ecto-NOX disulfide-thiol exchanger 1 increases expression ISO trichostatin A results in increased expression of ENOX1 mRNA CTD PMID:24935251 NCBI chr15:58,924,519...59,488,919
Ensembl chr15:59,215,018...59,488,918 		JBrowse link
G Enpep glutamyl aminopeptidase increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ENPEP mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENPEP mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:220,456,258...220,526,218
Ensembl chr 2:220,456,278...220,526,218 		JBrowse link
G Enpp1 ectonucleotide pyrophosphatase/phosphodiesterase 1 decreases expression ISO trichostatin A results in decreased expression of ENPP1 mRNA CTD PMID:24935251 NCBI chr 1:22,518,051...22,583,044
Ensembl chr 1:22,518,069...22,583,044 		JBrowse link
G Enpp2 ectonucleotide pyrophosphatase/phosphodiesterase 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ENPP2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENPP2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:88,092,140...88,214,758
Ensembl chr 7:88,092,140...88,214,957 		JBrowse link
G Enpp4 ectonucleotide pyrophosphatase/phosphodiesterase 4 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of ENPP4 mRNA
trichostatin A results in decreased expression of ENPP4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ENPP4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 9:24,386,351...24,396,248
Ensembl chr 9:24,360,272...24,396,152 		JBrowse link
G Enpp5 ectonucleotide pyrophosphatase/phosphodiesterase family member 5 increases expression ISO trichostatin A results in increased expression of ENPP5 mRNA CTD PMID:24935251 NCBI chr 9:24,407,574...24,415,029
Ensembl chr 9:24,408,218...24,414,867 		JBrowse link
G Entpd4 ectonucleoside triphosphate diphosphohydrolase 4 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ENTPD4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ENTPD4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:51,040,665...51,068,450
Ensembl chr15:51,040,673...51,068,441 		JBrowse link
G Entrep1 endosomal transmembrane epsin interactor 1 decreases expression ISO trichostatin A results in decreased expression of ENTREP1 mRNA CTD PMID:24935251 NCBI chr 1:231,018,987...231,073,474
Ensembl chr 1:231,018,987...231,102,708 		JBrowse link
G Entrep2 endosomal transmembrane epsin interactor 2 decreases expression ISO trichostatin A results in decreased expression of ENTREP2 mRNA CTD PMID:24935251 NCBI chr 1:127,699,636...128,111,850
Ensembl chr 1:127,699,636...128,111,850 		JBrowse link
G Eny2 ENY2, transcription and export complex 2 subunit decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ENY2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ENY2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:77,465,885...77,489,637
Ensembl chr 7:77,466,119...77,491,057 		JBrowse link
G Eogt EGF domain specific O-linked N-acetylglucosamine transferase increases expression
multiple interactions 		ISO trichostatin A results in increased expression of EOGT mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EOGT mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:131,275,587...131,313,243
Ensembl chr 4:131,276,573...131,311,926 		JBrowse link
G Ep300 E1A binding protein p300 affects localization
multiple interactions
increases response to substance
affects expression 		ISO
EXP 		trichostatin A affects the localization of EP300 protein
[trichostatin A co-treated with Quercetin] results in increased expression of EP300 protein; EP300 promotes the reaction [Genistein promotes the reaction [trichostatin A results in increased expression of TP53 mRNA]]; EP300 promotes the reaction [Genistein promotes the reaction [trichostatin A results in increased expression of TP53 protein]]; EP300 promotes the reaction [trichostatin A results in increased expression of TP53 protein]; EP300 protein affects the reaction [[trichostatin A co-treated with Quercetin] results in increased expression of TNFRSF10B mRNA]; EP300 protein affects the reaction [[trichostatin A co-treated with Quercetin] results in increased expression of TNFRSF10B protein]; EP300 protein affects the reaction [Quercetin promotes the reaction [trichostatin A results in increased activity of CASP10 protein]]; EP300 protein affects the reaction [Quercetin promotes the reaction [trichostatin A results in increased activity of CASP3 protein]]; EP300 protein affects the reaction [trichostatin A results in increased activity of CASP10 protein]; EP300 protein affects the reaction [trichostatin A results in increased activity of CASP3 protein]; trichostatin A promotes the reaction [[EP300 protein co-treated with EGR1 protein] results in increased expression of PTEN mRNA]; trichostatin A promotes the reaction [EP300 protein binds to APEX1 protein]; trichostatin A promotes the reaction [EP300 protein binds to TGFBR2 promoter]; trichostatin A promotes the reaction [Genistein results in increased expression of EP300 protein]
EP300 protein results in increased susceptibility to trichostatin A
trichostatin A affects the expression of EP300 mRNA 		CTD PMID:12477714 PMID:15647279 PMID:17330857 PMID:20856196 PMID:26768552 More... NCBI chr 7:114,987,857...115,058,652
Ensembl chr 7:114,946,982...115,058,574 		JBrowse link
G Epas1 endothelial PAS domain protein 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of EPAS1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPAS1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 6:13,543,252...13,626,147
Ensembl chr 6:13,544,389...13,624,729 		JBrowse link
G Epb41 erythrocyte membrane protein band 4.1 increases expression ISO trichostatin A results in increased expression of EPB41 mRNA CTD PMID:28542535 NCBI chr 5:149,394,080...149,548,178
Ensembl chr 5:149,394,096...149,543,540 		JBrowse link
G Epb41l1 erythrocyte membrane protein band 4.1-like 1 decreases expression ISO trichostatin A results in decreased expression of EPB41L1 mRNA CTD PMID:24935251 NCBI chr 3:165,389,295...165,512,821
Ensembl chr 3:165,389,293...165,510,498 		JBrowse link
G Epb41l2 erythrocyte membrane protein band 4.1-like 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of EPB41L2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:21,682,336...21,857,106
Ensembl chr 1:21,682,335...21,857,105 		JBrowse link
G Epb41l3 erythrocyte membrane protein band 4.1-like 3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of EPB41L3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 9:116,502,864...116,707,274
Ensembl chr 9:116,462,807...116,707,274 		JBrowse link
G Epb41l4a erythrocyte membrane protein band 4.1 like 4A increases expression ISO trichostatin A results in increased expression of EPB41L4A mRNA CTD PMID:24935251 NCBI chr18:25,680,169...25,890,998
Ensembl chr18:25,680,171...25,888,498 		JBrowse link
G Epb41l4b erythrocyte membrane protein band 4.1 like 4B increases expression ISO trichostatin A results in increased expression of EPB41L4B mRNA CTD PMID:24935251 NCBI chr 5:76,486,886...76,647,752
Ensembl chr 5:76,486,902...76,647,752 		JBrowse link
G Epb41l5 erythrocyte membrane protein band 4.1 like 5 decreases expression
increases expression
affects expression
multiple interactions 		ISO trichostatin A results in decreased expression of EPB41L5 mRNA
trichostatin A results in increased expression of EPB41L5 mRNA
trichostatin A affects the expression of EPB41L5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPB41L5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr13:33,221,705...33,321,400
Ensembl chr13:33,223,589...33,321,133 		JBrowse link
G Epc1 enhancer of polycomb homolog 1 decreases expression ISO trichostatin A results in decreased expression of EPC1 mRNA CTD PMID:24935251 NCBI chr17:59,198,513...59,289,535
Ensembl chr17:59,197,677...59,289,519 		JBrowse link
G Epc2 enhancer of polycomb homolog 2 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of EPC2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPC2 mRNA
trichostatin A affects the expression of EPC2 mRNA 		CTD PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 3:54,276,187...54,376,373
Ensembl chr 3:54,276,239...54,376,916 		JBrowse link
G Epcam epithelial cell adhesion molecule increases expression
multiple interactions 		ISO trichostatin A results in increased expression of EPCAM mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPCAM mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:12,633,715...12,649,678
Ensembl chr 6:12,631,611...12,649,702 		JBrowse link
G Epg5 ectopic P-granules 5 autophagy tethering factor affects expression ISO trichostatin A affects the expression of EPG5 mRNA CTD PMID:28542535 NCBI chr18:73,679,106...73,776,694
Ensembl chr18:73,679,116...73,776,677 		JBrowse link
G Epha1 Eph receptor A1 increases expression ISO trichostatin A results in increased expression of EPHA1 mRNA CTD PMID:24935251 NCBI chr 4:72,213,022...72,227,543
Ensembl chr 4:72,213,037...72,227,474 		JBrowse link
G Epha3 Eph receptor A3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of EPHA3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHA3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:26705709 PMID:27188386 NCBI chr11:14,585,041...14,920,721
Ensembl chr11:14,586,727...14,920,425 		JBrowse link
G Epha4 Eph receptor A4 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of EPHA4 mRNA
trichostatin A results in decreased expression of EPHA4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHA4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 9:86,263,982...86,406,744
Ensembl chr 9:86,263,982...86,406,755 		JBrowse link
G Epha7 Eph receptor A7 multiple interactions
increases expression
decreases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHA7 mRNA; trichostatin A inhibits the reaction [Nickel affects the expression of EPHA7 mRNA]
trichostatin A results in increased expression of EPHA7 mRNA
trichostatin A results in decreased expression of EPHA7 mRNA 		CTD PMID:14575637 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:47,771,776...47,925,189
Ensembl chr 5:47,771,865...47,925,058 		JBrowse link
G Ephb2 Eph receptor B2 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of EPHB2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB2 mRNA
trichostatin A affects the expression of EPHB2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 5:154,179,065...154,360,459
Ensembl chr 5:154,179,065...154,360,615 		JBrowse link
G Epn3 epsin 3 increases expression ISO trichostatin A results in increased expression of EPN3 mRNA CTD PMID:24935251 NCBI chr10:79,935,857...79,946,121
Ensembl chr10:79,935,857...79,944,235 		JBrowse link
G Epop elongin BC and polycomb repressive complex 2 associated protein increases expression
multiple interactions 		ISO trichostatin A results in increased expression of EPOP mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPOP mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:83,120,767...83,122,287
Ensembl chr10:83,119,970...83,122,423 		JBrowse link
G Epor erythropoietin receptor increases expression ISO trichostatin A results in increased expression of EPOR mRNA CTD PMID:24935251 NCBI chr 8:28,765,738...28,770,371
Ensembl chr 8:28,765,746...28,770,322 		JBrowse link
G Eppk1 epiplakin 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of EPPK1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPPK1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:109,697,607...109,718,468
Ensembl chr 7:109,697,607...109,718,468 		JBrowse link
G Eps8 EGFR pathway substrate 8, signaling adaptor increases expression ISO trichostatin A results in increased expression of EPS8 mRNA CTD PMID:24935251 NCBI chr 4:172,119,497...172,291,670
Ensembl chr 4:172,119,497...172,218,160 		JBrowse link
G Eps8l2 EPS8 signaling adaptor L2 increases expression ISO trichostatin A results in increased expression of EPS8L2 mRNA CTD PMID:24935251 NCBI chr 1:205,875,825...205,901,109
Ensembl chr 1:205,875,801...205,901,101 		JBrowse link
G Epsti1 epithelial stromal interaction 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of EPSTI1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPSTI1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:59,692,712...59,791,376
Ensembl chr15:59,693,142...59,791,380 		JBrowse link
G Erap1 endoplasmic reticulum aminopeptidase 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ERAP1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERAP1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:5,666,337...5,705,256
Ensembl chr 2:5,666,436...5,740,056 		JBrowse link
G Erbb3 erb-b2 receptor tyrosine kinase 3 increases expression
multiple interactions
affects expression 		ISO trichostatin A results in increased expression of ERBB3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERBB3 mRNA
trichostatin A affects the expression of ERBB3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 7:1,579,079...1,600,379
Ensembl chr 7:1,579,816...1,601,120 		JBrowse link
G Erbb4 erb-b2 receptor tyrosine kinase 4 decreases expression ISO trichostatin A results in decreased expression of ERBB4 mRNA CTD PMID:24935251 NCBI chr 9:76,973,386...78,045,633
Ensembl chr 9:76,973,227...78,045,772 		JBrowse link
G Erbin erbb2 interacting protein affects expression ISO trichostatin A affects the expression of ERBIN mRNA CTD PMID:28542535 NCBI chr 2:36,660,399...36,762,584
Ensembl chr 2:36,660,399...36,762,153 		JBrowse link
G Erc2 ELKS/RAB6-interacting/CAST family member 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ERC2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERC2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:26705709 PMID:27188386 NCBI chr16:2,819,399...3,680,258
Ensembl chr16:2,819,512...3,680,258 		JBrowse link
G Ercc1 ERCC excision repair 1, endonuclease non-catalytic subunit multiple interactions
decreases expression 		ISO trichostatin A inhibits the reaction [Glucose results in increased expression of ERCC1 mRNA]; trichostatin A inhibits the reaction [Glucose results in increased expression of ERCC1 protein]
trichostatin A results in decreased expression of ERCC1 mRNA; trichostatin A results in decreased expression of ERCC1 protein 		CTD PMID:22228707 NCBI chr 1:88,099,308...88,135,966
Ensembl chr 1:88,118,891...88,139,120 		JBrowse link
G Ercc2 ERCC excision repair 2, TFIIH core complex helicase subunit multiple interactions ISO trichostatin A inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of ERCC2 mRNA]; trichostatin A inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of ERCC2 protein] CTD PMID:32031413 NCBI chr 1:88,161,342...88,175,102
Ensembl chr 1:88,160,988...88,175,102 		JBrowse link
G Ercc4 ERCC excision repair 4, endonuclease catalytic subunit increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of ERCC4 mRNA
trichostatin A results in decreased expression of ERCC4 mRNA
trichostatin A inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of ERCC4 mRNA]; trichostatin A inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of ERCC4 protein]; trichostatin A inhibits the reaction [Glucose results in increased expression of ERCC4 mRNA]; trichostatin A inhibits the reaction [Glucose results in increased expression of ERCC4 protein] 		CTD PMID:22228707 PMID:24935251 PMID:32031413 NCBI chr10:2,926,085...2,958,176
Ensembl chr10:2,920,455...2,955,539 		JBrowse link
G Ercc6l2 ERCC excision repair 6 like 2 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of ERCC6L2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERCC6L2 mRNA
trichostatin A affects the expression of ERCC6L2 mRNA 		CTD PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr17:1,055,881...1,323,207
Ensembl chr17:1,222,139...1,316,056 		JBrowse link
G Erg ETS transcription factor ERG decreases expression ISO trichostatin A results in decreased expression of ERG mRNA CTD PMID:19805354 NCBI chr11:48,148,149...48,370,472
Ensembl chr11:48,148,153...48,370,688 		JBrowse link
G Ergic2 ERGIC and golgi 2 affects expression ISO trichostatin A affects the expression of ERGIC2 mRNA CTD PMID:28542535 NCBI chr 4:182,822,225...182,858,392
Ensembl chr 4:182,822,225...182,854,490 		JBrowse link
G Eri1 exoribonuclease 1 affects expression ISO trichostatin A affects the expression of ERI1 mRNA CTD PMID:28542535 NCBI chr16:63,427,412...63,447,521
Ensembl chr16:63,427,403...63,447,896 		JBrowse link
G Erlin1 ER lipid raft associated 1 decreases expression ISO trichostatin A results in decreased expression of ERLIN1 mRNA CTD PMID:24935251 NCBI chr 1:252,870,356...252,905,681
Ensembl chr 1:252,870,356...252,905,947 		JBrowse link
G Ermap erythroblast membrane associated protein (Scianna blood group) affects expression ISO trichostatin A affects the expression of ERMAP mRNA CTD PMID:28542535 NCBI chr 5:138,074,155...138,088,340
Ensembl chr 5:138,065,824...138,087,015
Ensembl chr 5:138,065,824...138,087,015 		JBrowse link
G Ermp1 endoplasmic reticulum metallopeptidase 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ERMP1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERMP1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:236,801,459...236,835,656
Ensembl chr 1:236,801,466...236,839,197 		JBrowse link
G Ero1a endoplasmic reticulum oxidoreductase 1 alpha increases expression ISO trichostatin A results in increased expression of ERO1A mRNA CTD PMID:24935251 NCBI chr15:20,974,771...21,010,170
Ensembl chr15:20,972,679...21,018,039 		JBrowse link
G Ero1b endoplasmic reticulum oxidoreductase 1 beta multiple interactions
decreases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERO1B mRNA
trichostatin A results in decreased expression of ERO1B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:92,913,696...92,987,401
Ensembl chr17:92,814,368...92,987,555 		JBrowse link
G Erp27 endoplasmic reticulum protein 27 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ERP27 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERP27 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:171,535,845...171,552,848
Ensembl chr 4:171,535,847...171,553,072 		JBrowse link
G Errfi1 ERBB receptor feedback inhibitor 1 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of ERRFI1 mRNA
trichostatin A results in decreased expression of ERRFI1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERRFI1 mRNA 		CTD PMID:17940511 PMID:26272509 PMID:27188386 NCBI chr 5:166,606,841...166,620,124
Ensembl chr 5:166,606,834...166,620,432 		JBrowse link
G Esam endothelial cell adhesion molecule affects expression ISO trichostatin A affects the expression of ESAM mRNA CTD PMID:28542535 NCBI chr 8:45,426,985...45,437,976
Ensembl chr 8:45,425,731...45,437,973 		JBrowse link
G Esco1 establishment of sister chromatid cohesion N-acetyltransferase 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ESCO1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ESCO1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr18:1,904,748...1,959,609
Ensembl chr18:1,904,762...1,959,805 		JBrowse link
G Esco2 establishment of sister chromatid cohesion N-acetyltransferase 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ESCO2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ESCO2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:44,210,124...44,230,785
Ensembl chr15:44,210,641...44,231,304
Ensembl chr15:44,210,641...44,231,304 		JBrowse link
G Esr1 estrogen receptor 1 multiple interactions
decreases expression
decreases stability
increases expression 		ISO [Decitabine co-treated with trichostatin A] affects the expression of ESR1 mRNA; [Decitabine co-treated with trichostatin A] promotes the reaction [TFAP2C protein binds to ESR1 promoter]; [Decitabine co-treated with trichostatin A] promotes the reaction [TFAP2C protein results in increased expression of ESR1 mRNA]; [Decitabine co-treated with trichostatin A] results in decreased expression of ESR1 mRNA; [Decitabine co-treated with trichostatin A] results in decreased expression of ESR1 protein; [Decitabine co-treated with trichostatin A] results in decreased stability of ESR1 mRNA; [Decitabine co-treated with trichostatin A] results in increased expression of ESR1 mRNA; [trichostatin A co-treated with TFAP2C protein] results in increased expression of ESR1 mRNA; Decitabine promotes the reaction [trichostatin A results in increased expression of ESR1 mRNA]; Raloxifene Hydrochloride inhibits the reaction [trichostatin A results in decreased expression of ESR1 mRNA]; TFAP2C protein promotes the reaction [[Decitabine co-treated with trichostatin A] results in increased expression of ESR1 mRNA]; trichostatin A promotes the reaction [Estradiol results in decreased expression of ESR1 mRNA]
trichostatin A results in decreased expression of ESR1 mRNA; trichostatin A results in decreased expression of ESR1 protein
trichostatin A results in decreased stability of ESR1 mRNA
[estradiol dipropionate co-treated with trichostatin A] results in decreased expression of ESR1 protein 		CTD PMID:15930180 PMID:17533736 PMID:17891453 PMID:18092350 PMID:18264725 More... NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354 		JBrowse link
G Esr2 estrogen receptor 2 multiple interactions
decreases methylation
increases expression 		ISO [Decitabine co-treated with trichostatin A] results in decreased methylation of ESR2 promoter; [Decitabine co-treated with trichostatin A] results in increased expression of ESR2 mRNA; [trichostatin A co-treated with Estradiol co-treated with Raloxifene Hydrochloride] results in increased expression of ESR2 protein; [trichostatin A co-treated with Estradiol] results in increased expression of ESR2 mRNA; [trichostatin A co-treated with Estradiol] results in increased expression of ESR2 protein; [trichostatin A co-treated with Raloxifene Hydrochloride] results in increased expression of ESR2 mRNA; [trichostatin A co-treated with Raloxifene Hydrochloride] results in increased expression of ESR2 protein; Decitabine promotes the reaction [trichostatin A results in increased expression of ESR2 mRNA]; Decitabine promotes the reaction [trichostatin A results in increased expression of ESR2 protein]; Raloxifene Hydrochloride promotes the reaction [[trichostatin A co-treated with Estradiol] results in increased expression of ESR2 mRNA]; trichostatin A promotes the reaction [Estradiol results in increased activity of ESR2 protein]
trichostatin A results in decreased methylation of ESR2 promoter
trichostatin A results in increased expression of ESR2 mRNA; trichostatin A results in increased expression of ESR2 protein 		CTD PMID:15103026 PMID:18092350 PMID:19331143 PMID:22476901 NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:100,545,206...100,644,709 		JBrowse link
G Esrp1 epithelial splicing regulatory protein 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ESRP1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRP1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:29,224,831...29,279,381
Ensembl chr 5:29,225,360...29,279,278 		JBrowse link
G Esrp2 epithelial splicing regulatory protein 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ESRP2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRP2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr19:50,944,401...50,951,919
Ensembl chr19:50,944,401...50,951,568 		JBrowse link
G Esrra estrogen related receptor, alpha increases activity ISO trichostatin A results in increased activity of ESRRA protein CTD PMID:11705994 NCBI chr 1:213,533,309...213,543,432
Ensembl chr 1:213,533,310...213,543,811 		JBrowse link
G Esrrg estrogen-related receptor gamma increases activity
increases expression 		ISO trichostatin A results in increased activity of ESRRG protein
trichostatin A results in increased expression of ESRRG mRNA 		CTD PMID:11705994 PMID:24935251 NCBI chr13:101,699,043...102,316,877
Ensembl chr13:101,889,706...102,316,877 		JBrowse link
G Esyt2 extended synaptotagmin 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ESYT2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESYT2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:143,359,870...143,455,600
Ensembl chr 6:143,362,694...143,455,593 		JBrowse link
G Etfrf1 electron transfer flavoprotein regulatory factor 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ETFRF1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ETFRF1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:179,910,651...179,916,095
Ensembl chr 4:179,910,914...179,916,095 		JBrowse link
G Etl4 enhancer trap locus 4 increases expression ISO trichostatin A results in increased expression of KIAA1217 mRNA CTD PMID:24935251 NCBI chr17:87,749,486...88,213,158
Ensembl chr17:87,403,819...88,213,158 		JBrowse link
G Etnk1 ethanolamine kinase 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ETNK1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETNK1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:177,857,001...177,901,278
Ensembl chr 4:177,856,960...177,924,721 		JBrowse link
G Etnppl ethanolamine-phosphate phospho-lyase increases expression ISO trichostatin A results in increased expression of ETNPPL mRNA CTD PMID:24935251 NCBI chr 2:221,847,210...221,868,827
Ensembl chr 2:221,847,250...221,866,357 		JBrowse link
G Ets1 ETS proto-oncogene 1, transcription factor increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ETS1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETS1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 8:39,303,936...39,426,022
Ensembl chr 8:39,303,925...39,426,021 		JBrowse link
G Etv1 ETS variant transcription factor 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ETV1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ETV1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:61,316,836...61,408,985
Ensembl chr 6:61,317,429...61,408,959 		JBrowse link
G Etv3 ETS variant transcription factor 3 affects expression ISO trichostatin A affects the expression of ETV3 mRNA CTD PMID:28542535 NCBI chr 2:175,263,389...175,278,217
Ensembl chr 2:175,263,459...175,278,208 		JBrowse link
G Etv5 ETS variant transcription factor 5 increases expression
decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in increased expression of ETV5 mRNA
trichostatin A results in decreased expression of ETV5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ETV5 mRNA
trichostatin A affects the expression of ETV5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr11:92,113,171...92,170,758
Ensembl chr11:92,113,224...92,170,767 		JBrowse link
G Etv6 ETS variant transcription factor 6 multiple interactions ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ETV6 mRNA CTD PMID:27188386 NCBI chr 4:168,580,405...168,819,817
Ensembl chr 4:168,580,138...168,819,802 		JBrowse link
G Eva1a eva-1 homolog A, regulator of programmed cell death increases expression ISO trichostatin A results in increased expression of EVA1A mRNA CTD PMID:24935251 NCBI chr 4:116,151,595...116,200,827
Ensembl chr 4:116,151,173...116,200,827 		JBrowse link
G Evi5 ecotropic viral integration site 5 decreases expression
affects expression 		ISO trichostatin A results in decreased expression of EVI5 mRNA
trichostatin A affects the expression of EVI5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:28542535 NCBI chr14:2,020,524...2,166,593
Ensembl chr14:2,020,581...2,166,593 		JBrowse link
G Ewsr1 EWS RNA-binding protein 1 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of EWSR1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EWSR1 mRNA
trichostatin A affects the expression of EWSR1 mRNA 		CTD PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr14:84,179,413...84,208,149
Ensembl chr14:84,179,618...84,208,095 		JBrowse link
G Exoc4 exocyst complex component 4 increases expression ISO trichostatin A results in increased expression of EXOC4 mRNA CTD PMID:24935251 NCBI chr 4:62,774,896...63,551,541
Ensembl chr 4:62,774,935...63,552,943 		JBrowse link
G Exoc5 exocyst complex component 5 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of EXOC5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EXOC5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:24,788,738...24,834,941
Ensembl chr15:24,790,337...24,834,970 		JBrowse link
G Exoc6 exocyst complex component 6 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of EXOC6 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EXOC6 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:244,727,084...244,870,263
Ensembl chr 1:244,711,981...244,870,396 		JBrowse link
G Exoc8 exocyst complex component 8 affects expression ISO trichostatin A affects the expression of EXOC8 mRNA CTD PMID:28542535 NCBI chr19:69,752,387...69,754,876
Ensembl chr19:69,727,231...69,804,820 		JBrowse link
G Exog exo/endonuclease G decreases expression ISO trichostatin A results in decreased expression of EXOG mRNA CTD PMID:28542535 NCBI chr 8:128,062,688...128,082,529
Ensembl chr 8:128,059,126...128,083,460 		JBrowse link
G Exosc10 exosome component 10 affects expression ISO trichostatin A affects the expression of EXOSC10 mRNA CTD PMID:28542535 NCBI chr 5:164,278,414...164,302,067
Ensembl chr 5:164,278,440...164,302,067 		JBrowse link
G Exosc2 exosome component 2 affects expression ISO trichostatin A affects the expression of EXOSC2 mRNA CTD PMID:28542535 NCBI chr 3:35,360,652...35,370,948
Ensembl chr 3:35,360,666...35,371,373 		JBrowse link
G Exosc8 exosome component 8 affects expression ISO trichostatin A affects the expression of EXOSC8 mRNA CTD PMID:28542535 NCBI chr 2:141,080,568...141,087,112
Ensembl chr 2:141,080,568...141,087,229 		JBrowse link
G Exph5 exophilin 5 increases expression ISO trichostatin A results in increased expression of EXPH5 mRNA CTD PMID:24935251 PMID:26705709 NCBI chr 8:62,595,116...62,671,575
Ensembl chr 8:62,595,116...62,671,575 		JBrowse link
G Ext1 exostosin glycosyltransferase 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of EXT1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EXT1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:86,265,651...86,544,488
Ensembl chr 7:86,259,900...86,544,567 		JBrowse link
G Eya1 EYA transcriptional coactivator and phosphatase 1 increases expression ISO trichostatin A results in increased expression of EYA1 mRNA CTD PMID:24935251 NCBI chr 5:9,646,599...9,884,609
Ensembl chr 5:9,646,591...9,884,614 		JBrowse link
G Eya2 EYA transcriptional coactivator and phosphatase 2 increases expression ISO trichostatin A results in increased expression of EYA2 mRNA CTD PMID:24935251 NCBI chr 3:174,754,772...174,938,035
Ensembl chr 3:174,818,554...174,938,034 		JBrowse link
G Eya3 EYA transcriptional coactivator and phosphatase 3 decreases expression ISO trichostatin A results in decreased expression of EYA3 mRNA CTD PMID:24935251 NCBI chr 5:150,090,535...150,218,855
Ensembl chr 5:150,137,256...150,218,852 		JBrowse link
G Eya4 EYA transcriptional coactivator and phosphatase 4 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of EYA4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EYA4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:23,991,431...24,235,132
Ensembl chr 1:23,991,431...24,235,131 		JBrowse link
G Ezh1 enhancer of zeste 1 polycomb repressive complex 2 subunit decreases expression ISO trichostatin A results in decreased expression of EZH1 mRNA CTD PMID:24935251 NCBI chr10:86,626,307...86,662,257
Ensembl chr10:86,626,308...86,652,620 		JBrowse link
G Ezr ezrin increases expression
multiple interactions 		ISO trichostatin A results in increased expression of EZR mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EZR mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:49,373,033...49,416,573
Ensembl chr 1:49,373,035...49,416,573 		JBrowse link
G F11r F11 receptor affects expression ISO trichostatin A affects the expression of F11R mRNA CTD PMID:28542535 NCBI chr13:86,406,229...86,429,819
Ensembl chr13:86,406,218...86,429,816 		JBrowse link
G F2r coagulation factor II (thrombin) receptor increases expression ISO trichostatin A results in increased expression of F2R mRNA CTD PMID:24935251 NCBI chr 2:28,604,066...28,620,579
Ensembl chr 2:28,604,066...28,620,579 		JBrowse link
G F2rl1 F2R like trypsin receptor 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of F2RL1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F2RL1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:28,507,003...28,519,954
Ensembl chr 2:28,507,003...28,519,954 		JBrowse link
G F2rl2 coagulation factor II (thrombin) receptor-like 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of F2RL2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of F2RL2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:28,706,766...28,711,808
Ensembl chr 2:28,706,501...28,712,473 		JBrowse link
G F3 coagulation factor III, tissue factor increases expression ISO trichostatin A results in increased expression of F3 mRNA CTD PMID:23463510 NCBI chr 2:212,511,675...212,523,375
Ensembl chr 2:212,511,680...212,523,369 		JBrowse link
G F5 coagulation factor V increases expression ISO trichostatin A results in increased expression of F5 mRNA CTD PMID:24935251 NCBI chr13:79,046,657...79,116,247
Ensembl chr13:79,046,448...79,116,247 		JBrowse link
G F8 coagulation factor VIII decreases expression ISO trichostatin A results in decreased expression of F8 mRNA CTD PMID:24935251 NCBI chr18:155,237...187,186
Ensembl chr18:155,309...186,683 		JBrowse link
G Fa2h fatty acid 2-hydroxylase increases expression ISO trichostatin A results in increased expression of FA2H mRNA CTD PMID:24935251 NCBI chr19:56,222,240...56,273,480
Ensembl chr19:56,222,242...56,273,623 		JBrowse link
G Fabp4 fatty acid binding protein 4 increases expression ISO trichostatin A results in increased expression of FABP4 mRNA CTD PMID:26705709 NCBI chr 2:93,488,251...93,492,961
Ensembl chr 2:93,488,271...93,492,972 		JBrowse link
G Fabp5 fatty acid binding protein 5 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of FABP5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FABP5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:93,672,451...93,676,186
Ensembl chr 2:93,672,458...93,676,127 		JBrowse link
G Fabp7 fatty acid binding protein 7 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of FABP7 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FABP7 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr20:37,667,125...37,673,299
Ensembl chr20:37,669,601...37,675,907 		JBrowse link
G Fads2 fatty acid desaturase 2 decreases expression ISO trichostatin A results in decreased expression of FADS2 mRNA CTD PMID:27188386 NCBI chr 1:216,132,277...216,172,190
Ensembl chr 1:216,133,676...216,172,066 		JBrowse link
G Fah fumarylacetoacetate hydrolase increases expression ISO trichostatin A results in increased expression of FAH mRNA CTD PMID:24935251 NCBI chr 1:147,957,931...147,980,708
Ensembl chr 1:147,957,935...147,981,046 		JBrowse link
G Fahd1 fumarylacetoacetate hydrolase domain containing 1 multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of FAHD1 mRNA] CTD PMID:14575637 NCBI chr10:14,378,058...14,379,497
Ensembl chr10:14,378,120...14,379,867 		JBrowse link
G Fahd2a fumarylacetoacetate hydrolase domain containing 2A increases expression ISO trichostatin A results in increased expression of FAHD2A mRNA CTD PMID:28542535 NCBI chr 3:135,110,480...135,118,653
Ensembl chr 3:135,109,482...135,118,853 		JBrowse link
G Fam107a family with sequence similarity 107, member A decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of FAM107A mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM107A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:19,038,726...19,060,644
Ensembl chr15:19,038,616...19,065,219 		JBrowse link
G Fam107b family with sequence similarity 107, member B decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of FAM107B mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM107B mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr17:79,387,795...79,594,165
Ensembl chr17:79,387,795...79,594,288 		JBrowse link
G Fam110b family with sequence similarity 110, member B increases expression
multiple interactions 		ISO trichostatin A results in increased expression of FAM110B mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM110B mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:23,587,093...23,727,188
Ensembl chr 5:23,586,867...23,799,583 		JBrowse link
G Fam110c family with sequence similarity 110, member C increases expression ISO trichostatin A results in increased expression of FAM110C mRNA CTD PMID:24935251 NCBI chr 6:53,366,013...53,372,270
Ensembl chr 6:53,352,870...53,401,117 		JBrowse link
G Fam114a1 family with sequence similarity 114, member A1 increases expression ISO trichostatin A results in increased expression of FAM114A1 mRNA CTD PMID:24935251 NCBI chr14:43,629,349...43,699,800
Ensembl chr14:43,629,375...43,699,800 		JBrowse link
G Fam117a family with sequence similarity 117, member A decreases expression
multiple interactions
affects expression
increases expression 		ISO trichostatin A results in decreased expression of FAM117A mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM117A mRNA
trichostatin A affects the expression of FAM117A mRNA
trichostatin A results in increased expression of FAM117A mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 PMID:33770205 NCBI chr10:80,778,229...80,822,119
Ensembl chr10:80,755,883...80,822,119 		JBrowse link
G Fam118b family with sequence similarity 118, member B affects expression ISO trichostatin A affects the expression of FAM118B mRNA CTD PMID:28542535 NCBI chr 8:41,824,522...41,875,190
Ensembl chr 8:41,824,158...41,846,256 		JBrowse link
G Fam120a family with sequence similarity 120 member A increases expression ISO trichostatin A results in increased expression of FAM120A mRNA CTD PMID:24935251 NCBI chr17:15,890,151...15,981,337
Ensembl chr17:15,890,605...15,981,332 		JBrowse link
G Fam120b family with sequence similarity 120 member B increases expression ISO trichostatin A results in increased expression of FAM120B mRNA CTD PMID:24935251 NCBI chr 1:64,993,104...65,058,160
Ensembl chr 1:65,012,060...65,058,160 		JBrowse link
G Fam124a family with sequence similarity 124 member A increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of FAM124A mRNA
trichostatin A results in decreased expression of FAM124A mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM124A mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:40,975,789...41,031,069
Ensembl chr15:40,975,877...41,029,628 		JBrowse link
G Fam131b family with sequence similarity 131, member B decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of FAM131B mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM131B mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:72,167,667...72,176,924
Ensembl chr 4:72,165,578...72,176,858 		JBrowse link
G Fam133b family with sequence similarity 133, member B increases expression ISO trichostatin A results in increased expression of FAM133B mRNA CTD PMID:24935251 NCBI chr 4:31,544,458...31,571,056
Ensembl chr 4:31,544,458...31,570,780 		JBrowse link
G Fam135a family with sequence similarity 135, member A increases expression ISO trichostatin A results in increased expression of FAM135A mRNA CTD PMID:24935251 NCBI chr 9:33,916,449...33,997,140
Ensembl chr 9:33,916,449...33,997,051 		JBrowse link
G Fam13a family with sequence similarity 13, member A increases expression ISO trichostatin A results in increased expression of FAM13A mRNA CTD PMID:28542535 NCBI chr 4:89,386,685...89,485,940
Ensembl chr 4:89,388,569...89,485,988 		JBrowse link
G Fam13c family with sequence similarity 13, member C increases expression
multiple interactions 		ISO trichostatin A results in increased expression of FAM13C mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM13C mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr20:18,064,706...18,186,888
Ensembl chr20:18,064,706...18,286,674 		JBrowse link
G Fam149a family with sequence similarity 149, member A increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of FAM149A mRNA
trichostatin A results in decreased expression of FAM149A mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM149A mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr16:53,587,841...53,647,072
Ensembl chr16:53,587,841...53,647,072 		JBrowse link
G Fam149b1 family with sequence similarity 149, member B1 increases expression ISO trichostatin A results in increased expression of FAM149B1 mRNA CTD PMID:24935251 NCBI chr15:3,978,377...4,016,323
Ensembl chr15:3,978,377...4,016,317 		JBrowse link
G Fam162a family with sequence similarity 162, member A increases expression
multiple interactions 		ISO trichostatin A results in increased expression of FAM162A mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM162A mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr11:78,186,260...78,215,186
Ensembl chr11:78,185,852...78,216,560 		JBrowse link
G Fam168a family with sequence similarity 168, member A decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of FAM168A mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM168A mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:164,469,447...164,615,542
Ensembl chr 1:164,469,471...164,615,506 		JBrowse link
G Fam171b family with sequence similarity 171, member B decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of FAM171B mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM171B mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:89,337,566...89,392,973
Ensembl chr 3:89,337,661...89,392,971 		JBrowse link
G Fam174b family with sequence similarity 174, member B decreases expression ISO trichostatin A results in decreased expression of FAM174B mRNA CTD PMID:24935251 NCBI chr 1:136,925,162...137,006,082
Ensembl chr 1:136,925,151...137,035,589 		JBrowse link
G Fam184a family with sequence similarity 184, member A increases expression ISO trichostatin A results in increased expression of FAM184A mRNA CTD PMID:24935251 NCBI chr20:33,477,089...33,599,296
Ensembl chr20:33,477,089...33,599,293 		JBrowse link
G Fam20c FAM20C, golgi associated secretory pathway kinase decreases expression ISO trichostatin A results in decreased expression of FAM20C mRNA CTD PMID:24935251 NCBI chr12:20,940,654...20,999,072
Ensembl chr12:20,940,654...20,998,318 		JBrowse link
G Fam210b family with sequence similarity 210, member B increases expression
multiple interactions 		ISO trichostatin A results in increased expression of FAM210B mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM210B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:181,536,665...181,546,830
Ensembl chr 3:181,536,673...181,546,834 		JBrowse link
G Fam221a family with sequence similarity 221, member A decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of FAM221A mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM221A mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:79,668,130...79,689,768
Ensembl chr 4:79,667,284...79,689,761 		JBrowse link
G Fam227a family with sequence similarity 227, member A affects expression ISO trichostatin A affects the expression of FAM227A mRNA CTD PMID:28542535 NCBI chr 7:113,054,751...113,096,898
Ensembl chr 7:113,054,751...113,096,868 		JBrowse link
G Fam241a family with sequence similarity 241 member A increases expression
affects expression 		ISO trichostatin A results in increased expression of FAM241A mRNA
trichostatin A affects the expression of FAM241A mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 2:219,019,025...219,049,648
Ensembl chr 2:219,018,241...219,049,770 		JBrowse link
G Fam3c FAM3 metabolism regulating signaling molecule C increases expression
multiple interactions 		ISO trichostatin A results in increased expression of FAM3C mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM3C mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:51,805,686...51,853,030
Ensembl chr 4:51,805,703...51,853,030 		JBrowse link
G Fam43a family with sequence similarity 43, member A increases expression
multiple interactions 		ISO trichostatin A results in increased expression of FAM43A mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM43A mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr11:83,633,165...83,636,313
Ensembl chr11:83,633,154...83,695,297 		JBrowse link
G Fam53a family with sequence similarity 53, member A increases expression ISO trichostatin A results in increased expression of FAM53A mRNA CTD PMID:24935251 NCBI chr14:81,308,127...81,348,930
Ensembl chr14:81,319,375...81,348,923 		JBrowse link
G Fam53c family with sequence similarity 53, member C affects expression ISO trichostatin A affects the expression of FAM53C mRNA CTD PMID:28542535 NCBI chr18:26,638,781...26,652,294
Ensembl chr18:26,638,062...26,652,290 		JBrowse link
G Fam72a family with sequence similarity 72, member A decreases expression ISO trichostatin A results in decreased expression of FAM72A mRNA CTD PMID:26272509 NCBI chr13:45,519,940...45,531,322
Ensembl chr13:45,519,818...45,531,324 		JBrowse link
G Fam76b family with sequence similarity 76, member B decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of FAM76B mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM76B mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 8:18,971,357...18,993,442
Ensembl chr 8:18,971,100...18,995,039 		JBrowse link
G Fam83a family with sequence similarity 83, member A multiple interactions ISO [decitabine co-treated with trichostatin A] inhibits the reaction [sodium arsenite affects the methylation of FAM83A promoter] CTD PMID:18448484 NCBI chr 7:91,412,366...91,436,819
Ensembl chr 7:91,412,366...91,436,910 		JBrowse link
G Fam89a family with sequence similarity 89, member A increases expression
multiple interactions 		ISO trichostatin A results in increased expression of FAM89A mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM89A mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr19:69,607,391...69,620,019
Ensembl chr19:69,607,391...69,620,019 		JBrowse link
G Fam89b family with sequence similarity 89, member B affects expression ISO trichostatin A affects the expression of FAM89B mRNA CTD PMID:28542535 NCBI chr 1:212,445,101...212,447,164
Ensembl chr 1:212,445,102...212,446,738 		JBrowse link
G Fam91a1 family with sequence similarity 91, member A1 affects expression ISO trichostatin A affects the expression of FAM91A1 mRNA CTD PMID:28542535 NCBI chr 7:91,857,261...91,897,019
Ensembl chr 7:91,859,062...91,898,195 		JBrowse link
G Fam98a family with sequence similarity 98, member A increases expression ISO trichostatin A results in increased expression of FAM98A mRNA CTD PMID:24935251 NCBI chr 6:25,626,108...25,640,767
Ensembl chr 6:25,625,984...25,640,767 		JBrowse link
G Fancm FA complementation group M decreases expression
affects expression 		ISO trichostatin A results in decreased expression of FANCM mRNA
trichostatin A affects the expression of FANCM mRNA 		CTD PMID:26272509 PMID:28542535 NCBI chr 6:88,862,898...88,916,701
Ensembl chr 6:88,863,306...88,921,652 		JBrowse link
G Fank1 fibronectin type III and ankyrin repeat domains 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of FANK1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FANK1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:198,007,496...198,114,790
Ensembl chr 1:198,007,547...198,115,561 		JBrowse link
G Farp1 FERM, ARH/RhoGEF and pleckstrin domain protein 1 decreases expression ISO trichostatin A results in decreased expression of FARP1 mRNA CTD PMID:24935251 NCBI chr15:104,531,196...104,770,148
Ensembl chr15:104,531,813...104,770,147 		JBrowse link
G Farsb phenylalanyl-tRNA synthetase subunit beta increases expression ISO trichostatin A results in increased expression of FARSB mRNA CTD PMID:24935251 NCBI chr 9:87,336,321...87,395,546
Ensembl chr 9:87,336,326...87,395,505 		JBrowse link
G Fas Fas cell surface death receptor multiple interactions
increases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAS mRNA; Decitabine promotes the reaction [trichostatin A results in increased expression of FAS mRNA] CTD PMID:18718068 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:241,205,935...241,246,104 		JBrowse link
G Fastkd2 FAST kinase domains 2 affects expression ISO trichostatin A affects the expression of FASTKD2 mRNA CTD PMID:28542535 NCBI chr 9:72,659,961...72,681,986
Ensembl chr 9:72,661,764...72,721,338 		JBrowse link
G Fat4 FAT atypical cadherin 4 increases expression
decreases expression 		ISO trichostatin A results in increased expression of FAT4 mRNA
trichostatin A results in decreased expression of FAT4 mRNA 		CTD PMID:24935251 NCBI chr 2:123,855,289...123,984,716
Ensembl chr 2:123,855,289...123,984,716 		JBrowse link
G Fbln1 fibulin 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBLN1 mRNA
trichostatin A results in increased expression of FBLN1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:118,190,347...118,269,965
Ensembl chr 7:118,190,478...118,269,965 		JBrowse link
G Fbln2 fibulin 2 increases expression ISO trichostatin A results in increased expression of FBLN2 mRNA CTD PMID:24935251 NCBI chr 4:125,261,464...125,321,030
Ensembl chr 4:125,261,607...125,321,029 		JBrowse link
G Fbln7 fibulin 7 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of FBLN7 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN7 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:136,564,825...136,601,205
Ensembl chr 3:136,564,917...136,601,198 		JBrowse link
G Fbn1 fibrillin 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of FBN1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBN1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:133,007,693...133,204,277
Ensembl chr 3:133,008,361...133,204,283 		JBrowse link
G Fbn2 fibrillin 2 increases expression ISO trichostatin A results in increased expression of FBN2 mRNA CTD PMID:24935251 NCBI chr18:53,696,197...53,901,992
Ensembl chr18:53,697,708...53,902,191 		JBrowse link
G Fbp1 fructose-bisphosphatase 1 multiple interactions ISO [trichostatin A affects the methylation of FBP1 promoter] which affects the expression of FBP1 mRNA CTD PMID:18938139 NCBI chr17:2,212,941...2,235,749
Ensembl chr17:2,213,492...2,235,746 		JBrowse link
G Fbp2 fructose-bisphosphatase 2 multiple interactions ISO [trichostatin A affects the methylation of FBP2 promoter] which affects the expression of FBP2 mRNA CTD PMID:18938139 NCBI chr17:2,241,767...2,259,371
Ensembl chr17:2,241,975...2,259,366 		JBrowse link
G Fbrsl1 fibrosin-like 1 increases expression ISO trichostatin A results in increased expression of FBRSL1 mRNA CTD PMID:24935251 NCBI chr12:51,891,211...51,979,715
Ensembl chr12:51,960,790...51,979,361 		JBrowse link
G Fbxl14 F-box and leucine-rich repeat protein 14 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of FBXL14 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXL14 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:154,334,820...154,338,638
Ensembl chr 4:154,334,092...154,377,959 		JBrowse link
G Fbxl16 F-box and leucine-rich repeat protein 16 increases expression ISO trichostatin A results in increased expression of FBXL16 mRNA CTD PMID:24935251 PMID:26705709 NCBI chr10:15,333,996...15,346,253
Ensembl chr10:15,334,014...15,346,232 		JBrowse link
G Fbxl18 F-box and leucine-rich repeat protein 18 affects expression ISO trichostatin A affects the expression of FBXL18 mRNA CTD PMID:28542535 NCBI chr12:16,781,901...16,812,728
Ensembl chr12:16,789,665...16,814,240 		JBrowse link
G Fbxl20 F-box and leucine-rich repeat protein 20 decreases expression ISO trichostatin A results in decreased expression of FBXL20 mRNA CTD PMID:24935251 NCBI chr10:83,577,038...83,640,022
Ensembl chr10:83,577,038...83,639,977 		JBrowse link
G Fbxl21 F-box and leucine-rich repeat protein 21 increases expression ISO trichostatin A results in increased expression of FBXL21P mRNA CTD PMID:24935251 NCBI chr17:8,063,731...8,082,920
Ensembl chr17:8,066,565...8,078,644 		JBrowse link
G Fbxl3 F-box and leucine-rich repeat protein 3 increases expression ISO trichostatin A results in increased expression of FBXL3 mRNA CTD PMID:24935251 NCBI chr15:86,321,504...86,341,387
Ensembl chr15:86,321,504...86,341,387 		JBrowse link
G Fbxl4 F-box and leucine-rich repeat protein 4 increases expression ISO trichostatin A results in increased expression of FBXL4 mRNA CTD PMID:24935251 NCBI chr 5:40,752,513...40,826,154
Ensembl chr 5:40,752,521...40,850,826 		JBrowse link
G Fbxo16 F-box protein 16 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of FBXO16 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO16 mRNA
trichostatin A affects the expression of FBXO16 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr15:43,667,207...43,717,096
Ensembl chr15:43,667,855...43,734,346 		JBrowse link
G Fbxo2 F-box protein 2 increases expression ISO trichostatin A results in increased expression of FBXO2 mRNA CTD PMID:24935251 NCBI chr 5:163,876,079...163,881,508
Ensembl chr 5:163,875,757...163,881,508 		JBrowse link
G Fbxo28 F-box protein 28 decreases expression ISO trichostatin A results in decreased expression of FBXO28 mRNA CTD PMID:24935251 NCBI chr13:96,527,667...96,553,138
Ensembl chr13:96,527,670...96,553,138 		JBrowse link
G Fbxo3 F-box protein 3 affects expression ISO trichostatin A affects the expression of FBXO3 mRNA CTD PMID:28542535 NCBI chr 3:110,872,185...110,904,479
Ensembl chr 3:110,872,220...110,904,479 		JBrowse link
G Fbxo33 F-box protein 33 affects expression ISO trichostatin A affects the expression of FBXO33 mRNA CTD PMID:28542535 NCBI chr 6:82,635,509...82,669,441
Ensembl chr 6:82,635,521...82,667,440 		JBrowse link
G Fbxo4 F-box protein 4 affects expression ISO trichostatin A affects the expression of FBXO4 mRNA CTD PMID:28542535 NCBI chr 2:54,902,394...54,915,388
Ensembl chr 2:54,902,394...54,915,388 		JBrowse link
G Fbxo43 F-box protein 43 increases expression ISO trichostatin A results in increased expression of FBXO43 mRNA CTD PMID:24935251 NCBI chr 7:69,218,298...69,231,873
Ensembl chr 7:69,218,299...69,230,310 		JBrowse link
G Fbxo44 F-box protein 44 affects expression ISO trichostatin A affects the expression of FBXO44 mRNA CTD PMID:28542535 NCBI chr 5:163,866,517...163,875,928
Ensembl chr 5:163,866,517...163,875,614 		JBrowse link
G Fbxo48 F-box protein 48 affects expression ISO trichostatin A affects the expression of FBXO48 mRNA CTD PMID:28542535 NCBI chr14:95,582,493...95,583,950
Ensembl chr14:95,581,279...95,587,616 		JBrowse link
G Fbxo5 F-box protein 5 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of FBXO5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:44,601,412...44,607,781
Ensembl chr 1:44,601,412...44,607,781 		JBrowse link
G Fbxo9 f-box protein 9 decreases expression
increases expression 		ISO trichostatin A results in decreased expression of FBXO9 mRNA
trichostatin A results in increased expression of FBXO9 mRNA 		CTD PMID:24935251 NCBI chr 8:87,838,787...87,864,362
Ensembl chr 8:87,838,789...87,864,504 		JBrowse link
G Fbxw7 F-box and WD repeat domain containing 7 affects expression ISO trichostatin A affects the expression of FBXW7 mRNA CTD PMID:28542535 NCBI chr 2:172,447,738...172,609,591
Ensembl chr 2:172,447,738...172,609,591 		JBrowse link
G Fchsd2 FCH and double SH3 domains 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of FCHSD2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FCHSD2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:164,775,916...165,097,391
Ensembl chr 1:164,775,926...165,097,391 		JBrowse link
G Fem1a fem-1 homolog A affects expression ISO trichostatin A affects the expression of FEM1A mRNA CTD PMID:28542535 NCBI chr 9:1,178,857...1,181,063
Ensembl chr 9:1,177,543...1,188,006 		JBrowse link
G Fer FER tyrosine kinase increases expression
multiple interactions 		ISO trichostatin A results in increased expression of FER mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FER mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:110,967,317...111,274,315
Ensembl chr 9:110,967,390...111,274,315 		JBrowse link
G Fermt1 FERM domain containing kindlin 1 increases expression
multiple interactions
affects expression 		ISO trichostatin A results in increased expression of FERMT1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FERMT1 mRNA
trichostatin A affects the expression of FERMT1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 3:140,624,434...140,666,419
Ensembl chr 3:140,624,434...140,666,419 		JBrowse link
G Fez1 fasciculation and elongation protein zeta 1 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of FEZ1 mRNA
trichostatin A results in decreased expression of FEZ1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZ1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 8:44,733,288...44,778,519
Ensembl chr 8:44,733,300...44,784,097 		JBrowse link
G Fezf2 Fez family zinc finger 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of FEZF2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZF2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:15,199,045...15,207,982
Ensembl chr15:15,204,193...15,207,982 		JBrowse link
G Fgd4 FYVE, RhoGEF and PH domain containing 4 increases expression ISO trichostatin A results in increased expression of FGD4 mRNA CTD PMID:26705709 NCBI chr11:97,904,182...98,055,190
Ensembl chr11:97,904,182...98,055,190 		JBrowse link
G Fgd5 FYVE, RhoGEF and PH domain containing 5 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of FGD5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGD5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:126,054,201...126,151,698
Ensembl chr 4:126,054,210...126,151,697 		JBrowse link
G Fgd6 FYVE, RhoGEF and PH domain containing 6 affects expression ISO trichostatin A affects the expression of FGD6 mRNA CTD PMID:28542535 NCBI chr 7:30,484,600...30,599,898
Ensembl chr 7:30,484,600...30,595,806 		JBrowse link
G Fgf10 fibroblast growth factor 10 increases expression ISO trichostatin A results in increased expression of FGF10 mRNA CTD PMID:23463510 NCBI chr 2:52,533,939...52,610,980
Ensembl chr 2:52,533,939...52,610,980 		JBrowse link
G Fgf12 fibroblast growth factor 12 multiple interactions ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF12 mRNA CTD PMID:27188386 NCBI chr11:85,501,947...86,069,543
Ensembl chr11:85,501,936...86,069,543 		JBrowse link
G Fgf13 fibroblast growth factor 13 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of FGF13 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF13 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr  X:142,312,381...142,838,581
Ensembl chr  X:142,312,391...142,423,536 		JBrowse link
G Fgf18 fibroblast growth factor 18 increases expression ISO trichostatin A results in increased expression of FGF18 mRNA CTD PMID:24935251 NCBI chr10:18,210,240...18,241,929
Ensembl chr10:18,210,512...18,240,933 		JBrowse link
G Fgf2 fibroblast growth factor 2 decreases expression
increases expression 		ISO trichostatin A results in decreased expression of FGF2 mRNA
trichostatin A results in increased expression of FGF2 mRNA 		CTD PMID:23463510 PMID:24935251 NCBI chr 2:122,164,454...122,218,796
Ensembl chr 2:122,164,454...122,224,493 		JBrowse link
G Fgf21 fibroblast growth factor 21 increases expression ISO trichostatin A results in increased expression of FGF21 mRNA; trichostatin A results in increased expression of FGF21 protein CTD PMID:22338096 NCBI chr 1:105,219,825...105,221,376
Ensembl chr 1:105,219,825...105,232,056 		JBrowse link
G Fgf4 fibroblast growth factor 4 increases expression ISO trichostatin A results in increased expression of FGF4 mRNA CTD PMID:24935251 NCBI chr 1:209,453,229...209,457,085
Ensembl chr 1:209,453,229...209,457,085 		JBrowse link
G Fgf8 fibroblast growth factor 8 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of FGF8 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF8 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:254,533,504...254,539,605
Ensembl chr 1:254,533,504...254,539,605 		JBrowse link
G Fgf9 fibroblast growth factor 9 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of FGF9 mRNA
trichostatin A results in decreased expression of FGF9 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:36,325,552...36,369,995
Ensembl chr15:36,325,599...36,367,926 		JBrowse link
G Fgfbp3 fibroblast growth factor binding protein 3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of FGFBP3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGFBP3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:244,056,569...244,058,574
Ensembl chr 1:244,056,307...244,065,654 		JBrowse link
G Fgfr1op2 FGFR1 oncogene partner 2 affects expression ISO trichostatin A affects the expression of FGFR1OP2 mRNA CTD PMID:28542535 NCBI chr 4:181,222,298...181,243,318
Ensembl chr 4:181,222,323...181,243,322 		JBrowse link
G Fgfr3 fibroblast growth factor receptor 3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of FGFR3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGFR3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:81,211,800...81,227,215
Ensembl chr14:81,211,800...81,227,209 		JBrowse link
G Fh fumarate hydratase increases expression
multiple interactions 		ISO trichostatin A results in increased expression of FH mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FH mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:90,056,565...90,082,450
Ensembl chr13:90,056,570...90,089,627 		JBrowse link
G Fhip1b FHF complex subunit HOOK interacting protein 1B affects expression ISO trichostatin A affects the expression of FHIP1B mRNA CTD PMID:28542535 NCBI chr 1:169,137,866...169,160,305
Ensembl chr 1:169,122,654...169,160,252 		JBrowse link
G Fhit fragile histidine triad diadenosine triphosphatase multiple interactions ISO [decitabine co-treated with trichostatin A] affects the expression of FHIT protein CTD PMID:17019711 NCBI chr15:16,365,401...17,872,901
Ensembl chr15:16,747,338...17,872,621 		JBrowse link
G Fhod3 formin homology 2 domain containing 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of FHOD3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FHOD3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr18:16,267,830...16,700,508
Ensembl chr18:16,267,977...16,700,508 		JBrowse link
G Fig4 FIG4 phosphoinositide 5-phosphatase decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of FIG4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FIG4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:46,183,225...46,306,686
Ensembl chr20:46,183,225...46,306,477 		JBrowse link
G Fign fidgetin, microtubule severing factor increases expression
multiple interactions 		ISO trichostatin A results in increased expression of FIGN mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FIGN mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:69,045,918...69,169,148
Ensembl chr 3:69,045,050...69,169,988 		JBrowse link
G Filip1 filamin A interacting protein 1 decreases expression
increases expression 		ISO trichostatin A results in decreased expression of FILIP1 mRNA
trichostatin A results in increased expression of FILIP1 mRNA 		CTD PMID:24935251 NCBI chr 8:89,641,509...89,836,772
Ensembl chr 8:89,644,579...89,802,771 		JBrowse link
G Fjx1 four-jointed box kinase 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of FJX1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FJX1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:109,229,223...109,231,324
Ensembl chr 3:109,227,170...109,232,479 		JBrowse link
G Fkbp11 FKBP prolyl isomerase 11 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of FKBP11 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FKBP11 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:131,750,828...131,757,784
Ensembl chr 7:131,750,672...131,770,123 		JBrowse link
G Fkbp14 FKBP prolyl isomerase 14 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of FKBP14 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FKBP14 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:85,035,840...85,051,917
Ensembl chr 4:85,037,145...85,051,808 		JBrowse link
G Fkbp1b FKBP prolyl isomerase 1B affects expression ISO trichostatin A affects the expression of FKBP1B mRNA CTD PMID:28542535 NCBI chr 6:33,551,583...33,570,055
Ensembl chr 6:33,558,517...33,568,129 		JBrowse link
G Fkbp7 FKBP prolyl isomerase 7 increases expression ISO trichostatin A results in increased expression of FKBP7 mRNA CTD PMID:24935251 NCBI chr 3:82,016,647...82,030,913
Ensembl chr 3:82,016,513...82,028,573 		JBrowse link
G Flacc1 flagellum associated containing coiled-coil domains 1 affects expression ISO trichostatin A affects the expression of FLACC1 mRNA CTD PMID:28542535 NCBI chr 9:67,809,731...67,837,793
Ensembl chr 9:67,809,739...67,837,793 		JBrowse link
G Fli1 Fli-1 proto-oncogene, ETS transcription factor increases expression ISO trichostatin A results in increased expression of FLI1 mRNA CTD PMID:24935251 NCBI chr 8:39,089,526...39,209,511
Ensembl chr 8:39,089,533...39,208,557 		JBrowse link
G Flnb filamin B increases expression
multiple interactions
affects expression 		ISO trichostatin A results in increased expression of FLNB mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLNB mRNA
trichostatin A affects the expression of FLNB mRNA 		CTD PMID:24935251 PMID:27188386 PMID:28542535 NCBI chr15:19,392,212...19,525,278
Ensembl chr15:19,392,216...19,525,209 		JBrowse link
G Flrt1 fibronectin leucine rich transmembrane protein 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of FLRT1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLRT1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:213,704,983...213,782,958
Ensembl chr 1:213,704,038...213,782,981 		JBrowse link
G Flrt2 fibronectin leucine rich transmembrane protein 2 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of FLRT2 mRNA
trichostatin A results in decreased expression of FLRT2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FLRT2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:120,507,998...120,603,133
Ensembl chr 6:120,507,689...120,609,004 		JBrowse link
G Flrt3 fibronectin leucine rich transmembrane protein 3 decreases expression ISO trichostatin A results in decreased expression of FLRT3 mRNA CTD PMID:24935251 NCBI chr 3:148,448,115...148,461,458
Ensembl chr 3:148,439,354...148,461,650 		JBrowse link
G Flt1 Fms related receptor tyrosine kinase 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of FLT1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLT1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:26705709 PMID:27188386 NCBI chr12:12,333,050...12,504,750
Ensembl chr12:12,333,430...12,504,750 		JBrowse link
G Flvcr2 FLVCR choline and putative heme transporter 2 increases expression ISO trichostatin A results in increased expression of FLVCR2 mRNA CTD PMID:24935251 NCBI chr 6:111,139,352...111,203,345
Ensembl chr 6:111,139,295...111,203,345 		JBrowse link
G Fmc1 formation of mitochondrial complex V assembly factor 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of FMC1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FMC1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:68,241,009...68,249,045
Ensembl chr 4:68,241,009...68,268,534 		JBrowse link
G Fmn1 formin 1 increases expression ISO trichostatin A results in increased expression of FMN1 mRNA CTD PMID:27188386 NCBI chr 3:120,555,445...120,939,978
Ensembl chr 3:120,555,431...120,933,124 		JBrowse link
G Fmn2 formin 2 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of FMN2 mRNA
trichostatin A results in decreased expression of FMN2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FMN2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr13:88,986,863...89,303,789
Ensembl chr13:88,986,842...89,303,789 		JBrowse link
G Fmnl2 formin-like 2 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of FMNL2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FMNL2 mRNA
trichostatin A affects the expression of FMNL2 mRNA 		CTD PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 3:57,758,236...58,033,832
Ensembl chr 3:57,758,191...58,033,831 		JBrowse link
G Fmo1 flavin containing dimethylaniline monoxygenase 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of FMO1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FMO1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr13:77,715,405...77,747,666
Ensembl chr13:77,715,402...77,747,874 		JBrowse link
G Fmr1 fragile X messenger ribonucleoprotein 1 increases expression ISO trichostatin A results in increased expression of FMR1 mRNA CTD PMID:24935251 NCBI chr  X:152,284,857...152,322,686
Ensembl chr  X:152,284,841...152,322,675 		JBrowse link
G Fn1 fibronectin 1 increases expression
multiple interactions
decreases expression 		ISO trichostatin A results in increased expression of FN1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FN1 mRNA; trichostatin A inhibits the reaction [Glucose results in increased expression of FN1 mRNA]
trichostatin A results in decreased expression of FN1 mRNA
trichostatin A inhibits the reaction [Folic Acid results in increased expression of FN1 mRNA] 		CTD PMID:22228707 PMID:24935251 PMID:26272509 PMID:27188386 PMID:39617304 NCBI chr 9:80,645,507...80,714,200
Ensembl chr 9:80,645,507...80,714,137 		JBrowse link
G Fndc11 fibronectin type III domain containing 11 decreases expression ISO trichostatin A results in decreased expression of FNDC11 mRNA CTD PMID:24935251 NCBI chr 3:188,708,045...188,710,670
Ensembl chr 3:188,707,334...188,714,164 		JBrowse link
G Fndc3a fibronectin type III domain containing 3a decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of FNDC3A mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FNDC3A mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:54,099,510...54,276,963
Ensembl chr15:54,099,510...54,276,407 		JBrowse link
G Fndc5 fibronectin type III domain containing 5 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of FNDC5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FNDC5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:146,765,951...146,775,611
Ensembl chr 5:146,751,416...146,778,540 		JBrowse link
G Fnip1 folliculin interacting protein 1 increases expression ISO trichostatin A results in increased expression of FNIP1 mRNA CTD PMID:24935251 NCBI chr10:39,068,432...39,151,552
Ensembl chr10:39,068,445...39,151,552 		JBrowse link
G Fnip2 folliculin interacting protein 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of FNIP2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FNIP2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:166,894,726...167,006,490
Ensembl chr 2:166,897,075...167,006,055 		JBrowse link
G Folr1 folate receptor alpha increases expression ISO trichostatin A results in increased expression of FOLR1 mRNA CTD PMID:39237058 NCBI chr 1:165,631,462...165,650,430
Ensembl chr 1:165,631,462...165,642,669 		JBrowse link
G Folr2 folate receptor beta multiple interactions ISO trichostatin A promotes the reaction [Tretinoin inhibits the reaction [RARG protein binds to FOLR2 promoter]]; trichostatin A promotes the reaction [Tretinoin promotes the reaction [SP1 protein binds to FOLR2 promoter]]; trichostatin A promotes the reaction [Tretinoin results in increased expression of FOLR2 mRNA]; trichostatin A promotes the reaction [Tretinoin results in increased expression of FOLR2 protein] CTD PMID:16740727 NCBI chr 1:165,612,047...165,630,382
Ensembl chr 1:165,612,063...165,617,731 		JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO trichostatin A promotes the reaction [IL3 protein results in increased expression of FOS mRNA] CTD PMID:25769527 NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598 		JBrowse link
G Foxa1 forkhead box A1 multiple interactions ISO [decitabine co-treated with trichostatin A] results in decreased expression of FOXA1 mRNA CTD PMID:17891453 NCBI chr 6:80,838,380...80,871,195
Ensembl chr 6:80,800,960...80,871,191 		JBrowse link
G Foxb1 forkhead box B1 multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of FOXB1 mRNA] CTD PMID:14575637 NCBI chr 8:79,288,161...79,290,781
Ensembl chr 8:79,287,616...79,291,490 		JBrowse link
G Foxc1 forkhead box C1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of FOXC1 mRNA
[Decitabine co-treated with trichostatin A] results in increased expression of FOXC1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC1 mRNA 		CTD PMID:17891453 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr17:32,840,119...32,844,100
Ensembl chr17:32,805,858...32,844,347 		JBrowse link
G Foxc2 forkhead box C2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of FOXC2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:66,094,718...66,097,420
Ensembl chr19:66,094,700...66,153,977 		JBrowse link
G Foxd3 forkhead box D3 decreases expression
increases expression
multiple interactions 		ISO trichostatin A results in decreased expression of FOXD3 mRNA
trichostatin A results in increased expression of FOXD3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXD3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:119,450,532...119,452,898
Ensembl chr 5:119,450,394...119,452,786 		JBrowse link
G Foxg1 forkhead box G1 affects expression
increases expression
decreases expression 		ISO trichostatin A affects the expression of FOXG1 mRNA
trichostatin A results in increased expression of FOXG1 mRNA
trichostatin A results in decreased expression of FOXG1 mRNA 		CTD PMID:22723015 PMID:24935251 PMID:26272509 NCBI chr 6:72,401,582...72,404,392
Ensembl chr 6:72,394,239...72,427,392 		JBrowse link
G Foxh1 forkhead box H1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of FOXH1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXH1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:110,268,608...110,272,105
Ensembl chr 7:110,268,612...110,270,692 		JBrowse link
G Foxj1 forkhead box J1 multiple interactions ISO [[decitabine co-treated with trichostatin A] affects the methylation of FOXJ1 promoter] which affects the expression of FOXJ1 mRNA CTD PMID:18836996 NCBI chr10:102,065,163...102,069,945
Ensembl chr10:102,065,170...102,069,241 		JBrowse link
G Foxk1 forkhead box K1 multiple interactions
decreases expression 		ISO [Decitabine co-treated with trichostatin A] results in decreased expression of FOXK1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FOXK1 mRNA
trichostatin A results in decreased expression of FOXK1 mRNA 		CTD PMID:17891453 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr12:17,223,599...17,288,564
Ensembl chr12:17,229,430...17,288,564 		JBrowse link
G Foxo1 forkhead box O1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of FOXO1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXO1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:138,462,697...138,541,419 		JBrowse link
G Foxo4 forkhead box O4 affects expression ISO trichostatin A affects the expression of FOXO4 mRNA CTD PMID:28542535 NCBI chr  X:70,425,218...70,432,120
Ensembl chr  X:70,425,563...70,432,120 		JBrowse link
G Foxo6 forkhead box O6 decreases expression ISO trichostatin A results in decreased expression of FOXO6 mRNA CTD PMID:24935251 NCBI chr 5:139,141,329...139,161,629
Ensembl chr 5:139,141,185...139,161,629 		JBrowse link
G Foxp3 forkhead box P3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of FOXP3 protein
[trichostatin A co-treated with Arsenic] results in increased expression of FOXP3 protein; trichostatin A inhibits the reaction [Arsenic results in increased expression of FOXP3 protein] 		CTD PMID:19545742 PMID:32735129 NCBI chr  X:17,580,380...17,601,181
Ensembl chr  X:17,580,380...17,595,894 		JBrowse link
G Foxq1 forkhead box Q1 increases expression ISO trichostatin A results in increased expression of FOXQ1 mRNA CTD PMID:24935251 NCBI chr17:33,121,454...33,124,087
Ensembl chr17:33,121,545...33,123,720 		JBrowse link
G Fras1 Fraser extracellular matrix complex subunit 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of FRAS1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FRAS1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:13,095,370...13,506,895
Ensembl chr14:13,095,370...13,504,664 		JBrowse link
G Frem1 Fras1 related extracellular matrix 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of FREM1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FREM1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:102,367,201...102,515,464
Ensembl chr 5:102,367,201...102,515,404 		JBrowse link
G Frem2 FRAS1 related extracellular matrix 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of FREM2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FREM2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:139,753,055...139,891,046
Ensembl chr 2:139,753,055...139,891,046 		JBrowse link
G Frmd3 FERM domain containing 3 increases expression ISO trichostatin A results in increased expression of FRMD3 mRNA CTD PMID:24935251 NCBI chr 5:92,810,989...93,077,326
Ensembl chr 5:92,810,736...93,077,325 		JBrowse link
G Frmd4a FERM domain containing 4A decreases expression
increases expression 		ISO trichostatin A results in decreased expression of FRMD4A mRNA
trichostatin A results in increased expression of FRMD4A mRNA 		CTD PMID:24935251 NCBI chr17:78,577,062...79,167,924
Ensembl chr17:78,579,277...79,167,663 		JBrowse link
G Frmd4b FERM domain containing 4B increases expression ISO trichostatin A results in increased expression of FRMD4B mRNA CTD PMID:24935251 NCBI chr 4:131,452,361...131,778,734
Ensembl chr 4:131,452,365...131,640,287 		JBrowse link
G Frmd5 FERM domain containing 5 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of FRMD5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRMD5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:128,945,812...129,217,134
Ensembl chr 3:128,927,671...129,217,074 		JBrowse link
G Frs2 fibroblast growth factor receptor substrate 2 affects expression ISO trichostatin A affects the expression of FRS2 mRNA CTD PMID:28542535 NCBI chr 7:54,597,182...54,678,656
Ensembl chr 7:54,597,182...54,678,774 		JBrowse link
G Fry FRY microtubule binding protein decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of FRY mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRY mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr12:9,530,360...9,773,391
Ensembl chr12:9,530,360...9,897,603 		JBrowse link
G Frzb frizzled-related protein decreases expression
multiple interactions
increases expression 		ISO trichostatin A results in decreased expression of FRZB mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRZB mRNA
Trichostatin A increases expression of Frzb mRNA in adenocarcinoma cells 		CTD
RGD		 PMID:24935251 PMID:26272509 PMID:27188386 PMID:27623992 RGD:32716395 NCBI chr 3:85,739,162...85,772,168
Ensembl chr 3:85,739,165...85,772,096 		JBrowse link
G Fsaf1 40S small subunit processome assembly factor 1 affects expression ISO trichostatin A affects the expression of FSAF1 mRNA CTD PMID:28542535 NCBI chr19:69,705,313...69,719,894
Ensembl chr19:69,705,321...69,720,093 		JBrowse link
G Fsbp fibrinogen silencer binding protein decreases expression ISO trichostatin A results in decreased expression of FSBP mRNA CTD PMID:26272509 NCBI chr 5:29,855,340...29,861,613
Ensembl chr 5:29,855,304...29,901,964 		JBrowse link
G Fscn1 fascin actin-bundling protein 1 affects expression ISO trichostatin A affects the expression of FSCN1 mRNA CTD PMID:28542535 NCBI chr12:16,710,601...16,723,734
Ensembl chr12:16,710,601...16,723,734 		JBrowse link
G Fsd1l fibronectin type III and SPRY domain containing 1-like decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of FSD1L mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FSD1L mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:73,052,565...73,130,292
Ensembl chr 5:73,054,274...73,130,292 		JBrowse link
G Fst follistatin decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of FST mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FST mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:47,856,345...47,863,670
Ensembl chr 2:47,856,345...47,863,491 		JBrowse link
G Fstl1 follistatin-like 1 increases expression ISO trichostatin A results in increased expression of FSTL1 mRNA CTD PMID:24935251 NCBI chr11:76,400,870...76,454,053
Ensembl chr11:76,391,315...76,455,126 		JBrowse link
G Ftl1 ferritin light chain 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of FTL mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FTL mRNA 		CTD PMID:24935251 PMID:24973648 PMID:26272509 PMID:27188386 NCBI chr 1:105,072,858...105,074,705
Ensembl chr  X:45,399,355...45,399,915
Ensembl chr 2:45,399,355...45,399,915
Ensembl chr 1:45,399,355...45,399,915 		JBrowse link
G Ftx FTX transcript, XIST regulator increases expression
multiple interactions 		ISO trichostatin A results in increased expression of FTX mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FTX mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr  X:72,654,112...72,696,097 JBrowse link
G Fubp1 far upstream element binding protein 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of FUBP1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FUBP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:243,819,529...243,846,544
Ensembl chr 2:243,819,218...243,846,428 		JBrowse link
G Fus Fus RNA binding protein multiple interactions ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FUS mRNA CTD PMID:27188386 NCBI chr 1:192,007,011...192,020,887
Ensembl chr 1:192,007,006...192,020,884 		JBrowse link
G Fut4 fucosyltransferase 4 increases expression ISO trichostatin A results in increased expression of FUT4 mRNA CTD PMID:24935251 NCBI chr 8:19,868,178...19,872,139
Ensembl chr 8:19,868,079...19,872,436 		JBrowse link
G Fut8 fucosyltransferase 8 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of FUT8 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FUT8 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:101,682,354...101,909,784
Ensembl chr 6:101,683,007...101,909,775 		JBrowse link
G Fut9 fucosyltransferase 9 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of FUT9 mRNA
trichostatin A results in decreased expression of FUT9 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FUT9 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:44,148,371...44,361,209
Ensembl chr 5:44,146,152...44,362,823 		JBrowse link
G Fxn frataxin affects expression ISO trichostatin A affects the expression of FXN mRNA CTD PMID:28542535 NCBI chr 1:231,300,457...231,323,989
Ensembl chr 1:231,300,150...231,323,989 		JBrowse link
G Fxyd3 FXYD domain-containing ion transport regulator 3 multiple interactions
increases expression 		ISO trichostatin A inhibits the reaction [Nickel affects the expression of FXYD3 mRNA]
trichostatin A results in increased expression of FXYD3 mRNA 		CTD PMID:14575637 PMID:24935251 NCBI chr 1:95,432,918...95,440,129
Ensembl chr 1:95,432,919...95,439,702 		JBrowse link
G Fxyd5 FXYD domain-containing ion transport regulator 5 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of FXYD5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FXYD5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:95,395,327...95,404,722
Ensembl chr 1:95,395,146...95,405,364 		JBrowse link
G Fyb2 FYN binding protein 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of FYB2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FYB2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:124,906,005...125,029,867
Ensembl chr 5:124,905,982...125,029,865 		JBrowse link
G Fyn FYN proto-oncogene, Src family tyrosine kinase increases expression
multiple interactions
affects expression 		ISO trichostatin A results in increased expression of FYN mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FYN mRNA
trichostatin A affects the expression of FYN mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr20:44,322,635...44,514,498
Ensembl chr20:44,322,361...44,515,479 		JBrowse link
G Fzd10 frizzled class receptor 10 increases expression ISO trichostatin A results in increased expression of FZD10 mRNA CTD PMID:24935251 PMID:26272509 NCBI chr12:33,734,364...33,737,559
Ensembl chr12:33,734,364...33,741,646 		JBrowse link
G Fzd2 frizzled class receptor 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of FZD2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:88,061,988...88,063,898
Ensembl chr10:88,061,667...88,065,396 		JBrowse link
G Fzd3 frizzled class receptor 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of FZD3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD3 mRNA 		CTD PMID:22723015 PMID:26272509 PMID:27188386 NCBI chr15:43,596,962...43,664,047
Ensembl chr15:43,596,965...43,663,960 		JBrowse link
G Fzd4 frizzled class receptor 4 multiple interactions
increases expression 		ISO trichostatin A inhibits the reaction [Nickel affects the expression of FZD4 mRNA]
trichostatin A results in increased expression of FZD4 mRNA 		CTD PMID:14575637 PMID:24935251 NCBI chr 1:152,692,507...152,701,372
Ensembl chr 1:152,692,507...152,701,372 		JBrowse link
G Fzd5 frizzled class receptor 5 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of FZD5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 9:73,606,860...73,614,039
Ensembl chr 9:73,606,860...73,618,612 		JBrowse link
G Fzd7 frizzled class receptor 7 increases expression ISO trichostatin A results in increased expression of FZD7 mRNA CTD PMID:24935251 NCBI chr 9:68,425,538...68,428,357
Ensembl chr 9:68,411,259...68,432,585 		JBrowse link
G Fzd8 frizzled class receptor 8 multiple interactions
decreases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD8 mRNA
trichostatin A results in decreased expression of FZD8 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:62,007,849...62,015,485
Ensembl chr17:62,007,627...62,015,961 		JBrowse link
G G2 G2 protein increases expression ISO trichostatin A results in increased expression of KIAA1549L mRNA CTD PMID:24935251 NCBI chr 3:110,961,478...111,237,308
Ensembl chr 3:110,961,478...111,237,223 		JBrowse link
G G2e3 G2/M-phase specific E3 ubiquitin protein ligase decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of G2E3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of G2E3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:74,498,801...74,530,703
Ensembl chr 6:74,503,109...74,528,198 		JBrowse link
G G3bp1 G3BP stress granule assembly factor 1 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of G3BP1 mRNA
trichostatin A results in decreased expression of G3BP1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of G3BP1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:40,087,533...40,120,931
Ensembl chr10:40,087,533...40,120,931 		JBrowse link
G G3bp2 G3BP stress granule assembly factor 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of G3BP2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of G3BP2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:16,216,684...16,304,828
Ensembl chr14:16,248,744...16,304,823 		JBrowse link
G Gabarapl2 GABA type A receptor associated protein like 2 affects expression ISO trichostatin A affects the expression of GABARAPL2 mRNA CTD PMID:28542535 NCBI chr19:56,819,826...56,830,662
Ensembl chr19:56,819,791...56,830,660 		JBrowse link
G Gabpa GA binding protein transcription factor subunit alpha decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of GABPA mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GABPA mRNA
trichostatin A affects the expression of GABPA mRNA 		CTD PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr11:37,375,040...37,404,060
Ensembl chr11:37,375,084...37,404,059 		JBrowse link
G Gabpb1 GA binding protein transcription factor subunit beta 1 decreases expression
affects expression 		ISO trichostatin A results in decreased expression of GABPB1 mRNA
trichostatin A affects the expression of GABPB1 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 3:134,333,339...134,380,239
Ensembl chr 3:134,333,339...134,361,344 		JBrowse link
G Gabra1 gamma-aminobutyric acid type A receptor subunit alpha 1 increases expression ISO trichostatin A results in increased expression of GABRA1 mRNA CTD PMID:24935251 NCBI chr10:27,096,731...27,152,563
Ensembl chr10:27,096,740...27,152,442 		JBrowse link
G Gabra5 gamma-aminobutyric acid type A receptor subunit alpha 5 increases expression ISO trichostatin A results in increased expression of GABRA5 mRNA CTD PMID:24935251 NCBI chr 1:117,404,446...117,517,424
Ensembl chr 1:117,404,494...117,516,635 		JBrowse link
G Gabrb2 gamma-aminobutyric acid type A receptor subunit beta 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB2 mRNA
trichostatin A results in increased expression of GABRB2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:27,438,127...27,657,680
Ensembl chr10:27,438,238...27,655,171 		JBrowse link
G Gabrb3 gamma-aminobutyric acid type A receptor subunit beta 3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of GABRB3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:117,602,772...117,838,230
Ensembl chr 1:117,431,842...117,836,725 		JBrowse link
G Gabrg2 gamma-aminobutyric acid type A receptor subunit gamma 2 increases expression ISO trichostatin A results in increased expression of GABRG2 mRNA CTD PMID:24935251 NCBI chr10:26,876,926...26,965,523
Ensembl chr10:26,876,926...26,965,523 		JBrowse link
G Gabrp gamma-aminobutyric acid type A receptor subunit pi increases expression ISO trichostatin A results in increased expression of GABRP mRNA CTD PMID:24935251 NCBI chr10:18,647,243...18,673,806
Ensembl chr10:18,647,243...18,673,727 		JBrowse link
G Gabrr1 gamma-aminobutyric acid type A receptor subunit rho 1 decreases expression ISO trichostatin A results in decreased expression of GABRR1 mRNA CTD PMID:26705709 NCBI chr 5:52,320,475...52,357,549
Ensembl chr 5:52,320,475...52,357,549 		JBrowse link
G Gad1 glutamate decarboxylase 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of GAD1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAD1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:75,777,260...75,818,099
Ensembl chr 3:75,777,534...75,818,759 		JBrowse link
G Gadd45a growth arrest and DNA-damage-inducible, alpha increases expression
multiple interactions 		ISO trichostatin A results in increased expression of GADD45A mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45A mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:97,484,502...97,486,807 		JBrowse link
G Gadd45b growth arrest and DNA-damage-inducible, beta increases expression
multiple interactions
affects expression 		ISO trichostatin A results in increased expression of GADD45B mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45B mRNA
trichostatin A affects the expression of GADD45B mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 7:9,428,689...9,430,991
Ensembl chr 7:9,428,689...9,430,718 		JBrowse link
G Gale UDP-galactose-4-epimerase increases expression ISO trichostatin A results in increased expression of GALE mRNA CTD PMID:24935251 NCBI chr 5:153,477,420...153,481,926
Ensembl chr 5:153,478,325...153,481,922 		JBrowse link
G Galnt10 polypeptide N-acetylgalactosaminyltransferase 10 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of GALNT10 mRNA
trichostatin A results in decreased expression of GALNT10 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GALNT10 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:42,321,691...42,468,087
Ensembl chr10:42,322,161...42,468,087 		JBrowse link
G Galnt12 polypeptide N-acetylgalactosaminyltransferase 12 decreases expression ISO trichostatin A results in decreased expression of GALNT12 mRNA CTD PMID:24935251 NCBI chr 5:66,180,171...66,208,931
Ensembl chr 5:66,180,164...66,208,938 		JBrowse link
G Galnt16 polypeptide N-acetylgalactosaminyltransferase 16 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of GALNT16 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GALNT16 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:105,900,987...105,982,039
Ensembl chr 6:105,901,153...105,991,350 		JBrowse link
G Galnt17 polypeptide N-acetylgalactosaminyltransferase 17 decreases expression ISO trichostatin A results in decreased expression of GALNT17 mRNA CTD PMID:24935251 NCBI chr12:30,959,460...31,418,150
Ensembl chr12:30,959,447...31,418,149 		JBrowse link
G Galnt18 polypeptide N-acetylgalactosaminyltransferase 18 increases expression ISO trichostatin A results in increased expression of GALNT18 mRNA CTD PMID:24935251 NCBI chr 1:175,027,832...175,338,883
Ensembl chr 1:175,027,839...175,338,883 		JBrowse link
G Galnt3 polypeptide N-acetylgalactosaminyltransferase 3 increases expression
multiple interactions
decreases expression 		ISO trichostatin A results in increased expression of GALNT3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT3 mRNA
trichostatin A results in decreased expression of GALNT3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 3:71,150,559...71,187,321
Ensembl chr 3:71,150,571...71,174,323 		JBrowse link
G Galntl5 polypeptide N-acetylgalactosaminyltransferase-like 5 increases expression ISO trichostatin A results in increased expression of GALNTL5 mRNA CTD PMID:24935251 NCBI chr 4:10,607,260...10,657,181
Ensembl chr 4:10,607,260...10,656,953 		JBrowse link
G Galp galanin-like peptide decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of GALP mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GALP mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:76,717,110...76,741,056
Ensembl chr 1:76,717,110...76,735,354 		JBrowse link
G Gap43 growth associated protein 43 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of GAP43 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAP43 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr11:71,882,131...71,975,799
Ensembl chr11:71,882,131...71,975,797 		JBrowse link
G Gapdh glyceraldehyde-3-phosphate dehydrogenase decreases expression ISO trichostatin A results in decreased expression of GAPDH protein CTD PMID:19294695 NCBI chr 4:159,648,592...159,653,436
Ensembl chr 4:159,648,592...159,653,377 		JBrowse link
G Gapvd1 GTPase activating protein and VPS9 domains 1 affects expression ISO trichostatin A affects the expression of GAPVD1 mRNA CTD PMID:28542535 NCBI chr 3:38,365,854...38,439,403
Ensembl chr 3:38,365,854...38,439,390 		JBrowse link
G Gar1 GAR1 ribonucleoprotein affects expression ISO trichostatin A affects the expression of GAR1 mRNA CTD PMID:28542535 NCBI chr 2:221,049,471...221,056,749
Ensembl chr 2:221,049,473...221,056,749 		JBrowse link
G Garin1b golgi associated RAB2 interactor 1B decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of GARIN1B mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GARIN1B mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:58,880,537...58,903,966
Ensembl chr 4:58,880,594...58,903,961 		JBrowse link
G Garnl3 GTPase activating Rap/RanGAP domain-like 3 decreases expression ISO trichostatin A results in decreased expression of GARNL3 mRNA CTD PMID:24935251 NCBI chr 3:36,686,388...36,830,011
Ensembl chr 3:36,686,389...36,830,020 		JBrowse link
G Garre1 granule associated Rac and RHOG effector 1 affects expression ISO trichostatin A affects the expression of GARRE1 mRNA CTD PMID:28542535 NCBI chr 1:95,999,305...96,077,641
Ensembl chr 1:95,996,429...96,051,620 		JBrowse link
G Gart phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase increases expression ISO trichostatin A results in increased expression of GART mRNA CTD PMID:24935251 NCBI chr11:44,351,841...44,377,086
Ensembl chr11:44,351,851...44,377,086 		JBrowse link
G Gas2 growth arrest-specific 2 increases expression ISO trichostatin A results in increased expression of GAS2 mRNA CTD PMID:24935251 NCBI chr 1:110,587,952...110,721,572
Ensembl chr 1:110,717,312...110,718,541 		JBrowse link
G Gas5 growth arrest specific 5 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of GAS5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAS5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr13:75,836,963...75,840,284 JBrowse link
G Gas7 growth arrest specific 7 increases expression ISO trichostatin A results in increased expression of GAS7 mRNA CTD PMID:24935251 NCBI chr10:52,651,690...52,882,244
Ensembl chr10:52,651,690...52,882,244 		JBrowse link
G Gask1b golgi associated kinase 1B increases expression ISO trichostatin A results in increased expression of GASK1B mRNA CTD PMID:24935251 NCBI chr 2:167,345,738...167,410,606
Ensembl chr 2:167,345,809...167,410,603 		JBrowse link
G Gata1 GATA binding protein 1 multiple interactions ISO [decitabine co-treated with trichostatin A] results in increased expression of GATA1 mRNA CTD PMID:17185465 NCBI chr  X:17,193,291...17,209,462
Ensembl chr  X:17,201,633...17,209,459 		JBrowse link
G Gata2 GATA binding protein 2 multiple interactions
increases expression 		ISO [Decitabine co-treated with trichostatin A] results in increased expression of GATA2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA2 mRNA
trichostatin A results in increased expression of GATA2 mRNA 		CTD PMID:17185465 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:122,211,501...122,225,058
Ensembl chr 4:122,211,829...122,225,055 		JBrowse link
G Gata3 GATA binding protein 3 multiple interactions
increases expression 		ISO [Decitabine co-treated with trichostatin A] results in decreased expression of GATA3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA3 mRNA
trichostatin A results in increased expression of GATA3 mRNA 		CTD PMID:17891453 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr17:73,544,234...73,575,670
Ensembl chr17:73,553,548...73,575,670 		JBrowse link
G Gatad1 GATA zinc finger domain containing 1 affects expression ISO trichostatin A affects the expression of GATAD1 mRNA CTD PMID:28542535 NCBI chr 4:31,462,251...31,473,827
Ensembl chr 4:31,462,309...31,503,921 		JBrowse link
G Gatad2b GATA zinc finger domain containing 2B decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of GATAD2B mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GATAD2B mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:178,046,192...178,127,633
Ensembl chr 2:178,046,085...178,147,315 		JBrowse link
G Gatm glycine amidinotransferase decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of GATM mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GATM mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:130,112,508...130,137,664
Ensembl chr 3:130,112,509...130,129,355 		JBrowse link
G Gbx2 gastrulation brain homeobox 2 increases expression ISO trichostatin A results in increased expression of GBX2 mRNA CTD PMID:24935251 NCBI chr 9:97,957,304...97,959,883
Ensembl chr 9:97,957,304...97,959,883 		JBrowse link
G Gca grancalcin affects expression ISO trichostatin A affects the expression of GCA mRNA CTD PMID:28542535 NCBI chr 3:67,705,874...67,738,475
Ensembl chr 3:67,705,890...67,737,387 		JBrowse link
G Gcat glycine C-acetyltransferase decreases expression ISO trichostatin A results in decreased expression of GCAT mRNA CTD PMID:27188386 NCBI chr 7:112,475,572...112,481,920
Ensembl chr 7:112,475,496...112,482,664 		JBrowse link
G Gcdh glutaryl-CoA dehydrogenase affects expression ISO trichostatin A affects the expression of GCDH mRNA CTD PMID:28542535 NCBI chr19:40,168,038...40,174,536
Ensembl chr19:40,168,141...40,175,686 		JBrowse link
G Gch1 GTP cyclohydrolase 1 increases expression ISO trichostatin A results in increased expression of GCH1 mRNA CTD PMID:24935251 NCBI chr15:22,884,006...22,917,412
Ensembl chr15:22,884,006...22,917,412 		JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit increases expression
multiple interactions 		ISO trichostatin A results in increased expression of GCLC mRNA
[Fenretinide co-treated with trichostatin A] results in increased expression of GCLC mRNA 		CTD PMID:21319187 NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893 		JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit affects expression ISO trichostatin A affects the expression of GCLM mRNA CTD PMID:28542535 NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:213,031,838...213,055,003 		JBrowse link
G Gcm1 glial cells missing transcription factor 1 multiple interactions ISO trichostatin A promotes the reaction [Colforsin results in increased acetylation of and results in increased activity of GCM1 protein] CTD PMID:16166624 NCBI chr 8:87,805,993...87,819,229
Ensembl chr 8:87,805,993...87,819,229 		JBrowse link
G Gcm2 glial cells missing transcription factor 2 increases expression ISO trichostatin A results in increased expression of GCM2 mRNA CTD PMID:24935251 NCBI chr17:23,858,379...23,867,495
Ensembl chr17:23,858,379...23,867,495 		JBrowse link
G Gcnt1 glucosaminyl (N-acetyl) transferase 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of GCNT1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GCNT1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:224,145,104...224,182,496
Ensembl chr 1:224,141,108...224,185,741 		JBrowse link
G Gcnt4 glucosaminyl (N-acetyl) transferase 4 decreases expression ISO trichostatin A results in decreased expression of GCNT4 mRNA CTD PMID:24935251 NCBI chr 2:29,987,944...30,017,708
Ensembl chr 2:29,984,327...30,017,982 		JBrowse link
G Gdap1 ganglioside-induced differentiation-associated-protein 1 increases expression ISO trichostatin A results in increased expression of GDAP1 mRNA CTD PMID:24935251 NCBI chr 5:6,715,935...6,735,013
Ensembl chr 5:6,715,935...6,735,313 		JBrowse link
G Gde1 glycerophosphodiester phosphodiesterase 1 affects expression ISO trichostatin A affects the expression of GDE1 mRNA CTD PMID:28542535 NCBI chr 1:182,451,182...182,466,569
Ensembl chr 1:182,451,184...182,466,772 		JBrowse link
G Gdf10 growth differentiation factor 10 increases expression ISO trichostatin A results in increased expression of GDF10 mRNA CTD PMID:24935251 PMID:26272509 NCBI chr16:9,243,434...9,256,788
Ensembl chr16:9,243,317...9,256,794 		JBrowse link
G Gdf11 growth differentiation factor 11 affects expression ISO trichostatin A affects the expression of GDF11 mRNA CTD PMID:28542535 NCBI chr 7:1,896,229...1,909,147
Ensembl chr 7:1,896,229...1,905,222 		JBrowse link
G Gdf15 growth differentiation factor 15 multiple interactions
increases expression 		ISO [trichostatin A results in increased expression of GDF15 protein] which results in increased cleavage of PARP1 protein; [trichostatin A results in increased stability of GDF15 mRNA] which results in increased expression of GDF15 protein; Cycloheximide inhibits the reaction [trichostatin A affects the expression of GDF15 mRNA]; Cycloheximide inhibits the reaction [trichostatin A affects the expression of GDF15 protein]; decitabine promotes the reaction [[trichostatin A affects the methylation of GDF15 promoter] which affects the expression of GDF15 mRNA]; decitabine promotes the reaction [[trichostatin A affects the methylation of GDF15 promoter] which affects the expression of GDF15 protein]; EGR1 protein affects the reaction [trichostatin A affects the expression of GDF15 mRNA]; SP1 protein affects the reaction [trichostatin A affects the expression of GDF15 mRNA]
trichostatin A results in increased expression of GDF15 mRNA 		CTD PMID:18801729 PMID:24935251 NCBI chr16:18,838,436...18,842,022
Ensembl chr16:18,838,436...18,842,022 		JBrowse link
G Gdpd1 glycerophosphodiester phosphodiesterase domain containing 1 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of GDPD1 mRNA
trichostatin A results in decreased expression of GDPD1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GDPD1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:72,318,716...72,381,143
Ensembl chr10:72,337,778...72,381,120 		JBrowse link
G Gem GTP binding protein overexpressed in skeletal muscle multiple interactions
decreases expression
increases expression 		ISO trichostatin A inhibits the reaction [Nickel affects the expression of GEM mRNA]
trichostatin A results in decreased expression of GEM mRNA
trichostatin A results in increased expression of GEM mRNA 		CTD PMID:14575637 PMID:24935251 NCBI chr 5:30,011,641...30,022,554
Ensembl chr 5:30,011,592...30,022,542 		JBrowse link
G Gemin4 gem (nuclear organelle) associated protein 4 affects expression ISO trichostatin A affects the expression of GEMIN4 mRNA CTD PMID:28542535 NCBI chr10:61,560,172...61,571,765
Ensembl chr10:61,564,657...61,596,532 		JBrowse link
G Gen1 GEN1 Holliday junction 5' flap endonuclease decreases expression ISO trichostatin A results in decreased expression of GEN1 mRNA CTD PMID:26272509 NCBI chr 6:39,666,675...39,697,480
Ensembl chr 6:39,667,286...39,697,480 		JBrowse link
G Gfap glial fibrillary acidic protein multiple interactions
increases expression 		EXP Finasteride inhibits the reaction [trichostatin A results in increased expression of GFAP mRNA]; Finasteride inhibits the reaction [trichostatin A results in increased expression of GFAP protein]
trichostatin A results in increased expression of GFAP mRNA; trichostatin A results in increased expression of GFAP protein 		CTD PMID:19360904 NCBI chr10:88,352,987...88,361,661
Ensembl chr10:88,352,986...88,361,685 		JBrowse link
G Gfpt2 glutamine-fructose-6-phosphate transaminase 2 increases expression ISO trichostatin A results in increased expression of GFPT2 mRNA CTD PMID:24935251 NCBI chr10:34,616,146...34,662,420
Ensembl chr10:34,615,370...34,662,419 		JBrowse link
G Gfra1 GDNF family receptor alpha 1 decreases expression
increases expression
multiple interactions 		ISO trichostatin A results in decreased expression of GFRA1 mRNA
trichostatin A results in increased expression of GFRA1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GFRA1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:267,325,297...267,557,037
Ensembl chr 1:267,326,817...267,556,501 		JBrowse link
G Gfra3 GDNF family receptor alpha 3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of GFRA3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GFRA3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr18:26,571,952...26,600,225
Ensembl chr18:26,571,921...26,600,225 		JBrowse link
G Gga2 golgi associated, gamma adaptin ear containing, ARF binding protein 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of GGA2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GGA2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:185,983,302...186,016,582
Ensembl chr 1:185,983,223...186,057,074 		JBrowse link
G Ggt1 gamma-glutamyltransferase 1 increases activity EXP trichostatin A results in increased activity of GGT1 protein CTD PMID:12030384 NCBI chr20:13,074,141...13,103,551
Ensembl chr20:13,074,141...13,088,050 		JBrowse link
G Ggt7 gamma-glutamyltransferase 7 affects expression ISO trichostatin A affects the expression of GGT7 mRNA CTD PMID:28542535 NCBI chr 3:164,438,240...164,464,059
Ensembl chr 3:164,437,812...164,463,068 		JBrowse link
G Ghr growth hormone receptor increases expression ISO trichostatin A results in increased expression of GHR mRNA CTD PMID:24935251 NCBI chr 2:54,269,066...54,532,595
Ensembl chr 2:54,270,206...54,532,331 		JBrowse link
G Ghrh growth hormone releasing hormone decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of GHRH mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GHRH mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:166,412,763...166,432,519
Ensembl chr 3:166,412,764...166,431,880 		JBrowse link
G Gins3 GINS complex subunit 3 affects expression ISO trichostatin A affects the expression of GINS3 mRNA CTD PMID:28542535 NCBI chr19:9,426,140...9,435,192
Ensembl chr19:9,399,759...9,434,679 		JBrowse link
G Gipr gastric inhibitory polypeptide receptor affects expression ISO trichostatin A affects the expression of GIPR mRNA CTD PMID:28542535 NCBI chr 1:87,932,316...87,956,084
Ensembl chr 1:87,932,623...87,942,492 		JBrowse link
G Git2 GIT ArfGAP 2 decreases expression ISO trichostatin A results in decreased expression of GIT2 mRNA CTD PMID:24935251 NCBI chr12:47,490,350...47,531,232
Ensembl chr12:47,490,369...47,533,250 		JBrowse link
G Gja3 gap junction protein, alpha 3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of GJA3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GJA3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr15:35,296,946...35,322,405
Ensembl chr15:35,295,523...35,322,809 		JBrowse link
G Gjb2 gap junction protein, beta 2 increases expression ISO trichostatin A results in increased expression of GJB2 mRNA CTD PMID:24935251 NCBI chr15:35,375,977...35,393,817
Ensembl chr15:35,375,692...35,393,877 		JBrowse link
G Gk glycerol kinase affects expression ISO trichostatin A affects the expression of GK mRNA CTD PMID:28542535 NCBI chr  X:54,106,708...54,189,940
Ensembl chr  X:54,112,214...54,196,701 		JBrowse link
G Gk5 glycerol kinase 5 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of GK5 mRNA
trichostatin A results in decreased expression of GK5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GK5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 8:105,562,018...105,630,975
Ensembl chr 8:105,562,050...105,631,978 		JBrowse link
G Gkap1 G kinase anchoring protein 1 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of GKAP1 mRNA
trichostatin A results in decreased expression of GKAP1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GKAP1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr17:6,389,377...6,429,091
Ensembl chr17:6,389,377...6,438,279 		JBrowse link
G Glb1l3 galactosidase, beta 1-like 3 increases expression ISO trichostatin A results in increased expression of GLB1L3 mRNA CTD PMID:24935251 NCBI chr 8:33,454,914...33,496,641
Ensembl chr 8:33,454,914...33,496,641 		JBrowse link
G Glcci1 glucocorticoid induced 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of GLCCI1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLCCI1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:37,274,271...37,601,898
Ensembl chr 4:37,529,364...37,599,802
Ensembl chr 4:37,529,364...37,599,802 		JBrowse link
G Glce glucuronic acid epimerase increases expression ISO trichostatin A results in increased expression of GLCE mRNA CTD PMID:24935251 NCBI chr 8:71,441,607...71,507,639
Ensembl chr 8:71,441,616...71,507,587 		JBrowse link
G Gli2 GLI family zinc finger 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of GLI2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLI2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr13:32,499,678...32,716,418
Ensembl chr13:32,499,678...32,716,418 		JBrowse link
G Gli3 GLI family zinc finger 3 decreases expression
increases expression 		ISO trichostatin A results in decreased expression of GLI3 mRNA
trichostatin A results in increased expression of GLI3 mRNA 		CTD PMID:22723015 PMID:24935251 NCBI chr17:54,134,064...54,405,198
Ensembl chr17:54,134,064...54,405,198 		JBrowse link
G Glis2 GLIS family zinc finger 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of GLIS2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:11,457,594...11,484,948
Ensembl chr10:11,457,792...11,477,995 		JBrowse link
G Glis3 GLIS family zinc finger 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of GLIS3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:235,389,567...235,809,416
Ensembl chr 1:235,392,651...235,809,221 		JBrowse link
G Glmn glomulin, FKBP associated protein increases expression ISO trichostatin A results in increased expression of GLMN mRNA CTD PMID:24935251 NCBI chr14:2,332,052...2,375,366
Ensembl chr14:2,332,497...2,375,695 		JBrowse link
G Glrb glycine receptor, beta increases expression ISO trichostatin A results in increased expression of GLRB mRNA CTD PMID:24935251 NCBI chr 2:168,432,736...168,505,614
Ensembl chr 2:168,432,736...168,505,614 		JBrowse link
G Glrx glutaredoxin increases expression ISO trichostatin A results in increased expression of GLRX mRNA CTD PMID:24935251 PMID:27188386 PMID:28542535 NCBI chr 2:7,073,737...7,083,548
Ensembl chr 2:7,073,759...7,083,543 		JBrowse link
G Glrx2 glutaredoxin 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of GLRX2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLRX2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr13:58,032,199...58,055,061
Ensembl chr13:58,032,401...58,043,150 		JBrowse link
G Gls glutaminase increases expression
multiple interactions
affects expression 		ISO trichostatin A results in increased expression of GLS mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLS mRNA
trichostatin A affects the expression of GLS mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 9:56,836,584...56,908,861
Ensembl chr 9:56,836,584...56,908,861 		JBrowse link
G Glt1d1 glycosyltransferase 1 domain containing 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of GLT1D1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLT1D1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr12:34,611,942...34,685,591
Ensembl chr12:34,612,643...34,685,468 		JBrowse link
G Glt8d2 glycosyltransferase 8 domain containing 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of GLT8D2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLT8D2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:22,917,055...22,968,616
Ensembl chr 7:22,917,100...22,968,930 		JBrowse link
G Glud1 glutamate dehydrogenase 1 decreases expression ISO trichostatin A results in decreased expression of GLUD1 mRNA CTD PMID:24935251 NCBI chr16:9,646,569...9,680,215
Ensembl chr16:9,646,509...9,680,210 		JBrowse link
G Glul glutamate-ammonia ligase multiple interactions
increases expression 		ISO trichostatin A inhibits the reaction [Dexamethasone results in increased expression of GLUL mRNA]
trichostatin A results in increased expression of GLUL mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLUL mRNA 		CTD PMID:23946490 PMID:26272509 PMID:27188386 NCBI chr13:68,519,500...68,585,554
Ensembl chr13:68,576,067...68,585,520 		JBrowse link
G Glyr1 glyoxylate reductase 1 homolog increases expression ISO trichostatin A results in increased expression of GLYR1 mRNA CTD PMID:24935251 NCBI chr10:11,038,577...11,074,093
Ensembl chr10:11,038,568...11,074,090 		JBrowse link
G Gm2a ganglioside GM2 activator increases expression ISO trichostatin A results in increased expression of GM2A mRNA CTD PMID:24935251 NCBI chr10:39,719,919...39,732,452
Ensembl chr10:39,719,938...39,732,451 		JBrowse link
G Gmeb2 glucocorticoid modulatory element binding protein 2 decreases expression ISO trichostatin A results in decreased expression of GMEB2 mRNA CTD PMID:24935251 NCBI chr 3:188,740,210...188,778,377
Ensembl chr 3:188,740,210...188,778,336 		JBrowse link
G Gmpr guanosine monophosphate reductase affects expression ISO trichostatin A affects the expression of GMPR mRNA CTD PMID:28542535 NCBI chr17:19,357,992...19,395,807
Ensembl chr17:19,357,992...19,431,655 		JBrowse link
G Gnai1 G protein subunit alpha i1 increases expression ISO trichostatin A results in increased expression of GNAI1 mRNA CTD PMID:24935251 NCBI chr 4:17,706,061...17,790,176
Ensembl chr 4:17,706,025...17,789,198 		JBrowse link
G Gnai2 G protein subunit alpha i2 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of GNAI2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNAI2 mRNA
trichostatin A affects the expression of GNAI2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 8:117,167,045...117,187,652
Ensembl chr 8:117,167,045...117,187,622 		JBrowse link
G Gnai3 G protein subunit alpha i3 affects expression ISO trichostatin A affects the expression of GNAI3 mRNA CTD PMID:28542535 NCBI chr 2:198,430,920...198,468,874 JBrowse link
G Gnao1 G protein subunit alpha o1 increases expression ISO trichostatin A results in increased expression of GNAO1 mRNA CTD PMID:28542535 NCBI chr19:11,040,788...11,198,437
Ensembl chr19:11,040,788...11,198,437 		JBrowse link
G Gnas GNAS complex locus increases expression
multiple interactions 		ISO trichostatin A results in increased expression of GNAS mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNAS mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:183,489,648...183,554,570
Ensembl chr 3:183,503,243...183,554,536 		JBrowse link
G Gnaz G protein subunit alpha z decreases expression
affects expression 		ISO trichostatin A results in decreased expression of GNAZ mRNA
trichostatin A affects the expression of GNAZ mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr20:13,642,853...13,693,616
Ensembl chr20:13,644,020...13,669,287 		JBrowse link
G Gnb5 G protein subunit beta 5 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of GNB5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNB5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:84,956,629...84,985,576
Ensembl chr 8:84,953,815...84,986,888 		JBrowse link
G Gng10 G protein subunit gamma 10 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of GNG10 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNG10 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:78,651,167...78,658,060
Ensembl chr 5:78,651,167...78,658,059 		JBrowse link
G Gng11 G protein subunit gamma 11 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of GNG11 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNG11 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:32,977,681...32,983,121
Ensembl chr 4:32,977,664...32,984,438 		JBrowse link
G Gng12 G protein subunit gamma 12 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of GNG12 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNG12 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:97,340,830...97,464,422
Ensembl chr 4:97,340,472...97,464,476 		JBrowse link
G Gng2 G protein subunit gamma 2 decreases expression
increases expression 		ISO trichostatin A results in decreased expression of GNG2 mRNA
trichostatin A results in increased expression of GNG2 mRNA 		CTD PMID:24935251 NCBI chr15:4,365,222...4,466,060
Ensembl chr15:4,365,135...4,466,059 		JBrowse link
G Gng7 G protein subunit gamma 7 affects expression ISO trichostatin A affects the expression of GNG7 mRNA CTD PMID:28542535 NCBI chr 7:9,348,148...9,411,924
Ensembl chr 7:9,348,218...9,411,923 		JBrowse link
G Gngt1 G protein subunit gamma transducin 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNGT1 mRNA
trichostatin A results in increased expression of GNGT1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:32,960,945...32,963,930
Ensembl chr 4:32,960,945...32,963,930 		JBrowse link
G Gnl3l G protein nucleolar 3 like increases expression
multiple interactions 		ISO trichostatin A results in increased expression of GNL3L mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNL3L mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:23,404,324...23,437,501
Ensembl chr  X:23,404,324...23,439,315 		JBrowse link
G Gnrhr gonadotropin releasing hormone receptor multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of GNRHR mRNA] CTD PMID:14575637 NCBI chr14:22,211,666...22,229,654 JBrowse link
G Golga4 golgin A4 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of GOLGA4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GOLGA4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 8:127,085,830...127,163,227
Ensembl chr 8:127,085,848...127,163,603 		JBrowse link
G Golm2 golgi membrane protein 2 affects expression ISO trichostatin A affects the expression of GOLM2 mRNA CTD PMID:28542535 NCBI chr 3:129,280,623...129,349,895
Ensembl chr 3:129,280,701...129,349,895 		JBrowse link
G Gopc golgi associated PDZ and coiled-coil motif containing increases expression ISO trichostatin A results in increased expression of GOPC mRNA CTD PMID:24935251 NCBI chr20:32,270,314...32,319,635
Ensembl chr20:32,270,314...32,319,611 		JBrowse link
G Gosr2 golgi SNAP receptor complex member 2 decreases expression ISO trichostatin A results in decreased expression of GOSR2 mRNA CTD PMID:24935251 NCBI chr10:89,085,323...89,105,665
Ensembl chr10:89,086,331...89,105,637 		JBrowse link
G Gpatch2 G patch domain containing 2 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of GPATCH2 mRNA
trichostatin A results in decreased expression of GPATCH2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPATCH2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr13:101,316,413...101,457,109
Ensembl chr13:101,316,413...101,457,109 		JBrowse link
G Gpatch2l G patch domain containing 2-like increases expression
multiple interactions 		ISO trichostatin A results in increased expression of GPATCH2L mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPATCH2L mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:111,614,344...111,666,603
Ensembl chr 6:111,614,416...111,666,602 		JBrowse link
G Gpatch4 G patch domain containing 4 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of GPATCH4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPATCH4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:175,797,503...175,816,547
Ensembl chr 2:175,807,682...175,817,358 		JBrowse link
G Gpc2 glypican 2 affects expression ISO trichostatin A affects the expression of GPC2 mRNA CTD PMID:28542535 NCBI chr12:22,391,489...22,397,822
Ensembl chr12:22,391,489...22,397,822 		JBrowse link
G Gpc3 glypican 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of GPC3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr  X:136,789,770...137,157,598
Ensembl chr  X:136,789,770...137,157,639 		JBrowse link
G Gpc4 glypican 4 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of GPC4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr  X:136,565,536...136,676,142
Ensembl chr  X:136,565,591...136,676,057 		JBrowse link
G Gpc6 glypican 6 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of GPC6 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC6 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:100,437,415...101,435,038
Ensembl chr15:100,437,943...101,435,027 		JBrowse link
G Gpd1l glycerol-3-phosphate dehydrogenase 1 like increases expression
multiple interactions 		ISO trichostatin A results in increased expression of GPD1L mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPD1L mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 8:123,469,282...123,498,948
Ensembl chr 8:123,466,667...123,498,908 		JBrowse link
G Gpd2 glycerol-3-phosphate dehydrogenase 2 affects expression ISO trichostatin A affects the expression of GPD2 mRNA CTD PMID:28542535 NCBI chr 3:62,209,432...62,346,590
Ensembl chr 3:62,210,814...62,346,593 		JBrowse link
G Gpi glucose-6-phosphate isomerase increases expression ISO trichostatin A results in increased expression of GPI mRNA CTD PMID:24935251 NCBI chr 1:95,965,389...95,996,932
Ensembl chr 1:95,965,396...95,993,261 		JBrowse link
G Gpm6a glycoprotein m6a increases expression
multiple interactions 		ISO trichostatin A results in increased expression of GPM6A mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPM6A mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr16:43,374,385...43,706,461
Ensembl chr16:43,374,385...43,706,705 		JBrowse link
G Gpm6b glycoprotein m6b increases expression
multiple interactions 		ISO trichostatin A results in increased expression of GPM6B mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPM6B mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr  X:31,689,485...31,836,199
Ensembl chr  X:31,690,359...31,733,272 		JBrowse link
G Gpnmb glycoprotein nmb increases expression ISO trichostatin A results in increased expression of GPNMB mRNA CTD PMID:24935251 NCBI chr 4:79,341,128...79,362,366
Ensembl chr 4:79,341,021...79,380,240 		JBrowse link
G Gpr137b G protein-coupled receptor 137B increases expression ISO trichostatin A results in increased expression of GPR137B mRNA CTD PMID:24935251 NCBI chr17:92,987,792...93,026,003
Ensembl chr17:92,942,559...93,025,911 		JBrowse link
G Gpr137c G protein-coupled receptor 137C increases expression ISO trichostatin A results in increased expression of GPR137C mRNA CTD PMID:24935251 NCBI chr15:20,905,923...20,972,318
Ensembl chr15:20,905,958...20,970,541 		JBrowse link
G Gpr146 G protein-coupled receptor 146 affects expression ISO trichostatin A affects the expression of GPR146 mRNA CTD PMID:28542535 NCBI chr12:20,365,790...20,381,122
Ensembl chr12:20,364,269...20,381,345 		JBrowse link
G Gpr153 G protein-coupled receptor 153 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of GPR153 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR153 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:168,064,134...168,075,697
Ensembl chr 5:168,064,311...168,074,532 		JBrowse link
G Gpr155 G protein-coupled receptor 155 affects expression ISO trichostatin A affects the expression of GPR155 mRNA CTD PMID:28542535 NCBI chr 3:78,623,931...78,677,803
Ensembl chr 3:78,607,976...78,677,803 		JBrowse link
G Gpr157 G protein-coupled receptor 157 increases expression ISO trichostatin A results in increased expression of GPR157 mRNA CTD PMID:24935251 NCBI chr 5:165,833,651...165,849,376
Ensembl chr 5:165,833,673...165,851,280 		JBrowse link
G Gpr158 G protein-coupled receptor 158 increases expression ISO trichostatin A results in increased expression of GPR158 mRNA CTD PMID:24935251 NCBI chr17:88,685,879...89,152,659
Ensembl chr17:88,742,823...89,152,658 		JBrowse link
G Gpr160 G protein-coupled receptor 160 increases expression ISO trichostatin A results in increased expression of GPR160 mRNA CTD PMID:24935251 NCBI chr 2:114,414,084...114,491,590
Ensembl chr 2:114,410,261...114,474,790 		JBrowse link
G Gpr161 G protein-coupled receptor 161 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of GPR161 mRNA
trichostatin A results in decreased expression of GPR161 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR161 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr13:80,111,271...80,156,517
Ensembl chr13:80,117,114...80,152,861 		JBrowse link
G Gpr183 G protein-coupled receptor 183 decreases expression ISO trichostatin A results in decreased expression of GPR183 mRNA CTD PMID:33770205 NCBI chr15:105,445,129...105,457,192
Ensembl chr15:105,437,561...105,466,977 		JBrowse link
G Gpr19 G protein-coupled receptor 19 decreases expression
increases expression
multiple interactions 		ISO trichostatin A results in decreased expression of GPR19 mRNA
trichostatin A results in increased expression of GPR19 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR19 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:26705709 PMID:27188386 NCBI chr 4:169,442,278...169,468,805
Ensembl chr 4:169,436,658...169,471,249 		JBrowse link
G Gpr20 G protein-coupled receptor 20 decreases expression ISO trichostatin A results in decreased expression of GPR20 mRNA CTD PMID:24935251 NCBI chr 7:107,490,419...107,500,993
Ensembl chr 7:107,490,713...107,500,966 		JBrowse link
G Gpr27 G protein-coupled receptor 27 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of GPR27 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR27 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:133,884,894...133,886,027
Ensembl chr 4:133,883,234...133,904,093 		JBrowse link
G Gpr37 G protein-coupled receptor 37 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of GPR37 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR37 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:55,104,355...55,126,420
Ensembl chr 4:55,104,365...55,126,494 		JBrowse link
G Gpr85 G protein-coupled receptor 85 increases expression ISO trichostatin A results in increased expression of GPR85 mRNA CTD PMID:24935251 NCBI chr 4:43,070,194...43,075,662
Ensembl chr 4:43,060,777...43,075,794 		JBrowse link
G Gprasp1 G protein-coupled receptor associated sorting protein 1 increases expression ISO trichostatin A results in increased expression of GPRASP1 mRNA CTD PMID:24935251 NCBI chr  X:103,556,493...103,564,275
Ensembl chr  X:103,501,377...103,565,649 		JBrowse link
G Gprasp2 G protein-coupled receptor associated sorting protein 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of GPRASP2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPRASP2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:103,609,304...103,615,450
Ensembl chr  X:103,501,226...103,641,988 		JBrowse link
G Gprasp3 G protein-coupled receptor associated sorting protein family member 3 decreases expression ISO trichostatin A results in decreased expression of GPRASP3 mRNA CTD PMID:24935251 NCBI chr  X:103,639,366...103,644,561
Ensembl chr  X:103,609,243...103,650,463 		JBrowse link
G Gprc5b G protein-coupled receptor, class C, group 5, member B decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of GPRC5B mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPRC5B mRNA 		CTD PMID:24935251 PMID:27188386 NCBI chr 1:182,748,247...182,772,711
Ensembl chr 1:182,748,247...182,772,757 		JBrowse link
G Gps2 G protein pathway suppressor 2 affects expression ISO trichostatin A affects the expression of GPS2 mRNA CTD PMID:28542535 NCBI chr10:55,136,043...55,139,106
Ensembl chr10:55,136,169...55,139,862 		JBrowse link
G Gpsm2 G-protein signaling modulator 2 increases expression
affects expression 		ISO trichostatin A results in increased expression of GPSM2 mRNA
trichostatin A affects the expression of GPSM2 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 2:199,015,250...199,063,788
Ensembl chr 2:199,015,250...199,063,056 		JBrowse link
G Gpx3 glutathione peroxidase 3 multiple interactions
increases expression 		ISO trichostatin A promotes the reaction [[decitabine affects the methylation of GPX3 promoter] which affects the expression of GPX3 protein]
trichostatin A increases expression of GPX3 mRNA and protein in epithelial cells of stomach 		CTD
RGD		 PMID:18664505 PMID:23071548 RGD:151665353 NCBI chr10:39,529,335...39,537,406
Ensembl chr10:39,529,448...39,537,405 		JBrowse link
G Gpx7 glutathione peroxidase 7 multiple interactions ISO trichostatin A promotes the reaction [[decitabine affects the methylation of GPX7 promoter] which affects the expression of GPX7 protein] CTD PMID:18664505 NCBI chr 5:128,373,881...128,381,866
Ensembl chr 5:128,372,875...128,381,725 		JBrowse link
G Gramd1b GRAM domain containing 1B decreases expression ISO trichostatin A results in decreased expression of GRAMD1B mRNA CTD PMID:24935251 NCBI chr 8:49,551,642...49,790,965
Ensembl chr 8:49,556,332...49,791,052 		JBrowse link
G Gramd1c GRAM domain containing 1C increases expression
decreases expression
affects expression 		ISO trichostatin A results in increased expression of GRAMD1C mRNA
trichostatin A results in decreased expression of GRAMD1C mRNA
trichostatin A affects the expression of GRAMD1C mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr11:70,139,076...70,224,478
Ensembl chr11:70,139,184...70,224,478 		JBrowse link
G Gramd2b GRAM domain containing 2B increases expression ISO trichostatin A results in increased expression of GRAMD2B mRNA CTD PMID:24935251 NCBI chr18:52,082,128...52,180,056
Ensembl chr18:52,082,029...52,180,054 		JBrowse link
G Gramd4 GRAM domain containing 4 increases expression ISO trichostatin A results in increased expression of GRAMD4 mRNA CTD PMID:24935251 NCBI chr 7:119,030,225...119,103,875
Ensembl chr 7:119,030,225...119,103,875 		JBrowse link
G Grb14 growth factor receptor bound protein 14 increases expression ISO trichostatin A results in increased expression of GRB14 mRNA CTD PMID:24935251 NCBI chr 3:69,976,331...70,091,921
Ensembl chr 3:69,976,339...70,091,921 		JBrowse link
G Grcc10 gene rich cluster, C10 gene multiple interactions ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C12ORF57 mRNA CTD PMID:27188386 NCBI chr 4:159,237,562...159,239,223 JBrowse link
G Greb1 growth regulating estrogen receptor binding 1 decreases expression
increases expression 		ISO trichostatin A results in decreased expression of GREB1 mRNA
trichostatin A results in increased expression of GREB1 mRNA 		CTD PMID:24935251 NCBI chr 6:45,169,289...45,321,973
Ensembl chr 6:45,169,289...45,291,126 		JBrowse link
G Grem1 gremlin 1, DAN family BMP antagonist increases expression
multiple interactions 		ISO trichostatin A results in increased expression of GREM1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GREM1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:120,966,639...120,978,319
Ensembl chr 3:120,966,623...120,979,089 		JBrowse link
G Grhl1 grainyhead-like transcription factor 1 increases expression
affects expression 		ISO trichostatin A results in increased expression of GRHL1 mRNA
trichostatin A affects the expression of GRHL1 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 6:46,935,947...46,986,126
Ensembl chr 6:46,935,967...46,980,264 		JBrowse link
G Grhl2 grainyhead-like transcription factor 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of GRHL2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:70,280,360...70,415,277
Ensembl chr 7:70,285,310...70,415,274 		JBrowse link
G Grhl3 grainyhead-like transcription factor 3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of GRHL3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:153,057,760...153,089,890
Ensembl chr 5:153,057,760...153,089,890 		JBrowse link
G Gria1 glutamate ionotropic receptor AMPA type subunit 1 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of GRIA1 mRNA
trichostatin A results in decreased expression of GRIA1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:41,710,540...42,030,105
Ensembl chr10:41,711,080...42,030,309 		JBrowse link
G Gria2 glutamate ionotropic receptor AMPA type subunit 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRIA2 mRNA; trichostatin A inhibits the reaction [Nickel affects the expression of GRIA2 mRNA]
trichostatin A results in increased expression of GRIA2 mRNA 		CTD PMID:14575637 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:168,247,490...168,367,616
Ensembl chr 2:168,247,496...168,367,616 		JBrowse link
G Gria3 glutamate ionotropic receptor AMPA type subunit 3 decreases expression
increases expression 		ISO trichostatin A results in decreased expression of GRIA3 mRNA
trichostatin A results in increased expression of GRIA3 mRNA 		CTD PMID:24935251 NCBI chr  X:125,103,975...125,369,690
Ensembl chr  X:125,103,782...125,369,679 		JBrowse link
G Gria4 glutamate ionotropic receptor AMPA type subunit 4 increases expression ISO trichostatin A results in increased expression of GRIA4 mRNA CTD PMID:24935251 NCBI chr 8:9,845,421...10,320,021
Ensembl chr 8:9,847,052...10,319,881 		JBrowse link
G Grik2 glutamate ionotropic receptor kainate type subunit 2 increases expression ISO trichostatin A results in increased expression of GRIK2 mRNA CTD PMID:24935251 NCBI chr20:53,717,564...54,415,283
Ensembl chr20:53,716,090...54,415,202 		JBrowse link
G Grik3 glutamate ionotropic receptor kainate type subunit 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of GRIK3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIK3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:143,052,442...143,268,873
Ensembl chr 5:143,052,442...143,268,873 		JBrowse link
G Grin2a glutamate ionotropic receptor NMDA type subunit 2A decreases expression ISO trichostatin A results in decreased expression of GRIN2A mRNA CTD PMID:24935251 NCBI chr10:6,136,458...6,560,003
Ensembl chr10:6,138,037...6,551,378 		JBrowse link
G Grk5 G protein-coupled receptor kinase 5 increases expression ISO trichostatin A results in increased expression of GRK5 mRNA CTD PMID:24935251 NCBI chr 1:270,014,314...270,208,294
Ensembl chr 1:270,014,282...270,204,928 		JBrowse link
G Grm3 glutamate metabotropic receptor 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of GRM3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRM3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:25,319,218...25,600,721
Ensembl chr 4:25,319,942...25,564,764 		JBrowse link
G Grp gastrin releasing peptide increases expression ISO trichostatin A results in increased expression of GRP mRNA CTD PMID:26272509 NCBI chr18:61,658,655...61,672,037
Ensembl chr18:61,658,250...61,672,037 		JBrowse link
G Gsap gamma-secretase activating protein decreases expression
increases expression 		ISO trichostatin A results in decreased expression of GSAP mRNA
trichostatin A results in increased expression of GSAP mRNA 		CTD PMID:24935251 NCBI chr 4:14,705,237...14,800,057
Ensembl chr 4:14,705,237...14,800,005 		JBrowse link
G Gsdme gasdermin E decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of GSDME mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GSDME mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:80,590,344...80,651,943
Ensembl chr 4:80,588,614...80,641,525 		JBrowse link
G Gskip GSK3B interacting protein affects expression ISO trichostatin A affects the expression of GSKIP mRNA CTD PMID:28542535 NCBI chr 6:130,357,241...130,373,221
Ensembl chr 6:130,370,042...130,373,873 		JBrowse link
G Gsn gelsolin increases expression
multiple interactions
affects expression 		ISO
EXP 		trichostatin A results in increased expression of GSN mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GSN mRNA
trichostatin A affects the expression of GSN mRNA
trichostatin A results in increased expression of GSN protein 		CTD PMID:12445420 PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 3:38,982,605...39,035,849
Ensembl chr 3:38,982,671...39,035,850 		JBrowse link
G Gspt1 G1 to S phase transition 1 increases expression ISO trichostatin A results in increased expression of GSPT1 mRNA CTD PMID:24935251 PMID:26272509 NCBI chr10:4,867,687...4,904,186
Ensembl chr10:4,869,465...4,908,040 		JBrowse link
G Gspt2 G1 to S phase transition 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of GSPT2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GSPT2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:63,582,649...63,597,467
Ensembl chr  X:63,582,690...63,700,401 		JBrowse link
G Gsta4 glutathione S-transferase alpha 4 multiple interactions ISO [Decitabine co-treated with trichostatin A] results in increased expression of GSTA4 mRNA CTD PMID:19444856 NCBI chr 8:87,947,247...87,964,490
Ensembl chr 8:87,930,566...87,964,488 		JBrowse link
G Gstk1 glutathione S-transferase kappa 1 multiple interactions ISO [decitabine co-treated with trichostatin A] results in increased expression of GSTK1 mRNA CTD PMID:19444856 NCBI chr 4:72,085,532...72,089,934
Ensembl chr 4:72,085,531...72,089,927 		JBrowse link
G Gstm2 glutathione S-transferase mu 2 affects expression
multiple interactions 		ISO trichostatin A affects the expression of GSTM2 mRNA
trichostatin A inhibits the reaction [nickel chloride results in decreased expression of GSTM2 mRNA]; trichostatin A promotes the reaction [[Decitabine affects the methylation of GSTM2 promoter] which affects the expression of GSTM2 protein] 		CTD PMID:18664505 PMID:38050843 NCBI chr 2:198,312,179...198,316,962 JBrowse link
G Gstm5 glutathione S-transferase, mu 5 multiple interactions
increases expression 		ISO trichostatin A inhibits the reaction [Nickel affects the expression of GSTM3 mRNA]
trichostatin A results in increased expression of GSTM3 mRNA 		CTD PMID:14575637 PMID:24935251 NCBI chr 2:198,219,769...198,222,732
Ensembl chr 2:198,219,647...198,222,731 		JBrowse link
G Gsto1 glutathione S-transferase omega 1 multiple interactions
increases expression 		ISO [decitabine co-treated with trichostatin A] results in increased expression of GSTO1 mRNA
trichostatin A results in increased expression of GSTO1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GSTO1 mRNA 		CTD PMID:19444856 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:256,662,377...256,672,515
Ensembl chr 1:256,662,531...256,676,167 		JBrowse link
G Gstp1 glutathione S-transferase pi 1 multiple interactions
affects expression 		ISO [decitabine co-treated with trichostatin A] results in increased expression of GSTP1 mRNA
trichostatin A affects the expression of GSTP1 protein 		CTD PMID:17891453 PMID:19294695 PMID:19444856 NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705 		JBrowse link
G Gtdc1 glycosyltransferase-like domain containing 1 decreases expression ISO trichostatin A results in decreased expression of QTMAN mRNA CTD PMID:24935251 NCBI chr 3:49,176,110...49,571,594
Ensembl chr 3:49,176,110...49,571,843 		JBrowse link
G Gtf2a1 general transcription factor 2A subunit 1 decreases expression ISO trichostatin A results in decreased expression of GTF2A1 mRNA CTD PMID:24935251 PMID:26272509 NCBI chr 6:116,219,614...116,252,220
Ensembl chr 6:116,219,614...116,252,220 		JBrowse link
G Gtf2h1 general transcription factor IIH subunit 1 decreases expression ISO trichostatin A results in decreased expression of GTF2H1 mRNA CTD PMID:24935251 NCBI chr 1:106,457,692...106,485,729
Ensembl chr 1:106,457,394...106,485,727 		JBrowse link
G Gtf2h5 general transcription factor IIH subunit 5 decreases expression ISO trichostatin A results in decreased expression of GTF2H5 mRNA CTD PMID:24935251 NCBI chr 1:49,061,904...49,068,612
Ensembl chr 1:49,061,959...49,070,039 		JBrowse link
G Gtf2i general transcription factor II I decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of GTF2I mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GTF2I mRNA
trichostatin A affects the expression of GTF2I mRNA 		CTD PMID:24935251 PMID:27188386 PMID:28542535 NCBI chr12:28,037,344...28,112,677
Ensembl chr12:28,037,853...28,112,677 		JBrowse link
G Gtf2ird1 GTF2I repeat domain containing 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of GTF2IRD1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GTF2IRD1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr12:27,890,594...27,997,506
Ensembl chr12:27,890,675...27,997,494 		JBrowse link
G Gtf2ird2 GTF2I repeat domain containing 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of GTF2IRD2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GTF2IRD2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr12:28,134,199...28,179,089
Ensembl chr12:28,133,792...28,172,876 		JBrowse link
G Gtf3c1 general transcription factor IIIC subunit 1 affects expression ISO trichostatin A affects the expression of GTF3C1 mRNA CTD PMID:28542535 NCBI chr 1:189,634,645...189,700,848
Ensembl chr 1:189,634,645...189,700,995 		JBrowse link
G Gtf3c2 general transcription factor IIIC subunit 2 affects expression ISO trichostatin A affects the expression of GTF3C2 mRNA CTD PMID:28542535 NCBI chr 6:30,913,263...30,941,305
Ensembl chr 6:30,923,106...30,940,465 		JBrowse link
G Gtpbp2 GTP binding protein 2 multiple interactions
increases expression 		ISO [decitabine co-treated with trichostatin A] results in increased expression of GTPBP2 mRNA
trichostatin A results in increased expression of GTPBP2 mRNA 		CTD PMID:20678512 NCBI chr 9:22,311,532...22,321,405
Ensembl chr 9:22,311,158...22,321,441 		JBrowse link
G Gtpbp6 GTP binding protein 6 (putative) affects expression ISO trichostatin A affects the expression of GTPBP6 mRNA CTD PMID:28542535 NCBI chr12:52,234,646...52,238,578
Ensembl chr12:52,234,572...52,238,578 		JBrowse link
G Gtse1 G-2 and S-phase expressed 1 decreases expression ISO trichostatin A results in decreased expression of GTSE1 mRNA CTD PMID:23770000 NCBI chr 7:118,829,793...118,846,662
Ensembl chr 7:118,829,903...118,846,661 		JBrowse link
G Guca1a guanylate cyclase activator 1A decreases expression
increases expression 		ISO trichostatin A results in decreased expression of GUCA1A mRNA
trichostatin A results in increased expression of GUCA1A mRNA 		CTD PMID:24935251 PMID:26272509 NCBI chr 9:21,080,782...21,096,221
Ensembl chr 9:21,086,642...21,096,221 		JBrowse link
G Gucy1a2 guanylate cyclase 1 soluble subunit alpha 2 decreases expression ISO trichostatin A results in decreased expression of GUCY1A2 mRNA CTD PMID:28542535 NCBI chr 8:8,785,212...9,174,322
Ensembl chr 8:8,785,121...9,174,272 		JBrowse link
G Gucy1b1 guanylate cyclase 1 soluble subunit beta 1 increases expression ISO trichostatin A results in increased expression of GUCY1B1 mRNA CTD PMID:24935251 NCBI chr 2:169,646,897...169,697,060
Ensembl chr 2:169,646,898...169,696,987 		JBrowse link
G Gucy2c guanylate cyclase 2C increases expression ISO trichostatin A results in increased expression of GUCY2C mRNA CTD PMID:24935251 NCBI chr 4:171,299,715...171,380,296
Ensembl chr 4:171,299,740...171,380,296 		JBrowse link
G Gulp1 GULP PTB domain containing engulfment adaptor 1 increases expression
decreases expression 		ISO trichostatin A results in increased expression of GULP1 mRNA
trichostatin A results in decreased expression of GULP1 mRNA 		CTD PMID:24935251 NCBI chr 9:54,114,823...54,391,058
Ensembl chr 9:54,114,731...54,397,452 		JBrowse link
G Gxylt2 glucoside xylosyltransferase 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of GXYLT2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GXYLT2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:134,903,595...135,006,066
Ensembl chr 4:134,903,859...134,987,956 		JBrowse link
G Gypc glycophorin C increases expression
multiple interactions 		ISO trichostatin A results in increased expression of GYPC mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GYPC mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr18:24,434,921...24,467,592
Ensembl chr18:24,434,922...24,440,053 		JBrowse link
G Gzmb granzyme B multiple interactions ISO trichostatin A inhibits the reaction [Arsenic results in increased expression of GZMB protein] CTD PMID:32735129 NCBI chr15:34,459,007...34,462,469
Ensembl chr15:34,459,007...34,462,469 		JBrowse link
G H1f0 H1.0 linker histone increases expression ISO trichostatin A results in increased expression of H1-0 mRNA CTD PMID:19606018 PMID:24935251 NCBI chr 7:112,473,280...112,475,140
Ensembl chr 7:112,473,222...112,475,006 		JBrowse link
G H1f10 H1.10 linker histone affects expression ISO trichostatin A affects the expression of H1-10 mRNA CTD PMID:28542535 NCBI chr 4:121,997,834...121,998,897
Ensembl chr 4:121,997,831...121,998,966 		JBrowse link
G H1f2 H1.2 linker histone, cluster member multiple interactions
decreases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H1-2 mRNA
trichostatin A results in decreased expression of H1-2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:41,818,962...41,820,453
Ensembl chr17:41,779,051...41,822,317 		JBrowse link
G H1f4 H1.4 linker histone, cluster member decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of H1-4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H1-4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr17:41,914,425...41,915,206
Ensembl chr17:41,914,431...41,916,129 		JBrowse link
G H2ac25 H2A clustered histone 25 affects expression ISO trichostatin A affects the expression of H2AC25 mRNA CTD PMID:28542535 NCBI chr10:44,233,283...44,234,835
Ensembl chr10:44,233,181...44,241,197 		JBrowse link
G H2ac6 H2A clustered histone 6 multiple interactions
decreases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2AC6 mRNA
trichostatin A results in decreased expression of H2AC6 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr17:47,403,701...47,404,167 JBrowse link
G H2aj H2A.J histone increases expression ISO trichostatin A results in increased expression of H2AJ mRNA CTD PMID:24935251 NCBI chr 4:171,406,922...171,407,406
Ensembl chr 4:171,406,177...171,408,845 		JBrowse link
G H2ax H2A.X variant histone affects expression
multiple interactions 		ISO
EXP 		trichostatin A affects the expression of H2AX mRNA
trichostatin A inhibits the reaction [potassium bromate results in increased phosphorylation of H2AX protein] 		CTD PMID:25015661 PMID:28542535 NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079 		JBrowse link
G H2bc12 H2B clustered histone 12 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of H2BC12 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC12 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr17:47,181,477...47,181,940
Ensembl chr17:47,121,467...47,182,816 		JBrowse link
G H2bc14 H2B clustered histone 14 multiple interactions
decreases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC5 mRNA
trichostatin A results in decreased expression of H2BC5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr17:47,488,627...47,489,008 JBrowse link
G H2bc21 H2B clustered histone 21 affects expression ISO trichostatin A affects the expression of H2BC11 mRNA CTD PMID:28542535 NCBI chr 2:186,469,452...186,471,899 JBrowse link
G H2bc27 H2B clustered histone 27 affects expression ISO trichostatin A affects the expression of H2BC26 mRNA CTD PMID:28542535 NCBI chr10:44,232,318...44,233,065
Ensembl chr10:44,232,318...44,233,065 		JBrowse link
G H2bc4 H2B clustered histone 4 multiple interactions ISO trichostatin A inhibits the reaction [Gentamicins results in decreased acetylation of H2BC4 protein] CTD PMID:19141081 NCBI chr17:47,388,085...47,392,349
Ensembl chr17:47,404,375...47,419,020 		JBrowse link
G H3f3b H3.3 histone B decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of H3-3B mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H3-3B mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:101,755,404...101,764,616
Ensembl chr10:101,755,404...101,757,636 		JBrowse link
G H3f4 H3.4 histone, cluster member multiple interactions
decreases methylation
increases acetylation 		ISO [[3-deazaneplanocin co-treated with trichostatin A] affects the acetylation of and affects the methylation of H3-4 protein] which affects the expression of DACT3; [[Decitabine co-treated with trichostatin A] affects the acetylation of H3-4 protein] which affects the expression of CDH1 mRNA; [Decitabine co-treated with trichostatin A co-treated with Tretinoin] affects the methylation of H3-4 protein; [Decitabine co-treated with trichostatin A co-treated with Tretinoin] affects the reaction [H3-4 protein modified form binds to RARB promoter]; [Decitabine co-treated with trichostatin A] affects the acetylation of H3-4 protein; [Decitabine co-treated with trichostatin A] affects the methylation of H3-4 protein; [Decitabine co-treated with trichostatin A] affects the reaction [H3-4 protein modified form binds to RARB gene]; [Decitabine co-treated with trichostatin A] results in decreased methylation of H3-4 protein; [trichostatin A affects the acetylation of H3-4 promoter] which affects the expression of IGFBP3 mRNA; [trichostatin A affects the acetylation of H3-4 protein] which affects the expression of CDH1 mRNA; trichostatin A promotes the reaction [H3-4 protein modified form binds to CCNA1 promoter]; trichostatin A promotes the reaction [H3-4 protein modified form binds to PTEN promoter]; trichostatin A promotes the reaction [H3-4 protein modified form binds to RARB gene]
trichostatin A results in decreased methylation of H3-4 protein
trichostatin A results in increased acetylation of H3-4; trichostatin A results in increased acetylation of H3-4 protein
trichostatin A results in increased acetylation of H3F4 protein 		CTD PMID:11689710 PMID:15959780 PMID:16505122 PMID:16740727 PMID:17330857 More... NCBI chr10:44,240,282...44,240,842 JBrowse link
G H4f3 H1.3 linker histone, cluster member decreases expression ISO trichostatin A results in decreased expression of H1-3 mRNA CTD PMID:24935251 PMID:26272509 NCBI chr17:41,979,562...41,980,341
Ensembl chr17:41,796,116...41,980,485 		JBrowse link
G Habp4 hyaluronan binding protein 4 affects expression ISO trichostatin A affects the expression of HABP4 mRNA CTD PMID:28542535 NCBI chr17:940,672...963,358
Ensembl chr17:941,389...963,300 		JBrowse link
G Hacd1 3-hydroxyacyl-CoA dehydratase 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of HACD1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HACD1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr17:81,992,284...82,014,676
Ensembl chr17:81,992,292...82,014,592 		JBrowse link
G Hacd4 3-hydroxyacyl-CoA dehydratase 4 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of HACD4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HACD4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:107,935,514...107,961,271
Ensembl chr 5:107,934,937...107,962,836 		JBrowse link
G Hagh hydroxyacyl glutathione hydrolase affects expression ISO trichostatin A affects the expression of HAGH mRNA CTD PMID:28542535 NCBI chr10:14,379,400...14,394,046
Ensembl chr10:14,382,410...14,394,043 		JBrowse link
G Hapln1 hyaluronan and proteoglycan link protein 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of HAPLN1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAPLN1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:22,366,967...22,431,709
Ensembl chr 2:22,366,967...22,429,098 		JBrowse link
G Has2 hyaluronan synthase 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of HAS2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAS2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:90,002,929...90,028,933
Ensembl chr 7:90,002,929...90,018,535 		JBrowse link
G Has3 hyaluronan synthase 3 increases expression ISO trichostatin A results in increased expression of HAS3 mRNA CTD PMID:24935251 PMID:26705709 NCBI chr19:51,668,276...51,691,042 JBrowse link
G Haus6 HAUS augmin like complex subunit 6 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of HAUS6 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HAUS6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:106,162,526...106,201,503
Ensembl chr 5:106,162,526...106,199,072 		JBrowse link
G Hbb hemoglobin subunit beta multiple interactions ISO trichostatin A inhibits the reaction [hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of HBB mRNA]] CTD PMID:30327826 NCBI chr 1:167,662,310...167,663,721
Ensembl chr 1:167,630,245...167,663,873 		JBrowse link
G Hbegf heparin-binding EGF-like growth factor increases expression ISO trichostatin A results in increased expression of HBEGF mRNA CTD PMID:26705709 NCBI chr18:28,380,337...28,390,220
Ensembl chr18:28,380,337...28,390,220 		JBrowse link
G Hbs1l HBS1-like translational GTPase increases expression ISO trichostatin A results in increased expression of HBS1L mRNA CTD PMID:24935251 NCBI chr 1:17,912,139...17,989,651
Ensembl chr 1:17,912,070...17,989,646 		JBrowse link
G Hcfc1 host cell factor C1 affects expression ISO trichostatin A affects the expression of HCFC1 mRNA CTD PMID:28542535 NCBI chr  X:156,839,100...156,864,132
Ensembl chr  X:156,839,100...156,863,813 		JBrowse link
G Hck HCK proto-oncogene, Src family tyrosine kinase increases expression ISO trichostatin A results in increased expression of HCK mRNA CTD PMID:24935251 NCBI chr 3:162,031,833...162,074,933
Ensembl chr 3:162,031,817...162,074,935 		JBrowse link
G Hcn1 hyperpolarization-activated cyclic nucleotide-gated potassium channel 1 increases expression ISO trichostatin A results in increased expression of HCN1 mRNA CTD PMID:26705709 NCBI chr 2:51,228,710...51,632,806
Ensembl chr 2:51,228,710...51,632,806 		JBrowse link
G Hdac1 histone deacetylase 1 decreases activity
decreases expression
multiple interactions 		ISO trichostatin A results in decreased activity of HDAC1 protein
trichostatin A results in decreased expression of HDAC1 protein
trichostatin A inhibits the reaction [hydroquinone results in increased expression of HDAC1 mRNA]
trichostatin A inhibits the reaction [Folic Acid results in increased expression of HDAC1 protein] 		CTD PMID:15103026 PMID:15927959 PMID:15930892 PMID:23285096 PMID:27220438 More... NCBI chr 5:147,138,328...147,165,387
Ensembl chr 5:147,138,156...147,165,387 		JBrowse link
G Hdac2 histone deacetylase 2 decreases activity
multiple interactions 		ISO
EXP 		trichostatin A results in decreased activity of HDAC2 protein
trichostatin A inhibits the reaction [hydroquinone results in increased expression of HDAC2 mRNA]
trichostatin A inhibits the reaction [bisphenol A results in increased expression of HDAC2 protein] 		CTD PMID:15103026 PMID:18421014 PMID:27220438 PMID:34838597 PMID:34973135 NCBI chr20:42,101,815...42,126,486
Ensembl chr20:42,102,861...42,126,311 		JBrowse link
G Hdac3 histone deacetylase 3 decreases expression
decreases activity
affects expression
multiple interactions 		ISO trichostatin A results in decreased expression of HDAC3 protein
trichostatin A results in decreased activity of HDAC3 protein
trichostatin A affects the expression of HDAC3 mRNA
Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]; trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]] 		CTD PMID:15103026 PMID:15930892 PMID:18676679 PMID:26883953 PMID:28542535 More... NCBI chr18:30,021,847...30,041,061
Ensembl chr18:30,021,941...30,041,025 		JBrowse link
G Hdac4 histone deacetylase 4 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of HDAC4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HDAC4 mRNA 		CTD PMID:22723015 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 9:99,950,972...100,200,994
Ensembl chr 9:99,955,116...100,197,637 		JBrowse link
G Hdac6 histone deacetylase 6 decreases activity ISO trichostatin A results in decreased activity of HDAC6 protein CTD PMID:15930892 NCBI chr  X:17,222,538...17,244,373
Ensembl chr  X:17,222,856...17,244,370 		JBrowse link
G Hdac9 histone deacetylase 9 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of HDAC9 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HDAC9 mRNA 		CTD PMID:22723015 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:56,489,472...57,351,654
Ensembl chr 6:56,490,988...57,351,835 		JBrowse link
G Hdgf heparin binding growth factor affects expression ISO trichostatin A affects the expression of HDGF mRNA CTD PMID:28542535 NCBI chr 2:175,668,290...175,677,614
Ensembl chr 2:175,668,324...175,677,225 		JBrowse link
G Hdgfl2 HDGF like 2 affects expression ISO trichostatin A affects the expression of HDGFL2 mRNA CTD PMID:28542535 NCBI chr 9:996,687...1,016,352
Ensembl chr 9:996,758...1,016,735 		JBrowse link
G Hdgfl3 HDGF like 3 decreases expression ISO trichostatin A results in decreased expression of HDGFL3 mRNA CTD PMID:24935251 NCBI chr 1:145,233,996...145,287,115
Ensembl chr 1:145,236,758...145,286,001 		JBrowse link
G Heatr1 HEAT repeat containing 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HEATR1 mRNA
trichostatin A results in decreased expression of HEATR1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:62,745,008...62,785,609
Ensembl chr17:62,745,008...62,785,186 		JBrowse link
G Hebp1 heme binding protein 1 increases expression ISO trichostatin A results in increased expression of HEBP1 mRNA CTD PMID:24935251 NCBI chr 4:169,705,665...169,735,199
Ensembl chr 4:169,705,668...169,735,199 		JBrowse link
G Heca hdc homolog, cell cycle regulator increases expression ISO trichostatin A results in increased expression of HECA mRNA CTD PMID:24935251 NCBI chr 1:14,345,306...14,395,226
Ensembl chr 1:14,345,306...14,395,191 		JBrowse link
G Hectd1 HECT domain E3 ubiquitin protein ligase 1 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of HECTD1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HECTD1 mRNA
trichostatin A affects the expression of HECTD1 mRNA 		CTD PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 6:74,916,803...75,003,408
Ensembl chr 6:74,916,803...75,003,408 		JBrowse link
G Hectd3 HECT domain E3 ubiquitin protein ligase 3 affects expression ISO trichostatin A affects the expression of HECTD3 mRNA CTD PMID:28542535 NCBI chr 5:135,706,437...135,715,173
Ensembl chr 5:135,706,473...135,714,421 		JBrowse link
G Hectd4 HECT domain E3 ubiquitin protein ligase 4 affects expression ISO trichostatin A affects the expression of HECTD4 mRNA CTD PMID:28542535 NCBI chr12:40,800,232...40,991,584
Ensembl chr12:40,843,770...40,991,798 		JBrowse link
G Helq helicase, POLQ-like increases expression ISO trichostatin A results in increased expression of HELQ mRNA CTD PMID:24935251 NCBI chr14:9,122,978...9,167,310
Ensembl chr14:9,122,978...9,167,310 		JBrowse link
G Helz2 helicase with zinc finger 2 affects expression ISO trichostatin A affects the expression of HELZ2 mRNA CTD PMID:28542535 NCBI chr 3:188,716,370...188,730,776
Ensembl chr 3:188,716,370...188,730,716 		JBrowse link
G Herc1 HECT and RLD domain containing E3 ubiquitin protein ligase family member 1 affects expression ISO trichostatin A affects the expression of HERC1 mRNA CTD PMID:28542535 NCBI chr 8:75,796,347...75,965,347
Ensembl chr 8:75,796,357...75,965,347 		JBrowse link
G Herc4 HECT and RLD domain containing E3 ubiquitin protein ligase 4 increases expression ISO trichostatin A results in increased expression of HERC4 mRNA CTD PMID:24935251 NCBI chr20:25,329,005...25,403,443
Ensembl chr20:25,328,822...25,403,372 		JBrowse link
G Herpud2 HERPUD family member 2 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of HERPUD2 mRNA
trichostatin A results in decreased expression of HERPUD2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HERPUD2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 8:31,849,216...31,894,219
Ensembl chr 8:31,849,216...31,894,219 		JBrowse link
G Hes1 hes family bHLH transcription factor 1 increases expression ISO trichostatin A results in increased expression of HES1 mRNA CTD PMID:24935251 NCBI chr11:84,210,632...84,213,045
Ensembl chr11:84,210,633...84,213,061 		JBrowse link
G Hes2 hes family bHLH transcription factor 2 increases expression ISO trichostatin A results in increased expression of HES2 mRNA CTD PMID:24935251 NCBI chr 5:167,947,948...167,964,660
Ensembl chr 5:167,949,918...167,955,601 		JBrowse link
G Hes5 hes family bHLH transcription factor 5 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of HES5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:170,804,511...170,807,988
Ensembl chr 5:170,803,940...170,806,021 		JBrowse link
G Hesx1 HESX homeobox 1 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of HESX1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HESX1 mRNA
trichostatin A affects the expression of HESX1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr16:2,198,589...2,200,694
Ensembl chr16:2,198,589...2,200,694 		JBrowse link
G Hey1 hes-related family bHLH transcription factor with YRPW motif 1 increases expression ISO trichostatin A results in increased expression of HEY1 mRNA CTD PMID:24935251 NCBI chr 2:95,003,935...95,006,457
Ensembl chr 2:95,002,943...95,007,624 		JBrowse link
G Heyl hes-related family bHLH transcription factor with YRPW motif-like increases expression ISO trichostatin A results in increased expression of HEYL mRNA CTD PMID:28542535 NCBI chr 5:140,793,271...140,810,262
Ensembl chr 5:140,793,271...140,810,262 		JBrowse link
G Hfm1 helicase for meiosis 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of HFM1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HFM1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:3,002,103...3,108,567
Ensembl chr14:3,001,906...3,084,401 		JBrowse link
G Hgf hepatocyte growth factor increases expression
multiple interactions 		ISO trichostatin A results in increased expression of HGF mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HGF mRNA 		CTD PMID:24935251 PMID:26238599 PMID:26272509 PMID:27188386 NCBI chr 4:19,628,902...19,700,467
Ensembl chr 4:19,632,267...19,700,851 		JBrowse link
G Hhex hematopoietically expressed homeobox multiple interactions
increases expression 		ISO trichostatin A results in increased expression of and affects the localization of HHEX protein
trichostatin A results in increased expression of HHEX mRNA 		CTD PMID:16854221 PMID:24935251 NCBI chr 1:244,602,945...244,608,532
Ensembl chr 1:244,602,825...244,608,604 		JBrowse link
G Hhip Hedgehog-interacting protein increases expression
multiple interactions 		ISO trichostatin A results in increased expression of HHIP mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HHIP mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr19:44,768,038...44,856,878
Ensembl chr19:44,767,536...44,862,795 		JBrowse link
G Hif3a hypoxia inducible factor 3 subunit alpha decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of HIF3A mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HIF3A mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:86,846,196...86,878,527
Ensembl chr 1:86,850,554...86,877,838 		JBrowse link
G Hint3 histidine triad nucleotide binding protein 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of HINT3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HINT3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:28,854,860...28,864,723
Ensembl chr 1:28,854,844...28,867,125 		JBrowse link
G Hip1 huntingtin interacting protein 1 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of HIP1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HIP1 mRNA
trichostatin A affects the expression of HIP1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr12:26,769,868...26,904,367
Ensembl chr12:26,769,961...26,904,296 		JBrowse link
G Hipk2 homeodomain interacting protein kinase 2 decreases expression ISO trichostatin A results in decreased expression of HIPK2 mRNA CTD PMID:27188386 NCBI chr 4:68,399,358...68,586,404
Ensembl chr 4:68,369,099...68,586,108 		JBrowse link
G Hipk3 homeodomain interacting protein kinase 3 affects expression ISO trichostatin A affects the expression of HIPK3 mRNA CTD PMID:28542535 NCBI chr 3:111,251,863...111,322,815
Ensembl chr 3:111,251,863...111,322,772 		JBrowse link
G Hira histone cell cycle regulator increases expression
multiple interactions 		ISO trichostatin A results in increased expression of HIRA mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HIRA mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:95,528,831...95,637,565
Ensembl chr11:95,528,831...95,638,549 		JBrowse link
G Hk1 hexokinase 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of HK1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HK1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr20:30,773,222...30,874,814
Ensembl chr20:30,773,220...30,874,814 		JBrowse link
G Hk2 hexokinase 2 decreases expression
increases expression
multiple interactions 		ISO trichostatin A results in decreased expression of HK2 mRNA
trichostatin A results in increased expression of HK2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HK2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:116,792,258...116,841,275
Ensembl chr 4:116,792,258...116,841,275 		JBrowse link
G Hlcs holocarboxylase synthetase multiple interactions ISO trichostatin A inhibits the reaction [chromium hexavalent ion results in increased expression of HLCS protein] CTD PMID:21641978 NCBI chr11:46,925,491...47,123,111
Ensembl chr11:46,925,491...47,105,082 		JBrowse link
G Hmbs hydroxymethylbilane synthase affects expression ISO trichostatin A affects the expression of HMBS mRNA CTD PMID:28542535 NCBI chr 8:53,570,364...53,577,758
Ensembl chr 8:53,570,364...53,577,802 		JBrowse link
G Hmcn1 hemicentin 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of HMCN1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMCN1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr13:65,165,532...65,634,681
Ensembl chr13:65,165,532...65,634,519 		JBrowse link
G Hmga2 high mobility group AT-hook 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of HMGA2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMGA2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:57,762,710...57,884,555
Ensembl chr 7:57,765,675...57,880,341 		JBrowse link
G Hmgb2 high mobility group box 2 affects expression ISO trichostatin A affects the expression of HMGB2 mRNA CTD PMID:28542535 NCBI chr16:37,721,374...37,723,950
Ensembl chr16:37,721,379...37,723,860 		JBrowse link
G Hmgcll1 3-hydroxy-3-methylglutaryl-CoA lyase like 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of HMGCLL1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HMGCLL1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 8:85,637,708...85,799,759
Ensembl chr 8:85,637,958...85,767,740 		JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase affects expression ISO trichostatin A affects the expression of HMGCR mRNA CTD PMID:28542535 NCBI chr 2:29,732,163...29,754,276
Ensembl chr 2:29,720,553...29,754,533 		JBrowse link
G Hmgn5 high mobility group nucleosome binding domain 5 increases expression ISO trichostatin A results in increased expression of HMGN5 mRNA CTD PMID:27188386 NCBI chr  X:78,161,439...78,170,613
Ensembl chr  X:78,161,442...78,169,924 		JBrowse link
G Hmmr hyaluronan-mediated motility receptor affects expression ISO trichostatin A affects the expression of HMMR mRNA CTD PMID:28542535 NCBI chr10:25,635,249...25,665,389
Ensembl chr10:25,635,915...25,665,390 		JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions
increases expression
affects expression 		ISO
EXP 		trichostatin A promotes the reaction [Fenretinide results in increased expression of HMOX1 mRNA]
trichostatin A results in increased expression of HMOX1 mRNA
trichostatin A affects the expression of HMOX1 mRNA
trichostatin A promotes the reaction [manganese chloride results in increased expression of HMOX1 mRNA]; trichostatin A promotes the reaction [manganese chloride results in increased expression of HMOX1 protein] 		CTD PMID:21319187 PMID:24973648 PMID:26272509 PMID:28542535 PMID:29054681 NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818 		JBrowse link
G Hmox2 heme oxygenase 2 increases expression ISO trichostatin A results in increased expression of HMOX2 mRNA CTD PMID:24935251 NCBI chr10:11,303,512...11,337,640
Ensembl chr10:11,303,512...11,318,800 		JBrowse link
G Hmx1 H6 family homeobox 1 multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of HMX1 mRNA] CTD PMID:14575637 NCBI chr14:79,585,840...79,589,626
Ensembl chr14:79,585,840...79,589,626 		JBrowse link
G Hmx2 H6 family homeobox 2 decreases expression ISO trichostatin A results in decreased expression of HMX2 mRNA CTD PMID:24935251 NCBI chr 1:195,749,284...195,758,347
Ensembl chr 1:195,749,284...195,756,945 		JBrowse link
G Hnf1b HNF1 homeobox B multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of HNF1B mRNA] CTD PMID:14575637 NCBI chr10:69,233,377...69,287,360
Ensembl chr10:69,233,131...69,287,361 		JBrowse link
G Hnmt histamine N-methyltransferase increases expression
multiple interactions
decreases expression 		ISO trichostatin A results in increased expression of HNMT mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HNMT mRNA
trichostatin A results in decreased expression of HNMT mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 3:26,978,274...27,010,291
Ensembl chr 3:26,977,933...27,010,482 		JBrowse link
G Hnrnpa1 heterogeneous nuclear ribonucleoprotein A1 increases expression ISO trichostatin A results in increased expression of HNRNPA1 mRNA CTD PMID:24935251 NCBI chr 7:136,253,633...136,260,085
Ensembl chr 7:136,253,278...136,260,085 		JBrowse link
G Hnrnpa2b1 heterogeneous nuclear ribonucleoprotein A2/B1 decreases expression ISO trichostatin A results in decreased expression of HNRNPA2B1 protein CTD PMID:19294695 NCBI chr 4:81,867,354...81,875,886
Ensembl chr 4:81,869,661...81,877,572 		JBrowse link
G Hnrnpa3 heterogeneous nuclear ribonucleoprotein A3 affects expression ISO trichostatin A affects the expression of HNRNPA3 mRNA CTD PMID:28542535 NCBI chr 3:80,984,470...80,999,413
Ensembl chr 3:80,985,969...80,996,043 		JBrowse link
G Hnrnpab heterogeneous nuclear ribonucleoprotein A/B affects expression ISO trichostatin A affects the expression of HNRNPAB mRNA CTD PMID:28542535 NCBI chr10:36,358,004...36,363,898
Ensembl chr10:36,358,006...36,364,307 		JBrowse link
G Hnrnpc heterogeneous nuclear ribonucleoprotein C decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of HNRNPC mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HNRNPC mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:27,253,098...27,282,779
Ensembl chr15:27,253,098...27,282,715 		JBrowse link
G Hnrnpd heterogeneous nuclear ribonucleoprotein D affects expression ISO trichostatin A affects the expression of HNRNPD mRNA CTD PMID:28542535 NCBI chr14:9,918,630...9,938,072
Ensembl chr14:9,919,739...9,938,066 		JBrowse link
G Hnrnph1 heterogeneous nuclear ribonucleoprotein H1 decreases expression ISO trichostatin A results in decreased expression of HNRNPH1 mRNA CTD PMID:24935251 NCBI chr10:35,187,412...35,203,909
Ensembl chr10:35,193,890...35,203,906 		JBrowse link
G Hnrnph3 heterogeneous nuclear ribonucleoprotein H3 affects expression ISO trichostatin A affects the expression of HNRNPH3 mRNA CTD PMID:28542535 NCBI chr20:25,619,540...25,624,397
Ensembl chr20:25,615,577...25,625,162 		JBrowse link
G Hnrnpk heterogeneous nuclear ribonucleoprotein K affects expression ISO trichostatin A affects the expression of HNRNPK mRNA CTD PMID:28542535 NCBI chr17:6,269,302...6,280,429
Ensembl chr17:6,268,385...6,280,565 		JBrowse link
G Hnrnpl heterogeneous nuclear ribonucleoprotein L affects expression ISO trichostatin A affects the expression of HNRNPL mRNA CTD PMID:28542535 NCBI chr 1:93,226,373...93,239,084
Ensembl chr 1:93,235,729...93,239,061 		JBrowse link
G Hnrnpll heterogeneous nuclear ribonucleoprotein L-like decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of HNRNPLL mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HNRNPLL mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:20,720,013...20,752,803
Ensembl chr 6:20,722,184...20,752,802 		JBrowse link
G Hnrnpr heterogeneous nuclear ribonucleoprotein R decreases expression ISO trichostatin A results in decreased expression of HNRNPR mRNA CTD PMID:24935251 NCBI chr 5:153,826,482...153,872,272
Ensembl chr 5:153,826,692...153,858,344 		JBrowse link
G Hnrnpu heterogeneous nuclear ribonucleoprotein U affects expression ISO trichostatin A affects the expression of HNRNPU mRNA CTD PMID:28542535 NCBI chr13:92,609,791...92,618,580
Ensembl chr13:92,605,216...92,618,612 		JBrowse link
G Homez homeobox and leucine zipper encoding decreases expression ISO trichostatin A results in decreased expression of HOMEZ mRNA CTD PMID:24935251 NCBI chr15:32,292,897...32,309,564
Ensembl chr15:32,291,048...32,321,319 		JBrowse link
G Hopx HOP homeobox increases expression
multiple interactions 		ISO trichostatin A results in increased expression of HOPX mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HOPX mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr14:31,410,235...31,437,189
Ensembl chr14:31,410,221...31,437,188 		JBrowse link
G Hotairm1 Hoxa transcript antisense RNA, myeloid-specific 1 multiple interactions ISO trichostatin A affects the reaction [hydroquinone affects the expression of HOTAIRM1 mRNA]; trichostatin A affects the reaction [hydroquinone affects the methylation of HOTAIRM1 promoter] CTD PMID:31899212 NCBI chr 4:82,589,415...82,592,913 JBrowse link
G Hoxa5 homeo box A5 multiple interactions ISO [decitabine co-treated with trichostatin A] results in increased expression of HOXA5 mRNA CTD PMID:17891453 NCBI chr 4:82,632,958...82,636,851
Ensembl chr 4:82,632,306...82,639,038 		JBrowse link
G Hoxb4 homeo box B4 multiple interactions ISO [decitabine co-treated with trichostatin A] results in increased expression of HOXB4 mRNA; [decitabine co-treated with trichostatin A] results in increased expression of HOXB4 protein CTD PMID:17185465 NCBI chr10:81,781,090...81,783,672
Ensembl chr10:81,781,090...81,783,666 		JBrowse link
G Hoxd1 homeo box D1 multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of HOXD1 mRNA] CTD PMID:14575637 NCBI chr 3:80,073,041...80,075,180
Ensembl chr 3:80,073,041...80,075,180 		JBrowse link
G Hpdl 4-hydroxyphenylpyruvate dioxygenase-like increases expression
multiple interactions 		ISO trichostatin A results in increased expression of HPDL mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPDL mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:135,523,258...135,524,864
Ensembl chr 5:135,523,262...135,535,704 		JBrowse link
G Hpgd 15-hydroxyprostaglandin dehydrogenase multiple interactions
increases expression 		ISO trichostatin A promotes the reaction [Azacitidine results in increased expression of HPGD mRNA]
trichostatin A results in increased expression of HPGD mRNA 		CTD PMID:19584167 NCBI chr16:38,996,876...39,034,831
Ensembl chr16:38,996,876...39,034,831 		JBrowse link
G Hpse heparanase increases expression ISO trichostatin A results in increased expression of HPSE mRNA CTD PMID:24935251 NCBI chr14:9,200,971...9,241,377
Ensembl chr14:9,188,275...9,241,754 		JBrowse link
G Hr HR, lysine demethylase and nuclear receptor corepressor multiple interactions
decreases expression 		ISO trichostatin A inhibits the reaction [HR protein inhibits the reaction [Calcitriol results in increased activity of VDR protein]]; trichostatin A inhibits the reaction [HR protein inhibits the reaction [Lithocholic Acid results in increased activity of VDR protein]]
trichostatin A results in decreased expression of HR mRNA 		CTD PMID:22466564 PMID:28542535 NCBI chr15:52,036,540...52,056,019
Ensembl chr15:52,036,540...52,056,015 		JBrowse link
G Hrh3 histamine receptor H3 increases expression ISO trichostatin A results in increased expression of HRH3 mRNA CTD PMID:28542535 NCBI chr 3:187,569,174...187,575,263
Ensembl chr 3:187,569,175...187,574,259 		JBrowse link
G Hrk harakiri, BCL2 interacting protein increases expression ISO trichostatin A results in increased expression of HRK mRNA CTD PMID:24935251 NCBI chr12:44,048,402...44,070,561
Ensembl chr12:44,048,402...44,070,561 		JBrowse link
G Hs3st1 heparan sulfate-glucosamine 3-sulfotransferase 1 increases expression ISO trichostatin A results in increased expression of HS3ST1 mRNA CTD PMID:24935251 NCBI chr14:75,398,101...75,429,628
Ensembl chr14:75,398,026...75,436,848 		JBrowse link
G Hs3st2 heparan sulfate-glucosamine 3-sulfotransferase 2 increases expression ISO trichostatin A results in increased expression of HS3ST2 mRNA CTD PMID:24935251 NCBI chr 1:185,387,445...185,508,700
Ensembl chr 1:185,386,761...185,508,700 		JBrowse link
G Hs3st3a1 heparan sulfate-glucosamine 3-sulfotransferase 3A1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of HS3ST3A1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HS3ST3A1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:49,593,208...49,679,854
Ensembl chr10:49,593,009...49,679,854 		JBrowse link
G Hs3st3b1 heparan sulfate-glucosamine 3-sulfotransferase 3B1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of HS3ST3B1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HS3ST3B1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:49,060,693...49,093,185
Ensembl chr10:49,060,693...49,093,185 		JBrowse link
G Hs3st5 heparan sulfate-glucosamine 3-sulfotransferase 5 increases expression ISO trichostatin A results in increased expression of HS3ST5 mRNA CTD PMID:24935251 NCBI chr20:41,661,785...41,972,550
Ensembl chr20:41,773,601...41,972,542 		JBrowse link
G Hs6st2 heparan sulfate 6-O-sulfotransferase 2 increases expression ISO trichostatin A results in increased expression of HS6ST2 mRNA CTD PMID:24935251 PMID:27188386 NCBI chr  X:135,887,224...136,182,388
Ensembl chr  X:135,888,472...136,182,353 		JBrowse link
G Hsbp1 heat shock factor binding protein 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of HSBP1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HSBP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:64,309,703...64,314,035
Ensembl chr19:64,309,703...64,314,035 		JBrowse link
G Hsd11b2 hydroxysteroid 11-beta dehydrogenase 2 increases expression ISO trichostatin A results in increased expression of HSD11B2 mRNA CTD PMID:24935251 NCBI chr19:50,307,569...50,312,812
Ensembl chr19:50,307,569...50,312,812 		JBrowse link
G Hsd17b1 hydroxysteroid (17-beta) dehydrogenase 1 decreases expression ISO trichostatin A results in decreased expression of HSD17B1 mRNA CTD PMID:24935251 NCBI chr10:86,510,011...86,512,211
Ensembl chr10:86,510,011...86,512,210 		JBrowse link
G Hsd17b14 hydroxysteroid (17-beta) dehydrogenase 14 decreases expression ISO trichostatin A results in decreased expression of HSD17B14 mRNA CTD PMID:24935251 NCBI chr 1:105,165,695...105,176,045
Ensembl chr 1:105,165,695...105,176,510 		JBrowse link
G Hsd17b6 hydroxysteroid (17-beta) dehydrogenase 6 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of HSD17B6 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSD17B6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:831,407...850,950
Ensembl chr 7:831,421...850,873 		JBrowse link
G Hsdl2 hydroxysteroid dehydrogenase like 2 increases expression
affects expression 		ISO trichostatin A results in increased expression of HSDL2 mRNA
trichostatin A affects the expression of HSDL2 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 5:79,238,881...79,274,051
Ensembl chr 5:79,212,525...79,274,798 		JBrowse link
G Hsf1 heat shock transcription factor 1 decreases activity ISO trichostatin A results in decreased activity of HSF1 protein CTD PMID:34170685 NCBI chr 7:110,076,710...110,103,665
Ensembl chr 7:110,076,710...110,103,665 		JBrowse link
G Hsf2 heat shock transcription factor 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of HSF2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HSF2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr20:37,366,301...37,393,922
Ensembl chr20:37,366,279...37,401,022 		JBrowse link
G Hsp90aa1 heat shock protein 90 alpha family class A member 1 affects expression
multiple interactions
increases acetylation 		ISO
EXP 		trichostatin A affects the expression of HSP90AA1 protein
[trichostatin A co-treated with decitabine] results in decreased expression of HSP90AA1 protein
trichostatin A results in increased acetylation of HSP90AA1 protein
trichostatin A inhibits the reaction [HSP90AA1 protein binds to NR3C1 protein] 		CTD PMID:19294695 PMID:31778773 NCBI chr 6:135,523,604...135,529,687
Ensembl chr 6:135,523,616...135,528,499 		JBrowse link
G Hsp90b1 heat shock protein 90 beta family member 1 affects expression ISO trichostatin A affects the expression of HSP90B1 mRNA CTD PMID:28542535 NCBI chr 7:22,997,962...23,012,293
Ensembl chr 7:22,997,962...23,012,293 		JBrowse link
G Hspa12a heat shock protein family A (Hsp70) member 12A increases expression ISO trichostatin A results in increased expression of HSPA12A mRNA CTD PMID:24935251 NCBI chr 1:267,921,780...268,083,171
Ensembl chr 1:267,921,782...268,082,794 		JBrowse link
G Hspa13 heat shock protein family A (Hsp70) member 13 decreases expression ISO trichostatin A results in decreased expression of HSPA13 mRNA CTD PMID:24935251 NCBI chr11:27,862,717...27,876,898
Ensembl chr11:27,862,593...27,876,898 		JBrowse link
G Hspa1b heat shock protein family A (Hsp70) member 1B affects expression ISO trichostatin A affects the expression of HSPA1B mRNA CTD PMID:28542535 NCBI chr20:3,859,756...3,863,800
Ensembl chr20:3,855,780...3,877,979 		JBrowse link
G Hspa1l heat shock protein family A (Hsp70) member 1 like multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of HSPA1L mRNA] CTD PMID:14575637 NCBI chr20:3,853,496...3,860,223
Ensembl chr20:3,853,331...3,876,877 		JBrowse link
G Hspa2 heat shock protein family A (Hsp70) member 2 increases expression
affects expression 		ISO trichostatin A results in increased expression of HSPA2 mRNA
trichostatin A affects the expression of HSPA2 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 6:100,864,172...100,866,946
Ensembl chr 6:100,864,553...100,867,133 		JBrowse link
G Hspa4l heat shock protein family A (Hsp70) member 4 like increases expression
multiple interactions 		ISO trichostatin A results in increased expression of HSPA4L mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:125,668,346...125,726,404
Ensembl chr 2:125,668,236...125,720,986 		JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 decreases expression
affects expression 		ISO trichostatin A results in decreased expression of HSPA5 mRNA
trichostatin A affects the expression of HSPA5 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:38,453,041...38,458,790 		JBrowse link
G Hspa9 heat shock protein family A (Hsp70) member 9 decreases expression ISO trichostatin A results in decreased expression of HSPA9 protein CTD PMID:19294695 NCBI chr18:26,810,004...26,832,958
Ensembl chr18:26,804,774...26,828,398 		JBrowse link
G Hspg2 heparan sulfate proteoglycan 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of HSPG2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPG2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:154,960,818...155,061,971
Ensembl chr 5:154,960,846...155,061,971 		JBrowse link
G Htatip2 HIV-1 Tat interactive protein 2 decreases expression ISO trichostatin A results in decreased expression of HTATIP2 mRNA CTD PMID:24935251 NCBI chr 1:108,609,424...108,624,810
Ensembl chr 1:108,605,811...108,624,815 		JBrowse link
G Htatsf1 HIV-1 Tat specific factor 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of HTATSF1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HTATSF1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:139,972,742...139,986,923
Ensembl chr  X:139,972,742...139,986,923 		JBrowse link
G Htr2c 5-hydroxytryptamine receptor 2C increases expression ISO trichostatin A results in increased expression of HTR2C mRNA CTD PMID:24935251 NCBI chr  X:115,453,190...115,682,325
Ensembl chr  X:115,452,842...115,682,324 		JBrowse link
G Htra1 HtrA serine peptidase 1 decreases expression ISO trichostatin A results in decreased expression of HTRA1 mRNA CTD PMID:24935251 NCBI chr 1:194,928,069...194,977,619
Ensembl chr 1:194,927,687...194,977,620 		JBrowse link
G Htra2 HtrA serine peptidase 2 multiple interactions ISO [vorinostat co-treated with trichostatin A] affects the localization of HTRA2 protein CTD PMID:16026644 NCBI chr 4:117,114,631...117,117,793
Ensembl chr 4:117,114,633...117,117,793 		JBrowse link
G Hycc1 hyccin PI4KA lipid kinase complex subunit 1 affects expression ISO trichostatin A affects the expression of HYCC1 mRNA CTD PMID:28542535 NCBI chr 4:12,024,692...12,131,504
Ensembl chr 4:12,024,739...12,131,501 		JBrowse link
G Hycc2 hyccin PI4KA lipid kinase complex subunit 2 affects expression ISO trichostatin A affects the expression of HYCC2 mRNA CTD PMID:28542535 NCBI chr 9:67,551,064...67,623,353
Ensembl chr 9:67,551,064...67,587,186 		JBrowse link
G Iapp islet amyloid polypeptide increases expression ISO trichostatin A results in increased expression of IAPP mRNA CTD PMID:24935251 NCBI chr 4:176,968,097...176,975,363
Ensembl chr 4:176,968,097...176,975,363 		JBrowse link
G Ibsp integrin-binding sialoprotein multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of IBSP mRNA] CTD PMID:14575637 NCBI chr14:5,744,497...5,757,242
Ensembl chr14:5,744,501...5,775,299 		JBrowse link
G Id1 inhibitor of DNA binding 1 increases expression ISO trichostatin A results in increased expression of ID1 mRNA CTD PMID:24935251 NCBI chr 3:161,671,525...161,672,691
Ensembl chr 3:161,671,538...161,672,685 		JBrowse link
G Id2 inhibitor of DNA binding 2 increases expression ISO trichostatin A results in increased expression of ID2 mRNA CTD PMID:24935251 NCBI chr 6:47,469,162...47,470,995
Ensembl chr 6:47,457,554...47,472,961 		JBrowse link
G Id4 inhibitor of DNA binding 4 increases expression ISO trichostatin A results in increased expression of ID4 mRNA CTD PMID:24935251 NCBI chr17:16,595,724...16,598,293
Ensembl chr17:16,595,724...16,598,492 		JBrowse link
G Idh3a isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha increases expression
affects expression 		ISO trichostatin A results in increased expression of IDH3A mRNA
trichostatin A affects the expression of IDH3A mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 8:63,867,882...63,887,223
Ensembl chr 8:63,867,820...63,887,223 		JBrowse link
G Idi1 isopentenyl-diphosphate delta isomerase 1 affects expression ISO trichostatin A affects the expression of IDI1 mRNA CTD PMID:28542535 NCBI chr17:66,539,761...66,547,524
Ensembl chr17:66,539,763...66,547,524 		JBrowse link
G Ido1 indoleamine 2,3-dioxygenase 1 decreases expression ISO trichostatin A results in decreased expression of IDO1 mRNA CTD PMID:24935251 NCBI chr16:74,133,259...74,145,328
Ensembl chr16:74,133,259...74,145,328 		JBrowse link
G Ids iduronate 2-sulfatase increases expression
multiple interactions 		ISO trichostatin A results in increased expression of IDS mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDS mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr  X:154,070,781...154,093,681
Ensembl chr  X:154,070,781...154,091,444 		JBrowse link
G Ier3 immediate early response 3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of IER3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IER3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr20:2,933,173...2,934,377
Ensembl chr20:2,933,174...2,934,377 		JBrowse link
G Ier5 immediate early response 5 increases expression
multiple interactions
affects expression 		ISO trichostatin A results in increased expression of IER5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IER5 mRNA
trichostatin A affects the expression of IER5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr13:69,820,450...69,822,542
Ensembl chr13:69,820,451...69,822,543 		JBrowse link
G Ier5l immediate early response 5-like increases expression ISO trichostatin A results in increased expression of IER5L mRNA CTD PMID:24935251 NCBI chr 3:34,141,866...34,143,457
Ensembl chr 3:34,139,672...34,144,452 		JBrowse link
G Iffo2 intermediate filament family orphan 2 increases expression ISO trichostatin A results in increased expression of IFFO2 mRNA CTD PMID:24935251 NCBI chr 5:157,114,089...157,160,135
Ensembl chr 5:157,114,089...157,160,135 		JBrowse link
G Ifi30 IFI30, lysosomal thiol reductase affects expression ISO trichostatin A affects the expression of IFI30 mRNA CTD PMID:28542535 NCBI chr16:18,709,570...18,713,635
Ensembl chr16:18,709,563...18,715,711 		JBrowse link
G Ifih1 interferon induced with helicase C domain 1 increases expression ISO trichostatin A results in increased expression of IFIH1 mRNA CTD PMID:24935251 NCBI chr 3:67,635,924...67,683,968
Ensembl chr 3:67,637,545...67,683,968 		JBrowse link
G Ifit3 interferon-induced protein with tetratricopeptide repeats 3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of IFIT3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFIT3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:241,527,326...241,532,469
Ensembl chr 1:241,526,880...241,532,521 		JBrowse link
G Ifitm1 interferon induced transmembrane protein 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of IFITM1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFITM1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:205,496,757...205,498,796
Ensembl chr 1:205,496,807...205,498,776 		JBrowse link
G Ifng interferon gamma multiple interactions ISO trichostatin A inhibits the reaction [IL15 protein results in increased expression of IFNG protein]; trichostatin A inhibits the reaction [Nickel affects the expression of IFNG mRNA]
trichostatin A affects the reaction [bisphenol A affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]]; trichostatin A inhibits the reaction [[bisphenol A affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of CD36 mRNA]; trichostatin A inhibits the reaction [[bisphenol A affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of MARCO mRNA]; trichostatin A inhibits the reaction [[bisphenol A affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in increased expression of IL6 mRNA]; trichostatin A inhibits the reaction [[bisphenol A affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in increased expression of TNF mRNA]; trichostatin A inhibits the reaction [enterotoxin B, staphylococcal results in increased secretion of IFNG protein]; trichostatin A promotes the reaction [[bisphenol A affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of NOS2 mRNA] 		CTD PMID:14575637 PMID:24200994 PMID:29301935 PMID:29718165 NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216 		JBrowse link
G Ifngr2 interferon gamma receptor 2 affects expression ISO trichostatin A affects the expression of IFNGR2 mRNA CTD PMID:28542535 NCBI chr11:44,265,703...44,283,975
Ensembl chr11:44,265,703...44,283,975 		JBrowse link
G Ift20 intraflagellar transport 20 affects expression ISO trichostatin A affects the expression of IFT20 mRNA CTD PMID:28542535 NCBI chr10:63,930,629...63,936,174
Ensembl chr10:63,930,681...63,936,172 		JBrowse link
G Ift27 intraflagellar transport 27 multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of IFT27 mRNA] CTD PMID:14575637 NCBI chr 7:111,619,145...111,635,129
Ensembl chr 7:111,619,077...111,634,936 		JBrowse link
G Ift52 intraflagellar transport 52 affects expression ISO trichostatin A affects the expression of IFT52 mRNA CTD PMID:28542535 NCBI chr 3:172,091,591...172,116,497
Ensembl chr 3:172,092,017...172,116,493 		JBrowse link
G Ift56 intraflagellar transport 56 decreases expression ISO trichostatin A results in decreased expression of IFT56 mRNA CTD PMID:24935251 NCBI chr 4:68,057,530...68,115,494
Ensembl chr 4:68,057,580...68,119,338 		JBrowse link
G Ift57 intraflagellar transport 57 decreases expression
affects expression 		ISO trichostatin A results in decreased expression of IFT57 mRNA
trichostatin A affects the expression of IFT57 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr11:64,528,349...64,593,545
Ensembl chr11:64,528,349...64,593,545 		JBrowse link
G Ift70a2 intraflagellar transport 70A2 increases expression ISO trichostatin A results in increased expression of IFT70A mRNA CTD PMID:24935251 NCBI chr 3:81,306,455...81,308,896
Ensembl chr 3:81,307,245...81,320,093 		JBrowse link
G Ift74 intraflagellar transport 74 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of IFT74 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IFT74 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:114,576,106...114,679,581
Ensembl chr 5:114,593,397...114,679,581 		JBrowse link
G Ift80 intraflagellar transport 80 affects expression ISO trichostatin A affects the expression of IFT80 mRNA CTD PMID:28542535 NCBI chr 2:155,455,773...155,550,082
Ensembl chr 2:155,455,774...155,550,275 		JBrowse link
G Igdcc3 immunoglobulin superfamily, DCC subclass, member 3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of IGDCC3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGDCC3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 8:74,556,348...74,603,136
Ensembl chr 8:74,556,348...74,603,136 		JBrowse link
G Igdcc4 immunoglobulin superfamily, DCC subclass, member 4 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of IGDCC4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGDCC4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 8:74,517,082...74,552,834
Ensembl chr 8:74,517,086...74,552,834 		JBrowse link
G Igf1 insulin-like growth factor 1 increases expression ISO trichostatin A results in increased expression of IGF1 mRNA CTD PMID:23463510 NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:24,130,137...24,246,764 		JBrowse link
G Igf1r insulin-like growth factor 1 receptor decreases expression ISO trichostatin A results in decreased expression of IGF1R mRNA CTD PMID:28542535 NCBI chr 1:130,959,787...131,248,664
Ensembl chr 1:130,959,997...131,248,664 		JBrowse link
G Igf2 insulin-like growth factor 2 increases expression ISO trichostatin A results in increased expression of IGF2 mRNA CTD PMID:24935251 PMID:26272509 NCBI chr 1:207,243,873...207,261,263
Ensembl chr 1:207,243,873...207,260,667 		JBrowse link
G Igf2bp3 insulin-like growth factor 2 mRNA binding protein 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of IGF2BP3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGF2BP3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:79,391,367...79,525,923
Ensembl chr 4:79,393,067...79,525,730 		JBrowse link
G Igf2r insulin-like growth factor 2 receptor affects expression ISO trichostatin A affects the expression of IGF2R mRNA CTD PMID:28542535 NCBI chr 1:50,526,878...50,615,265
Ensembl chr 1:50,526,878...50,615,265 		JBrowse link
G Igfbp3 insulin-like growth factor binding protein 3 multiple interactions
decreases expression 		ISO [trichostatin A affects the acetylation of H3-4 promoter] which affects the expression of IGFBP3 mRNA
trichostatin A results in decreased expression of IGFBP3 mRNA 		CTD PMID:16505122 PMID:26272509 NCBI chr14:86,270,208...86,277,944
Ensembl chr14:86,270,208...86,277,944 		JBrowse link
G Igfbp5 insulin-like growth factor binding protein 5 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of IGFBP5 mRNA
trichostatin A results in decreased expression of IGFBP5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGFBP5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 9:81,901,605...81,914,187
Ensembl chr 9:81,897,616...81,914,390 		JBrowse link
G Igfbp7 insulin-like growth factor binding protein 7 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of IGFBP7 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGFBP7 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr14:31,091,681...31,151,623
Ensembl chr14:31,091,347...31,151,620 		JBrowse link
G Igfbpl1 insulin-like growth factor binding protein-like 1 increases expression ISO trichostatin A results in increased expression of IGFBPL1 mRNA CTD PMID:24935251 NCBI chr 5:64,872,056...64,887,461
Ensembl chr 5:64,872,057...64,887,461 		JBrowse link
G Igsf1 immunoglobulin superfamily, member 1 increases expression ISO trichostatin A results in increased expression of IGSF1 mRNA CTD PMID:26705709 NCBI chr  X:133,947,717...133,963,154
Ensembl chr  X:133,947,429...133,962,962 		JBrowse link
G Igsf10 immunoglobulin superfamily, member 10 increases expression ISO trichostatin A results in increased expression of IGSF10 mRNA CTD PMID:24935251 NCBI chr 2:145,725,868...145,754,850
Ensembl chr 2:145,725,878...145,754,579 		JBrowse link
G Igsf11 immunoglobulin superfamily, member 11 increases expression ISO trichostatin A results in increased expression of IGSF11 mRNA CTD PMID:24935251 NCBI chr11:75,238,706...75,389,748
Ensembl chr11:75,236,545...75,390,425 		JBrowse link
G Igsf21 immunoglobin superfamily, member 21 decreases expression ISO trichostatin A results in decreased expression of IGSF21 mRNA CTD PMID:24935251 NCBI chr 5:157,570,964...157,795,290
Ensembl chr 5:157,570,964...157,795,290 		JBrowse link
G Ikzf2 IKAROS family zinc finger 2 increases expression ISO trichostatin A results in increased expression of IKZF2 mRNA CTD PMID:24935251 PMID:26705709 NCBI chr 9:78,495,670...78,640,896
Ensembl chr 9:78,492,275...78,640,463 		JBrowse link
G Ikzf3 IKAROS family zinc finger 3 affects expression
multiple interactions 		ISO trichostatin A affects the expression of IKZF3 mRNA; trichostatin A affects the expression of IKZF3 protein
trichostatin A promotes the reaction [decitabine results in increased expression of IKZF3 mRNA] 		CTD PMID:18206652 NCBI chr10:83,956,850...84,049,861
Ensembl chr10:83,962,030...84,049,861 		JBrowse link
G Il10rb interleukin 10 receptor subunit beta increases expression ISO trichostatin A results in increased expression of IL10RB mRNA CTD PMID:24935251 NCBI chr11:44,132,471...44,154,062
Ensembl chr11:44,132,189...44,154,053 		JBrowse link
G Il11 interleukin 11 increases expression ISO trichostatin A results in increased expression of IL11 mRNA CTD PMID:24935251 NCBI chr 1:78,098,622...78,104,915
Ensembl chr 1:78,096,930...78,104,915 		JBrowse link
G Il12a interleukin 12A multiple interactions
increases expression 		ISO trichostatin A inhibits the reaction [Lipopolysaccharides results in increased expression of IL12A mRNA]
trichostatin A results in increased expression of IL12A mRNA 		CTD PMID:12470611 NCBI chr 2:155,275,734...155,282,997
Ensembl chr 2:155,275,625...155,282,997 		JBrowse link
G Il12b interleukin 12B multiple interactions ISO trichostatin A inhibits the reaction [Lipopolysaccharides results in increased expression of IL12B mRNA] CTD PMID:12470611 NCBI chr10:29,390,300...29,405,194
Ensembl chr10:29,389,905...29,405,194 		JBrowse link
G Il13ra1 interleukin 13 receptor subunit alpha 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of IL13RA1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL13RA1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr  X:120,213,670...120,294,777
Ensembl chr  X:120,214,075...120,274,461 		JBrowse link
G Il15 interleukin 15 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of IL15 mRNA
trichostatin A inhibits the reaction [IL15 protein results in increased expression of IFNG protein] 		CTD PMID:24935251 PMID:29301935 NCBI chr19:42,536,160...42,611,349
Ensembl chr19:42,545,346...42,611,348 		JBrowse link
G Il17rd interleukin 17 receptor D decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of IL17RD mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL17RD mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr16:2,235,172...2,489,827
Ensembl chr16:2,235,169...2,301,850 		JBrowse link
G Il18 interleukin 18 increases expression ISO trichostatin A results in increased expression of IL18 mRNA CTD PMID:24935251 NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286 		JBrowse link
G Il1a interleukin 1 alpha decreases expression
increases expression 		ISO trichostatin A results in decreased expression of IL1A mRNA
trichostatin A results in increased expression of IL1A mRNA 		CTD PMID:24935251 NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013 		JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO [trichostatin A co-treated with Dexamethasone] inhibits the reaction [IL1B protein promotes the reaction [H4C16 protein modified form binds to CSF2 promoter]]; trichostatin A inhibits the reaction [[Theophylline co-treated with Dexamethasone] inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]]; trichostatin A inhibits the reaction [Dexamethasone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]]; trichostatin A inhibits the reaction [IL1B protein results in increased expression of VCAM1 protein]; trichostatin A promotes the reaction [IL1B protein results in increased expression of TGFB1 mRNA] CTD PMID:12070353 PMID:16365456 PMID:19281832 NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601 		JBrowse link
G Il1r1 interleukin 1 receptor type 1 increases expression ISO trichostatin A results in increased expression of IL1R1 mRNA CTD PMID:24935251 NCBI chr 9:50,000,558...50,076,579
Ensembl chr 9:50,000,566...50,076,579 		JBrowse link
G Il1rapl1 interleukin 1 receptor accessory protein-like 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of IL1RAPL1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL1RAPL1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr  X:55,322,779...56,827,486
Ensembl chr  X:55,328,964...56,826,613 		JBrowse link
G Il2 interleukin 2 multiple interactions ISO trichostatin A inhibits the reaction [enterotoxin B, staphylococcal results in increased secretion of IL2 protein] CTD PMID:24200994 NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:121,932,968...121,937,672 		JBrowse link
G Il20rb interleukin 20 receptor subunit beta increases expression ISO trichostatin A results in increased expression of IL20RB mRNA CTD PMID:24935251 NCBI chr 8:109,858,108...109,896,066
Ensembl chr 8:109,854,012...109,889,363 		JBrowse link
G Il27ra interleukin 27 receptor subunit alpha increases expression
multiple interactions 		ISO trichostatin A results in increased expression of IL27RA mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL27RA mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr19:41,014,730...41,026,740
Ensembl chr19:41,014,730...41,026,760 		JBrowse link
G Il2ra interleukin 2 receptor subunit alpha multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of IL2RA mRNA] CTD PMID:14575637 NCBI chr17:71,759,802...71,808,475
Ensembl chr17:71,759,802...71,808,507 		JBrowse link
G Il3 interleukin 3 multiple interactions ISO trichostatin A inhibits the reaction [IL3 protein promotes the reaction [BRD2 protein binds to CISH promoter]]; trichostatin A inhibits the reaction [IL3 protein results in increased expression of CISH mRNA]; trichostatin A inhibits the reaction [IL3 protein results in increased expression of MYC mRNA]; trichostatin A inhibits the reaction [IL3 protein results in increased expression of OSM mRNA]; trichostatin A promotes the reaction [IL3 protein results in increased expression of FOS mRNA] CTD PMID:25769527 NCBI chr10:38,906,460...38,908,810
Ensembl chr10:38,906,460...38,908,810 		JBrowse link
G Il36rn interleukin 36 receptor antagonist multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of IL36RN mRNA] CTD PMID:14575637 NCBI chr 3:27,442,679...27,449,306
Ensembl chr 3:27,442,709...27,449,306 		JBrowse link
G Il6 interleukin 6 multiple interactions
increases expression 		ISO trichostatin A inhibits the reaction [[bisphenol A affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in increased expression of IL6 mRNA]; trichostatin A inhibits the reaction [enterotoxin B, staphylococcal results in increased secretion of IL6 protein]
trichostatin A results in increased expression of IL6 mRNA 		CTD PMID:24200994 PMID:24935251 PMID:29718165 NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610 		JBrowse link
G Il6r interleukin 6 receptor increases expression
affects expression 		ISO trichostatin A results in increased expression of IL6R mRNA
trichostatin A affects the expression of IL6R mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 2:177,582,020...177,646,705
Ensembl chr 2:177,582,164...177,645,221 		JBrowse link
G Il6st interleukin 6 cytokine family signal transducer increases expression ISO trichostatin A results in increased expression of IL6ST mRNA CTD PMID:19223499 NCBI chr 2:45,798,872...45,839,501
Ensembl chr 2:45,799,380...45,843,182 		JBrowse link
G Il7r interleukin 7 receptor decreases expression
increases expression 		ISO trichostatin A results in decreased expression of IL7R protein
trichostatin A results in increased expression of IL7R mRNA 		CTD PMID:19545742 PMID:26705709 NCBI chr 2:60,179,561...60,204,937
Ensembl chr 2:60,181,382...60,211,027 		JBrowse link
G Ildr1 immunoglobulin-like domain containing receptor 1 increases expression ISO trichostatin A results in increased expression of ILDR1 mRNA CTD PMID:24935251 NCBI chr11:77,591,146...77,624,268
Ensembl chr11:77,569,621...77,624,140 		JBrowse link
G Ildr2 immunoglobulin-like domain containing receptor 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ILDR2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ILDR2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:81,051,723...81,113,590
Ensembl chr13:81,051,647...81,109,861 		JBrowse link
G Ilf3 interleukin enhancer binding factor 3 multiple interactions ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ILF3 mRNA CTD PMID:27188386 NCBI chr 8:28,198,454...28,236,634
Ensembl chr 8:28,198,543...28,236,612 		JBrowse link
G Immp1l inner mitochondrial membrane peptidase subunit 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of IMMP1L mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IMMP1L mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:112,840,015...112,904,297
Ensembl chr 3:112,840,113...112,904,296 		JBrowse link
G Immt inner membrane mitochondrial protein increases expression ISO trichostatin A results in increased expression of IMMT mRNA CTD PMID:24935251 NCBI chr 4:105,438,657...105,477,370
Ensembl chr 4:105,438,712...105,477,368 		JBrowse link
G Impg1 interphotoreceptor matrix proteoglycan 1 increases expression ISO trichostatin A results in increased expression of IMPG1 mRNA CTD PMID:27188386 NCBI chr 8:90,123,821...90,269,903
Ensembl chr 8:90,123,821...90,269,903 		JBrowse link
G Inafm2 InaF motif containing 2 increases expression ISO trichostatin A results in increased expression of INAFM2 mRNA CTD PMID:26272509 NCBI chr 3:126,182,124...126,185,194
Ensembl chr 3:126,182,056...126,198,456 		JBrowse link
G Inava innate immunity activator decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of INAVA mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of INAVA mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr13:50,218,149...50,238,430
Ensembl chr13:50,218,150...50,238,454 		JBrowse link
G Incenp inner centromere protein decreases expression ISO trichostatin A results in decreased expression of INCENP mRNA CTD PMID:19606018 NCBI chr 1:215,945,558...216,017,247
Ensembl chr 1:215,948,283...215,977,084 		JBrowse link
G Ing1 inhibitor of growth family, member 1 affects expression ISO trichostatin A affects the expression of ING1 mRNA CTD PMID:28542535 NCBI chr16:84,639,378...84,649,498
Ensembl chr16:84,639,381...84,647,616 		JBrowse link
G Ing3 inhibitor of growth family, member 3 decreases expression ISO trichostatin A results in decreased expression of ING3 mRNA CTD PMID:24935251 NCBI chr 4:51,439,218...51,469,502
Ensembl chr 4:51,443,763...51,470,951 		JBrowse link
G Ing4 inhibitor of growth family, member 4 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ING4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ING4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:159,528,183...159,536,762
Ensembl chr 4:159,528,189...159,536,761 		JBrowse link
G Ing5 inhibitor of growth family, member 5 decreases expression
affects expression 		ISO trichostatin A results in decreased expression of ING5 mRNA
trichostatin A affects the expression of ING5 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 9:101,772,845...101,793,734
Ensembl chr 9:101,773,724...101,793,728 		JBrowse link
G Inhba inhibin subunit beta A increases expression ISO trichostatin A results in increased expression of INHBA mRNA CTD PMID:26705709 NCBI chr17:53,787,159...53,810,942
Ensembl chr17:53,791,444...53,804,508 		JBrowse link
G Inhbb inhibin subunit beta B multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of INHBB mRNA] CTD PMID:14575637 NCBI chr13:33,083,671...33,089,373
Ensembl chr13:33,083,671...33,089,609 		JBrowse link
G Inip INTS3 and NABP interacting protein affects expression ISO trichostatin A affects the expression of INIP mRNA CTD PMID:28542535 NCBI chr 5:79,443,317...79,457,552
Ensembl chr 5:79,443,317...79,457,552 		JBrowse link
G Ino80 INO80 complex ATPase subunit affects expression ISO trichostatin A affects the expression of INO80 mRNA CTD PMID:28542535 NCBI chr 3:126,822,280...126,919,532
Ensembl chr 3:126,822,280...126,919,532 		JBrowse link
G Ino80d INO80 complex subunit D affects expression ISO trichostatin A affects the expression of INO80D mRNA CTD PMID:28542535 NCBI chr 9:71,940,941...72,007,879
Ensembl chr 9:71,951,031...72,040,232 		JBrowse link
G Inpp1 inositol polyphosphate-1-phosphatase increases expression ISO trichostatin A results in increased expression of INPP1 mRNA CTD PMID:24935251 NCBI chr 9:56,161,816...56,209,774
Ensembl chr 9:56,161,852...56,234,569 		JBrowse link
G Inpp4b inositol polyphosphate-4-phosphatase type II B increases expression
multiple interactions 		ISO trichostatin A results in increased expression of INPP4B mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP4B mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr19:42,824,710...43,575,039
Ensembl chr19:42,829,871...43,185,091 		JBrowse link
G Inpp5a inositol polyphosphate-5-phosphatase A affects expression ISO trichostatin A affects the expression of INPP5A mRNA CTD PMID:28542535 NCBI chr 1:203,619,676...203,810,035
Ensembl chr 1:203,619,637...203,810,028 		JBrowse link
G Inpp5d inositol polyphosphate-5-phosphatase D increases expression ISO trichostatin A results in increased expression of INPP5D mRNA CTD PMID:24935251 NCBI chr 9:95,735,533...95,840,584
Ensembl chr 9:95,735,530...95,840,589 		JBrowse link
G Inpp5f inositol polyphosphate-5-phosphatase F affects expression ISO trichostatin A affects the expression of INPP5F mRNA CTD PMID:28542535 NCBI chr 1:192,620,891...192,700,681
Ensembl chr 1:192,620,891...192,700,681 		JBrowse link
G Inpp5k inositol polyphosphate-5-phosphatase K affects expression ISO trichostatin A affects the expression of INPP5K mRNA CTD PMID:28542535 NCBI chr10:60,974,183...60,995,047
Ensembl chr10:60,973,950...60,995,046 		JBrowse link
G Inppl1 inositol polyphosphate phosphatase-like 1 affects expression ISO trichostatin A affects the expression of INPPL1 mRNA CTD PMID:28542535 NCBI chr 1:165,595,047...165,609,503
Ensembl chr 1:165,595,063...165,609,503 		JBrowse link
G Ins1 insulin 1 multiple interactions EXP trichostatin A inhibits the reaction [Dexamethasone inhibits the reaction [Glucose results in increased secretion of INS1 protein]] CTD PMID:31778773 NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682 		JBrowse link
G Insc INSC, spindle orientation adaptor protein increases expression
multiple interactions 		ISO trichostatin A results in increased expression of INSC mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INSC mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:178,427,360...178,534,827
Ensembl chr 1:178,427,423...178,535,047 		JBrowse link
G Insig1 insulin induced gene 1 affects expression ISO trichostatin A affects the expression of INSIG1 mRNA CTD PMID:28542535 NCBI chr 4:8,049,339...8,057,812
Ensembl chr 4:8,049,556...8,057,778 		JBrowse link
G Insig2 insulin induced gene 2 affects expression ISO trichostatin A affects the expression of INSIG2 mRNA CTD PMID:28542535 NCBI chr13:35,025,160...35,052,937
Ensembl chr13:35,025,164...35,047,658 		JBrowse link
G Insm1 INSM transcriptional repressor 1 decreases expression ISO trichostatin A results in decreased expression of INSM1 mRNA CTD PMID:24935251 NCBI chr 3:154,093,310...154,096,243
Ensembl chr 3:154,092,734...154,096,047 		JBrowse link
G Ints10 integrator complex subunit 10 affects expression ISO trichostatin A affects the expression of INTS10 mRNA CTD PMID:28542535 NCBI chr16:25,682,818...25,735,840
Ensembl chr16:25,682,050...25,734,528 		JBrowse link
G Ints4 integrator complex subunit 4 decreases expression ISO trichostatin A results in decreased expression of INTS4 mRNA CTD PMID:24935251 NCBI chr 1:161,201,284...161,265,042
Ensembl chr 1:161,197,708...161,269,124 		JBrowse link
G Ints6 integrator complex subunit 6 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of INTS6 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of INTS6 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:41,080,584...41,224,350
Ensembl chr15:41,109,125...41,197,519 		JBrowse link
G Ip6k3 inositol hexakisphosphate kinase 3 increases expression ISO trichostatin A results in increased expression of IP6K3 mRNA CTD PMID:24935251 NCBI chr20:5,225,706...5,247,293
Ensembl chr20:5,226,134...5,273,392 		JBrowse link
G Ipo5 importin 5 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of IPO5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IPO5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:104,397,626...104,447,985
Ensembl chr15:104,397,276...104,447,985 		JBrowse link
G Ipo9 importin 9 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of IPO9 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IPO9 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:49,362,244...49,414,477
Ensembl chr13:49,365,716...49,414,477 		JBrowse link
G Ipp intracisternal A particle-promoted polypeptide decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of IPP mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IPP mRNA
trichostatin A affects the expression of IPP mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 5:135,199,198...135,237,912
Ensembl chr 5:135,180,109...135,238,000 		JBrowse link
G Iqca1 IQ motif containing with AAA domain 1 increases expression ISO trichostatin A results in increased expression of DRC11 mRNA CTD PMID:24935251 NCBI chr 9:98,074,389...98,190,233
Ensembl chr 9:98,073,887...98,190,066 		JBrowse link
G Iqcg IQ motif containing G affects expression ISO trichostatin A affects the expression of DRC9 mRNA CTD PMID:28542535 NCBI chr11:81,235,204...81,276,249
Ensembl chr11:81,235,090...81,276,249 		JBrowse link
G Iqck IQ motif containing K increases expression ISO trichostatin A results in increased expression of IQCK mRNA CTD PMID:24935251 NCBI chr 1:182,630,678...182,748,325
Ensembl chr 1:182,630,673...182,748,325 		JBrowse link
G Iqgap1 IQ motif containing GTPase activating protein 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of IQGAP1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IQGAP1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:144,088,788...144,178,989
Ensembl chr 1:144,088,793...144,179,043 		JBrowse link
G Irak1bp1 interleukin-1 receptor-associated kinase 1 binding protein 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of IRAK1BP1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IRAK1BP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:92,608,468...92,628,377
Ensembl chr 8:92,611,843...92,628,377 		JBrowse link
G Irak3 interleukin-1 receptor-associated kinase 3 increases expression ISO trichostatin A results in increased expression of IRAK3 mRNA CTD PMID:24935251 NCBI chr 7:57,538,522...57,600,166
Ensembl chr 7:57,539,557...57,598,706 		JBrowse link
G Irf1 interferon regulatory factor 1 affects expression ISO trichostatin A affects the expression of IRF1 mRNA CTD PMID:28542535 NCBI chr10:38,417,935...38,424,946
Ensembl chr10:38,417,148...38,424,947 		JBrowse link
G Irf2bp2 interferon regulatory factor 2 binding protein 2 increases expression
multiple interactions
affects expression 		ISO trichostatin A results in increased expression of IRF2BP2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRF2BP2 mRNA
trichostatin A affects the expression of IRF2BP2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr19:71,456,689...71,462,368
Ensembl chr19:71,456,689...71,462,368 		JBrowse link
G Irf2bpl interferon regulatory factor 2 binding protein-like decreases expression ISO trichostatin A results in decreased expression of IRF2BPL mRNA CTD PMID:27188386 NCBI chr 6:112,258,149...112,262,264
Ensembl chr 6:112,258,188...112,263,280 		JBrowse link
G Irf6 interferon regulatory factor 6 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of IRF6 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRF6 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr13:107,200,876...107,220,083
Ensembl chr13:107,200,731...107,220,049 		JBrowse link
G Irf8 interferon regulatory factor 8 multiple interactions ISO trichostatin A affects the reaction [[decitabine affects the methylation of IRF8 promoter] which affects the expression of IRF8 protein] CTD PMID:18922617 NCBI chr19:65,699,284...65,721,066
Ensembl chr19:65,699,284...65,721,062 		JBrowse link
G Irgm immunity-related GTPase M affects expression ISO trichostatin A affects the expression of IRGM mRNA CTD PMID:28542535 NCBI chr10:33,734,640...33,742,720
Ensembl chr10:33,732,961...33,743,228 		JBrowse link
G Irs1 insulin receptor substrate 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of IRS1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRS1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 9:91,001,137...91,053,959
Ensembl chr 9:90,993,519...91,054,538 		JBrowse link
G Irs2 insulin receptor substrate 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of IRS2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRS2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr16:85,190,310...85,214,543
Ensembl chr16:85,190,111...85,214,543 		JBrowse link
G Irs4 insulin receptor substrate 4 decreases expression ISO trichostatin A results in decreased expression of IRS4 mRNA CTD PMID:24935251 NCBI chr  X:110,132,490...110,148,473
Ensembl chr  X:110,132,405...110,149,088 		JBrowse link
G Irx1 iroquois homeobox 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of IRX1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:33,123,122...33,128,951
Ensembl chr 1:33,123,122...33,128,951 		JBrowse link
G Irx2 iroquois homeobox 2 decreases expression
increases expression
multiple interactions 		ISO trichostatin A results in decreased expression of IRX2 mRNA
trichostatin A results in increased expression of IRX2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:32,489,512...32,494,930
Ensembl chr 1:32,489,512...32,494,930 		JBrowse link
G Irx3 iroquois homeobox 3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of IRX3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr19:31,384,803...31,388,241
Ensembl chr19:31,384,833...31,388,238 		JBrowse link
G Irx5 iroquois homeobox 5 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of IRX5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr19:30,812,033...30,816,885
Ensembl chr19:30,797,202...30,815,029 		JBrowse link
G Isl1 ISL LIM homeobox 1 increases expression ISO trichostatin A results in increased expression of ISL1 mRNA CTD PMID:24935251 NCBI chr 2:49,813,618...49,823,442
Ensembl chr 2:49,813,618...49,823,442 		JBrowse link
G Ist1 IST1 factor associated with ESCRT-III decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of IST1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IST1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:54,558,353...54,580,551
Ensembl chr19:54,558,353...54,580,491 		JBrowse link
G Itfg2 integrin alpha FG-GAP repeat containing 2 affects expression ISO trichostatin A affects the expression of ITFG2 mRNA CTD PMID:28542535 NCBI chr 4:163,371,125...163,384,676
Ensembl chr 4:163,338,702...163,384,367 		JBrowse link
G Itga1 integrin subunit alpha 1 increases expression
affects expression 		ISO trichostatin A results in increased expression of ITGA1 mRNA
trichostatin A affects the expression of ITGA1 mRNA 		CTD PMID:26705709 PMID:28542535 NCBI chr 2:48,379,181...48,545,336
Ensembl chr 2:48,386,249...48,545,284 		JBrowse link
G Itga2 integrin subunit alpha 2 increases expression ISO trichostatin A results in increased expression of ITGA2 mRNA CTD PMID:24935251 NCBI chr 2:48,253,412...48,354,509
Ensembl chr 2:48,253,412...48,354,509 		JBrowse link
G Itga4 integrin subunit alpha 4 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ITGA4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:84,569,487...84,646,276
Ensembl chr 3:84,560,369...84,641,039 		JBrowse link
G Itga6 integrin subunit alpha 6 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ITGA6 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ITGA6 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:77,012,168...77,097,076
Ensembl chr 3:77,017,766...77,097,076 		JBrowse link
G Itga7 integrin subunit alpha 7 decreases expression ISO trichostatin A results in decreased expression of ITGA7 mRNA CTD PMID:24935251 NCBI chr 7:1,944,447...1,973,347
Ensembl chr 7:1,944,460...1,973,339 		JBrowse link
G Itga8 integrin subunit alpha 8 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ITGA8 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA8 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr17:80,213,139...80,410,633
Ensembl chr17:80,213,143...80,410,633 		JBrowse link
G Itga9 integrin subunit alpha 9 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ITGA9 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA9 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 8:127,185,244...127,493,296
Ensembl chr 8:127,169,226...127,493,296 		JBrowse link
G Itgal integrin subunit alpha L multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of ITGAL mRNA] CTD PMID:14575637 NCBI chr 1:191,348,424...191,386,228
Ensembl chr 1:191,348,542...191,386,225 		JBrowse link
G Itgam integrin subunit alpha M multiple interactions
increases expression 		ISO decitabine promotes the reaction [trichostatin A results in increased expression of ITGAM mRNA] CTD PMID:18718068 NCBI chr 1:192,089,496...192,139,947
Ensembl chr 1:192,089,542...192,139,943 		JBrowse link
G Itgb3 integrin subunit beta 3 increases expression ISO trichostatin A results in increased expression of ITGB3 mRNA CTD PMID:23463510 PMID:26238599 NCBI chr10:90,009,927...90,067,787
Ensembl chr10:90,009,900...90,067,800 		JBrowse link
G Itgb5 integrin subunit beta 5 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ITGB5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ITGB5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr11:80,333,588...80,449,373
Ensembl chr11:80,333,590...80,449,373 		JBrowse link
G Itgb6 integrin subunit beta 6 increases expression ISO trichostatin A results in increased expression of ITGB6 mRNA CTD PMID:24935251 NCBI chr 3:65,454,964...65,579,179
Ensembl chr 3:65,456,713...65,530,333 		JBrowse link
G Itgb8 integrin subunit beta 8 decreases expression
increases expression 		ISO trichostatin A results in decreased expression of ITGB8 mRNA
trichostatin A results in increased expression of ITGB8 mRNA 		CTD PMID:24935251 NCBI chr 6:146,267,982...146,351,245
Ensembl chr 6:146,165,484...146,351,245 		JBrowse link
G Itih5 inter-alpha-trypsin inhibitor heavy chain 5 increases expression ISO trichostatin A results in increased expression of ITIH5 mRNA CTD PMID:24935251 NCBI chr17:73,161,886...73,261,930
Ensembl chr17:73,161,611...73,262,496 		JBrowse link
G Itm2a integral membrane protein 2A increases expression ISO trichostatin A results in increased expression of ITM2A mRNA CTD PMID:24935251 PMID:27188386 NCBI chr  X:76,559,183...76,565,144
Ensembl chr  X:76,559,181...76,565,437 		JBrowse link
G Itpk1 inositol-tetrakisphosphate 1-kinase decreases expression ISO trichostatin A results in decreased expression of ITPK1 mRNA CTD PMID:28542535 NCBI chr 6:127,475,589...127,609,320
Ensembl chr 6:127,476,808...127,609,062 		JBrowse link
G Itpkb inositol-trisphosphate 3-kinase B multiple interactions ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITPKB mRNA CTD PMID:27188386 NCBI chr13:94,601,072...94,696,180
Ensembl chr13:94,601,167...94,696,179 		JBrowse link
G Itpr1 inositol 1,4,5-trisphosphate receptor, type 1 increases expression
multiple interactions
affects expression 		ISO trichostatin A results in increased expression of ITPR1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITPR1 mRNA
trichostatin A affects the expression of ITPR1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 4:142,743,401...143,066,505
Ensembl chr 4:142,743,334...143,066,504 		JBrowse link
G Itpr2 inositol 1,4,5-trisphosphate receptor, type 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ITPR2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITPR2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:180,759,325...181,165,361
Ensembl chr 4:180,760,442...181,164,763 		JBrowse link
G Itpr3 inositol 1,4,5-trisphosphate receptor, type 3 increases expression ISO trichostatin A results in increased expression of ITPR3 mRNA CTD PMID:24935251 NCBI chr20:5,138,553...5,204,189
Ensembl chr20:5,118,834...5,204,184 		JBrowse link
G Itprid2 ITPR interacting domain containing 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ITPRID2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITPRID2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:84,943,572...84,980,993
Ensembl chr 3:84,939,808...84,980,899 		JBrowse link
G Itprip inositol 1,4,5-trisphosphate receptor interacting protein increases expression ISO trichostatin A results in increased expression of ITPRIP mRNA CTD PMID:24935251 NCBI chr 1:256,704,087...256,727,661
Ensembl chr 1:256,699,832...256,727,644 		JBrowse link
G Itpripl2 ITPRIP like 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of ITPRIPL2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITPRIPL2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:182,235,361...182,237,256
Ensembl chr 1:182,231,093...182,245,858 		JBrowse link
G Itsn2 intersectin 2 decreases expression ISO trichostatin A results in decreased expression of ITSN2 mRNA CTD PMID:28542535 NCBI chr 6:33,336,086...33,446,818
Ensembl chr 6:33,336,441...33,446,818 		JBrowse link
G Ivns1abp influenza virus NS1A binding protein increases expression
multiple interactions 		ISO trichostatin A results in increased expression of IVNS1ABP mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IVNS1ABP mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:65,977,069...65,996,685
Ensembl chr13:65,977,045...65,997,547 		JBrowse link
G Iws1 interacts with SUPT6H, CTD assembly factor 1 affects expression ISO trichostatin A affects the expression of IWS1 mRNA CTD PMID:28542535 NCBI chr18:23,969,352...24,011,560
Ensembl chr18:23,969,733...24,010,415 		JBrowse link
G Jade1 jade family PHD finger 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of JADE1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JADE1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:126,471,124...126,524,252
Ensembl chr 2:126,471,124...126,524,252 		JBrowse link
G Jade2 jade family PHD finger 2 decreases expression
affects expression 		ISO trichostatin A results in decreased expression of JADE2 mRNA
trichostatin A affects the expression of JADE2 mRNA 		CTD PMID:24935251 PMID:28542535 PMID:33770205 NCBI chr10:36,576,187...36,625,129
Ensembl chr10:36,576,187...36,623,532 		JBrowse link
G Jag1 jagged canonical Notch ligand 1 decreases expression
increases expression
multiple interactions 		ISO trichostatin A results in decreased expression of JAG1 mRNA
trichostatin A results in increased expression of JAG1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JAG1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:26705709 PMID:27188386 NCBI chr 3:144,859,453...144,894,883
Ensembl chr 3:144,859,453...144,894,872 		JBrowse link
G Jag2 jagged canonical Notch ligand 2 multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of JAG2 mRNA] CTD PMID:14575637 NCBI chr 6:137,804,133...137,826,738
Ensembl chr 6:137,804,133...137,826,738 		JBrowse link
G Jak1 Janus kinase 1 increases expression
affects expression 		ISO trichostatin A results in increased expression of JAK1 mRNA
trichostatin A affects the expression of JAK1 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 5:120,895,606...121,004,207
Ensembl chr 5:120,896,046...120,996,758 		JBrowse link
G Jak2 Janus kinase 2 multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of JAK2 mRNA] CTD PMID:14575637 NCBI chr 1:236,408,905...236,468,769
Ensembl chr 1:236,408,662...236,468,762 		JBrowse link
G Jakmip1 janus kinase and microtubule interacting protein 1 increases expression ISO trichostatin A results in increased expression of JAKMIP1 mRNA CTD PMID:24935251 NCBI chr14:77,871,034...77,991,566
Ensembl chr14:77,871,034...77,991,525 		JBrowse link
G Jazf1 JAZF zinc finger 1 increases expression ISO trichostatin A results in increased expression of JAZF1 mRNA CTD PMID:24935251 NCBI chr 4:83,210,054...83,513,790
Ensembl chr 4:83,210,058...83,513,644 		JBrowse link
G Jcad junctional cadherin 5 associated increases expression
multiple interactions 		ISO trichostatin A results in increased expression of JCAD mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JCAD mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr17:57,784,634...57,826,213
Ensembl chr17:57,784,634...57,826,183 		JBrowse link
G Jkamp JNK1/MAPK8-associated membrane protein decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of JKAMP mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JKAMP mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:96,383,976...96,397,917
Ensembl chr 6:96,366,624...96,398,432 		JBrowse link
G Jmjd1c jumonji domain containing 1C decreases expression
increases expression 		ISO trichostatin A results in decreased expression of JMJD1C mRNA
trichostatin A results in increased expression of JMJD1C mRNA 		CTD PMID:24935251 PMID:26272509 NCBI chr20:21,330,990...21,508,580
Ensembl chr20:21,330,990...21,461,916 		JBrowse link
G Jph1 junctophilin 1 increases expression ISO trichostatin A results in increased expression of JPH1 mRNA CTD PMID:24935251 NCBI chr 5:6,813,553...6,920,488
Ensembl chr 5:6,813,602...6,906,241 		JBrowse link
G Jph3 junctophilin 3 decreases expression ISO trichostatin A results in decreased expression of JPH3 mRNA CTD PMID:24935251 NCBI chr19:66,702,497...66,763,948
Ensembl chr19:66,702,680...66,763,937 		JBrowse link
G Jph4 junctophilin 4 increases expression ISO trichostatin A results in increased expression of JPH4 mRNA CTD PMID:24935251 NCBI chr15:32,549,536...32,558,859
Ensembl chr15:32,549,555...32,558,859 		JBrowse link
G Jpt1 Jupiter microtubule associated homolog 1 affects expression ISO trichostatin A affects the expression of JPT1 mRNA CTD PMID:28542535 NCBI chr10:101,243,428...101,261,464
Ensembl chr10:101,243,424...101,261,469 		JBrowse link
G Jpt2 Jupiter microtubule associated homolog 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of JPT2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JPT2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:14,467,652...14,487,769
Ensembl chr10:14,467,661...14,535,664 		JBrowse link
G Jrk Jrk helix-turn-helix protein affects expression ISO trichostatin A affects the expression of JRK mRNA CTD PMID:28542535 NCBI chr 7:108,479,646...108,484,329
Ensembl chr 7:108,453,398...108,495,813 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions
increases expression 		ISO DUSP1 mutant form inhibits the reaction [trichostatin A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of JUN protein]]; trichostatin A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of JUN protein]
trichostatin A results in increased expression of JUN mRNA 		CTD PMID:21911040 PMID:24935251 PMID:26272509 NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285 		JBrowse link
G Junb JunB proto-oncogene, AP-1 transcription factor subunit affects expression ISO trichostatin A affects the expression of JUNB mRNA CTD PMID:16505122 NCBI chr19:40,081,126...40,082,910
Ensembl chr19:40,073,541...40,085,218 		JBrowse link
G Kalrn kalirin, RhoGEF kinase increases expression
decreases expression 		ISO trichostatin A results in increased expression of KALRN mRNA
trichostatin A results in decreased expression of KALRN mRNA 		CTD PMID:24935251 PMID:27188386 NCBI chr11:79,703,345...80,309,210
Ensembl chr11:79,703,366...80,133,329 		JBrowse link
G Kank2 KN motif and ankyrin repeat domains 2 affects expression ISO trichostatin A affects the expression of KANK2 mRNA CTD PMID:28542535 NCBI chr 8:28,587,770...28,617,212
Ensembl chr 8:28,587,770...28,616,993 		JBrowse link
G Kank4 KN motif and ankyrin repeat domains 4 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of KANK4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KANK4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:118,516,994...118,581,024
Ensembl chr 5:118,517,971...118,581,002 		JBrowse link
G Kansl1 KAT8 regulatory NSL complex subunit 1 increases expression
affects expression 		ISO trichostatin A results in increased expression of KANSL1 mRNA
trichostatin A affects the expression of KANSL1 mRNA 		CTD PMID:26272509 PMID:28542535 NCBI chr10:89,737,637...89,868,620
Ensembl chr10:89,737,637...89,868,620 		JBrowse link
G Kat2b lysine acetyltransferase 2B affects localization
multiple interactions
increases expression
decreases expression 		ISO trichostatin A affects the localization of KAT2B protein
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT2B mRNA; trichostatin A promotes the reaction [KAT2B protein binds to TGFBR2 promoter]
trichostatin A results in increased expression of KAT2B mRNA
trichostatin A results in decreased expression of KAT2B mRNA 		CTD PMID:15647279 PMID:22723015 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 9:6,799,101...6,903,616
Ensembl chr 9:6,799,145...6,903,616 		JBrowse link
G Kat5 lysine acetyltransferase 5 decreases expression ISO trichostatin A results in decreased expression of KAT5 mRNA CTD PMID:24935251 PMID:28542535 NCBI chr 1:212,325,089...212,332,640
Ensembl chr 1:212,325,090...212,332,587 		JBrowse link
G Kat6a lysine acetyltransferase 6A decreases expression ISO trichostatin A results in decreased expression of KAT6A mRNA CTD PMID:24935251 NCBI chr16:75,787,411...75,868,584
Ensembl chr16:75,787,411...75,866,099 		JBrowse link
G Kat6b lysine acetyltransferase 6B decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of KAT6B mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT6B mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr15:2,688,535...2,861,443
Ensembl chr15:2,688,811...2,844,343 		JBrowse link
G Kat7 lysine acetyltransferase 7 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of KAT7 mRNA; trichostatin A results in decreased expression of MYST2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT7 mRNA
trichostatin A affects the expression of KAT7 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr10:80,718,335...80,752,387
Ensembl chr10:80,718,335...80,752,387 		JBrowse link
G Kazn kazrin, periplakin interacting protein increases expression ISO trichostatin A results in increased expression of KAZN mRNA CTD PMID:24935251 NCBI chr 5:159,675,803...160,666,084
Ensembl chr 5:159,675,803...160,664,154 		JBrowse link
G Kbtbd11 kelch repeat and BTB domain containing 11 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of KBTBD11 mRNA
trichostatin A results in decreased expression of KBTBD11 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KBTBD11 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr16:81,318,596...81,340,334
Ensembl chr16:81,313,093...81,340,390 		JBrowse link
G Kbtbd2 kelch repeat and BTB domain containing 2 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of KBTBD2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KBTBD2 mRNA
trichostatin A affects the expression of KBTBD2 mRNA 		CTD PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 4:87,358,133...87,380,399
Ensembl chr 4:87,358,133...87,380,399 		JBrowse link
G Kbtbd4 kelch repeat and BTB domain containing 4 decreases expression ISO trichostatin A results in decreased expression of KBTBD4 mRNA CTD PMID:24935251 PMID:26272509 NCBI chr 3:97,339,500...97,345,599
Ensembl chr 3:97,339,084...97,345,598 		JBrowse link
G Kcmf1 potassium channel modulatory factor 1 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of KCMF1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCMF1 mRNA
trichostatin A affects the expression of KCMF1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 4:106,447,974...106,508,359
Ensembl chr 4:106,447,981...106,508,359 		JBrowse link
G Kcna1 potassium voltage-gated channel subfamily A member 1 decreases expression ISO trichostatin A results in decreased expression of KCNA1 mRNA CTD PMID:24935251 NCBI chr 4:161,150,378...161,160,051
Ensembl chr 4:161,147,418...161,160,044 		JBrowse link
G Kcna2 potassium voltage-gated channel subfamily A member 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of KCNA2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNA2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:197,392,746...197,406,606
Ensembl chr 2:197,392,698...197,407,519 		JBrowse link
G Kcna5 potassium voltage-gated channel subfamily A member 5 decreases expression ISO trichostatin A results in decreased expression of KCNA5 mRNA CTD PMID:24935251 NCBI chr 4:161,040,853...161,044,311
Ensembl chr 4:160,996,950...161,044,408 		JBrowse link
G Kcnb1 potassium voltage-gated channel subfamily B member 1 decreases expression ISO trichostatin A results in decreased expression of KCNB1 mRNA CTD PMID:24935251 NCBI chr 3:176,239,285...176,332,408
Ensembl chr 3:176,242,589...176,332,408 		JBrowse link
G Kcnd2 potassium voltage-gated channel subfamily D member 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of KCND2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCND2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:50,741,595...51,243,540
Ensembl chr 4:50,742,839...51,243,522 		JBrowse link
G Kcne1 potassium voltage-gated channel subfamily E regulatory subunit 1 increases expression ISO trichostatin A results in increased expression of KCNE1 mRNA CTD PMID:24935251 NCBI chr11:45,066,875...45,080,024
Ensembl chr11:45,064,162...45,081,247 		JBrowse link
G Kcng1 potassium voltage-gated channel modifier subfamily G member 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of KCNG1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNG1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:177,379,593...177,412,986
Ensembl chr 3:177,392,031...177,411,507 		JBrowse link
G Kcng3 potassium voltage-gated channel modifier subfamily G member 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of KCNG3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNG3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:16,803,842...16,851,791
Ensembl chr 6:16,803,665...16,851,791 		JBrowse link
G Kcnh2 potassium voltage-gated channel subfamily H member 2 decreases expression ISO trichostatin A results in decreased expression of KCNH2 mRNA CTD PMID:24935251 NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421 		JBrowse link
G Kcnh5 potassium voltage-gated channel subfamily H member 5 increases expression
decreases expression 		ISO trichostatin A results in increased expression of KCNH5 mRNA
trichostatin A results in decreased expression of KCNH5 mRNA 		CTD PMID:24935251 NCBI chr 6:99,350,947...99,643,856
Ensembl chr 6:99,360,302...99,643,856 		JBrowse link
G Kcnh8 potassium voltage-gated channel subfamily H member 8 decreases expression ISO trichostatin A results in decreased expression of KCNH8 mRNA CTD PMID:24935251 NCBI chr 9:5,742,683...6,182,445
Ensembl chr 9:5,742,683...6,182,445 		JBrowse link
G Kcnj13 potassium inwardly-rectifying channel, subfamily J, member 13 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of KCNJ13 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ13 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 9:95,509,228...95,528,400
Ensembl chr 9:95,510,877...95,520,817 		JBrowse link
G Kcnj2 potassium inwardly-rectifying channel, subfamily J, member 2 decreases expression
increases expression 		ISO trichostatin A results in decreased expression of KCNJ2 mRNA
trichostatin A results in increased expression of KCNJ2 mRNA 		CTD PMID:24935251 NCBI chr10:96,560,225...96,570,788
Ensembl chr10:96,565,600...96,570,901 		JBrowse link
G Kcnj4 potassium inwardly-rectifying channel, subfamily J, member 4 decreases expression ISO trichostatin A results in decreased expression of KCNJ4 mRNA CTD PMID:24935251 NCBI chr 7:112,927,494...112,954,547
Ensembl chr 7:112,922,532...112,954,826 		JBrowse link
G Kcnj8 potassium inwardly-rectifying channel, subfamily J, member 8 increases expression ISO trichostatin A results in increased expression of KCNJ8 mRNA CTD PMID:24935251 PMID:27188386 NCBI chr 4:177,240,692...177,246,548
Ensembl chr 4:177,239,908...177,246,531 		JBrowse link
G Kcnk1 potassium two pore domain channel subfamily K member 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of KCNK1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNK1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr19:70,856,985...70,895,053
Ensembl chr19:70,856,985...70,895,051 		JBrowse link
G Kcnk10 potassium two pore domain channel subfamily K member 10 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of KCNK10 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:123,419,778...123,555,820
Ensembl chr 6:123,423,950...123,555,614 		JBrowse link
G Kcnk5 potassium two pore domain channel subfamily K member 5 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of KCNK5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNK5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:4,171,625...4,213,896
Ensembl chr15:4,171,610...4,213,897 		JBrowse link
G Kcnk6 potassium two pore domain channel subfamily K member 6 increases expression ISO trichostatin A results in increased expression of KCNK6 mRNA CTD PMID:24935251 NCBI chr 1:93,652,888...93,661,419 JBrowse link
G Kcnma1 potassium calcium-activated channel subfamily M alpha 1 multiple interactions
decreases expression 		ISO trichostatin A inhibits the reaction [Nickel affects the expression of KCNMA1 mRNA]
trichostatin A results in decreased expression of KCNMA1 mRNA 		CTD PMID:14575637 PMID:24935251 NCBI chr15:351,065...1,057,117
Ensembl chr15:351,659...1,057,117 		JBrowse link
G Kcnmb3 potassium calcium-activated channel subfamily M regulatory beta subunit 3 increases expression ISO trichostatin A results in increased expression of KCNMB3 mRNA CTD PMID:24935251 NCBI chr 2:117,184,165...117,198,519
Ensembl chr 2:117,182,431...117,200,919 		JBrowse link
G Kcnq4 potassium voltage-gated channel subfamily Q member 4 increases expression ISO trichostatin A results in increased expression of KCNQ4 mRNA CTD PMID:24935251 NCBI chr 5:139,560,366...139,612,212
Ensembl chr 5:139,560,366...139,612,102 		JBrowse link
G Kcns3 potassium voltage-gated channel, modifier subfamily S, member 3 decreases expression
multiple interactions
increases expression 		ISO trichostatin A results in decreased expression of KCNS3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNS3 mRNA
trichostatin A results in increased expression of KCNS3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:39,527,410...39,584,105
Ensembl chr 6:39,523,777...39,618,848 		JBrowse link
G Kcnt2 potassium sodium-activated channel subfamily T member 2 increases expression ISO trichostatin A results in increased expression of KCNT2 mRNA CTD PMID:24935251 NCBI chr13:54,214,831...54,609,889
Ensembl chr13:54,215,307...54,607,924 		JBrowse link
G Kcnv1 potassium voltage-gated channel modifier subfamily V member 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of KCNV1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNV1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:78,145,319...78,153,794
Ensembl chr 7:78,145,319...78,153,816 		JBrowse link
G Kctd1 potassium channel tetramerization domain containing 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of KCTD1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr18:6,396,947...6,591,026
Ensembl chr18:6,396,947...6,515,191 		JBrowse link
G Kctd11 potassium channel tetramerization domain containing 11 decreases expression ISO trichostatin A results in decreased expression of KCTD11 mRNA CTD PMID:24935251 NCBI chr10:55,101,292...55,103,455
Ensembl chr10:55,100,801...55,103,583 		JBrowse link
G Kctd12 potassium channel tetramerization domain containing 12 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of KCTD12 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD12 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:86,214,786...86,220,725
Ensembl chr15:86,214,840...86,224,539 		JBrowse link
G Kctd15 potassium channel tetramerization domain containing 15 decreases expression ISO trichostatin A results in decreased expression of KCTD15 mRNA CTD PMID:24935251 NCBI chr 1:96,395,794...96,411,502
Ensembl chr 1:96,395,794...96,410,631 		JBrowse link
G Kctd16 potassium channel tetramerization domain containing 16 decreases expression ISO trichostatin A results in decreased expression of KCTD16 mRNA CTD PMID:24935251 NCBI chr18:32,417,306...32,711,928
Ensembl chr18:32,419,225...32,712,820 		JBrowse link
G Kctd18 potassium channel tetramerization domain containing 18 increases expression ISO trichostatin A results in increased expression of KCTD18 mRNA CTD PMID:24935251 NCBI chr 9:66,996,440...67,061,069
Ensembl chr 9:66,996,447...67,061,069 		JBrowse link
G Kctd7 potassium channel tetramerization domain containing 7 decreases expression ISO trichostatin A results in decreased expression of KCTD7 mRNA CTD PMID:27188386 NCBI chr12:32,157,141...32,168,463
Ensembl chr12:32,159,297...32,168,292 		JBrowse link
G Kdelr2 KDEL endoplasmic reticulum protein retention receptor 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of KDELR2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KDELR2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr12:16,252,424...16,270,737
Ensembl chr12:16,252,424...16,270,719 		JBrowse link
G Kdelr3 KDEL endoplasmic reticulum protein retention receptor 3 increases expression ISO trichostatin A results in increased expression of KDELR3 mRNA CTD PMID:24935251 NCBI chr 7:112,959,632...112,969,858
Ensembl chr 7:112,959,718...112,969,858 		JBrowse link
G Kdm1b lysine demethylase 1B affects expression ISO trichostatin A affects the expression of KDM1B mRNA CTD PMID:28542535 NCBI chr17:17,809,232...17,850,141
Ensembl chr17:17,809,232...17,850,068 		JBrowse link
G Kdm3b lysine demethylase 3B affects expression ISO trichostatin A affects the expression of KDM3B mRNA CTD PMID:28542535 NCBI chr18:26,655,004...26,710,814
Ensembl chr18:26,655,687...26,710,814 		JBrowse link
G Kdm4a lysine demethylase 4A decreases activity
increases expression
decreases expression 		ISO trichostatin A results in decreased activity of KDM4A protein
trichostatin A results in increased expression of KDM4A mRNA
trichostatin A results in decreased expression of KDM4A mRNA 		CTD PMID:15927959 NCBI chr 5:136,958,178...137,004,942
Ensembl chr 5:136,958,178...137,004,951 		JBrowse link
G Kdm4b lysine demethylase 4B increases expression
affects expression 		ISO trichostatin A results in increased expression of KDM4B mRNA
trichostatin A affects the expression of KDM4B mRNA 		CTD PMID:15927959 PMID:28542535 NCBI chr 9:1,245,885...1,324,384
Ensembl chr 9:1,245,899...1,324,384 		JBrowse link
G Kdm4c lysine demethylase 4C increases expression ISO trichostatin A results in increased expression of KDM4C mRNA CTD PMID:24935251 NCBI chr 5:93,146,404...93,353,040
Ensembl chr 5:93,146,969...93,353,040 		JBrowse link
G Kdm4d lysine demethylase 4D decreases expression ISO trichostatin A results in decreased expression of KDM4D mRNA CTD PMID:24935251 NCBI chr 8:19,561,253...19,586,412
Ensembl chr 8:19,548,676...19,587,331 		JBrowse link
G Kdm5c lysine demethylase 5C decreases expression ISO trichostatin A results in decreased expression of KDM5C mRNA CTD PMID:24935251 NCBI chr  X:24,821,568...24,866,423
Ensembl chr  X:24,824,859...24,866,423 		JBrowse link
G Kdm6a lysine demethylase 6A decreases expression
increases expression 		ISO trichostatin A results in decreased expression of KDM6A mRNA
trichostatin A results in increased expression of KDM6A mRNA 		CTD PMID:24935251 PMID:26272509 NCBI chr  X:6,920,374...7,060,027
Ensembl chr  X:6,920,343...7,059,960 		JBrowse link
G Kdm6b lysine demethylase 6B decreases expression ISO trichostatin A results in decreased expression of KDM6B mRNA CTD PMID:27188386 NCBI chr10:54,619,520...54,641,014
Ensembl chr10:54,619,544...54,629,610 		JBrowse link
G Kdsr 3-ketodihydrosphingosine reductase increases expression ISO trichostatin A results in increased expression of KDSR mRNA CTD PMID:24935251 NCBI chr13:23,374,101...23,408,779
Ensembl chr13:23,376,779...23,408,897 		JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 affects expression ISO trichostatin A affects the expression of KEAP1 mRNA CTD PMID:28542535 NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:28,044,555...28,054,042 		JBrowse link
G Kiaa0040 KIAA0040 ortholog increases expression ISO trichostatin A results in increased expression of KIAA0040 mRNA CTD PMID:24935251 NCBI chr13:74,807,959...74,845,530
Ensembl chr13:74,807,982...74,845,530 		JBrowse link
G Kiaa0930 KIAA0930 homolog affects expression ISO trichostatin A affects the expression of KIAA0930 mRNA CTD PMID:28542535 NCBI chr 7:117,947,898...117,987,601
Ensembl chr 7:117,947,898...117,987,636 		JBrowse link
G Kiaa1191 KIAA1191 homolog affects expression ISO trichostatin A affects the expression of KIAA1191 mRNA CTD PMID:28542535 NCBI chr17:10,054,249...10,066,922
Ensembl chr17:10,054,265...10,067,095 		JBrowse link
G Kiaa1671 KIAA1671 homolog decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of KIAA1671 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIAA1671 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr12:49,069,929...49,212,604
Ensembl chr12:49,069,940...49,212,604 		JBrowse link
G Kiaa1755 KIAA1755 ortholog increases expression
multiple interactions 		ISO trichostatin A results in increased expression of KIAA1755 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA1755 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:167,270,476...167,305,337
Ensembl chr 3:167,192,612...167,304,240 		JBrowse link
G Kiaa1958 KIAA1958 homolog decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of KIAA1958 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIAA1958 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:79,286,708...79,432,859
Ensembl chr 5:79,286,708...79,432,859 		JBrowse link
G Kics2 KICSTOR subunit 2 increases expression ISO trichostatin A results in increased expression of KICS2 mRNA CTD PMID:24935251 NCBI chr 7:59,169,703...59,182,974
Ensembl chr 7:59,169,543...59,184,551 		JBrowse link
G Kidins220 kinase D-interacting substrate 220 increases expression
affects expression 		ISO trichostatin A results in increased expression of KIDINS220 mRNA
trichostatin A affects the expression of KIDINS220 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 6:47,346,790...47,435,599
Ensembl chr 6:47,346,832...47,431,865 		JBrowse link
G Kif13a kinesin family member 13A decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of KIF13A mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIF13A mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr17:17,972,227...18,154,763
Ensembl chr17:17,972,325...18,154,760 		JBrowse link
G Kif13b kinesin family member 13B affects expression ISO trichostatin A affects the expression of KIF13B mRNA CTD PMID:28542535 NCBI chr15:43,084,059...43,241,719
Ensembl chr15:43,080,910...43,241,719 		JBrowse link
G Kif15 kinesin family member 15 affects expression ISO trichostatin A affects the expression of KIF15 mRNA CTD PMID:28542535 NCBI chr 8:131,479,340...131,550,209
Ensembl chr 8:131,479,337...131,550,202 		JBrowse link
G Kif16b kinesin family member 16B increases expression ISO trichostatin A results in increased expression of KIF16B mRNA CTD PMID:24935251 NCBI chr 3:150,428,233...150,707,755
Ensembl chr 3:150,366,838...150,707,770 		JBrowse link
G Kif18a kinesin family member 18A decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of KIF18A mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIF18A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:116,219,007...116,279,378
Ensembl chr 3:116,219,007...116,279,227 		JBrowse link
G Kif1b kinesin family member 1B increases expression ISO trichostatin A results in increased expression of KIF1B mRNA CTD PMID:24935251 NCBI chr 5:164,890,778...165,025,848
Ensembl chr 5:164,894,763...165,008,841 		JBrowse link
G Kif21a kinesin family member 21A decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of KIF21A mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIF21A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:123,942,079...124,058,594
Ensembl chr 7:123,942,081...124,058,540 		JBrowse link
G Kif21b kinesin family member 21B increases expression ISO trichostatin A results in increased expression of KIF21B mRNA CTD PMID:24935251 NCBI chr13:50,127,842...50,177,822
Ensembl chr13:50,127,842...50,177,822 		JBrowse link
G Kif22 kinesin family member 22 affects expression ISO trichostatin A affects the expression of KIF22 mRNA CTD PMID:28542535 NCBI chr 1:191,065,875...191,080,955
Ensembl chr 1:191,065,875...191,080,878 		JBrowse link
G Kif26a kinesin family member 26A decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of KIF26A mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIF26A mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:137,035,986...137,072,027
Ensembl chr 6:137,033,789...137,072,022 		JBrowse link
G Kif3a kinesin family member 3a increases expression
affects expression 		ISO trichostatin A results in increased expression of KIF3A mRNA
trichostatin A affects the expression of KIF3A mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr10:38,226,388...38,263,062
Ensembl chr10:38,226,741...38,260,516 		JBrowse link
G Kif3c kinesin family member 3C affects expression ISO trichostatin A affects the expression of KIF3C mRNA CTD PMID:28542535 NCBI chr 6:32,086,879...32,125,812
Ensembl chr 6:32,086,124...32,126,066 		JBrowse link
G Kif5c kinesin family member 5C increases expression ISO trichostatin A results in increased expression of KIF5C mRNA CTD PMID:28542535 NCBI chr 3:54,441,266...54,591,630
Ensembl chr 3:54,441,310...54,594,813 		JBrowse link
G Kif6 kinesin family member 6 increases expression ISO trichostatin A results in increased expression of KIF6 mRNA CTD PMID:27188386 NCBI chr 9:18,573,925...18,870,789
Ensembl chr 9:18,573,789...18,870,729 		JBrowse link
G Kifap3 kinesin-associated protein 3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of KIFAP3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIFAP3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr13:78,660,849...78,797,821
Ensembl chr13:78,660,871...78,797,820 		JBrowse link
G Kin Kin17 DNA and RNA binding protein affects expression ISO trichostatin A affects the expression of KIN mRNA CTD PMID:28542535 NCBI chr17:73,323,189...73,333,542
Ensembl chr17:73,322,801...73,333,542 		JBrowse link
G Kirrel1 kirre like nephrin family adhesion molecule 1 decreases expression ISO trichostatin A results in decreased expression of KIRREL1 mRNA CTD PMID:24935251 NCBI chr 2:174,819,564...174,912,998
Ensembl chr 2:174,819,572...174,912,960 		JBrowse link
G Kirrel3 kirre like nephrin family adhesion molecule 3 increases expression ISO trichostatin A results in increased expression of KIRREL3 mRNA CTD PMID:24935251 NCBI chr 8:41,123,692...41,663,528
Ensembl chr 8:41,123,878...41,664,147 		JBrowse link
G Kiss1r KISS1 receptor increases expression ISO trichostatin A results in increased expression of KISS1R mRNA CTD PMID:24935251 NCBI chr 7:10,435,766...10,439,424
Ensembl chr 7:10,435,766...10,439,424 		JBrowse link
G Kit KIT proto-oncogene receptor tyrosine kinase increases expression
multiple interactions 		ISO trichostatin A results in increased expression of KIT mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIT mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr14:32,901,615...32,978,895
Ensembl chr14:32,903,033...32,978,812 		JBrowse link
G Kitlg KIT ligand increases expression
multiple interactions 		ISO trichostatin A results in increased expression of KITLG mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KITLG mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:36,782,621...36,863,796
Ensembl chr 7:36,782,638...36,863,793 		JBrowse link
G Kiz kizuna centrosomal protein decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of KIZ mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIZ mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:154,730,873...154,838,410
Ensembl chr 3:154,730,634...154,838,410 		JBrowse link
G Klf15 KLF transcription factor 15 increases expression ISO trichostatin A results in increased expression of KLF15 mRNA CTD PMID:24935251 NCBI chr 4:124,522,652...124,535,613
Ensembl chr 4:124,522,909...124,542,373 		JBrowse link
G Klf2 KLF transcription factor 2 affects expression ISO trichostatin A affects the expression of KLF2 mRNA CTD PMID:28542535 NCBI chr16:17,555,136...17,557,768
Ensembl chr16:17,555,136...17,557,768 		JBrowse link
G Klf4 KLF transcription factor 4 increases expression
multiple interactions 		EXP trichostatin A results in increased expression of KLF4 mRNA
trichostatin A inhibits the reaction [Corticosterone results in decreased expression of KLF4 mRNA]; trichostatin A inhibits the reaction [Corticosterone results in decreased expression of KLF4 protein] 		CTD PMID:19729022 PMID:31306741 NCBI chr 5:75,074,107...75,079,182
Ensembl chr 5:75,074,236...75,078,592 		JBrowse link
G Klf5 KLF transcription factor 5 multiple interactions
increases expression 		ISO [Decitabine co-treated with trichostatin A] results in increased expression of KLF5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF5 mRNA
trichostatin A results in increased expression of KLF5 mRNA 		CTD PMID:20678512 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:82,472,081...82,487,267
Ensembl chr15:82,472,065...82,487,262 		JBrowse link
G Klf6 KLF transcription factor 6 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of KLF6 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF6 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr17:69,449,483...69,458,478
Ensembl chr17:69,441,493...69,498,601 		JBrowse link
G Klf9 KLF transcription factor 9 increases expression ISO trichostatin A results in increased expression of KLF9 mRNA CTD PMID:24935251 NCBI chr 1:230,126,646...230,151,641
Ensembl chr 1:230,126,646...230,151,641 		JBrowse link
G Klhdc1 kelch domain containing 1 increases expression ISO trichostatin A results in increased expression of KLHDC1 mRNA CTD PMID:24935251 NCBI chr 6:93,406,226...93,501,475
Ensembl chr 6:93,448,758...93,501,702 		JBrowse link
G Klhdc8a kelch domain containing 8A decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of KLHDC8A mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHDC8A mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr13:46,287,011...46,296,429
Ensembl chr13:46,288,344...46,296,429 		JBrowse link
G Klhdc8b kelch domain containing 8B decreases expression ISO trichostatin A results in decreased expression of KLHDC8B mRNA CTD PMID:24935251 NCBI chr 8:118,020,136...118,025,102
Ensembl chr 8:118,020,376...118,025,102 		JBrowse link
G Klhl13 kelch-like family member 13 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of KLHL13 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHL13 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr  X:118,747,298...118,912,279
Ensembl chr  X:118,747,298...118,855,035 		JBrowse link
G Klhl14 kelch-like family member 14 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of KLHL14 mRNA
trichostatin A results in decreased expression of KLHL14 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHL14 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr18:13,079,159...13,192,728
Ensembl chr18:13,079,159...13,193,557 		JBrowse link
G Klhl15 kelch-like family member 15 affects expression ISO trichostatin A affects the expression of KLHL15 mRNA CTD PMID:28542535 NCBI chr  X:62,987,762...63,043,980
Ensembl chr  X:62,989,426...63,039,870 		JBrowse link
G Klhl2 kelch-like family member 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of KLHL2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHL2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:29,627,171...29,739,782
Ensembl chr16:29,627,237...29,739,957 		JBrowse link
G Klhl21 kelch-like family member 21 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of KLHL21 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLHL21 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:167,797,621...167,806,276
Ensembl chr 5:167,797,591...167,806,276 		JBrowse link
G Klhl24 kelch-like family member 24 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of KLHL24 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHL24 mRNA
trichostatin A affects the expression of KLHL24 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr11:94,348,024...94,382,085
Ensembl chr11:94,351,157...94,382,050 		JBrowse link
G Klhl25 kelch-like family member 25 affects expression ISO trichostatin A affects the expression of KLHL25 mRNA CTD PMID:28542535 NCBI chr 1:139,134,655...139,159,898
Ensembl chr 1:139,122,977...139,165,970 		JBrowse link
G Klhl26 kelch-like family member 26 affects expression ISO trichostatin A affects the expression of KLHL26 mRNA CTD PMID:28542535 NCBI chr16:18,986,095...19,011,297
Ensembl chr16:18,985,865...19,011,297 		JBrowse link
G Klhl28 kelch-like family member 28 affects expression ISO trichostatin A affects the expression of KLHL28 mRNA CTD PMID:28542535 NCBI chr 6:88,723,624...88,755,072
Ensembl chr 6:88,727,205...88,752,457 		JBrowse link
G Klhl29 kelch-like family member 29 increases expression ISO trichostatin A results in increased expression of KLHL29 mRNA CTD PMID:24935251 NCBI chr 6:33,805,922...34,110,055
Ensembl chr 6:33,805,922...34,110,055 		JBrowse link
G Klhl4 kelch-like family member 4 increases expression ISO trichostatin A results in increased expression of KLHL4 mRNA CTD PMID:24935251 NCBI chr  X:83,626,047...83,916,328
Ensembl chr  X:83,819,076...83,916,328 		JBrowse link
G Klhl41 kelch-like family member 41 increases expression ISO trichostatin A results in increased expression of KLHL41 mRNA CTD PMID:24935251 NCBI chr 3:74,842,118...74,855,244 JBrowse link
G Klhl42 kelch-like family, member 42 decreases expression
affects expression 		ISO trichostatin A results in decreased expression of KLHL42 mRNA
trichostatin A affects the expression of KLHL42 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 4:181,730,343...181,760,899
Ensembl chr 4:181,735,244...181,757,013 		JBrowse link
G Klhl7 kelch-like family member 7 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of KLHL7 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHL7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:11,898,766...11,947,796
Ensembl chr 4:11,898,769...11,947,796 		JBrowse link
G Klhl8 kelch-like family member 8 increases expression ISO trichostatin A results in increased expression of KLHL8 mRNA CTD PMID:24935251 NCBI chr14:6,112,472...6,158,001
Ensembl chr14:6,112,490...6,157,966 		JBrowse link
G Klk1c10 kallikrein 1-related peptidase C10 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of KLK3 mRNA
[trichostatin A co-treated with Decitabine] results in increased expression of KLK3 mRNA; trichostatin A inhibits the reaction [Curcumin results in decreased expression of KLK3 mRNA] 		CTD PMID:18092350 PMID:19805354 PMID:22258452 NCBI chr 1:103,539,527...103,543,586
Ensembl chr 1:103,539,527...103,543,586 		JBrowse link
G Klk8 kallikrein related-peptidase 8 increases expression ISO trichostatin A results in increased expression of KLK8 mRNA CTD PMID:24935251 NCBI chr 1:103,388,352...103,395,195
Ensembl chr 1:103,388,352...103,395,195 		JBrowse link
G Klkb1 kallikrein B1 increases expression ISO trichostatin A results in increased expression of KLKB1 mRNA CTD PMID:24935251 NCBI chr16:53,690,180...53,714,570
Ensembl chr16:53,691,220...53,716,339 		JBrowse link
G Klrg1 killer cell lectin like receptor G1 multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of KLRG1 mRNA] CTD PMID:14575637 NCBI chr 4:157,127,571...157,139,372
Ensembl chr 4:157,127,571...157,139,372 		JBrowse link
G Klrg2 killer cell lectin like receptor G2 increases expression ISO trichostatin A results in increased expression of KLRG2 mRNA CTD PMID:24935251 NCBI chr 4:68,314,347...68,341,759
Ensembl chr 4:68,330,660...68,341,043 		JBrowse link
G Kmt2a lysine methyltransferase 2A decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of KMT2A mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KMT2A mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 8:54,013,547...54,089,219
Ensembl chr 8:54,013,547...54,089,317 		JBrowse link
G Kmt5b lysine methyltransferase 5B decreases expression
affects expression 		ISO trichostatin A results in decreased expression of KMT5B mRNA
trichostatin A affects the expression of KMT5B mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 1:210,429,672...210,479,042
Ensembl chr 1:210,430,127...210,479,035 		JBrowse link
G Knl1 kinetochore scaffold 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KNL1 mRNA
trichostatin A results in decreased expression of KNL1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:126,483,498...126,545,774
Ensembl chr 3:126,483,544...126,545,774 		JBrowse link
G Kpna5 karyopherin subunit alpha 5 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of KPNA5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KPNA5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:31,365,647...31,430,793
Ensembl chr20:31,365,656...31,430,792 		JBrowse link
G Kpnb1 karyopherin subunit beta 1 decreases expression ISO trichostatin A results in decreased expression of KPNB1 mRNA CTD PMID:19606018 PMID:28542535 NCBI chr10:82,642,082...82,670,856
Ensembl chr10:82,642,082...82,670,856 		JBrowse link
G Krcc1 lysine-rich coiled-coil 1 increases expression ISO trichostatin A results in increased expression of KRCC1 mRNA CTD PMID:24935251 NCBI chr 4:104,819,958...104,832,987
Ensembl chr 4:104,819,190...104,855,484 		JBrowse link
G Kremen1 kringle containing transmembrane protein 1 increases expression ISO trichostatin A results in increased expression of KREMEN1 mRNA CTD PMID:24935251 NCBI chr14:84,295,931...84,361,534
Ensembl chr14:84,297,700...84,361,614 		JBrowse link
G Kremen2 kringle containing transmembrane protein 2 increases expression ISO trichostatin A results in increased expression of KREMEN2 mRNA CTD PMID:24935251 NCBI chr10:13,267,986...13,272,103
Ensembl chr10:13,267,986...13,271,986 		JBrowse link
G Krt10 keratin 10 multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of KRT10 mRNA] CTD PMID:14575637 NCBI chr10:84,834,865...84,839,160
Ensembl chr10:84,834,840...84,839,160 		JBrowse link
G Krt18 keratin 18 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of KRT18 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT18 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:135,036,168...135,039,844
Ensembl chr 7:135,035,982...135,039,848
Ensembl chr10:135,035,982...135,039,848 		JBrowse link
G Krt19 keratin 19 increases expression ISO trichostatin A results in increased expression of KRT19 mRNA CTD PMID:24935251 PMID:26705709 NCBI chr10:85,576,235...85,580,952
Ensembl chr10:85,576,235...85,580,952 		JBrowse link
G Krt222 keratin 222 increases expression ISO trichostatin A results in increased expression of KRT222 mRNA CTD PMID:24935251 NCBI chr10:84,680,331...84,693,374
Ensembl chr10:84,680,331...84,692,173 		JBrowse link
G Krt8 keratin 8 affects expression
multiple interactions
increases expression 		ISO trichostatin A affects the expression of KRT8 protein
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT8 mRNA; [trichostatin A co-treated with Decitabine] results in decreased expression of KRT8 protein
trichostatin A results in increased expression of KRT8 mRNA 		CTD PMID:19294695 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:135,002,886...135,010,339
Ensembl chr 7:135,002,894...135,010,403 		JBrowse link
G Krtdap keratinocyte differentiation associated protein decreases expression ISO trichostatin A results in decreased expression of KRTDAP mRNA CTD PMID:24935251 NCBI chr 1:95,165,844...95,169,025
Ensembl chr 1:95,165,862...95,169,012 		JBrowse link
G Ksr1 kinase suppressor of ras 1 increases expression ISO trichostatin A results in increased expression of KSR1 mRNA CTD PMID:28542535 NCBI chr10:64,459,786...64,596,083
Ensembl chr10:64,459,786...64,596,082 		JBrowse link
G L1cam L1 cell adhesion molecule increases expression
multiple interactions 		ISO trichostatin A results in increased expression of L1CAM mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of L1CAM mRNA 		CTD PMID:24935251 PMID:26272509 PMID:26705709 PMID:27188386 NCBI chr  X:156,748,597...156,775,116
Ensembl chr  X:156,748,597...156,775,077 		JBrowse link
G L1td1 LINE-1 type transposase domain containing 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of L1TD1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of L1TD1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:118,488,688...118,501,591
Ensembl chr 5:118,488,688...118,501,591 		JBrowse link
G L3mbtl1 L3MBTL histone methyl-lysine binding protein 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of L3MBTL1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of L3MBTL1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:172,014,774...172,053,181
Ensembl chr 3:172,021,416...172,053,181 		JBrowse link
G L3mbtl2 L3MBTL histone methyl-lysine binding protein 2 decreases expression ISO trichostatin A results in decreased expression of L3MBTL2 mRNA CTD PMID:24935251 NCBI chr 7:115,066,427...115,087,625
Ensembl chr 7:115,066,486...115,087,598 		JBrowse link
G L3mbtl3 L3MBTL histone methyl-lysine binding protein 3 increases expression ISO trichostatin A results in increased expression of L3MBTL3 mRNA CTD PMID:24935251 NCBI chr 1:20,807,679...20,908,609
Ensembl chr 1:20,808,973...20,908,608 		JBrowse link
G Lacc1 laccase domain containing 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of LACC1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACC1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:58,799,477...58,816,840
Ensembl chr15:58,786,637...58,816,840 		JBrowse link
G Lactb lactamase, beta increases expression
multiple interactions
affects expression 		ISO trichostatin A results in increased expression of LACTB mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACTB mRNA
trichostatin A affects the expression of LACTB mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 8:76,452,679...76,469,986
Ensembl chr 8:76,452,349...76,468,716 		JBrowse link
G Lama2 laminin subunit alpha 2 increases expression ISO trichostatin A results in increased expression of LAMA2 mRNA CTD PMID:24935251 NCBI chr 1:19,492,126...20,140,056
Ensembl chr 1:19,244,599...20,140,056 		JBrowse link
G Lama4 laminin subunit alpha 4 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of LAMA4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMA4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr20:43,946,898...44,087,972
Ensembl chr20:43,946,898...44,087,972 		JBrowse link
G Lamc1 laminin subunit gamma 1 increases expression ISO trichostatin A results in increased expression of LAMC1 mRNA CTD PMID:24935251 NCBI chr13:67,924,872...68,051,986
Ensembl chr13:67,924,872...68,051,986 		JBrowse link
G Lamc2 laminin subunit gamma 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of LAMC2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMC2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr13:67,835,199...67,894,694
Ensembl chr13:67,835,199...67,895,102 		JBrowse link
G Lamp2 lysosomal-associated membrane protein 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of LAMP2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMP2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr  X:122,038,734...122,087,745
Ensembl chr  X:121,922,187...122,087,675 		JBrowse link
G Lamp3 lysosomal-associated membrane protein 3 multiple interactions
increases expression 		ISO [Decitabine co-treated with trichostatin A] results in increased expression of LAMP3 mRNA; Estradiol inhibits the reaction [[Decitabine co-treated with trichostatin A] results in increased expression of LAMP3 mRNA]; Estradiol inhibits the reaction [trichostatin A results in increased expression of LAMP3 mRNA] CTD PMID:20678512 PMID:24935251 NCBI chr11:94,657,817...94,726,451
Ensembl chr11:94,661,399...94,726,195 		JBrowse link
G Lancl2 LanC like glutathione S-transferase 2 decreases expression
affects expression 		ISO trichostatin A results in decreased expression of LANCL2 mRNA
trichostatin A affects the expression of LANCL2 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 4:88,771,974...88,813,920
Ensembl chr 4:88,773,437...88,832,899 		JBrowse link
G Larp1 La ribonucleoprotein 1, translational regulator affects expression ISO trichostatin A affects the expression of LARP1 mRNA CTD PMID:28542535 NCBI chr10:42,691,833...42,746,816
Ensembl chr10:42,691,600...42,746,816 		JBrowse link
G Larp1b La ribonucleoprotein 1B increases expression
affects expression 		ISO trichostatin A results in increased expression of LARP1B mRNA
trichostatin A affects the expression of LARP1B mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 2:125,860,935...125,897,189
Ensembl chr 2:125,863,997...125,897,189 		JBrowse link
G Larp4 La ribonucleoprotein 4 decreases expression ISO trichostatin A results in decreased expression of LARP4 mRNA CTD PMID:24935251 NCBI chr 7:132,983,276...133,031,514
Ensembl chr 7:132,980,385...133,029,633 		JBrowse link
G Larp7 La ribonucleoprotein 7, transcriptional regulator increases expression
affects expression 		ISO trichostatin A results in increased expression of LARP7 mRNA
trichostatin A affects the expression of LARP7 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 2:218,672,145...218,687,332
Ensembl chr 2:218,672,208...218,687,308 		JBrowse link
G Lars1 leucyl-tRNA synthetase 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of LARS1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LARS1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:34,452,567...34,507,030
Ensembl chr18:34,452,561...34,506,938 		JBrowse link
G Lats2 large tumor suppressor kinase 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of LATS2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LATS2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:35,940,632...35,992,225
Ensembl chr15:35,940,632...35,980,842 		JBrowse link
G Layn layilin multiple interactions
increases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAYN mRNA
trichostatin A results in increased expression of LAYN mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 8:60,261,325...60,280,797
Ensembl chr 8:60,263,456...60,281,418 		JBrowse link
G Lbh LBH regulator of WNT signaling pathway increases expression ISO trichostatin A results in increased expression of LBH mRNA CTD PMID:24935251 NCBI chr 6:28,321,040...28,344,855
Ensembl chr 6:28,321,040...28,370,238 		JBrowse link
G Lca5 lebercilin LCA5 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of LCA5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LCA5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:93,187,735...93,255,060
Ensembl chr 8:93,197,702...93,254,991 		JBrowse link
G Lck LCK proto-oncogene, Src family tyrosine kinase increases expression ISO trichostatin A results in increased expression of LCK mRNA CTD PMID:24935251 NCBI chr 5:147,172,642...147,201,267
Ensembl chr 5:147,172,642...147,201,267 		JBrowse link
G Lclat1 lysocardiolipin acyltransferase 1 affects expression ISO trichostatin A affects the expression of LCLAT1 mRNA CTD PMID:28542535 NCBI chr 6:27,980,749...28,125,076
Ensembl chr 6:27,982,936...28,112,511 		JBrowse link
G Lcmt1 leucine carboxyl methyltransferase 1 affects expression ISO trichostatin A affects the expression of LCMT1 mRNA CTD PMID:28542535 NCBI chr 1:187,335,173...187,391,195
Ensembl chr 1:187,327,706...187,391,516 		JBrowse link
G Lcor ligand dependent nuclear receptor corepressor decreases expression ISO trichostatin A results in decreased expression of LCOR mRNA CTD PMID:24935251 NCBI chr 1:250,247,965...250,354,985
Ensembl chr 1:250,247,934...250,354,985 		JBrowse link
G Lctl lactase-like decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of LCTL mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LCTL mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 8:73,506,096...73,534,668
Ensembl chr 8:73,513,634...73,534,668 		JBrowse link
G Ldb2 LIM domain binding 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of LDB2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LDB2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr14:70,489,243...70,810,573
Ensembl chr14:70,489,620...70,810,574 		JBrowse link
G Ldb3 LIM domain binding 3 increases expression ISO trichostatin A results in increased expression of LDB3 mRNA CTD PMID:24935251 NCBI chr16:9,862,161...9,926,338
Ensembl chr16:9,862,161...9,926,985 		JBrowse link
G Ldha lactate dehydrogenase A increases expression
multiple interactions 		ISO trichostatin A results in increased expression of LDHA mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LDHA mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:106,508,092...106,517,512
Ensembl chr 1:106,502,182...106,517,521 		JBrowse link
G Ldlrad3 low density lipoprotein receptor class A domain containing 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of LDLRAD3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LDLRAD3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:108,694,528...108,936,330
Ensembl chr 3:108,694,528...108,936,368 		JBrowse link
G Ldlrap1 low density lipoprotein receptor adaptor protein 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of LDLRAP1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LDLRAP1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:152,239,296...152,262,290
Ensembl chr 5:152,229,505...152,262,290 		JBrowse link
G Lef1 lymphoid enhancer binding factor 1 multiple interactions
increases expression 		ISO [3-deazaneplanocin co-treated with trichostatin A] affects the expression of LEF1 protein; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LEF1 mRNA; trichostatin A inhibits the reaction [butylbenzyl phthalate promotes the reaction [[TCF4 protein binds to LEF1 protein] which binds to VIM protein]]; trichostatin A inhibits the reaction [Dibutyl Phthalate promotes the reaction [[TCF4 protein binds to LEF1 protein] which binds to VIM protein]]
trichostatin A results in increased expression of LEF1 mRNA 		CTD PMID:18538736 PMID:22552774 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:222,340,541...222,453,931
Ensembl chr 2:222,340,704...222,453,929 		JBrowse link
G Lemd1 LEM domain containing 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of LEMD1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LEMD1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr13:46,183,860...46,250,105
Ensembl chr13:46,218,085...46,250,562 		JBrowse link
G Lep leptin increases expression
multiple interactions 		ISO trichostatin A results in increased expression of LEP mRNA
trichostatin A promotes the reaction [decitabine results in increased expression of LEP mRNA] 		CTD PMID:17502362 NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:58,626,523...58,640,661 		JBrowse link
G Lepr leptin receptor decreases expression ISO trichostatin A results in decreased expression of LEPR; trichostatin A results in decreased expression of LEPR mRNA CTD PMID:22560341 PMID:24935251 NCBI chr 5:121,409,735...121,593,201
Ensembl chr 5:121,474,099...121,591,215 		JBrowse link
G Letm1 leucine zipper and EF-hand containing transmembrane protein 1 multiple interactions ISO [decitabine co-treated with trichostatin A] results in decreased expression of LETM1 mRNA CTD PMID:17891453 NCBI chr14:81,167,268...81,206,776
Ensembl chr14:81,162,309...81,209,459 		JBrowse link
G Lfng LFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of LFNG mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LFNG mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr12:19,144,474...19,152,951
Ensembl chr12:19,124,662...19,152,918 		JBrowse link
G Lgals1 galectin 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of LGALS1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:112,365,695...112,368,801
Ensembl chr 7:112,361,850...112,368,800 		JBrowse link
G Lgals3 galectin 3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of LGALS3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:23,099,795...23,111,731
Ensembl chr15:23,086,841...23,111,737 		JBrowse link
G Lgals8 galectin 8 increases expression ISO trichostatin A results in increased expression of LGALS8 mRNA CTD PMID:24935251 NCBI chr17:62,716,368...62,744,272
Ensembl chr17:62,719,828...62,744,482 		JBrowse link
G Lgi1 leucine-rich, glioma inactivated 1 increases expression ISO trichostatin A results in increased expression of LGI1 mRNA CTD PMID:24935251 NCBI chr 1:245,455,691...245,497,036
Ensembl chr 1:245,455,599...245,499,095 		JBrowse link
G Lgr4 leucine-rich repeat-containing G protein-coupled receptor 4 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of LGR4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LGR4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:116,901,968...117,004,584
Ensembl chr 3:116,901,968...117,004,153 		JBrowse link
G Lgr5 leucine rich repeat containing G protein coupled receptor 5 decreases expression
increases expression 		ISO trichostatin A results in decreased expression of LGR5 mRNA
trichostatin A results in increased expression of LGR5 mRNA 		CTD PMID:24935251 NCBI chr 7:52,973,151...53,107,964
Ensembl chr 7:52,974,332...53,108,163 		JBrowse link
G Lhfpl1 LHFPL tetraspan subfamily member 1 increases expression ISO trichostatin A results in increased expression of LHFPL1 mRNA CTD PMID:24935251 NCBI chr  X:113,612,200...113,670,060
Ensembl chr  X:113,612,200...113,670,060 		JBrowse link
G Lhfpl6 LHFPL tetraspan subfamily member 6 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of LHFPL6 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHFPL6 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:139,276,810...139,474,740
Ensembl chr 2:139,276,789...139,474,737 		JBrowse link
G Lhx2 LIM homeobox 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of LHX2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LHX2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:42,523,345...42,553,646
Ensembl chr 3:42,535,744...42,553,645 		JBrowse link
G Lhx5 LIM homeobox 5 decreases expression ISO trichostatin A results in decreased expression of LHX5 mRNA CTD PMID:24935251 NCBI chr12:41,786,746...41,795,183
Ensembl chr12:41,786,746...41,795,183 		JBrowse link
G Lhx8 LIM homeobox 8 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of LHX8 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHX8 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:245,904,712...245,929,376
Ensembl chr 2:245,904,712...245,929,376 		JBrowse link
G Lifr LIF receptor subunit alpha decreases expression
increases expression
multiple interactions 		ISO trichostatin A results in decreased expression of LIFR mRNA
trichostatin A results in increased expression of LIFR mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIFR mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:57,951,787...58,020,357
Ensembl chr 2:57,952,975...58,020,364 		JBrowse link
G Lig3 DNA ligase 3 affects expression ISO trichostatin A affects the expression of LIG3 mRNA CTD PMID:28542535 NCBI chr10:68,215,371...68,238,705
Ensembl chr10:68,215,407...68,238,704 		JBrowse link
G Lig4 DNA ligase 4 increases expression ISO trichostatin A results in increased expression of LIG4 mRNA CTD PMID:24935251 NCBI chr16:86,220,345...86,228,930
Ensembl chr16:86,220,279...86,229,926 		JBrowse link
G Lim2 lens intrinsic membrane protein 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of LIM2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIM2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:102,974,188...102,980,358
Ensembl chr 1:102,974,188...102,980,358 		JBrowse link
G Lima1 LIM domain and actin binding 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of LIMA1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIMA1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 7:132,780,556...132,880,343
Ensembl chr 7:132,780,556...132,880,386 		JBrowse link
G Limch1 LIM and calponin homology domains 1 decreases expression
increases expression 		ISO trichostatin A results in decreased expression of LIMCH1 mRNA
trichostatin A results in increased expression of LIMCH1 mRNA 		CTD PMID:24935251 NCBI chr14:41,466,433...41,779,477
Ensembl chr14:41,466,433...41,778,837 		JBrowse link
G Lin7a lin-7 homolog A, crumbs cell polarity complex component decreases expression ISO trichostatin A results in decreased expression of LIN7A mRNA CTD PMID:24935251 PMID:26272509 NCBI chr 7:44,473,568...44,629,074
Ensembl chr 7:44,473,347...44,625,208 		JBrowse link
G Lingo2 leucine rich repeat and Ig domain containing 2 increases expression ISO trichostatin A results in increased expression of LINGO2 mRNA CTD PMID:24935251 NCBI chr 5:55,166,250...56,488,672
Ensembl chr 5:55,156,997...56,489,155 		JBrowse link
G Lipa lipase A, lysosomal acid type multiple interactions
increases expression 		ISO trichostatin A inhibits the reaction [Nickel affects the expression of LIPA mRNA]
trichostatin A results in increased expression of LIPA mRNA 		CTD PMID:14575637 PMID:24935251 NCBI chr 1:241,437,524...241,470,936
Ensembl chr 1:241,437,524...241,470,740 		JBrowse link
G Litaf lipopolysaccharide-induced TNF factor increases expression
multiple interactions 		ISO trichostatin A results in increased expression of LITAF mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LITAF mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:5,163,258...5,199,930
Ensembl chr10:5,163,242...5,199,930 		JBrowse link
G Lix1 limb and CNS expressed 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of LIX1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIX1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:66,802,044...66,859,040
Ensembl chr 1:66,802,272...66,860,627 		JBrowse link
G Llgl1 LLGL scribble cell polarity complex component 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of LLGL1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LLGL1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:45,878,936...45,893,609
Ensembl chr10:45,879,012...45,893,603 		JBrowse link
G Llgl2 LLGL scribble cell polarity complex component 2 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of LLGL2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LLGL2 mRNA
trichostatin A affects the expression of LLGL2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr10:101,549,911...101,585,466
Ensembl chr10:101,549,862...101,585,464 		JBrowse link
G Lman1 lectin, mannose-binding, 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of LMAN1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMAN1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr18:61,778,971...61,800,960
Ensembl chr18:61,772,917...61,800,820 		JBrowse link
G Lmf1 lipase maturation factor 1 increases expression ISO trichostatin A results in increased expression of LMF1 mRNA CTD PMID:24935251 PMID:26272509 NCBI chr10:15,094,432...15,188,665
Ensembl chr10:15,098,138...15,188,664 		JBrowse link
G Lmna lamin A/C affects expression ISO trichostatin A affects the expression of LMNA mRNA CTD PMID:28542535 NCBI chr 2:176,237,564...176,265,301
Ensembl chr 2:176,237,564...176,288,072 		JBrowse link
G Lmnb1 lamin B1 decreases expression
affects expression 		ISO trichostatin A results in decreased expression of LMNB1 mRNA
trichostatin A affects the expression of LMNB1 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr18:52,373,939...52,413,284
Ensembl chr18:52,373,757...52,413,283 		JBrowse link
G Lmo1 LIM domain only 1 decreases expression ISO trichostatin A results in decreased expression of LMO1 mRNA CTD PMID:24935251 NCBI chr 1:172,567,156...172,603,282
Ensembl chr 1:172,567,156...172,603,157 		JBrowse link
G Lmo2 LIM domain only 2 decreases expression
increases expression 		ISO trichostatin A results in decreased expression of LMO2 mRNA
trichostatin A results in increased expression of LMO2 mRNA 		CTD PMID:24935251 NCBI chr 3:110,810,162...110,832,895
Ensembl chr 3:110,809,912...110,833,075 		JBrowse link
G Lmo3 LIM domain only 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of LMO3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:172,965,944...173,028,980
Ensembl chr 4:172,965,951...173,025,156 		JBrowse link
G Lmo4 LIM domain only 4 decreases expression
increases expression
multiple interactions 		ISO trichostatin A results in decreased expression of LMO4 mRNA
trichostatin A results in increased expression of LMO4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LMO4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:235,924,574...235,941,609
Ensembl chr 2:235,924,403...235,941,275 		JBrowse link
G Lmo7 LIM domain 7 increases expression ISO trichostatin A results in increased expression of LMO7 mRNA CTD PMID:24935251 PMID:26705709 NCBI chr15:84,981,689...85,184,554
Ensembl chr15:84,981,735...85,184,551 		JBrowse link
G Lmtk3 lemur tyrosine kinase 3 affects expression ISO trichostatin A affects the expression of LMTK3 mRNA CTD PMID:28542535 NCBI chr 1:105,397,504...105,417,146
Ensembl chr 1:105,397,460...105,422,196 		JBrowse link
G Lnpep leucyl and cystinyl aminopeptidase increases expression
multiple interactions 		ISO trichostatin A results in increased expression of LNPEP mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNPEP mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:66,931,712...67,027,610
Ensembl chr 1:66,931,712...67,027,610 		JBrowse link
G Lnpk lunapark, ER junction formation factor decreases expression ISO trichostatin A results in decreased expression of LNPK mRNA CTD PMID:26272509 NCBI chr 3:79,826,318...79,894,514
Ensembl chr 3:79,832,753...79,894,403 		JBrowse link
G Lnx1 ligand of numb-protein X 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of LNX1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr14:33,868,517...33,971,217
Ensembl chr14:33,868,571...33,971,217 		JBrowse link
G Lnx2 ligand of numb-protein X 2 affects expression ISO trichostatin A affects the expression of LNX2 mRNA CTD PMID:28542535 NCBI chr12:13,119,139...13,184,401
Ensembl chr12:13,119,139...13,184,401 		JBrowse link
G Lonp2 lon peptidase 2, peroxisomal increases expression ISO trichostatin A results in increased expression of LONP2 mRNA CTD PMID:24935251 NCBI chr19:36,580,736...36,672,242
Ensembl chr19:36,580,736...36,672,242 		JBrowse link
G Lonrf2 LON peptidase N-terminal domain and ring finger 2 decreases expression ISO trichostatin A results in decreased expression of LONRF2 mRNA CTD PMID:26705709 NCBI chr 9:48,524,962...48,566,353
Ensembl chr 9:48,530,549...48,570,807 		JBrowse link
G Lonrf3 LON peptidase N-terminal domain and ring finger 3 increases expression ISO trichostatin A results in increased expression of LONRF3 mRNA CTD PMID:24935251 NCBI chr  X:120,430,975...120,469,648
Ensembl chr  X:120,430,996...120,464,572 		JBrowse link
G Loxl2 lysyl oxidase-like 2 multiple interactions ISO trichostatin A promotes the reaction [decitabine results in increased expression of LOXL2 mRNA] CTD PMID:19330836 NCBI chr15:51,091,547...51,182,843
Ensembl chr15:51,069,997...51,182,842 		JBrowse link
G Lpar1 lysophosphatidic acid receptor 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of LPAR1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LPAR1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:78,024,139...78,147,071
Ensembl chr 5:78,024,139...78,142,188 		JBrowse link
G Lpar3 lysophosphatidic acid receptor 3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of LPAR3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LPAR3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:237,785,371...237,854,199
Ensembl chr 2:237,787,766...237,854,197 		JBrowse link
G Lpar4 lysophosphatidic acid receptor 4 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of LPAR4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LPAR4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr  X:76,106,319...76,119,807
Ensembl chr  X:76,106,071...76,119,808 		JBrowse link
G Lpar6 lysophosphatidic acid receptor 6 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of LPAR6 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LPAR6 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:54,826,110...54,827,919
Ensembl chr15:54,823,717...54,978,783 		JBrowse link
G Lpcat1 lysophosphatidylcholine acyltransferase 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of LPCAT1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LPCAT1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:31,594,621...31,644,946
Ensembl chr 1:31,594,622...31,644,946 		JBrowse link
G Lpcat2 lysophosphatidylcholine acyltransferase 2 increases expression ISO trichostatin A results in increased expression of LPCAT2 mRNA CTD PMID:24935251 NCBI chr19:30,261,369...30,325,715
Ensembl chr19:30,262,676...30,325,775 		JBrowse link
G Lpcat3 lysophosphatidylcholine acyltransferase 3 affects expression ISO trichostatin A affects the expression of LPCAT3 mRNA CTD PMID:28542535 NCBI chr 4:159,154,690...159,196,176
Ensembl chr 4:159,154,158...159,196,358 		JBrowse link
G Lpgat1 lysophosphatidylglycerol acyltransferase 1 increases expression ISO trichostatin A results in increased expression of LPGAT1 mRNA CTD PMID:24935251 PMID:26272509 NCBI chr13:105,825,630...105,896,366
Ensembl chr13:105,820,468...105,896,364 		JBrowse link
G Lpl lipoprotein lipase decreases expression ISO trichostatin A results in decreased expression of LPL mRNA CTD PMID:24935251 NCBI chr16:25,596,205...25,621,928
Ensembl chr16:25,596,211...25,622,107 		JBrowse link
G Lpp LIM domain containing preferred translocation partner in lipoma increases expression
multiple interactions 		ISO trichostatin A results in increased expression of LPP mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LPP mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr11:89,292,060...89,933,973
Ensembl chr11:89,305,187...89,805,264 		JBrowse link
G Lratd1 LRAT domain containing 1 decreases expression ISO trichostatin A results in decreased expression of LRATD1 mRNA CTD PMID:24935251 NCBI chr 6:42,646,515...42,650,988
Ensembl chr 6:42,640,190...42,651,204 		JBrowse link
G Lratd2 LRAT domain containing 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of LRATD2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRATD2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:94,270,753...94,276,445
Ensembl chr 7:94,073,513...94,277,046 		JBrowse link
G Lrch1 leucine rich repeats and calponin homology domain containing 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of LRCH1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRCH1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:56,469,403...56,659,201
Ensembl chr15:56,481,395...56,659,100 		JBrowse link
G Lrch2 leucine rich repeats and calponin homology domain containing 2 increases expression ISO trichostatin A results in increased expression of LRCH2 mRNA CTD PMID:24935251 NCBI chr  X:115,903,760...115,986,569
Ensembl chr  X:115,903,767...115,986,266 		JBrowse link
G Lrfn4 leucine rich repeat and fibronectin type III domain containing 4 affects expression ISO trichostatin A affects the expression of LRFN4 mRNA CTD PMID:28542535 NCBI chr 1:211,317,980...211,321,272
Ensembl chr 1:211,317,980...211,321,272 		JBrowse link
G Lrig1 leucine-rich repeats and immunoglobulin-like domains 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of LRIG1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRIG1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:128,687,723...128,788,219
Ensembl chr 4:128,687,723...128,788,219 		JBrowse link
G Lrig3 leucine-rich repeats and immunoglobulin-like domains 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of LRIG3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRIG3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:63,701,724...63,751,898
Ensembl chr 7:63,701,778...63,752,261 		JBrowse link
G Lrp1 LDL receptor related protein 1 increases expression ISO trichostatin A results in increased expression of LRP1 mRNA CTD PMID:28542535 NCBI chr 7:65,265,639...65,346,196
Ensembl chr 7:65,265,639...65,346,196 		JBrowse link
G Lrp10 LDL receptor related protein 10 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of LRP10 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRP10 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:31,891,358...31,897,530
Ensembl chr15:31,891,362...31,897,528 		JBrowse link
G Lrp11 LDL receptor related protein 11 increases expression ISO trichostatin A results in increased expression of LRP11 mRNA CTD PMID:24935251 NCBI chr 1:3,868,665...3,928,513
Ensembl chr 1:3,899,985...3,928,507 		JBrowse link
G Lrp12 LDL receptor related protein 12 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of LRP12 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP12 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:72,825,979...72,897,308
Ensembl chr 7:72,825,979...72,897,171 		JBrowse link
G Lrp2 LDL receptor related protein 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of LRP2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:74,597,148...74,754,535
Ensembl chr 3:74,597,148...74,754,535 		JBrowse link
G Lrp4 LDL receptor related protein 4 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of LRP4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRP4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:97,885,373...97,939,366
Ensembl chr 3:97,885,400...97,939,370 		JBrowse link
G Lrp6 LDL receptor related protein 6 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of LRP6 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP6 mRNA 		CTD PMID:22723015 PMID:26272509 PMID:27188386 NCBI chr 4:168,997,937...169,131,716
Ensembl chr 4:169,000,968...169,131,716 		JBrowse link
G Lrp8 LDL receptor related protein 8 decreases expression
affects expression 		ISO trichostatin A results in decreased expression of LRP8 mRNA
trichostatin A affects the expression of LRP8 mRNA 		CTD PMID:27188386 PMID:28542535 NCBI chr 5:127,792,236...127,864,207
Ensembl chr 5:127,792,299...127,864,207 		JBrowse link
G Lrpprc leucine-rich pentatricopeptide repeat containing increases expression ISO trichostatin A results in increased expression of LRPPRC mRNA CTD PMID:24935251 NCBI chr 6:15,612,638...15,695,113
Ensembl chr 6:15,612,655...15,695,116 		JBrowse link
G Lrrc17 leucine rich repeat containing 17 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of LRRC17 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRC17 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:14,393,632...14,424,048
Ensembl chr 4:14,393,640...14,424,048 		JBrowse link
G Lrrc20 leucine rich repeat containing 20 decreases expression ISO trichostatin A results in decreased expression of LRRC20 mRNA CTD PMID:24935251 NCBI chr20:29,965,673...30,071,185
Ensembl chr20:29,972,001...30,071,184 		JBrowse link
G Lrrc32 leucine rich repeat containing 32 increases expression ISO trichostatin A results in increased expression of LRRC32 mRNA CTD PMID:26705709 NCBI chr 1:162,196,995...162,209,563
Ensembl chr 1:162,197,653...162,209,563 		JBrowse link
G Lrrc34 leucine rich repeat containing 34 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of LRRC34 mRNA
trichostatin A results in decreased expression of LRRC34 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC34 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:114,680,787...114,702,961
Ensembl chr 2:114,680,094...114,702,961 		JBrowse link
G Lrrc3b leucine rich repeat containing 3B multiple interactions
decreases expression 		ISO [[Decitabine co-treated with trichostatin A] affects the methylation of LRRC3B promoter] which affects the expression of LRRC3B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC3B mRNA
trichostatin A results in decreased expression of LRRC3B mRNA 		CTD PMID:18757430 PMID:24935251 PMID:26272509 PMID:26705709 PMID:27188386 NCBI chr15:12,404,309...12,481,618
Ensembl chr15:12,336,369...12,481,866 		JBrowse link
G Lrrc4 leucine rich repeat containing 4 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of LRRC4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:58,398,942...58,402,538
Ensembl chr 4:58,397,302...58,402,808 		JBrowse link
G Lrrc41 leucine rich repeat containing 41 decreases expression
affects expression 		ISO trichostatin A results in decreased expression of LRRC41 mRNA
trichostatin A affects the expression of LRRC41 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 5:134,791,256...134,812,177
Ensembl chr 5:134,791,256...134,812,177 		JBrowse link
G Lrrc49 leucine rich repeat containing 49 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of LRRC49 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC49 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 8:69,948,962...70,056,579
Ensembl chr 8:69,948,972...70,079,636 		JBrowse link
G Lrrc4c leucine rich repeat containing 4C increases expression
multiple interactions 		ISO trichostatin A results in increased expression of LRRC4C mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRC4C mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:102,760,152...104,139,222
Ensembl chr 3:103,970,485...104,146,212 		JBrowse link
G Lrrc55 leucine rich repeat containing 55 decreases expression ISO trichostatin A results in decreased expression of LRRC55 mRNA CTD PMID:24935251 NCBI chr 3:90,676,547...90,687,392
Ensembl chr 3:90,680,160...90,685,280 		JBrowse link
G Lrrc58 leucine rich repeat containing 58 increases expression ISO trichostatin A results in increased expression of LRRC58 mRNA CTD PMID:24935251 NCBI chr11:76,355,987...76,368,309
Ensembl chr11:76,344,923...76,368,309 		JBrowse link
G Lrrc66 leucine rich repeat containing 66 decreases expression ISO trichostatin A results in decreased expression of LRRC66 mRNA CTD PMID:24935251 NCBI chr14:34,932,814...34,959,046
Ensembl chr14:34,933,161...34,959,044 		JBrowse link
G Lrrc69 leucine rich repeat containing 69 increases expression ISO trichostatin A results in increased expression of LRRC69 mRNA CTD PMID:24935251 NCBI chr 5:32,820,840...32,979,176
Ensembl chr 5:32,820,840...32,979,375 		JBrowse link
G Lrrc8b leucine rich repeat containing 8 VRAC subunit B decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of LRRC8B mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC8B mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr14:4,655,273...4,721,648
Ensembl chr14:4,655,273...4,721,076 		JBrowse link
G Lrrc8c leucine rich repeat containing 8 VRAC subunit C increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of LRRC8C mRNA
trichostatin A results in decreased expression of LRRC8C mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC8C mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr14:4,528,721...4,621,259
Ensembl chr14:4,531,823...4,620,049 		JBrowse link
G Lrrc8e leucine rich repeat containing 8 VRAC subunit E increases expression ISO trichostatin A results in increased expression of LRRC8E mRNA CTD PMID:24935251 NCBI chr12:7,376,103...7,387,250
Ensembl chr12:7,380,585...7,387,249 		JBrowse link
G Lrrfip1 LRR binding FLII interacting protein 1 increases expression ISO trichostatin A results in increased expression of LRRFIP1 mRNA CTD PMID:24935251 NCBI chr 9:99,039,590...99,167,805
Ensembl chr 9:99,039,614...99,167,779 		JBrowse link
G Lrrk2 leucine-rich repeat kinase 2 increases expression ISO trichostatin A results in increased expression of LRRK2 mRNA CTD PMID:24935251 NCBI chr 7:124,706,246...124,867,234
Ensembl chr 7:124,706,080...124,867,239 		JBrowse link
G Lrrn1 leucine rich repeat neuronal 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of LRRN1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRN1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:142,032,805...142,072,320
Ensembl chr 4:142,032,041...142,074,760 		JBrowse link
G Lrrn3 leucine rich repeat neuronal 3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of LRRN3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRN3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:64,216,164...64,247,293
Ensembl chr 6:64,215,878...64,247,614 		JBrowse link
G Lrrn4 leucine rich repeat neuronal 4 increases expression ISO trichostatin A results in increased expression of LRRN4 mRNA CTD PMID:24935251 NCBI chr 3:140,592,303...140,603,986
Ensembl chr 3:140,592,076...140,605,574 		JBrowse link
G Lrrtm1 leucine rich repeat transmembrane neuronal 1 increases expression ISO trichostatin A results in increased expression of LRRTM1 mRNA CTD PMID:24935251 PMID:26272509 NCBI chr 4:111,246,213...111,295,638
Ensembl chr 4:111,235,054...111,276,818 		JBrowse link
G Lrrtm4 leucine rich repeat transmembrane neuronal 4 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of LRRTM4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRTM4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:114,103,783...114,894,696
Ensembl chr 4:114,103,870...114,109,726 		JBrowse link
G Lsm11 LSM11, U7 small nuclear RNA associated affects expression ISO trichostatin A affects the expression of LSM11 mRNA CTD PMID:28542535 NCBI chr10:30,869,168...30,887,275
Ensembl chr10:30,872,054...30,887,269 		JBrowse link
G Lsm14b LSM family member 14B decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of LSM14B mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LSM14B mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:187,503,251...187,514,041
Ensembl chr 3:187,503,045...187,512,473 		JBrowse link
G Lsm8 LSM8 homolog, U6 small nuclear RNA associated decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of LSM8 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LSM8 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:48,272,128...48,277,994
Ensembl chr 4:48,272,164...48,280,162 		JBrowse link
G Lsmem1 leucine-rich single-pass membrane protein 1 affects expression ISO trichostatin A affects the expression of LSMEM1 mRNA CTD PMID:28542535 NCBI chr 6:62,978,880...62,988,750
Ensembl chr 6:62,978,885...62,988,750 		JBrowse link
G Lsr lipolysis stimulated lipoprotein receptor decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of LSR mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LSR mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:95,313,830...95,329,471
Ensembl chr 1:95,313,033...95,329,354 		JBrowse link
G Lss lanosterol synthase affects expression ISO trichostatin A affects the expression of LSS mRNA CTD PMID:28542535 NCBI chr20:12,090,641...12,118,230
Ensembl chr20:12,073,543...12,118,253 		JBrowse link
G Lta4h leukotriene A4 hydrolase affects expression ISO trichostatin A affects the expression of LTA4H mRNA CTD PMID:28542535 NCBI chr 7:29,856,846...29,888,642
Ensembl chr 7:29,856,802...29,888,641 		JBrowse link
G Ltb lymphotoxin beta multiple interactions
increases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LTB mRNA
trichostatin A results in increased expression of LTB mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr20:3,632,209...3,634,054
Ensembl chr20:3,632,210...3,634,054 		JBrowse link
G Ltbp1 latent transforming growth factor beta binding protein 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of LTBP1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LTBP1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:25,781,625...26,177,346
Ensembl chr 6:25,781,638...26,454,036 		JBrowse link
G Ltbr lymphotoxin beta receptor decreases expression
affects expression 		EXP
ISO 		trichostatin A results in decreased expression of LTBR mRNA
trichostatin A affects the expression of LTBR mRNA 		CTD PMID:23558232 PMID:28542535 NCBI chr 4:159,795,115...159,801,571
Ensembl chr 4:159,795,115...159,807,296 		JBrowse link
G Ltn1 listerin E3 ubiquitin protein ligase 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LTN1 mRNA
trichostatin A results in decreased expression of LTN1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr11:40,090,169...40,147,159
Ensembl chr11:40,090,169...40,147,303 		JBrowse link
G Lto1 LTO1 maturation factor of ABCE1 decreases expression ISO trichostatin A results in decreased expression of LTO1 mRNA CTD PMID:24935251 NCBI chr 1:209,502,900...209,510,237
Ensembl chr 1:209,498,312...209,517,347 		JBrowse link
G Luc7l2 LUC7 pre-mRNA splicing factor like 2 affects expression ISO trichostatin A affects the expression of LUC7L2 mRNA CTD PMID:28542535 NCBI chr 4:68,251,435...68,314,861
Ensembl chr 4:68,271,414...68,314,837 		JBrowse link
G Lurap1l leucine rich adaptor protein 1-like increases expression ISO trichostatin A results in increased expression of LURAP1L mRNA CTD PMID:24935251 NCBI chr 5:100,402,921...100,455,479
Ensembl chr 5:100,407,483...100,455,478 		JBrowse link
G Luzp1 leucine zipper protein 1 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of LUZP1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LUZP1 mRNA
trichostatin A affects the expression of LUZP1 mRNA 		CTD PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 5:153,989,570...154,065,071
Ensembl chr 5:153,987,683...154,070,438 		JBrowse link
G Ly6al1 lymphocyte antigen 6 complex, locus A like 1 multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of LY6A mRNA] CTD PMID:14575637 NCBI chr 7:108,892,342...108,898,892
Ensembl chr 7:108,892,339...108,895,989 		JBrowse link
G Ly6k lymphocyte antigen 6 family member K increases expression ISO trichostatin A results in increased expression of LY6K mRNA CTD PMID:24935251 NCBI chr 7:108,572,732...108,575,450
Ensembl chr 7:108,572,732...108,575,450 		JBrowse link
G Ly75 lymphocyte antigen 75 increases expression ISO trichostatin A results in increased expression of LY75 mRNA CTD PMID:24935251 NCBI chr 3:65,173,395...65,260,878
Ensembl chr 3:65,173,395...65,260,878 		JBrowse link
G Lyn LYN proto-oncogene, Src family tyrosine kinase increases expression
multiple interactions 		ISO trichostatin A results in increased expression of LYN mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYN mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:21,437,127...21,553,097
Ensembl chr 5:21,437,084...21,554,461 		JBrowse link
G Lypd1 Ly6/Plaur domain containing 1 decreases expression
increases expression
multiple interactions 		ISO trichostatin A results in decreased expression of LYPD1 mRNA
trichostatin A results in increased expression of LYPD1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYPD1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr13:39,874,937...39,922,385
Ensembl chr13:39,879,096...39,922,338 		JBrowse link
G Lypd6 Ly6/Plaur domain containing 6 increases expression ISO trichostatin A results in increased expression of LYPD6 mRNA CTD PMID:24935251 NCBI chr 3:54,896,618...55,041,928
Ensembl chr 3:54,896,575...55,041,929 		JBrowse link
G Lypd6b Ly6/Plaur domain containing 6B increases expression ISO trichostatin A results in increased expression of LYPD6B mRNA CTD PMID:24935251 PMID:26705709 NCBI chr 3:54,608,320...54,769,974
Ensembl chr 3:54,757,444...54,769,974 		JBrowse link
G Lyrm2 LYR motif containing 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of LYRM2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LYRM2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:51,994,540...51,996,818
Ensembl chr 5:51,994,543...51,997,979 		JBrowse link
G Lyset lysosomal enzyme trafficking factor affects expression ISO trichostatin A affects the expression of LYSET mRNA CTD PMID:28542535 NCBI chr 6:127,649,401...127,651,143
Ensembl chr 6:127,649,450...127,652,661 		JBrowse link
G Lysmd4 LysM domain containing 4 affects expression ISO trichostatin A affects the expression of LYSMD4 mRNA CTD PMID:28542535 NCBI chr 1:130,249,340...130,255,357
Ensembl chr 1:130,249,479...130,255,357 		JBrowse link
G Lyst lysosomal trafficking regulator increases expression
multiple interactions
affects expression 		ISO trichostatin A results in increased expression of LYST mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYST mRNA
trichostatin A affects the expression of LYST mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr17:93,225,509...93,427,650
Ensembl chr17:93,225,540...93,427,650 		JBrowse link
G Lyz2 lysozyme 2 increases expression ISO trichostatin A results in increased expression of LYZ mRNA CTD PMID:17000900 NCBI chr 7:54,792,715...54,798,060
Ensembl chr 7:54,792,716...54,798,011 		JBrowse link
G Lyzl6 lysozyme-like 6 increases expression ISO trichostatin A results in increased expression of LYZL6 mRNA CTD PMID:27188386 NCBI chr10:89,044,375...89,049,210
Ensembl chr10:89,044,375...89,049,210 		JBrowse link
G Lzts1 leucine zipper tumor suppressor 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of LZTS1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LZTS1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr16:25,309,502...25,364,942
Ensembl chr16:25,309,507...25,364,940 		JBrowse link
G Mab21l2 mab-21 like 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MAB21L2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAB21L2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:174,244,538...174,247,620
Ensembl chr 2:174,238,828...174,252,064 		JBrowse link
G Macc1 MET transcriptional regulator MACC1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MACC1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MACC1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:146,495,544...146,574,254
Ensembl chr 6:146,495,861...146,574,260 		JBrowse link
G Macf1 microtubule-actin crosslinking factor 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACF1 mRNA
trichostatin A results in decreased expression of MACF1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:140,908,829...141,234,127
Ensembl chr 5:140,908,837...141,233,890 		JBrowse link
G Macir macrophage immunometabolism regulator increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MACIR mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MACIR mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 9:105,868,072...105,888,128
Ensembl chr 9:105,866,641...105,889,758 		JBrowse link
G Macrod2 mono-ADP ribosylhydrolase 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MACROD2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROD2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:148,173,821...150,191,077
Ensembl chr 3:148,173,829...150,188,058 		JBrowse link
G Macroh2a1 macroH2A.1 histone decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MACROH2A1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROH2A1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr17:8,484,340...8,547,268
Ensembl chr17:8,484,246...8,547,257 		JBrowse link
G Mad2l1 mitotic arrest deficient 2 like 1 decreases expression ISO trichostatin A results in decreased expression of MAD2L1 mRNA CTD PMID:23770000 NCBI chr 4:97,236,419...97,247,603
Ensembl chr 4:97,236,503...97,243,222 		JBrowse link
G Madd MAP-kinase activating death domain increases expression EXP trichostatin A results in increased expression of MADD mRNA CTD PMID:23558232 NCBI chr 3:97,570,141...97,613,688
Ensembl chr 3:97,570,787...97,613,509 		JBrowse link
G Maf MAF bZIP transcription factor increases expression ISO trichostatin A results in increased expression of MAF mRNA CTD PMID:24935251 NCBI chr19:60,259,200...60,622,145
Ensembl chr19:60,269,541...60,621,378 		JBrowse link
G Mafb MAF bZIP transcription factor B multiple interactions
increases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAFB mRNA; trichostatin A inhibits the reaction [Nickel affects the expression of MAFB mRNA]
trichostatin A results in increased expression of MAFB mRNA 		CTD PMID:14575637 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:169,417,890...169,419,810
Ensembl chr 3:169,416,945...169,419,975 		JBrowse link
G Maff MAF bZIP transcription factor F increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MAFF mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAFF mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:112,792,787...112,804,139
Ensembl chr 7:112,791,416...112,804,147 		JBrowse link
G Magee1 MAGE family member E1 decreases expression ISO trichostatin A results in decreased expression of MAGEE1 mRNA CTD PMID:24935251 NCBI chr  X:74,254,848...74,258,395
Ensembl chr  X:74,254,958...74,258,371 		JBrowse link
G Magel2 MAGE family member L2 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of MAGEL2 mRNA
trichostatin A results in decreased expression of MAGEL2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAGEL2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:125,292,033...125,296,575
Ensembl chr 1:125,292,033...125,296,575 		JBrowse link
G Magi2 membrane associated guanylate kinase, WW and PDZ domain containing 2 increases expression ISO trichostatin A results in increased expression of MAGI2 mRNA CTD PMID:24935251 NCBI chr 4:15,278,518...16,762,427
Ensembl chr 4:15,278,518...16,762,199 		JBrowse link
G Magt1 magnesium transporter 1 affects expression ISO trichostatin A affects the expression of MAGT1 mRNA CTD PMID:28542535 NCBI chr  X:75,104,040...75,145,247
Ensembl chr  X:75,106,172...75,145,365 		JBrowse link
G Mak male germ cell-associated kinase decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of MAK mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAK mRNA
trichostatin A affects the expression of MAK mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr17:23,889,417...23,936,857
Ensembl chr17:23,889,516...23,936,855 		JBrowse link
G Mal2 mal, T-cell differentiation protein 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MAL2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAL2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:87,790,239...87,823,219
Ensembl chr 7:87,790,239...87,850,403 		JBrowse link
G Mamdc2 MAM domain containing 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MAMDC2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAMDC2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:230,290,482...230,443,014
Ensembl chr 1:230,290,499...230,442,711 		JBrowse link
G Maml2 mastermind-like transcriptional coactivator 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MAML2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAML2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:18,552,480...18,869,923
Ensembl chr 8:18,552,281...18,869,900 		JBrowse link
G Maml3 mastermind-like transcriptional coactivator 3 increases expression ISO trichostatin A results in increased expression of MAML3 mRNA CTD PMID:24935251 NCBI chr 2:137,871,267...138,288,615
Ensembl chr 2:137,871,267...138,287,960 		JBrowse link
G Man1a1 mannosidase, alpha, class 1A, member 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MAN1A1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAN1A1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr20:33,745,158...33,928,584
Ensembl chr20:33,745,165...33,928,584 		JBrowse link
G Man1a2 mannosidase, alpha, class 1A, member 2 increases expression ISO trichostatin A results in increased expression of MAN1A2 mRNA CTD PMID:24935251 NCBI chr 2:190,636,134...190,784,975
Ensembl chr 2:190,615,094...190,784,975 		JBrowse link
G Man1c1 mannosidase, alpha, class 1C, member 1 increases expression ISO trichostatin A results in increased expression of MAN1C1 mRNA CTD PMID:24935251 NCBI chr 5:152,057,839...152,197,737
Ensembl chr 5:152,057,967...152,197,138 		JBrowse link
G Man2a1 mannosidase, alpha, class 2A, member 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MAN2A1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAN2A1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:111,698,913...111,855,257
Ensembl chr 9:111,698,913...111,867,850 		JBrowse link
G Mansc1 MANSC domain containing 1 increases expression ISO trichostatin A results in increased expression of MANSC1 mRNA CTD PMID:24935251 NCBI chr 4:169,170,164...169,190,379
Ensembl chr 4:169,170,164...169,189,864 		JBrowse link
G Maoa monoamine oxidase A increases expression ISO trichostatin A results in increased expression of MAOA mRNA CTD PMID:24935251 NCBI chr  X:8,615,239...8,681,372
Ensembl chr  X:8,615,239...8,682,631 		JBrowse link
G Maob monoamine oxidase B decreases expression ISO trichostatin A results in decreased expression of MAOB mRNA CTD PMID:24935251 NCBI chr  X:8,490,405...8,594,065
Ensembl chr  X:8,490,344...8,594,375 		JBrowse link
G Map1a microtubule-associated protein 1A affects expression ISO trichostatin A affects the expression of MAP1A mRNA CTD PMID:28542535 NCBI chr 3:128,716,907...128,736,638
Ensembl chr 3:128,716,940...128,740,159 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta affects localization
increases cleavage
increases expression
affects expression
multiple interactions 		ISO
EXP 		trichostatin A affects the localization of MAP1LC3B protein modified form
trichostatin A results in increased cleavage of MAP1LC3B protein
trichostatin A results in increased expression of MAP1LC3B mRNA; trichostatin A results in increased expression of MAP1LC3B protein modified form
trichostatin A affects the expression of MAP1LC3B mRNA
Chloroquine promotes the reaction [trichostatin A results in increased expression of MAP1LC3B protein modified form]
ATG7 gene mutant form inhibits the reaction [trichostatin A promotes the reaction [Cisplatin results in increased expression of MAP1LC3B protein modified form]]; ATG7 gene mutant form inhibits the reaction [trichostatin A results in increased expression of MAP1LC3B protein modified form]; trichostatin A promotes the reaction [Cisplatin results in increased expression of MAP1LC3B protein modified form] 		CTD PMID:19606018 PMID:20543569 PMID:20962572 PMID:28542535 PMID:29476062 NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358
Ensembl chr16:66,574,407...66,584,358 		JBrowse link
G Map2 microtubule-associated protein 2 increases expression
affects expression 		ISO trichostatin A results in increased expression of MAP2 mRNA
trichostatin A affects the expression of MAP2 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 9:75,173,038...75,431,606
Ensembl chr 9:75,288,262...75,428,459 		JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 multiple interactions
affects expression 		ISO MAP2K1 protein mutant form results in decreased activity of [perifosine co-treated with trichostatin A]
trichostatin A affects the expression of MAP2K1 mRNA 		CTD PMID:15781658 PMID:28542535 NCBI chr 8:73,578,747...73,650,184
Ensembl chr 8:73,578,752...73,650,184 		JBrowse link
G Map2k6 mitogen-activated protein kinase kinase 6 multiple interactions
increases expression
decreases expression 		EXP
ISO 		trichostatin A inhibits the reaction [Cisplatin results in decreased expression of MAP2K6 mRNA]
trichostatin A results in increased expression of MAP2K6 mRNA
trichostatin A results in decreased expression of MAP2K6 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP2K6 mRNA 		CTD PMID:23558232 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:95,872,747...95,987,747
Ensembl chr10:95,872,546...95,987,721 		JBrowse link
G Map2k7 mitogen activated protein kinase kinase 7 affects expression ISO trichostatin A affects the expression of MAP2K7 mRNA CTD PMID:28542535 NCBI chr12:7,389,032...7,398,377
Ensembl chr12:7,389,155...7,398,377 		JBrowse link
G Map3k13 mitogen-activated protein kinase kinase kinase 13 affects expression ISO trichostatin A affects the expression of MAP3K13 mRNA CTD PMID:28542535 NCBI chr11:92,596,436...92,741,717
Ensembl chr11:92,601,738...92,739,663 		JBrowse link
G Map3k20 mitogen-activated protein kinase kinase kinase 20 increases expression
multiple interactions
affects expression 		ISO trichostatin A results in increased expression of MAP3K20 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP3K20 mRNA
trichostatin A affects the expression of MAP3K20 mRNA 		CTD PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 3:77,538,146...77,697,540
Ensembl chr 3:77,537,956...77,697,538 		JBrowse link
G Map3k21 mitogen-activated protein kinase kinase kinase 21 increases expression ISO trichostatin A results in increased expression of MAP3K21 mRNA CTD PMID:24935251 NCBI chr19:70,776,233...70,810,889
Ensembl chr19:70,777,472...70,810,882 		JBrowse link
G Map3k4 mitogen activated protein kinase kinase kinase 4 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MAP3K4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP3K4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:50,977,870...51,067,117
Ensembl chr 1:50,979,586...51,067,117 		JBrowse link
G Map3k5 mitogen-activated protein kinase kinase kinase 5 increases expression ISO trichostatin A results in increased expression of MAP3K5 mRNA CTD PMID:24935251 NCBI chr 1:16,505,387...16,723,899
Ensembl chr 1:16,505,596...16,723,898 		JBrowse link
G Map3k6 mitogen-activated protein kinase kinase kinase 6 increases expression ISO trichostatin A results in increased expression of MAP3K6 mRNA CTD PMID:24935251 NCBI chr 5:150,724,029...150,736,113
Ensembl chr 5:150,724,216...150,736,111 		JBrowse link
G Map3k7 mitogen activated protein kinase kinase kinase 7 affects expression ISO trichostatin A affects the expression of MAP3K7 mRNA CTD PMID:28542535 NCBI chr 5:51,149,524...51,212,012
Ensembl chr 5:51,154,352...51,212,012 		JBrowse link
G Map3k8 mitogen-activated protein kinase kinase kinase 8 increases expression ISO trichostatin A results in increased expression of MAP3K8 mRNA CTD PMID:24935251 NCBI chr17:58,078,175...58,098,455
Ensembl chr17:58,078,320...58,098,452 		JBrowse link
G Map3k9 mitogen-activated protein kinase kinase kinase 9 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MAP3K9 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP3K9 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:107,155,008...107,220,304
Ensembl chr 6:107,161,534...107,220,061 		JBrowse link
G Map4k2 mitogen activated protein kinase kinase kinase kinase 2 multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of MAP4K2 mRNA] CTD PMID:14575637 NCBI chr 1:213,074,360...213,090,042
Ensembl chr 1:213,074,377...213,096,987 		JBrowse link
G Map4k4 mitogen-activated protein kinase kinase kinase kinase 4 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MAP4K4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP4K4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 9:49,696,573...49,822,353
Ensembl chr 9:49,696,700...49,822,353 		JBrowse link
G Map4k5 mitogen-activated protein kinase kinase kinase kinase 5 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MAP4K5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP4K5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:94,020,079...94,112,943
Ensembl chr 6:94,020,079...94,112,943 		JBrowse link
G Map6 microtubule-associated protein 6 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of MAP6 mRNA
trichostatin A results in decreased expression of MAP6 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP6 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:162,980,339...163,046,548
Ensembl chr 1:162,980,181...163,046,548 		JBrowse link
G Map7 microtubule-associated protein 7 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MAP7 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP7 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:16,730,000...16,857,173
Ensembl chr 1:16,730,075...16,857,170 		JBrowse link
G Map7d2 MAP7 domain containing 2 increases expression
decreases expression 		ISO trichostatin A results in increased expression of MAP7D2 mRNA
trichostatin A results in decreased expression of MAP7D2 mRNA 		CTD PMID:24935251 NCBI chr  X:39,181,091...39,296,814
Ensembl chr  X:39,181,091...39,296,695 		JBrowse link
G Map9 microtubule-associated protein 9 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MAP9 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP9 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:170,005,792...170,042,003
Ensembl chr 2:170,006,834...170,042,001 		JBrowse link
G Mapda N6-Methyl-AMP deaminase decreases expression ISO trichostatin A results in decreased expression of MAPDA mRNA CTD PMID:24935251 NCBI chr 3:128,555,604...128,583,809
Ensembl chr 3:128,555,604...128,575,708
Ensembl chr 3:128,555,604...128,575,708 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
decreases activity
increases phosphorylation 		ISO [perifosine co-treated with trichostatin A] results in decreased activity of MAPK1 protein
trichostatin A results in decreased activity of MAPK1 protein
trichostatin A results in increased phosphorylation of MAPK1 protein 		CTD PMID:15179185 PMID:15781658 PMID:23073524 NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825 		JBrowse link
G Mapk10 mitogen activated protein kinase 10 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MAPK10 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAPK10 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:6,802,247...7,094,103
Ensembl chr14:6,802,295...7,094,100 		JBrowse link
G Mapk12 mitogen-activated protein kinase 12 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MAPK12 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAPK12 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:122,085,647...122,096,307
Ensembl chr 7:122,085,913...122,096,307 		JBrowse link
G Mapk14 mitogen activated protein kinase 14 multiple interactions
affects expression 		ISO DUSP1 mutant form inhibits the reaction [trichostatin A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK14 protein]]; trichostatin A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK14 protein]
trichostatin A affects the expression of MAPK14 mRNA 		CTD PMID:21911040 PMID:28542535 NCBI chr20:6,751,288...6,812,294
Ensembl chr20:6,751,357...6,812,294 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
decreases activity
increases phosphorylation 		ISO [perifosine co-treated with trichostatin A] results in decreased activity of MAPK3 protein
trichostatin A results in decreased activity of MAPK3 protein
trichostatin A results in increased phosphorylation of MAPK3 protein 		CTD PMID:15179185 PMID:15781658 PMID:23073524 NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411 		JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions
decreases expression
affects expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAPK8 mRNA; [perifosine co-treated with trichostatin A] results in increased activity of MAPK8 protein; DUSP1 mutant form inhibits the reaction [trichostatin A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK8 protein]]; trichostatin A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK8 protein]
trichostatin A results in decreased expression of MAPK8 mRNA
trichostatin A affects the expression of MAPK8 mRNA 		CTD PMID:15781658 PMID:21911040 PMID:22723015 PMID:26272509 PMID:27188386 More... NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427 		JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions ISO DUSP1 mutant form inhibits the reaction [trichostatin A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK9 protein]]; trichostatin A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK9 protein] CTD PMID:21911040 NCBI chr10:34,670,750...34,711,972
Ensembl chr10:34,670,756...34,712,228 		JBrowse link
G Mapkapk2 MAPK activated protein kinase 2 decreases expression ISO trichostatin A results in decreased expression of MAPKAPK2 mRNA CTD PMID:24935251 NCBI chr13:45,066,027...45,112,326
Ensembl chr13:45,066,031...45,112,326 		JBrowse link
G Mapkbp1 mitogen activated protein kinase binding protein 1 decreases expression ISO trichostatin A results in decreased expression of MAPKBP1 mRNA CTD PMID:24935251 NCBI chr 3:127,401,612...127,452,152
Ensembl chr 3:127,401,612...127,449,983 		JBrowse link
G Mapt microtubule-associated protein tau increases expression ISO trichostatin A results in increased expression of MAPT mRNA CTD PMID:24935251 NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,638,599...89,736,108 		JBrowse link
G Marchf4 membrane associated ring-CH-type finger 4 increases expression ISO trichostatin A results in increased expression of MARCHF4 mRNA CTD PMID:26705709 NCBI chr 9:81,527,703...81,647,448
Ensembl chr 9:81,527,703...81,647,448 		JBrowse link
G Marchf7 membrane associated ring-CH-type finger 7 affects expression ISO trichostatin A affects the expression of MARCHF7 mRNA CTD PMID:28542535 NCBI chr 3:65,090,640...65,128,768
Ensembl chr 3:65,090,310...65,128,864 		JBrowse link
G Marco macrophage receptor with collagenous structure multiple interactions ISO trichostatin A inhibits the reaction [[bisphenol A affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of MARCO mRNA] CTD PMID:29718165 NCBI chr13:34,169,011...34,210,340
Ensembl chr13:34,169,011...34,201,255 		JBrowse link
G Mark1 microtubule affinity regulating kinase 1 multiple interactions
increases expression 		ISO trichostatin A inhibits the reaction [Nickel affects the expression of MARK1 mRNA]
trichostatin A results in increased expression of MARK1 mRNA 		CTD PMID:14575637 PMID:24935251 NCBI chr13:98,981,727...99,086,998
Ensembl chr13:98,983,020...99,086,701 		JBrowse link
G Marveld3 MARVEL domain containing 3 increases expression ISO trichostatin A results in increased expression of MARVELD3 mRNA CTD PMID:24935251 NCBI chr19:54,818,180...54,832,871
Ensembl chr19:54,818,180...54,832,871 		JBrowse link
G Matcap2 microtubule associated tyrosine carboxypeptidase 2 increases expression
affects expression 		ISO trichostatin A results in increased expression of MATCAP2 mRNA
trichostatin A affects the expression of MATCAP2 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 8:29,197,154...29,247,056
Ensembl chr 8:29,196,927...29,247,058 		JBrowse link
G Matn2 matrilin 2 decreases expression ISO trichostatin A results in decreased expression of MATN2 mRNA CTD PMID:24935251 NCBI chr 7:67,380,140...67,529,767
Ensembl chr 7:67,380,168...67,530,153 		JBrowse link
G Matr3 matrin 3 affects expression
multiple interactions 		ISO trichostatin A affects the expression of MATR3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MATR3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:27,428,190...27,474,421
Ensembl chr18:27,432,179...27,470,421 		JBrowse link
G Mau2 MAU2 sister chromatid cohesion factor decreases expression ISO trichostatin A results in decreased expression of MAU2 mRNA CTD PMID:28542535 NCBI chr16:19,417,812...19,448,922
Ensembl chr16:19,417,613...19,445,841 		JBrowse link
G Maz MYC associated zinc finger protein affects expression ISO trichostatin A affects the expression of MAZ mRNA CTD PMID:28542535 NCBI chr 1:191,060,271...191,065,722
Ensembl chr 1:191,060,280...191,065,339 		JBrowse link
G Mbd2 methyl-CpG binding domain protein 2 multiple interactions
increases expression 		ISO [decitabine co-treated with trichostatin A] inhibits the reaction [MBD2 protein binds to CLDN3 promoter]
trichostatin A results in increased expression of MBD2 mRNA 		CTD PMID:17986852 PMID:24935251 NCBI chr18:66,449,196...66,516,112
Ensembl chr18:66,449,358...66,516,111 		JBrowse link
G Mbd4 methyl-CpG binding domain 4 DNA glycosylase multiple interactions ISO trichostatin A inhibits the reaction [Folic Acid results in increased expression of MBD4 protein] CTD PMID:39617304 NCBI chr 4:150,565,646...150,577,433
Ensembl chr 4:150,565,655...150,577,578 		JBrowse link
G Mbd5 methyl-CpG binding domain protein 5 multiple interactions
decreases expression 		ISO [Decitabine co-treated with trichostatin A] results in decreased expression of MBD5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MBD5 mRNA
trichostatin A results in decreased expression of MBD5 mRNA 		CTD PMID:17891453 PMID:26272509 PMID:27188386 NCBI chr 3:53,742,458...54,147,970
Ensembl chr 3:54,075,084...54,139,389 		JBrowse link
G Mbip MAP3K12 binding inhibitory protein 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MBIP mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MBIP mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:79,543,223...79,560,476
Ensembl chr 6:79,543,223...79,560,474 		JBrowse link
G Mblac2 metallo-beta-lactamase domain containing 2 increases expression ISO trichostatin A results in increased expression of MBLAC2 mRNA CTD PMID:24935251 NCBI chr 2:13,721,752...13,764,558
Ensembl chr 2:13,721,360...13,766,626 		JBrowse link
G Mbnl1 muscleblind-like splicing regulator 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MBNL1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBNL1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:146,789,570...146,964,136
Ensembl chr 2:146,789,596...146,964,134 		JBrowse link
G Mbnl2 muscleblind-like splicing regulator 2 increases expression
multiple interactions
affects expression 		ISO trichostatin A results in increased expression of MBNL2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBNL2 mRNA
trichostatin A affects the expression of MBNL2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr15:103,792,134...103,949,827
Ensembl chr15:103,792,152...103,949,827 		JBrowse link
G Mbnl3 muscleblind-like splicing regulator 3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MBNL3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBNL3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr  X:135,526,256...135,621,499
Ensembl chr  X:135,532,494...135,621,976 		JBrowse link
G Mboat1 membrane bound O-acyltransferase domain containing 1 increases expression
affects expression 		ISO trichostatin A results in increased expression of MBOAT1 mRNA
trichostatin A affects the expression of MBOAT1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:28542535 NCBI chr17:34,540,032...34,653,705
Ensembl chr17:34,540,041...34,653,698 		JBrowse link
G Mbp myelin basic protein decreases expression
increases expression 		ISO trichostatin A results in decreased expression of MBP mRNA
trichostatin A results in increased expression of MBP mRNA 		CTD PMID:22927334 PMID:24935251 NCBI chr18:78,130,652...78,241,174
Ensembl chr18:78,130,325...78,241,174 		JBrowse link
G Mbtd1 mbt domain containing 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MBTD1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MBTD1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:79,336,041...79,392,315
Ensembl chr10:79,335,235...79,392,315 		JBrowse link
G Mcc MCC regulator of WNT signaling pathway multiple interactions
increases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCC mRNA
trichostatin A results in increased expression of MCC mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr18:37,042,350...37,517,114
Ensembl chr18:37,049,253...37,517,076 		JBrowse link
G Mcf2l MCF.2 cell line derived transforming sequence-like decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MCF2L mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MCF2L mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr16:83,209,277...83,355,683
Ensembl chr16:83,209,280...83,354,956 		JBrowse link
G Mchr1 melanin-concentrating hormone receptor 1 increases expression ISO trichostatin A results in increased expression of MCHR1 mRNA CTD PMID:24935251 NCBI chr 7:114,641,721...114,644,913
Ensembl chr 7:114,641,580...114,644,919 		JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member decreases expression
multiple interactions
increases expression 		ISO trichostatin A results in decreased expression of MCL1 protein
trichostatin A inhibits the reaction [Arsenic Trioxide results in decreased expression of MCL1 protein]
trichostatin A results in increased expression of MCL1 protein 		CTD PMID:16009488 PMID:32305283 NCBI chr 2:185,884,840...185,912,532
Ensembl chr 2:185,908,168...185,938,782 		JBrowse link
G Mcm2 minichromosome maintenance complex component 2 multiple interactions
decreases expression 		ISO pyrazolanthrone inhibits the reaction [trichostatin A results in decreased expression of MCM2 protein]
trichostatin A results in decreased expression of MCM2 mRNA; trichostatin A results in decreased expression of MCM2 protein 		CTD PMID:23770000 NCBI chr 4:122,903,679...122,918,205
Ensembl chr 4:122,903,682...122,918,094 		JBrowse link
G Mcm3 minichromosome maintenance complex component 3 decreases expression ISO trichostatin A results in decreased expression of MCM3 mRNA CTD PMID:19606018 PMID:23770000 NCBI chr 9:30,715,602...30,733,746
Ensembl chr 9:30,715,602...30,733,746 		JBrowse link
G Mcm4 minichromosome maintenance complex component 4 decreases expression ISO trichostatin A results in decreased expression of MCM4 mRNA CTD PMID:23770000 NCBI chr11:98,762,599...98,776,300
Ensembl chr11:98,762,634...98,776,536 		JBrowse link
G Mcm5 minichromosome maintenance complex component 5 decreases expression
affects expression 		ISO trichostatin A results in decreased expression of MCM5 mRNA
trichostatin A affects the expression of MCM5 mRNA 		CTD PMID:23770000 PMID:28542535 NCBI chr19:13,488,813...13,510,131
Ensembl chr19:13,488,813...13,517,758 		JBrowse link
G Mcm7 minichromosome maintenance complex component 7 multiple interactions
affects expression 		ISO trichostatin A inhibits the reaction [Nickel affects the expression of MCM7 mRNA]
trichostatin A affects the expression of MCM7 mRNA 		CTD PMID:14575637 PMID:28542535 NCBI chr12:22,155,921...22,163,320
Ensembl chr12:22,155,921...22,163,771 		JBrowse link
G Mcoln1 mucolipin TRP cation channel 1 affects expression ISO trichostatin A affects the expression of MCOLN1 mRNA CTD PMID:28542535 NCBI chr12:6,357,851...6,372,151
Ensembl chr12:6,357,807...6,372,151 		JBrowse link
G Mcoln3 mucolipin TRP cation channel 3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MCOLN3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCOLN3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:237,596,544...237,705,770
Ensembl chr 2:237,626,302...237,705,769 		JBrowse link
G Mcph1 microcephalin 1 decreases expression ISO trichostatin A results in decreased expression of MCPH1 mRNA CTD PMID:24935251 NCBI chr16:77,724,251...77,926,773
Ensembl chr16:77,724,251...77,926,462 		JBrowse link
G Mcrs1 microspherule protein 1 affects expression ISO trichostatin A affects the expression of MCRS1 mRNA CTD PMID:28542535 NCBI chr 7:132,262,719...132,271,533
Ensembl chr 7:132,262,722...132,271,533 		JBrowse link
G Mctp1 multiple C2 and transmembrane domain containing 1 decreases expression
increases expression 		ISO trichostatin A results in decreased expression of MCTP1 mRNA
trichostatin A results in increased expression of MCTP1 mRNA 		CTD PMID:24935251 PMID:27188386 NCBI chr 2:7,798,968...8,493,596
Ensembl chr 2:7,803,382...8,493,596 		JBrowse link
G Mctp2 multiple C2 and transmembrane domain containing 2 increases expression ISO trichostatin A results in increased expression of MCTP2 mRNA CTD PMID:24935251 NCBI chr 1:135,179,845...135,412,798
Ensembl chr 1:135,179,845...135,412,694 		JBrowse link
G Mcub mitochondrial calcium uniporter dominant negative subunit beta decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MCUB mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MCUB mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:221,153,525...221,223,814
Ensembl chr 2:221,153,525...221,223,814 		JBrowse link
G Mdc1 mediator of DNA damage checkpoint 1 affects expression ISO trichostatin A affects the expression of MDC1 mRNA CTD PMID:28542535 NCBI chr20:2,898,496...2,914,960
Ensembl chr20:2,900,308...2,914,960 		JBrowse link
G Mdfic MyoD family inhibitor domain containing multiple interactions
increases expression 		ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MDFIC mRNA
trichostatin A results in increased expression of MDFIC mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:44,938,301...45,018,157
Ensembl chr 4:44,938,480...45,018,156 		JBrowse link
G Mdga2 MAM domain containing glycosylphosphatidylinositol anchor 2 increases expression ISO trichostatin A results in increased expression of MDGA2 mRNA CTD PMID:24935251 NCBI chr 6:90,482,687...91,346,784
Ensembl chr 6:90,498,119...91,344,413 		JBrowse link
G Mdh1 malate dehydrogenase 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MDH1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MDH1 mRNA 		CTD PMID:24935251 PMID:27188386 NCBI chr14:99,831,934...99,847,227
Ensembl chr14:99,831,615...99,847,232 		JBrowse link
G Mdm1 Mdm1 nuclear protein decreases expression ISO trichostatin A results in decreased expression of MDM1 mRNA CTD PMID:24935251 NCBI chr 7:55,615,459...55,651,889
Ensembl chr 7:55,615,608...55,651,888 		JBrowse link
G Mdm2 MDM2 proto-oncogene affects expression ISO trichostatin A affects the expression of MDM2 mRNA CTD PMID:28542535 NCBI chr 7:55,176,558...55,201,757
Ensembl chr 7:55,176,560...55,200,791 		JBrowse link
G Mdm4 MDM4 regulator of p53 affects expression ISO trichostatin A affects the expression of MDM4 mRNA CTD PMID:28542535 NCBI chr13:46,922,236...47,068,241
Ensembl chr13:46,958,298...47,026,372 		JBrowse link
G Mdn1 midasin AAA ATPase 1 increases expression ISO trichostatin A results in increased expression of MDN1 mRNA CTD PMID:24935251 PMID:26272509 NCBI chr 5:51,851,785...51,982,688
Ensembl chr 5:51,851,809...51,982,688 		JBrowse link
G Me1 malic enzyme 1 increases expression ISO trichostatin A results in increased expression of ME1 mRNA CTD PMID:24935251 PMID:26272509 NCBI chr 8:96,429,057...96,540,244
Ensembl chr 8:96,429,057...96,540,275 		JBrowse link
G Me3 malic enzyme 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of ME3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ME3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:152,946,595...153,148,026
Ensembl chr 1:152,946,628...153,148,026 		JBrowse link
G Mecom MDS1 and EVI1 complex locus decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MECOM mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MECOM mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:114,837,815...115,393,052
Ensembl chr 2:114,837,840...115,393,038 		JBrowse link
G Mecp2 methyl CpG binding protein 2 multiple interactions ISO [decitabine co-treated with trichostatin A] results in decreased expression of MECP2 mRNA; trichostatin A inhibits the reaction [MECP2 protein binds to CCNA1 promoter] CTD PMID:17698632 PMID:17891453 NCBI chr  X:156,932,481...156,995,981
Ensembl chr  X:156,941,234...156,943,560 		JBrowse link
G Med13 mediator complex subunit 13 decreases expression ISO trichostatin A results in decreased expression of MED13 mRNA CTD PMID:24935251 NCBI chr10:71,584,354...71,674,614
Ensembl chr10:71,584,354...71,673,901 		JBrowse link
G Med13l mediator complex subunit 13L increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MED13L mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MED13L mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr12:43,468,556...43,665,819
Ensembl chr12:43,468,556...43,665,819 		JBrowse link
G Med14 mediator complex subunit 14 decreases expression ISO trichostatin A results in decreased expression of MED14 mRNA CTD PMID:24935251 NCBI chr  X:12,709,406...12,800,642
Ensembl chr  X:12,709,472...12,800,640 		JBrowse link
G Med17 mediator complex subunit 17 increases expression ISO trichostatin A results in increased expression of MED17 mRNA CTD PMID:24935251 NCBI chr 8:20,382,995...20,401,993
Ensembl chr 8:20,382,995...20,401,993 		JBrowse link
G Med20 mediator complex subunit 20 affects expression ISO trichostatin A affects the expression of MED20 mRNA CTD PMID:28542535 NCBI chr 9:20,867,681...20,880,288
Ensembl chr 9:20,867,681...20,880,011 		JBrowse link
G Med30 mediator complex subunit 30 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MED30 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MED30 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:85,894,638...85,916,373
Ensembl chr 7:85,894,605...85,917,973 		JBrowse link
G Med6 mediator complex subunit 6 decreases expression ISO trichostatin A results in decreased expression of MED6 mRNA CTD PMID:24935251 NCBI chr 6:107,001,664...107,015,130
Ensembl chr 6:106,990,116...107,015,130 		JBrowse link
G Mef2a myocyte enhancer factor 2a multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of MEF2A mRNA] CTD PMID:14575637 NCBI chr 1:130,258,083...130,392,819
Ensembl chr 1:130,260,339...130,392,162 		JBrowse link
G Mef2c myocyte enhancer factor 2C increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MEF2C mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEF2C mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:15,708,732...15,871,639
Ensembl chr 2:15,708,924...15,871,640 		JBrowse link
G Meg3 maternally expressed 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MEG3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MEG3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:134,274,056...134,306,249 JBrowse link
G Megf10 multiple EGF-like domains 10 decreases expression ISO trichostatin A results in decreased expression of MEGF10 mRNA CTD PMID:24935251 NCBI chr18:52,803,292...52,953,431
Ensembl chr18:52,847,781...52,950,675 		JBrowse link
G Meioc meiosis specific with coiled-coil domain decreases expression
increases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MEIOC mRNA
trichostatin A results in increased expression of MEIOC mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MEIOC mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:88,128,939...88,147,833
Ensembl chr10:88,128,990...88,147,829 		JBrowse link
G Meis1 Meis homeobox 1 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of MEIS1 mRNA
trichostatin A results in decreased expression of MEIS1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MEIS1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr14:97,356,949...97,499,646
Ensembl chr14:97,322,748...97,495,083 		JBrowse link
G Meis2 Meis homeobox 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MEIS2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEIS2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:123,197,066...123,399,002
Ensembl chr 3:123,197,066...123,397,751 		JBrowse link
G Meltf melanotransferrin increases expression ISO trichostatin A results in increased expression of MELTF mRNA CTD PMID:26705709 PMID:27188386 NCBI chr11:82,389,420...82,411,270
Ensembl chr11:82,389,420...82,411,270 		JBrowse link
G Meox1 mesenchyme homeobox 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MEOX1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEOX1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:87,318,668...87,338,169
Ensembl chr10:87,318,695...87,337,976 		JBrowse link
G Mepce methylphosphate capping enzyme decreases expression ISO trichostatin A results in decreased expression of MEPCE mRNA CTD PMID:24935251 PMID:28542535 NCBI chr12:24,548,596...24,553,315
Ensembl chr12:24,548,596...24,553,877 		JBrowse link
G Mertk MER proto-oncogene, tyrosine kinase decreases expression
affects expression 		ISO trichostatin A results in decreased expression of MERTK mRNA
trichostatin A affects the expression of MERTK mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 3:136,391,936...136,498,366
Ensembl chr 3:136,383,560...136,500,192 		JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase increases expression ISO trichostatin A results in increased expression of MET mRNA CTD PMID:24935251 PMID:26238599 NCBI chr 4:46,756,823...46,864,041
Ensembl chr 4:46,756,506...46,870,821 		JBrowse link
G Metrnl meteorin-like, glial cell differentiation regulator increases expression
multiple interactions
affects expression 		ISO trichostatin A results in increased expression of METRNL mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of METRNL mRNA
trichostatin A affects the expression of METRNL mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr10:107,462,148...107,476,143
Ensembl chr10:107,462,109...107,476,135 		JBrowse link
G Mettl16 methyltransferase 16, RNA N6-adenosine affects expression ISO trichostatin A affects the expression of METTL16 mRNA CTD PMID:28542535 NCBI chr10:60,139,317...60,185,438
Ensembl chr10:60,139,330...60,187,571 		JBrowse link
G Mettl18 methyltransferase 18, RPL3 N3(tau)-histidine affects expression ISO trichostatin A affects the expression of METTL18 mRNA CTD PMID:28542535 NCBI chr13:78,879,053...78,881,226
Ensembl chr13:78,838,447...78,912,730 		JBrowse link
G Mettl21a methyltransferase 21A, HSPA lysine decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of METTL21A mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of METTL21A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:73,400,223...73,484,677
Ensembl chr 9:73,471,813...73,481,339 		JBrowse link
G Mettl3 methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit affects expression ISO trichostatin A affects the expression of METTL3 mRNA CTD PMID:28542535 NCBI chr15:27,476,659...27,491,134
Ensembl chr15:27,476,660...27,487,487 		JBrowse link
G Mettl8 methyltransferase 8, tRNA N3-cytidine increases expression
multiple interactions 		ISO trichostatin A results in increased expression of METTL8 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of METTL8 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:76,140,465...76,271,367
Ensembl chr 3:76,144,178...76,271,400 		JBrowse link
G Mex3b mex-3 RNA binding family member B decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MEX3B mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MEX3B mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:146,264,319...146,268,554
Ensembl chr 1:146,264,318...146,268,543 		JBrowse link
G Mfap3l microfibril associated protein 3 like increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of MFAP3L mRNA
trichostatin A results in decreased expression of MFAP3L mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFAP3L mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr16:34,422,490...34,465,544
Ensembl chr16:34,426,696...34,441,709 		JBrowse link
G Mfge8 milk fat globule EGF and factor V/VIII domain containing decreases expression ISO trichostatin A results in decreased expression of MFGE8 mRNA CTD PMID:24935251 NCBI chr 1:142,474,027...142,489,431
Ensembl chr 1:142,474,028...142,489,431 		JBrowse link
G Mfhas1 multifunctional ROCO family signaling regulator 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MFHAS1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFHAS1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:63,248,833...63,336,441
Ensembl chr16:63,250,455...63,336,602 		JBrowse link
G Mfn1 mitofusin 1 affects expression ISO trichostatin A affects the expression of MFN1 mRNA CTD PMID:28542535 NCBI chr 2:117,240,525...117,288,017
Ensembl chr 2:117,241,759...117,290,190 		JBrowse link
G Mfng MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MFNG mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFNG mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:112,191,288...112,209,129
Ensembl chr 7:112,161,071...112,209,129 		JBrowse link
G Mfsd4b2 major facilitator superfamily domain containing 4B2 affects expression ISO trichostatin A affects the expression of SLC60A2 mRNA CTD PMID:28542535 NCBI chr20:44,899,164...44,907,624
Ensembl chr20:44,899,164...44,907,624 		JBrowse link
G Mfsd6 major facilitator superfamily domain containing 6 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MFSD6 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MFSD6 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 9:56,265,152...56,350,449
Ensembl chr 9:56,265,237...56,350,446 		JBrowse link
G Mfsd9 major facilitator superfamily domain containing 9 decreases expression ISO trichostatin A results in decreased expression of SLC67A2 mRNA CTD PMID:24935251 PMID:26272509 NCBI chr 9:50,515,209...50,534,698
Ensembl chr 9:50,515,214...50,534,707 		JBrowse link
G Mgarp mitochondria-localized glutamic acid-rich protein increases expression ISO trichostatin A results in increased expression of MGARP mRNA CTD PMID:26705709 PMID:27188386 NCBI chr 2:137,582,152...137,590,294
Ensembl chr 2:137,582,152...137,590,481 		JBrowse link
G Mgat4a alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase A increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of MGAT4A mRNA
trichostatin A results in decreased expression of MGAT4A mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MGAT4A mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 9:47,169,229...47,282,577
Ensembl chr 9:47,169,232...47,282,574 		JBrowse link
G Mgat5b alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase B increases expression ISO trichostatin A results in increased expression of MGAT5B mRNA CTD PMID:24619417 NCBI chr10:102,619,559...102,689,023
Ensembl chr10:102,619,559...102,689,017 		JBrowse link
G Mgmt O-6-methylguanine-DNA methyltransferase multiple interactions ISO [decitabine co-treated with trichostatin A] results in increased expression of MGMT mRNA CTD PMID:15657354 NCBI chr 1:201,140,832...201,367,481
Ensembl chr 1:201,140,661...201,367,482 		JBrowse link
G Mgp matrix Gla protein multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of MGP mRNA] CTD PMID:14575637 NCBI chr 4:171,497,472...171,500,888
Ensembl chr 4:171,497,471...171,500,859 		JBrowse link
G Mgst1 microsomal glutathione S-transferase 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MGST1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MGST1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:172,760,930...172,776,157
Ensembl chr 4:172,760,886...172,776,875 		JBrowse link
G Mgst2 microsomal glutathione S-transferase 2 increases expression ISO trichostatin A results in increased expression of MGST2 mRNA CTD PMID:24935251 NCBI chr 2:137,821,787...137,866,664
Ensembl chr 2:137,836,140...137,866,661 		JBrowse link
G Mia MIA SH3 domain containing increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MIA mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIA mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:91,601,326...91,603,019
Ensembl chr 1:91,601,327...91,603,019 		JBrowse link
G Mia2 MIA SH3 domain ER export factor 2 increases expression ISO trichostatin A results in increased expression of MIA2 mRNA CTD PMID:24935251 NCBI chr 6:82,522,398...82,620,136
Ensembl chr 6:82,522,422...82,620,178 		JBrowse link
G Miat myocardial infarction associated transcript decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MIAT mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIAT mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr12:50,075,026...50,090,259 JBrowse link
G Mib2 MIB E3 ubiquitin protein ligase 2 decreases expression ISO trichostatin A results in decreased expression of MIB2 mRNA CTD PMID:24935251 NCBI chr 5:171,526,037...171,542,479
Ensembl chr 5:171,526,037...171,541,910 		JBrowse link
G Mical1 microtubule associated monooxygenase, calponin and LIM domain containing 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MICAL1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MICAL1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr20:46,547,983...46,568,487
Ensembl chr20:46,556,536...46,568,487 		JBrowse link
G Mical2 microtubule associated monooxygenase, calponin and LIM domain containing 2 affects expression ISO trichostatin A affects the expression of MICAL2 mRNA CTD PMID:28542535 NCBI chr 1:175,780,441...175,965,157
Ensembl chr 1:175,825,596...175,905,155 		JBrowse link
G Micall1 MICAL-like 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MICALL1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MICALL1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:112,557,192...112,587,618
Ensembl chr 7:112,557,192...112,587,618 		JBrowse link
G Micall2 MICAL-like 2 affects expression ISO trichostatin A affects the expression of MICALL2 mRNA CTD PMID:28542535 NCBI chr12:20,013,037...20,041,795
Ensembl chr12:20,012,985...20,041,795 		JBrowse link
G Micb MHC class I polypeptide-related sequence B increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MICB mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MICB mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:87,623,826...87,641,075
Ensembl chr 1:87,623,826...87,640,872 		JBrowse link
G Micu3 mitochondrial calcium uptake family, member 3 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of MICU3 mRNA
trichostatin A results in decreased expression of MICU3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MICU3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr16:58,624,702...58,714,302
Ensembl chr16:58,629,208...58,714,045 		JBrowse link
G Mid1 midline 1 increases expression ISO trichostatin A results in increased expression of MID1 mRNA CTD PMID:24935251 NCBI chr  X:27,678,248...28,053,049
Ensembl chr  X:27,681,867...27,906,105 		JBrowse link
G Mid1ip1 MID1 interacting protein 1 increases expression
multiple interactions
affects expression 		ISO trichostatin A results in increased expression of MID1IP1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MID1IP1 mRNA
trichostatin A affects the expression of MID1IP1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr  X:14,733,539...14,735,859
Ensembl chr  X:14,732,830...14,739,079 		JBrowse link
G Mideas mitotic deacetylase associated SANT domain protein increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MIDEAS mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIDEAS mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:109,519,011...109,585,631
Ensembl chr 6:109,519,011...109,560,312 		JBrowse link
G Midn midnolin decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MIDN mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIDN mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:10,198,761...10,210,563
Ensembl chr 7:10,200,306...10,207,203 		JBrowse link
G Mier3 MIER family member 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MIER3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIER3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:45,021,167...45,049,745
Ensembl chr 2:45,021,283...45,049,745 		JBrowse link
G Mif macrophage migration inhibitory factor increases expression ISO trichostatin A results in increased expression of MIF mRNA CTD PMID:24935251 NCBI chr20:12,767,138...12,791,222
Ensembl chr 4:134,041,774...134,042,121
Ensembl chr20:134,041,774...134,042,121 		JBrowse link
G Miga1 mitoguardin 1 increases expression ISO trichostatin A results in increased expression of MIGA1 mRNA CTD PMID:27188386 NCBI chr 2:243,884,071...243,939,059
Ensembl chr 2:243,886,617...243,937,086 		JBrowse link
G Mipol1 mirror-image polydactyly 1 increases expression ISO trichostatin A results in increased expression of MIPOL1 mRNA CTD PMID:24935251 NCBI chr 6:80,490,330...80,825,413
Ensembl chr 6:80,490,312...80,825,413 		JBrowse link
G Mir106b microRNA 106b multiple interactions
decreases expression 		ISO MIR106B mRNA affects the reaction [trichostatin A affects the expression of CDKN1A protein]; MIR106B mRNA inhibits the reaction [trichostatin A results in increased expression of CDKN1A mRNA]
trichostatin A results in decreased expression of MIR106B mRNA 		CTD PMID:26559563 NCBI chr12:22,157,053...22,157,134 JBrowse link
G Mir10a microRNA 10a increases expression ISO trichostatin A results in increased expression of MIR10A mRNA CTD PMID:24896083 NCBI chr10:81,779,709...81,779,818
Ensembl chr10:81,779,709...81,779,818 		JBrowse link
G Mir128-1 microRNA 128-1 decreases expression ISO trichostatin A results in decreased expression of MIR128-1 mRNA CTD PMID:24896083 NCBI chr13:42,251,884...42,251,965
Ensembl chr13:42,251,884...42,251,965 		JBrowse link
G Mir135b microRNA 135b increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MIR135B mRNA
decitabine promotes the reaction [trichostatin A results in increased expression of MIR135B mRNA] 		CTD PMID:27570640 NCBI chr13:46,191,018...46,191,114
Ensembl chr13:46,191,018...46,191,114 		JBrowse link
G Mir137 microRNA 137 decreases expression ISO trichostatin A results in decreased expression of MIR137 mRNA CTD PMID:24896083 NCBI chr 2:209,165,709...209,165,810
Ensembl chr 2:209,165,712...209,165,813 		JBrowse link
G Mir145 microRNA 145 increases expression ISO trichostatin A results in increased expression of MIR145 mRNA CTD PMID:24896083 NCBI chr18:57,369,983...57,370,070 JBrowse link
G Mir155 microRNA 155 multiple interactions ISO trichostatin A promotes the reaction [hydroquinone results in increased expression of MIR155 mRNA] CTD PMID:30448557 NCBI chr11:37,261,114...37,261,178
Ensembl chr11:37,261,114...37,261,178 		JBrowse link
G Mir196b microRNA 196b multiple interactions
increases expression 		ISO decitabine promotes the reaction [trichostatin A results in increased expression of MIR196B mRNA] CTD PMID:27570640 NCBI chr 4:82,661,101...82,661,185 JBrowse link
G Mir206 microRNA 206 increases expression ISO trichostatin A results in increased expression of MIR206 mRNA CTD PMID:24896083 NCBI chr 9:30,590,697...30,590,780
Ensembl chr 9:30,590,697...30,590,780 		JBrowse link
G Mir21 microRNA 21 increases expression ISO trichostatin A results in increased expression of MIR21 mRNA CTD PMID:24935251 NCBI chr10:71,902,600...71,902,691 JBrowse link
G Mir214 microRNA 214 increases expression ISO trichostatin A results in increased expression of MIR214 mRNA CTD PMID:24896083 NCBI chr13:77,121,645...77,121,752
Ensembl chr13:77,121,643...77,121,752 		JBrowse link
G Mir224 microRNA 224 increases expression ISO trichostatin A increased expression of miR244 in a human liver cell line RGD PMID:22459148 RGD:18182922 NCBI chr  X:155,107,130...155,107,211 JBrowse link
G Mir30c2 microRNA 30c-2 multiple interactions ISO [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR30C2 mRNA CTD PMID:27188386 NCBI chr 9:33,253,682...33,253,765
Ensembl chr 9:33,253,682...33,253,765 		JBrowse link
G Mis18bp1 MIS18 binding protein 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MIS18BP1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIS18BP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:88,918,743...88,968,225
Ensembl chr 6:88,918,745...88,967,629 		JBrowse link
G Mitf melanocyte inducing transcription factor increases expression
multiple interactions
affects expression 		ISO trichostatin A results in increased expression of MITF mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MITF mRNA
trichostatin A affects the expression of MITF mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 4:131,965,676...132,177,790
Ensembl chr 4:131,965,714...132,177,790 		JBrowse link
G Mki67 marker of proliferation Ki-67 decreases expression
affects expression 		ISO trichostatin A results in decreased expression of MKI67 mRNA
trichostatin A affects the expression of MKI67 mRNA 		CTD PMID:23770000 PMID:28542535 NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:199,926,150...199,952,593 		JBrowse link
G Mkln1 muskelin 1 decreases expression
increases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MKLN1 mRNA
trichostatin A results in increased expression of MKLN1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MKLN1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:60,939,239...61,095,214
Ensembl chr 4:60,937,817...61,095,210 		JBrowse link
G Mknk2 MAPK interacting serine/threonine kinase 2 affects expression ISO trichostatin A affects the expression of MKNK2 mRNA CTD PMID:28542535 NCBI chr 7:9,690,385...9,701,527
Ensembl chr 7:9,690,421...9,701,529 		JBrowse link
G Mkrn1 makorin ring finger protein 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MKRN1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MKRN1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:69,142,710...69,170,211
Ensembl chr 4:69,142,723...69,164,020 		JBrowse link
G Mkx mohawk homeobox increases expression ISO trichostatin A results in increased expression of MKX mRNA CTD PMID:24935251 NCBI chr17:59,772,113...59,851,160
Ensembl chr17:59,773,570...59,850,345 		JBrowse link
G Mlf1 myeloid leukemia factor 1 increases expression ISO trichostatin A results in increased expression of MLF1 mRNA CTD PMID:24935251 NCBI chr 2:153,958,060...153,991,705
Ensembl chr 2:153,958,546...153,994,220 		JBrowse link
G Mlh1 mutL homolog 1 multiple interactions ISO [decitabine co-treated with trichostatin A] affects the methylation of MLH1 promoter CTD PMID:18069755 NCBI chr 8:120,074,871...120,112,109
Ensembl chr 8:120,065,900...120,112,011 		JBrowse link
G Mlkl mixed lineage kinase domain like pseudokinase affects expression ISO trichostatin A affects the expression of MLKL mRNA CTD PMID:28542535 NCBI chr19:56,186,860...56,213,886
Ensembl chr19:56,186,860...56,213,858 		JBrowse link
G Mllt10 MLLT10, histone lysine methyltransferase DOT1L cofactor decreases expression ISO trichostatin A results in decreased expression of MLLT10 mRNA CTD PMID:24935251 NCBI chr17:85,729,964...85,857,791
Ensembl chr17:85,730,751...85,857,789 		JBrowse link
G Mllt3 MLLT3, super elongation complex subunit increases expression
affects expression 		ISO trichostatin A results in increased expression of MLLT3 mRNA
trichostatin A affects the expression of MLLT3 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 5:107,305,008...107,561,352
Ensembl chr 5:107,284,766...107,561,352 		JBrowse link
G Mllt6 MLLT6, PHD finger containing affects expression ISO trichostatin A affects the expression of MLLT6 mRNA CTD PMID:28542535 NCBI chr10:83,152,317...83,175,264
Ensembl chr10:83,153,698...83,175,250 		JBrowse link
G Mlph melanophilin increases expression ISO trichostatin A results in increased expression of MLPH mRNA CTD PMID:24935251 NCBI chr 9:98,955,036...98,990,566
Ensembl chr 9:98,955,141...98,990,556 		JBrowse link
G Mlst8 MTOR associated protein, LST8 homolog affects expression ISO trichostatin A affects the expression of MLST8 mRNA CTD PMID:28542535 NCBI chr10:14,002,927...14,008,678
Ensembl chr10:14,002,938...14,008,678 		JBrowse link
G Mmaa metabolism of cobalamin associated A decreases expression ISO trichostatin A results in decreased expression of MMAA mRNA CTD PMID:24935251 NCBI chr19:45,523,352...45,553,602
Ensembl chr19:45,523,379...45,555,375 		JBrowse link
G Mme membrane metallo-endopeptidase increases expression ISO trichostatin A results in increased expression of MME mRNA CTD PMID:24935251 NCBI chr 2:149,806,826...149,957,381
Ensembl chr 2:149,872,291...149,953,463 		JBrowse link
G Mmp1 matrix metallopeptidase 1 multiple interactions ISO CAT protein affects the reaction [trichostatin A promotes the reaction [SOD2 protein results in increased expression of MMP1 mRNA]]; trichostatin A promotes the reaction [SOD2 protein results in increased expression of MMP1 mRNA] CTD PMID:24973648 NCBI chr 8:12,943,453...12,963,966
Ensembl chr 8:12,943,453...12,963,964 		JBrowse link
G Mmp10 matrix metallopeptidase 10 increases expression ISO trichostatin A results in increased expression of MMP10 mRNA CTD PMID:24935251 NCBI chr 8:12,974,707...12,982,613
Ensembl chr 8:12,974,707...12,982,613 		JBrowse link
G Mmp12 matrix metallopeptidase 12 multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of MMP12 mRNA] CTD PMID:14575637 NCBI chr 8:12,866,652...12,876,554
Ensembl chr 8:12,866,641...12,884,478 		JBrowse link
G Mmp13 matrix metallopeptidase 13 multiple interactions ISO [decitabine co-treated with trichostatin A] results in increased expression of MMP13 mRNA CTD PMID:17891453 NCBI chr 8:12,782,829...12,793,108
Ensembl chr 8:12,782,813...12,793,105 		JBrowse link
G Mmp14 matrix metallopeptidase 14 affects expression ISO trichostatin A affects the expression of MMP14 mRNA CTD PMID:28542535 NCBI chr15:31,857,824...31,867,049
Ensembl chr15:31,857,546...31,869,893 		JBrowse link
G Mmp16 matrix metallopeptidase 16 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MMP16 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MMP16 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:36,109,265...36,353,252
Ensembl chr 5:36,109,265...36,353,252 		JBrowse link
G Mmp2 matrix metallopeptidase 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MMP2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MMP2 mRNA; AKT1 protein modified form inhibits the reaction [trichostatin A inhibits the reaction [Oxygen deficiency results in increased expression of MMP2 mRNA]]; trichostatin A inhibits the reaction [Oxygen deficiency results in increased expression of MMP2 mRNA]; trichostatin A inhibits the reaction [Oxygen deficiency results in increased expression of MMP2 protein]
trichostatin A promotes the reaction [Folic Acid results in increased expression of MMP2 mRNA] 		CTD PMID:24935251 PMID:26272509 PMID:26509796 PMID:27188386 PMID:39617304 NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856 		JBrowse link
G Mmp3 matrix metallopeptidase 3 multiple interactions ISO trichostatin A affects the reaction [Arsenic results in decreased expression of MMP3 protein] CTD PMID:39617304 NCBI chr 8:12,925,267...12,938,828
Ensembl chr 8:12,925,280...12,938,826 		JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions ISO AKT1 protein modified form inhibits the reaction [trichostatin A inhibits the reaction [Oxygen deficiency results in increased expression of MMP9 mRNA]]; trichostatin A inhibits the reaction [Oxygen deficiency results in increased expression of MMP9 mRNA]; trichostatin A inhibits the reaction [Oxygen deficiency results in increased expression of MMP9 protein] CTD PMID:26509796 NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442 		JBrowse link
G Mmrn1 multimerin 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MMRN1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MMRN1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:91,205,462...91,280,862
Ensembl chr 4:91,233,240...91,280,861 		JBrowse link
G Mn1 MN1 proto-oncogene, transcriptional regulator increases expression ISO trichostatin A results in increased expression of MN1 mRNA CTD PMID:24935251 NCBI chr12:50,841,632...50,880,795
Ensembl chr12:50,841,632...50,880,795 		JBrowse link
G Mnat1 MNAT1 component of CDK activating kinase affects expression ISO trichostatin A affects the expression of MNAT1 mRNA CTD PMID:28542535 NCBI chr 6:97,550,566...97,706,598
Ensembl chr 6:97,550,543...97,706,595 		JBrowse link
G Mnd1 meiotic nuclear divisions 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MND1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MND1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:171,731,523...171,794,124
Ensembl chr 2:171,731,523...171,794,095 		JBrowse link
G Mns1 meiosis-specific nuclear structural 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MNS1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MNS1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 8:82,029,587...82,050,276
Ensembl chr 8:82,029,587...82,050,274 		JBrowse link
G Mob1a MOB kinase activator 1A decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MOB1A mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MOB1A mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:117,389,278...117,406,255
Ensembl chr 4:117,389,186...117,406,250 		JBrowse link
G Mob3b MOB kinase activator 3B decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MOB3B mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MOB3B mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:54,342,509...54,534,164
Ensembl chr 5:54,338,056...54,454,678 		JBrowse link
G Mocos molybdenum cofactor sulfurase increases expression ISO trichostatin A results in increased expression of MOCOS mRNA CTD PMID:24935251 NCBI chr18:16,206,402...16,251,928
Ensembl chr18:16,206,402...16,251,928 		JBrowse link
G Mocs2 molybdenum cofactor synthesis 2 decreases expression ISO trichostatin A results in decreased expression of MOCS2 mRNA CTD PMID:24935251 NCBI chr 2:48,237,655...48,249,394
Ensembl chr 2:48,237,655...48,249,394 		JBrowse link
G Mosmo modulator of smoothened decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MOSMO mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MOSMO mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:184,648,985...184,719,820
Ensembl chr 1:184,648,985...184,719,820 		JBrowse link
G Mospd2 motile sperm domain containing 2 affects expression ISO trichostatin A affects the expression of MOSPD2 mRNA CTD PMID:28542535 NCBI chr  X:33,052,063...33,105,550
Ensembl chr  X:33,052,004...33,107,635 		JBrowse link
G Mov10 Mov10 RNA helicase decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MOV10 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MOV10 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:194,982,014...195,003,513
Ensembl chr 2:194,982,014...195,003,442 		JBrowse link
G Moxd1 monooxygenase, DBH-like 1 decreases expression ISO trichostatin A results in decreased expression of MOXD1 mRNA CTD PMID:27188386 NCBI chr 1:22,894,543...22,984,599
Ensembl chr 1:22,894,543...22,984,223 		JBrowse link
G Mpc1 mitochondrial pyruvate carrier 1 increases expression ISO trichostatin A results in increased expression of MPC1 mRNA CTD PMID:24935251 NCBI chr 1:54,985,305...54,996,979
Ensembl chr 1:54,985,301...54,997,064 		JBrowse link
G Mphosph9 M-phase phosphoprotein 9 decreases expression ISO trichostatin A results in decreased expression of MPHOSPH9 mRNA CTD PMID:26272509 NCBI chr12:37,936,442...38,007,053
Ensembl chr12:37,936,885...38,003,348 		JBrowse link
G Mpl MPL proto-oncogene, thrombopoietin receptor multiple interactions ISO [trichostatin A co-treated with Decitabine] promotes the reaction [hydroquinone results in increased expression of MPL mRNA] CTD PMID:22245671 NCBI chr 5:137,259,288...137,281,540
Ensembl chr 5:137,259,288...137,272,177 		JBrowse link
G Mpo myeloperoxidase multiple interactions ISO [decitabine co-treated with trichostatin A] results in increased expression of MPO mRNA CTD PMID:17185465 NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056 		JBrowse link
G Mprip myosin phosphatase Rho interacting protein increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MPRIP mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MPRIP mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:44,953,472...45,073,388
Ensembl chr10:44,953,500...45,073,388 		JBrowse link
G Mpz myelin protein zero increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MPZ mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MPZ mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr13:86,103,290...86,109,156
Ensembl chr13:86,103,290...86,109,155 		JBrowse link
G Mpzl1 myelin protein zero-like 1 increases expression ISO trichostatin A results in increased expression of MPZL1 mRNA CTD PMID:24935251 NCBI chr13:80,385,454...80,422,315
Ensembl chr13:80,385,456...80,422,390 		JBrowse link
G Mpzl2 myelin protein zero-like 2 increases expression ISO trichostatin A results in increased expression of MPZL2 mRNA CTD PMID:24935251 NCBI chr 8:54,244,920...54,256,064
Ensembl chr 8:54,243,556...54,256,074 		JBrowse link
G Mrm1 mitochondrial rRNA methyltransferase 1 affects expression ISO trichostatin A affects the expression of MRM1 mRNA CTD PMID:28542535 NCBI chr10:70,187,842...70,194,785
Ensembl chr10:70,188,748...70,194,131 		JBrowse link
G Mrm3 mitochondrial rRNA methyltransferase 3 multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of MRM3 mRNA] CTD PMID:14575637 NCBI chr10:61,594,155...61,623,659
Ensembl chr10:61,593,999...61,600,865 		JBrowse link
G Mrnip MRN complex interacting protein affects expression ISO trichostatin A affects the expression of MRNIP mRNA CTD PMID:28542535 NCBI chr10:35,002,440...35,026,555 JBrowse link
G Mrpl12 mitochondrial ribosomal protein L12 affects expression ISO trichostatin A affects the expression of MRPL12 mRNA CTD PMID:28542535 NCBI chr10:106,256,746...106,261,249
Ensembl chr10:106,256,547...106,263,088 		JBrowse link
G Mrpl15 mitochondrial ribosomal protein L15 affects expression ISO trichostatin A affects the expression of MRPL15 mRNA CTD PMID:28542535 NCBI chr 5:19,527,745...19,539,061
Ensembl chr 5:19,524,588...19,538,004 		JBrowse link
G Mrpl30 mitochondrial ribosomal protein L30 decreases expression ISO trichostatin A results in decreased expression of MRPL30 mRNA CTD PMID:24935251 NCBI chr 9:47,621,226...47,631,986
Ensembl chr 9:47,621,227...47,633,484 		JBrowse link
G Mrpl46 mitochondrial ribosomal protein L46 affects expression ISO trichostatin A affects the expression of MRPL46 mRNA CTD PMID:28542535 NCBI chr 1:142,108,266...142,117,030
Ensembl chr 1:142,106,531...142,117,030 		JBrowse link
G Mrpl50 mitochondrial ribosomal protein L50 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MRPL50 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MRPL50 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:68,662,933...68,668,087
Ensembl chr 5:68,662,939...68,669,748 		JBrowse link
G Mrps14 mitochondrial ribosomal protein S14 increases expression ISO trichostatin A results in increased expression of MRPS14 mRNA CTD PMID:24935251 NCBI chr13:74,962,597...74,968,344
Ensembl chr13:74,962,515...74,970,975 		JBrowse link
G Mrps18b mitochondrial ribosomal protein S18B affects expression ISO trichostatin A affects the expression of MRPS18B mRNA CTD PMID:28542535 NCBI chr20:2,842,978...2,849,065
Ensembl chr20:2,842,528...2,849,065 		JBrowse link
G Mrps22 mitochondrial ribosomal protein S22 affects expression ISO trichostatin A affects the expression of MRPS22 mRNA CTD PMID:28542535 NCBI chr 8:108,063,468...108,076,638
Ensembl chr 8:108,063,471...108,076,638 		JBrowse link
G Mrps5 mitochondrial ribosomal protein S5 affects expression ISO trichostatin A affects the expression of MRPS5 mRNA CTD PMID:28542535 NCBI chr 3:135,274,333...135,290,577
Ensembl chr 3:135,274,493...135,291,640 		JBrowse link
G Mrto4 MRT4 homolog, ribosome maturation factor affects expression ISO trichostatin A affects the expression of MRTO4 mRNA CTD PMID:28542535 NCBI chr 5:156,884,985...156,891,738
Ensembl chr 5:156,884,985...156,891,738 		JBrowse link
G Ms4a2 membrane spanning 4-domains A2 multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of MS4A2 mRNA] CTD PMID:14575637 NCBI chr 1:217,864,855...217,873,934
Ensembl chr 1:217,865,159...217,873,108 		JBrowse link
G Msantd3 Myb/SANT DNA binding domain containing 3 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of MSANTD3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MSANTD3 mRNA
trichostatin A affects the expression of MSANTD3 mRNA 		CTD PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 5:67,661,551...67,687,971
Ensembl chr 5:67,661,912...67,684,384 		JBrowse link
G Msantd4 Myb/SANT DNA binding domain containing 4 with coiled-coils decreases expression ISO trichostatin A results in decreased expression of MSANTD4 mRNA CTD PMID:24935251 NCBI chr 8:9,801,921...9,812,529
Ensembl chr 8:9,801,903...9,812,529 		JBrowse link
G Msi2 musashi RNA-binding protein 2 decreases expression ISO trichostatin A results in decreased expression of MSI2 mRNA CTD PMID:24935251 NCBI chr10:73,640,960...74,007,497
Ensembl chr10:73,646,139...74,007,552 		JBrowse link
G Msl1 MSL complex subunit 1 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of MSL1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MSL1 mRNA
trichostatin A affects the expression of MSL1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr10:84,251,362...84,263,384
Ensembl chr10:84,251,642...84,261,971 		JBrowse link
G Msl3 MSL complex subunit 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MSL3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MSL3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:29,210,388...29,228,060
Ensembl chr  X:29,210,427...29,228,054 		JBrowse link
G Msr1 macrophage scavenger receptor 1 increases expression ISO trichostatin A results in increased expression of MSR1 mRNA CTD PMID:29718165 NCBI chr16:59,421,250...59,507,070
Ensembl chr16:59,421,057...59,507,070 		JBrowse link
G Msrb3 methionine sulfoxide reductase B3 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of MSRB3 mRNA
trichostatin A results in decreased expression of MSRB3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MSRB3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:58,188,827...58,311,459
Ensembl chr 7:57,968,124...58,311,116 		JBrowse link
G Mstn myostatin increases expression
affects expression 		ISO trichostatin A results in increased expression of MSTN mRNA
trichostatin A affects the expression of MSTN mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 9:55,944,513...55,950,913
Ensembl chr 9:55,944,513...55,950,913 		JBrowse link
G Msx1 msh homeobox 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MSX1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr14:77,185,802...77,189,735
Ensembl chr14:77,185,802...77,189,735 		JBrowse link
G Msx2 msh homeobox 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MSX2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr17:11,102,284...11,107,949
Ensembl chr17:11,102,247...11,107,945 		JBrowse link
G Mt1-ps3 metallothionein 1, pseudogene 3 increases expression ISO trichostatin A results in increased expression of MT1E mRNA CTD PMID:26705709 NCBI chr17:79,695,812...79,696,200
Ensembl chr17:79,695,809...79,696,200 		JBrowse link
G Mt1a metallothionein 1A multiple interactions ISO chromium hexavalent ion inhibits the reaction [trichostatin A promotes the reaction [Zinc results in increased expression of MT1 mRNA]]; trichostatin A promotes the reaction [Zinc results in increased expression of MT1 mRNA] CTD PMID:21467744 NCBI chr19:10,831,959...10,832,975
Ensembl chr17:79,695,809...79,696,200
Ensembl chr  X:79,695,809...79,696,200
Ensembl chr19:79,695,809...79,696,200 		JBrowse link
G Mta2 metastasis associated 1 family, member 2 affects expression ISO trichostatin A affects the expression of MTA2 mRNA CTD PMID:28542535 NCBI chr 1:215,267,286...215,276,008
Ensembl chr 1:215,267,046...215,276,062 		JBrowse link
G Mta3 metastasis associated 1 family, member 3 decreases expression
affects expression 		ISO trichostatin A results in decreased expression of MTA3 mRNA
trichostatin A affects the expression of MTA3 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 6:16,619,575...16,739,732
Ensembl chr 6:16,621,998...16,739,485 		JBrowse link
G Mtap methylthioadenosine phosphorylase increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MTAP mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTAP mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:108,990,270...109,036,494
Ensembl chr 5:108,988,830...109,055,214 		JBrowse link
G Mtdh metadherin increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MTDH mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTDH mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:67,192,592...67,250,819
Ensembl chr 7:67,192,393...67,249,584 		JBrowse link
G Mthfd1 methylenetetrahydrofolate dehydrogenase, cyclohydrolase and formyltetrahydrofolate synthetase 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MTHFD1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTHFD1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:100,713,510...100,781,013
Ensembl chr 6:100,713,681...100,781,957 		JBrowse link
G Mthfd1l methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MTHFD1L mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTHFD1L mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:42,849,424...43,038,313
Ensembl chr 1:42,849,374...43,038,309 		JBrowse link
G Mthfd2l methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2-like increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MTHFD2L mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTHFD2L mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr14:17,374,139...17,455,508
Ensembl chr14:17,374,144...17,454,322 		JBrowse link
G Mtif2 mitochondrial translational initiation factor 2 affects expression ISO trichostatin A affects the expression of MTIF2 mRNA CTD PMID:28542535 NCBI chr14:107,465,719...107,486,663
Ensembl chr14:107,466,861...107,487,003 		JBrowse link
G Mtm1 myotubularin 1 decreases expression ISO trichostatin A results in decreased expression of MTM1 mRNA CTD PMID:26272509 NCBI chr 6:6,234,917...6,252,874
Ensembl chr 6:6,234,922...6,252,961 		JBrowse link
G Mtmr7 myotubularin related protein 7 increases expression ISO trichostatin A results in increased expression of MTMR7 mRNA CTD PMID:28542535 NCBI chr16:58,344,755...58,435,682
Ensembl chr16:58,344,767...58,436,615 		JBrowse link
G Mtr 5-methyltetrahydrofolate-homocysteine methyltransferase increases expression ISO trichostatin A results in increased expression of MTR mRNA CTD PMID:24935251 NCBI chr17:62,911,705...62,996,544
Ensembl chr17:62,911,771...62,996,541 		JBrowse link
G Mtres1 mitochondrial transcription rescue factor 1 increases expression
affects expression 		ISO trichostatin A results in increased expression of MTRES1 mRNA
trichostatin A affects the expression of MTRES1 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr20:48,604,479...48,622,364
Ensembl chr20:48,604,372...48,622,014 		JBrowse link
G Mtrex Mtr4 exosome RNA helicase affects expression ISO trichostatin A affects the expression of MTREX mRNA CTD PMID:28542535 NCBI chr 2:46,233,528...46,293,827
Ensembl chr 2:46,194,647...46,293,827 		JBrowse link
G Mtrf1l mitochondrial translation release factor 1 like increases expression ISO trichostatin A results in increased expression of MTRF1L mRNA CTD PMID:28542535 NCBI chr 1:44,614,162...44,626,367
Ensembl chr 1:44,615,921...44,626,178 		JBrowse link
G Mtss1 MTSS I-BAR domain containing 1 increases expression ISO trichostatin A results in increased expression of MTSS1 mRNA CTD PMID:24935251 PMID:28542535 NCBI chr 7:92,378,228...92,517,444
Ensembl chr 7:92,378,238...92,517,303 		JBrowse link
G Mttp microsomal triglyceride transfer protein multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of MTTP mRNA] CTD PMID:14575637 NCBI chr 2:229,286,501...229,327,650
Ensembl chr 2:229,286,501...229,327,650 		JBrowse link
G Mturn maturin, neural progenitor differentiation regulator homolog decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MTURN mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MTURN mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:85,137,825...85,158,790
Ensembl chr 4:85,137,846...85,158,789 		JBrowse link
G Muc15 mucin 15, cell surface associated increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MUC15 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC15 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:117,749,161...117,761,466
Ensembl chr 3:117,749,324...117,762,101 		JBrowse link
G Muc4 mucin 4, cell surface associated multiple interactions
increases expression 		ISO [Decitabine co-treated with trichostatin A] results in increased expression of MUC4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC4 mRNA
trichostatin A results in increased expression of MUC4 mRNA 		CTD PMID:19127263 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr11:81,513,321...81,575,200 JBrowse link
G Mustn1 musculoskeletal, embryonic nuclear protein 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MUSTN1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUSTN1 mRNA 		CTD PMID:24935251 PMID:27188386 NCBI chr16:6,079,355...6,081,608
Ensembl chr16:6,079,277...6,081,586 		JBrowse link
G Mvk mevalonate kinase decreases expression ISO trichostatin A results in decreased expression of MVK mRNA CTD PMID:27188386 NCBI chr12:47,802,002...47,819,503
Ensembl chr12:47,802,002...47,819,503 		JBrowse link
G Mx1 MX dynamin like GTPase 1 multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of MX1 mRNA] CTD PMID:14575637 NCBI chr11:50,269,056...50,294,699
Ensembl chr11:50,269,057...50,292,904 		JBrowse link
G Mxi1 MAX interactor 1, dimerization protein increases expression
affects expression 		ISO trichostatin A results in increased expression of MXI1 mRNA
trichostatin A affects the expression of MXI1 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 1:262,329,274...262,389,037
Ensembl chr 1:262,328,875...262,389,036 		JBrowse link
G Mxra7 matrix remodeling associated 7 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of MXRA7 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MXRA7 mRNA
trichostatin A affects the expression of MXRA7 mRNA 		CTD PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr10:102,501,848...102,530,231
Ensembl chr10:102,489,604...102,530,231 		JBrowse link
G Myb MYB proto-oncogene, transcription factor decreases expression ISO trichostatin A results in decreased expression of MYB mRNA CTD PMID:24935251 NCBI chr 1:17,759,309...17,793,306
Ensembl chr 1:17,759,309...17,792,547 		JBrowse link
G Mybbp1a MYB binding protein 1a affects expression ISO trichostatin A affects the expression of MYBBP1A mRNA CTD PMID:28542535 NCBI chr10:57,555,458...57,565,819
Ensembl chr10:57,555,452...57,566,041 		JBrowse link
G Mybl1 MYB proto-oncogene like 1 increases expression
affects expression 		ISO trichostatin A results in increased expression of MYBL1 mRNA
trichostatin A affects the expression of MYBL1 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr 5:14,365,768...14,401,012
Ensembl chr 5:14,365,768...14,399,588 		JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions
decreases expression
affects expression 		ISO [3-deazaneplanocin co-treated with trichostatin A] affects the expression of MYC protein; [Decitabine co-treated with trichostatin A] results in increased expression of MYC mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYC mRNA
trichostatin A inhibits the reaction [IL3 protein results in increased expression of MYC mRNA]
trichostatin A results in decreased expression of MYC mRNA
trichostatin A affects the expression of MYC mRNA 		CTD PMID:12414619 PMID:17185465 PMID:18538736 PMID:24935251 PMID:25769527 More... NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028 		JBrowse link
G Mycbp2 MYC binding protein 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MYCBP2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYCBP2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:86,352,061...86,590,126
Ensembl chr15:86,352,061...86,590,325 		JBrowse link
G Mycl MYCL proto-oncogene, bHLH transcription factor decreases expression
increases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of MYCL mRNA
trichostatin A results in increased expression of MYCL mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYCL mRNA
trichostatin A affects the expression of MYCL mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 5:140,559,843...140,566,704
Ensembl chr 5:140,560,152...140,566,699 		JBrowse link
G Mycn MYCN proto-oncogene, bHLH transcription factor decreases expression
increases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MYCN mRNA
trichostatin A results in increased expression of MYCN mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYCN mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:41,446,683...41,452,584
Ensembl chr 6:41,446,684...41,452,508 		JBrowse link
G Myct1 myc target 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MYCT1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYCT1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:44,423,478...44,434,751
Ensembl chr 1:44,423,544...44,436,992 		JBrowse link
G Myd88 MYD88, innate immune signal transduction adaptor affects expression ISO trichostatin A affects the expression of MYD88 mRNA CTD PMID:28542535 NCBI chr 8:127,952,161...127,956,230
Ensembl chr 8:127,952,161...127,956,230 		JBrowse link
G Myef2 myelin expression factor 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MYEF2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYEF2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:132,791,694...132,827,572
Ensembl chr 3:132,791,694...132,827,523 		JBrowse link
G Myh2 myosin heavy chain 2 decreases expression ISO trichostatin A results in decreased expression of MYH2 mRNA CTD PMID:24935251 NCBI chr10:52,355,739...52,382,235
Ensembl chr10:52,355,739...52,382,235 		JBrowse link
G Myh3 myosin heavy chain 3 multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of MYH3 mRNA] CTD PMID:14575637 NCBI chr10:52,269,185...52,293,000
Ensembl chr10:52,269,185...52,293,000 		JBrowse link
G Myh7 myosin heavy chain 7 multiple interactions EXP trichostatin A inhibits the reaction [Phenylephrine results in increased expression of MYH7 mRNA] CTD PMID:15593114 NCBI chr15:32,416,525...32,439,851
Ensembl chr15:32,416,527...32,438,194 		JBrowse link
G Myh9 myosin, heavy chain 9 increases expression ISO trichostatin A results in increased expression of MYH9 mRNA CTD PMID:26238599 NCBI chr 7:111,224,291...111,304,963
Ensembl chr 7:111,224,291...111,304,963 		JBrowse link
G Mylip myosin regulatory light chain interacting protein increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MYLIP mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr17:19,492,826...19,514,490
Ensembl chr17:19,492,826...19,514,471 		JBrowse link
G Mylk myosin light chain kinase decreases expression
increases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MYLK mRNA
trichostatin A results in increased expression of MYLK mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA 		CTD PMID:24935251 PMID:26238599 PMID:26272509 PMID:27188386 NCBI chr11:79,288,243...79,535,450
Ensembl chr11:79,288,243...79,535,659 		JBrowse link
G Myo10 myosin X decreases expression
increases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MYO10 mRNA
trichostatin A results in increased expression of MYO10 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO10 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:77,831,532...78,036,137
Ensembl chr 2:77,831,532...78,036,137 		JBrowse link
G Myo19 myosin XIX affects expression ISO trichostatin A affects the expression of MYO19 mRNA CTD PMID:28542535 NCBI chr10:70,250,500...70,279,867
Ensembl chr10:70,250,022...70,279,858 		JBrowse link
G Myo1b myosin Ib increases expression ISO trichostatin A results in increased expression of MYO1B mRNA CTD PMID:24935251 NCBI chr 9:57,182,059...57,344,335
Ensembl chr 9:57,181,987...57,344,328 		JBrowse link
G Myo1d myosin ID increases expression ISO trichostatin A results in increased expression of MYO1D mRNA CTD PMID:24935251 NCBI chr10:65,986,900...66,263,538
Ensembl chr10:65,975,122...66,263,958 		JBrowse link
G Myo1e myosin IE increases expression ISO trichostatin A results in increased expression of MYO1E mRNA CTD PMID:24935251 NCBI chr 8:79,768,828...79,961,048
Ensembl chr 8:79,753,596...79,961,045 		JBrowse link
G Myo3b myosin IIIB decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of MYO3B mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYO3B mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:75,228,017...75,636,272
Ensembl chr 3:75,228,017...75,636,272 		JBrowse link
G Myo5b myosin Vb increases expression ISO trichostatin A results in increased expression of MYO5B mRNA CTD PMID:24935251 NCBI chr18:70,313,717...70,613,918
Ensembl chr18:70,311,990...70,613,918 		JBrowse link
G Myo5c myosin VC increases expression ISO trichostatin A results in increased expression of MYO5C mRNA CTD PMID:24935251 NCBI chr 8:84,870,031...84,946,996
Ensembl chr 8:84,870,043...84,946,996 		JBrowse link
G Myo7a myosin VIIA increases expression ISO trichostatin A results in increased expression of MYO7A mRNA CTD PMID:24935251 NCBI chr 1:161,755,110...161,825,397
Ensembl chr 1:161,755,110...161,825,365 		JBrowse link
G Myo9a myosin IXA increases expression ISO trichostatin A results in increased expression of MYO9A mRNA CTD PMID:24935251 NCBI chr 8:69,044,853...69,248,094
Ensembl chr 8:69,044,885...69,245,231 		JBrowse link
G Myocd myocardin increases expression ISO trichostatin A results in increased expression of MYOCD mRNA CTD PMID:24935251 PMID:26705709 NCBI chr10:50,332,356...50,426,819
Ensembl chr10:50,332,356...50,426,819 		JBrowse link
G Myof myoferlin increases expression
multiple interactions 		ISO trichostatin A results in increased expression of MYOF mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYOF mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:245,086,109...245,234,768
Ensembl chr 1:245,086,109...245,234,768 		JBrowse link
G Myoz2 myozenin 2 increases expression ISO trichostatin A results in increased expression of MYOZ2 mRNA CTD PMID:26705709 NCBI chr 2:213,826,052...213,852,778
Ensembl chr 2:213,826,052...213,852,914 		JBrowse link
G Myrip myosin VIIA and Rab interacting protein increases expression ISO trichostatin A results in increased expression of MYRIP mRNA CTD PMID:24935251 NCBI chr 8:128,895,371...129,062,420
Ensembl chr 8:128,895,371...129,062,420 		JBrowse link
G Myt1l myelin transcription factor 1-like multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of MYT1L mRNA] CTD PMID:14575637 NCBI chr 6:51,892,858...52,291,830
Ensembl chr 6:52,155,754...52,291,828 		JBrowse link
G Myzap myocardial zonula adherens protein affects expression ISO trichostatin A affects the expression of MYZAP mRNA CTD PMID:28542535 NCBI chr 8:81,036,599...81,123,933
Ensembl chr 8:81,036,601...81,123,810 		JBrowse link
G N4bp1 Nedd4 binding protein 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of N4BP1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of N4BP1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr19:36,396,082...36,446,835
Ensembl chr19:36,396,324...36,446,835 		JBrowse link
G N4bp2 NEDD4 binding protein 2 affects expression ISO trichostatin A affects the expression of N4BP2 mRNA CTD PMID:28542535 NCBI chr14:42,696,415...42,819,535
Ensembl chr14:42,763,601...42,825,039 		JBrowse link
G N4bp2l1 NEDD4 binding protein 2-like 1 increases expression ISO trichostatin A results in increased expression of N4BP2L1 mRNA CTD PMID:24935251 NCBI chr12:4,938,199...4,965,003
Ensembl chr12:4,927,142...4,963,045 		JBrowse link
G N4bp2l2 NEDD4 binding protein 2-like 2 increases expression ISO trichostatin A results in increased expression of N4BP2L2 mRNA CTD PMID:24935251 NCBI chr12:4,972,967...5,038,027
Ensembl chr12:4,972,990...5,033,405 		JBrowse link
G N4bp3 Nedd4 binding protein 3 decreases expression ISO trichostatin A results in decreased expression of N4BP3 mRNA CTD PMID:24935251 NCBI chr10:36,400,053...36,407,609
Ensembl chr10:36,400,057...36,407,637 		JBrowse link
G N6amt1 N-6 adenine-specific DNA methyltransferase 1 decreases expression ISO trichostatin A results in decreased expression of HEMK2 mRNA CTD PMID:24935251 NCBI chr11:40,071,017...40,083,463
Ensembl chr11:40,070,993...40,083,680 		JBrowse link
G Naa16 N(alpha)-acetyltransferase 16, NatA auxiliary subunit decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of NAA16 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NAA16 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:61,120,704...61,179,979
Ensembl chr15:61,120,704...61,180,146 		JBrowse link
G Naa25 N(alpha)-acetyltransferase 25, NatB auxiliary subunit increases expression ISO trichostatin A results in increased expression of NAA25 mRNA CTD PMID:26272509 NCBI chr12:40,758,909...40,811,192
Ensembl chr12:40,758,728...40,811,291 		JBrowse link
G Naaa N-acylethanolamine acid amidase increases expression ISO trichostatin A results in increased expression of NAAA mRNA CTD PMID:24935251 NCBI chr14:16,061,599...16,080,703
Ensembl chr14:16,061,583...16,080,702 		JBrowse link
G Naalad2 N-acetylated alpha-linked acidic dipeptidase 2 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of NAALAD2 mRNA
trichostatin A results in decreased expression of NAALAD2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NAALAD2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 8:23,682,499...23,756,066
Ensembl chr 8:23,683,395...23,756,060 		JBrowse link
G Nab2 Ngfi-A binding protein 2 multiple interactions ISO trichostatin A inhibits the reaction [BDNF protein results in increased expression of NAB2 protein] CTD PMID:24204683 NCBI chr 7:65,382,863...65,389,527
Ensembl chr 7:65,382,863...65,389,255 		JBrowse link
G Nabp1 nucleic acid binding protein 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of NABP1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NABP1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 9:57,570,326...57,625,926
Ensembl chr 9:57,618,505...57,626,052 		JBrowse link
G Nabp2 nucleic acid binding protein 2 multiple interactions
decreases ubiquitination
increases acetylation 		ISO Niacinamide promotes the reaction [trichostatin A results in decreased ubiquitination of NABP2 protein]; Niacinamide promotes the reaction [trichostatin A results in increased acetylation of NABP2 protein]; trichostatin A promotes the reaction [Niacinamide results in decreased ubiquitination of NABP2 protein]; trichostatin A promotes the reaction [Niacinamide results in increased acetylation of NABP2 protein] CTD PMID:26170237 NCBI chr 7:1,415,491...1,421,113
Ensembl chr 7:1,415,492...1,422,682 		JBrowse link
G Naca nascent polypeptide associated complex subunit alpha multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of NACA mRNA] CTD PMID:14575637 NCBI chr 7:1,053,474...1,066,606
Ensembl chr 7:1,054,338...1,066,605 		JBrowse link
G Nadk2 NAD kinase 2, mitochondrial decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of NADK2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NADK2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:59,844,854...59,886,989
Ensembl chr 2:59,844,854...59,886,988 		JBrowse link
G Naip6 NLR family, apoptosis inhibitory protein 6 increases expression ISO trichostatin A results in increased expression of NAIP mRNA CTD PMID:24935251 NCBI chr 2:33,241,520...33,293,184
Ensembl chr 2:33,241,521...33,276,859 		JBrowse link
G Nalf1 NALCN channel auxiliary factor 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of NALF1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NALF1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr16:86,415,540...86,938,150
Ensembl chr16:86,415,488...86,938,150 		JBrowse link
G Nampt nicotinamide phosphoribosyltransferase increases expression ISO trichostatin A results in increased expression of NAMPT mRNA CTD PMID:24935251 NCBI chr 6:55,152,756...55,189,547
Ensembl chr 6:55,151,926...55,189,544 		JBrowse link
G Nanog Nanog homeobox increases expression
multiple interactions 		ISO trichostatin A results in increased expression of NANOG mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANOG mRNA 		CTD PMID:22723015 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:157,615,687...157,623,061
Ensembl chr 4:157,615,687...157,623,061 		JBrowse link
G Nanos1 nanos C2HC-type zinc finger 1 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of NANOS1 mRNA
trichostatin A results in decreased expression of NANOS1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NANOS1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:269,883,713...269,887,611
Ensembl chr 1:269,883,536...269,895,417 		JBrowse link
G Nans N-acetylneuraminate synthase increases expression
multiple interactions 		ISO trichostatin A results in increased expression of NANS mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANS mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:65,575,970...65,593,164
Ensembl chr 5:65,576,015...65,610,547 		JBrowse link
G Nap1l5 nucleosome assembly protein 1-like 5 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of NAP1L5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NAP1L5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 4:89,352,834...89,354,704
Ensembl chr 4:89,351,926...89,361,736 		JBrowse link
G Napepld N-acyl phosphatidylethanolamine phospholipase D increases expression ISO trichostatin A results in increased expression of NAPEPLD mRNA CTD PMID:24935251 NCBI chr 4:14,251,591...14,291,010
Ensembl chr 4:14,252,692...14,291,014 		JBrowse link
G Narf nuclear prelamin A recognition factor affects expression ISO trichostatin A affects the expression of NARF mRNA CTD PMID:28542535 NCBI chr10:107,017,344...107,035,777
Ensembl chr10:107,016,510...107,037,283 		JBrowse link
G Nat2 N-acetyltransferase 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of NAT2 mRNA
[trichostatin A co-treated with Benzo(a)pyrene] results in increased expression of NAT2 mRNA 		CTD PMID:24935251 PMID:30439556 NCBI chr16:26,974,874...27,005,191
Ensembl chr16:26,974,601...26,976,304 		JBrowse link
G Nat8l N-acetyltransferase 8-like decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of NAT8L mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NAT8L mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:80,980,629...80,987,264
Ensembl chr14:80,980,629...80,987,463 		JBrowse link
G Nav1 neuron navigator 1 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of NAV1 mRNA
trichostatin A results in decreased expression of NAV1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NAV1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr13:49,418,755...49,671,117
Ensembl chr13:49,418,755...49,671,004 		JBrowse link
G Nav2 neuron navigator 2 increases expression ISO trichostatin A results in increased expression of NAV2 mRNA CTD PMID:24935251 NCBI chr 1:107,799,968...108,458,546
Ensembl chr 1:107,805,096...108,458,546 		JBrowse link
G Nav3 neuron navigator 3 decreases expression
increases expression
multiple interactions 		ISO trichostatin A results in decreased expression of NAV3 mRNA
trichostatin A results in increased expression of NAV3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NAV3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:26705709 PMID:27188386 NCBI chr 7:46,938,577...47,726,839
Ensembl chr 7:46,940,670...47,504,893 		JBrowse link
G Nbas NBAS subunit of NRZ tethering complex increases expression
decreases expression 		ISO trichostatin A results in increased expression of NBAS mRNA
trichostatin A results in decreased expression of NBAS mRNA 		CTD PMID:24935251 NCBI chr 6:41,777,253...42,081,895
Ensembl chr 6:41,755,851...42,081,895 		JBrowse link
G Nbl1 NBL1, DAN family BMP antagonist decreases expression ISO trichostatin A results in decreased expression of NBL1 mRNA CTD PMID:24935251 NCBI chr 5:156,601,986...156,613,182
Ensembl chr 5:156,601,986...156,613,186 		JBrowse link
G Nbn nibrin affects expression ISO trichostatin A affects the expression of NBN mRNA CTD PMID:28542535 NCBI chr 5:34,256,678...34,291,163
Ensembl chr 5:34,256,627...34,291,162 		JBrowse link
G Ncald neurocalcin delta decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of NCALD mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCALD mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:70,417,683...70,849,763
Ensembl chr 7:70,419,433...70,849,482 		JBrowse link
G Ncam1 neural cell adhesion molecule 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of NCAM1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NCAM1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 8:58,762,088...59,062,131
Ensembl chr 8:58,762,116...59,061,971 		JBrowse link
G Ncan neurocan decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of NCAN mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCAN mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr16:19,335,907...19,362,371
Ensembl chr16:19,335,907...19,362,371 		JBrowse link
G Ncapd2 non-SMC condensin I complex, subunit D2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of NCAPD2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCAPD2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:159,655,051...159,677,938
Ensembl chr 4:159,655,051...159,677,938 		JBrowse link
G Ncbp2 nuclear cap binding protein subunit 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of NCBP2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NCBP2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:82,326,002...82,334,839
Ensembl chr11:82,322,716...82,335,116 		JBrowse link
G Nceh1 neutral cholesterol ester hydrolase 1 increases expression ISO trichostatin A results in increased expression of NCEH1 mRNA CTD PMID:24935251 NCBI chr 2:112,003,677...112,064,274
Ensembl chr 2:112,003,502...112,064,272 		JBrowse link
G Nck1 NCK adaptor protein 1 multiple interactions ISO [decitabine co-treated with trichostatin A] results in increased expression of NCK1 mRNA CTD PMID:20678512 NCBI chr 8:109,897,723...109,958,247
Ensembl chr 8:109,897,724...109,958,247 		JBrowse link
G Nckap5 NCK-associated protein 5 increases expression ISO trichostatin A results in increased expression of NCKAP5 mRNA CTD PMID:26705709 NCBI chr13:39,922,576...40,835,849
Ensembl chr13:39,922,737...40,835,521 		JBrowse link
G Ncoa2 nuclear receptor coactivator 2 affects expression ISO trichostatin A affects the expression of NCOA2 mRNA CTD PMID:28542535 NCBI chr 5:10,618,712...10,852,776
Ensembl chr 5:10,618,722...10,852,776 		JBrowse link
G Ncoa3 nuclear receptor coactivator 3 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of NCOA3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCOA3 mRNA
trichostatin A affects the expression of NCOA3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 3:175,157,824...175,237,831
Ensembl chr 3:175,157,821...175,240,631 		JBrowse link
G Ncoa4 nuclear receptor coactivator 4 multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of NCOA4 mRNA] CTD PMID:14575637 NCBI chr16:7,395,502...7,415,846
Ensembl chr16:7,401,802...7,415,840 		JBrowse link
G Ncoa7 nuclear receptor coactivator 7 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of NCOA7 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NCOA7 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:28,674,614...28,835,891
Ensembl chr 1:28,675,426...28,835,886 		JBrowse link
G Ncor2 nuclear receptor co-repressor 2 affects localization
multiple interactions 		EXP
ISO 		trichostatin A affects the localization of NCOR2 protein
Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]; trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]] 		CTD PMID:15773917 PMID:26883953 NCBI chr12:37,127,736...37,289,612
Ensembl chr12:37,127,686...37,289,612 		JBrowse link
G Ncr1 natural cytotoxicity triggering receptor 1 multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of NCR1 mRNA] CTD PMID:14575637 NCBI chr 1:78,657,409...78,665,255
Ensembl chr 1:78,659,262...78,703,273 		JBrowse link
G Ndc1 NDC1 transmembrane nucleoporin affects expression ISO trichostatin A affects the expression of NDC1 mRNA CTD PMID:28542535 NCBI chr 5:127,384,172...127,431,093
Ensembl chr 5:127,384,665...127,431,090 		JBrowse link
G Ndc80 NDC80 kinetochore complex component decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of NDC80 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDC80 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:118,853,806...118,887,582
Ensembl chr 9:118,853,806...118,887,568 		JBrowse link
G Ndfip2 Nedd4 family interacting protein 2 increases expression
affects expression 		ISO trichostatin A results in increased expression of NDFIP2 mRNA
trichostatin A affects the expression of NDFIP2 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr15:88,394,548...88,500,881
Ensembl chr15:88,395,032...88,503,600 		JBrowse link
G Ndp norrin cystine knot growth factor NDP decreases expression ISO trichostatin A results in decreased expression of NDP mRNA CTD PMID:24935251 NCBI chr  X:8,379,569...8,404,019
Ensembl chr  X:8,379,569...8,406,802 		JBrowse link
G Ndst1 N-deacetylase and N-sulfotransferase 1 affects expression ISO trichostatin A affects the expression of NDST1 mRNA CTD PMID:28542535 NCBI chr18:56,407,308...56,470,007
Ensembl chr18:56,411,200...56,448,612 		JBrowse link
G Ndst4 N-deacetylase and N-sulfotransferase 4 increases expression ISO trichostatin A results in increased expression of NDST4 mRNA CTD PMID:27188386 NCBI chr 2:216,461,542...216,794,035
Ensembl chr 2:216,461,543...216,794,035 		JBrowse link
G Ndufa2 NADH:ubiquinone oxidoreductase subunit A2 affects expression ISO trichostatin A affects the expression of NDUFA2 mRNA CTD PMID:28542535 NCBI chr18:28,629,795...28,631,884
Ensembl chr18:28,629,795...28,631,884 		JBrowse link
G Ndufaf4 NADH:ubiquinone oxidoreductase complex assembly factor 4 affects expression ISO trichostatin A affects the expression of NDUFAF4 mRNA CTD PMID:28542535 NCBI chr 5:43,401,795...43,406,967 JBrowse link
G Ndufb6 NADH:ubiquinone oxidoreductase subunit B6 multiple interactions
increases expression 		ISO trichostatin A inhibits the reaction [Nickel affects the expression of NDUFB6 mRNA]
trichostatin A results in increased expression of NDUFB6 mRNA 		CTD PMID:14575637 PMID:24935251 NCBI chr 5:60,196,585...60,206,152
Ensembl chr 5:60,196,585...60,206,055 		JBrowse link
G Ndufc2 NADH:ubiquinone oxidoreductase subunit C2 multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of NDUFC2 mRNA] CTD PMID:14575637 NCBI chr 1:161,122,370...161,129,413
Ensembl chr 1:161,123,150...161,129,419 		JBrowse link
G Necab2 N-terminal EF-hand calcium binding protein 2 decreases expression ISO trichostatin A results in decreased expression of NECAB2 mRNA CTD PMID:24935251 NCBI chr19:64,409,627...64,436,371
Ensembl chr19:64,409,751...64,436,369 		JBrowse link
G Nectin2 nectin cell adhesion molecule 2 decreases expression ISO trichostatin A results in decreased expression of NECTIN2 mRNA CTD PMID:24935251 NCBI chr 1:88,500,086...88,535,474
Ensembl chr 1:88,500,087...88,535,305 		JBrowse link
G Nedd4l NEDD4 like E3 ubiquitin protein ligase increases expression
multiple interactions 		ISO trichostatin A results in increased expression of NEDD4L mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEDD4L mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr18:60,663,918...60,996,824
Ensembl chr18:60,663,970...60,996,824 		JBrowse link
G Nedd9 neural precursor cell expressed, developmentally down-regulated 9 decreases expression ISO trichostatin A results in decreased expression of NEDD9 mRNA CTD PMID:24935251 NCBI chr17:23,495,531...23,673,780
Ensembl chr17:23,495,492...23,675,668 		JBrowse link
G Nefh neurofilament heavy chain increases expression ISO trichostatin A results in increased expression of NEFH mRNA CTD PMID:24935251 NCBI chr14:84,044,428...84,054,413
Ensembl chr14:84,044,023...84,054,417 		JBrowse link
G Nefl neurofilament light chain increases expression
multiple interactions 		ISO trichostatin A results in increased expression of NEFL mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEFL mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:46,477,330...46,481,203
Ensembl chr15:46,458,204...46,482,515 		JBrowse link
G Nefm neurofilament medium chain increases expression ISO trichostatin A results in increased expression of NEFM mRNA CTD PMID:24935251 PMID:26272509 NCBI chr15:46,535,857...46,541,161
Ensembl chr15:46,535,517...46,541,163 		JBrowse link
G Negr1 neuronal growth regulator 1 increases expression ISO trichostatin A results in increased expression of NEGR1 mRNA CTD PMID:24935251 PMID:26705709 PMID:27188386 NCBI chr 2:248,283,164...249,015,538
Ensembl chr 2:248,283,353...249,018,410 		JBrowse link
G Nek2 NIMA-related kinase 2 affects expression ISO trichostatin A affects the expression of NEK2 mRNA CTD PMID:28542535 NCBI chr13:105,936,809...105,950,054
Ensembl chr13:105,936,788...105,950,056 		JBrowse link
G Nell2 neural EGFL like 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of NELL2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NELL2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 7:128,222,333...128,542,127
Ensembl chr 7:128,078,103...128,651,917 		JBrowse link
G Neo1 neogenin 1 decreases expression ISO trichostatin A results in decreased expression of NEO1 mRNA CTD PMID:24935251 NCBI chr 8:68,169,711...68,322,158
Ensembl chr 8:68,169,716...68,322,152 		JBrowse link
G Nepro nucleolus and neural progenitor protein decreases expression ISO trichostatin A results in decreased expression of RMP64 mRNA CTD PMID:24935251 NCBI chr11:69,464,263...69,476,429
Ensembl chr11:69,464,265...69,509,978 		JBrowse link
G Nes nestin decreases methylation
increases acetylation
increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in decreased methylation of NES gene
trichostatin A results in increased acetylation of NES enhancer
trichostatin A results in increased expression of NES mRNA
trichostatin A results in decreased expression of NES mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NES mRNA 		CTD PMID:19415779 PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:175,735,715...175,745,631
Ensembl chr 2:175,736,551...175,746,228 		JBrowse link
G Neto1 neuropilin and tolloid like 1 increases expression ISO trichostatin A results in increased expression of NETO1 mRNA CTD PMID:24935251 NCBI chr18:81,905,455...82,028,730
Ensembl chr18:81,910,355...82,024,505 		JBrowse link
G Neu1 neuraminidase 1 affects expression
increases expression 		ISO trichostatin A affects the expression of NEU1 mRNA
trichostatin A results in increased expression of NEU1 mRNA 		CTD PMID:28542535 PMID:33770205 NCBI chr20:3,902,120...3,906,383
Ensembl chr20:3,902,120...3,906,383 		JBrowse link
G Neurl1b neuralized E3 ubiquitin protein ligase 1B increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of NEURL1B mRNA
trichostatin A results in decreased expression of NEURL1B mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEURL1B mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:17,258,317...17,289,362
Ensembl chr10:17,258,328...17,289,362 		JBrowse link
G Nexmif neurite extension and migration factor increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of NEXMIF mRNA
trichostatin A results in decreased expression of NEXMIF mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEXMIF mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr  X:73,153,786...73,284,943
Ensembl chr  X:73,153,786...73,178,639 		JBrowse link
G Nf1 neurofibromin 1 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of NF1 mRNA
trichostatin A results in decreased expression of NF1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NF1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:64,803,986...65,037,086
Ensembl chr10:64,804,266...65,034,946 		JBrowse link
G Nfasc neurofascin decreases expression ISO trichostatin A results in decreased expression of NFASC mRNA CTD PMID:24935251 NCBI chr13:46,549,369...46,735,989
Ensembl chr13:46,549,369...46,736,139 		JBrowse link
G Nfat5 nuclear factor of activated T-cells 5 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of NFAT5 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFAT5 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr19:52,108,982...52,196,418
Ensembl chr19:52,109,483...52,196,418 		JBrowse link
G Nfatc4 nuclear factor of activated T-cells 4 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of NFATC4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NFATC4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr15:33,256,912...33,284,522
Ensembl chr15:33,274,153...33,285,582 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 increases expression
multiple interactions
affects expression 		ISO
EXP 		trichostatin A results in increased expression of NFE2L2 mRNA
[Decitabine co-treated with trichostatin A] results in decreased methylation of NFE2L2 promoter; [trichostatin A co-treated with Decitabine] results in decreased methylation of NFE2L2 promoter
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFE2L2 mRNA
trichostatin A affects the expression of NFE2L2 mRNA
[manganese chloride results in increased susceptibility to trichostatin A] which results in increased expression of NFE2L2 mRNA; trichostatin A promotes the reaction [manganese chloride results in increased expression of and results in increased activity of NFE2L2 protein] 		CTD PMID:24935251 PMID:26272509 PMID:26991801 PMID:27188386 PMID:28542535 More... NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090 		JBrowse link
G Nfe2l3 NFE2 like bZIP transcription factor 3 increases expression ISO trichostatin A results in increased expression of NFE2L3 mRNA CTD PMID:24935251 NCBI chr 4:81,837,404...81,865,258
Ensembl chr 4:81,837,404...81,865,532 		JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 affects expression ISO trichostatin A affects the expression of NFKB1 mRNA CTD PMID:28542535 NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088 		JBrowse link
G Nfkbia NFKB inhibitor alpha increases expression ISO trichostatin A results in increased expression of NFKBIA mRNA CTD PMID:15899819 NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072 		JBrowse link
G Nfyb nuclear transcription factor Y subunit beta decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of NFYB mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NFYB mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:22,852,543...22,868,116
Ensembl chr 7:22,852,546...22,882,294 		JBrowse link
G Ngf nerve growth factor multiple interactions ISO trichostatin A inhibits the reaction [Clioquinol inhibits the reaction [NGF protein results in increased phosphorylation of NTRK1 protein]] CTD PMID:25758465 NCBI chr 2:192,589,580...192,642,971
Ensembl chr 2:192,589,582...192,643,834 		JBrowse link
G Ngfr nerve growth factor receptor increases expression
multiple interactions 		ISO trichostatin A results in increased expression of NGFR mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NGFR mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:81,012,077...81,030,305
Ensembl chr10:81,012,089...81,030,305 		JBrowse link
G Nhs NHS actin remodeling regulator increases expression ISO trichostatin A results in increased expression of NHS mRNA CTD PMID:24935251 NCBI chr  X:36,185,067...36,524,711
Ensembl chr  X:36,438,178...36,524,708 		JBrowse link
G Niban2 niban apoptosis regulator 2 increases expression ISO trichostatin A results in increased expression of NIBAN2 mRNA CTD PMID:24935251 NCBI chr 3:36,572,356...36,621,968
Ensembl chr 3:36,572,377...36,621,967 		JBrowse link
G Nid1 nidogen 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of NID1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NID1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr17:93,069,013...93,142,416
Ensembl chr17:93,069,278...93,142,386 		JBrowse link
G Nid2 nidogen 2 increases expression ISO trichostatin A results in increased expression of NID2 mRNA CTD PMID:24935251 NCBI chr15:4,507,224...4,562,949
Ensembl chr15:4,506,756...4,562,949 		JBrowse link
G Nifk nucleolar protein interacting with the FHA domain of MKI67 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of NIFK mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NIFK mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr13:31,946,119...31,955,950
Ensembl chr13:31,946,108...31,959,561 		JBrowse link
G Nin ninein decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of NIN mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NIN mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:94,261,382...94,363,679
Ensembl chr 6:94,263,206...94,363,610 		JBrowse link
G Nip7 nucleolar pre-rRNA processing protein NIP7 affects expression ISO trichostatin A affects the expression of NIP7 mRNA CTD PMID:28542535 NCBI chr19:51,872,306...51,874,448
Ensembl chr19:51,872,364...51,876,120 		JBrowse link
G Nipa1 NIPA magnesium transporter 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of NIPA1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NIPA1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:115,608,221...116,010,503
Ensembl chr 1:115,974,481...116,010,812 		JBrowse link
G Nipal1 NIPA-like domain containing 1 increases expression ISO trichostatin A results in increased expression of NIPAL1 mRNA CTD PMID:24935251 NCBI chr14:35,891,645...35,915,658
Ensembl chr14:35,891,647...35,915,658 		JBrowse link
G Nipal2 NIPA-like domain containing 2 increases expression ISO trichostatin A results in increased expression of NIPAL2 mRNA CTD PMID:24935251 NCBI chr 7:67,659,628...67,771,105
Ensembl chr 7:67,659,628...67,769,959 		JBrowse link
G Nipbl NIPBL, cohesin loading factor decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of NIPBL mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NIPBL mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:59,126,676...59,314,841
Ensembl chr 2:59,126,676...59,293,277 		JBrowse link
G Nipsnap1 nipsnap homolog 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of NIPSNAP1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NIPSNAP1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr14:83,957,714...83,981,579
Ensembl chr14:83,957,702...83,981,576 		JBrowse link
G Nit1 nitrilase 1 affects expression ISO trichostatin A affects the expression of NIT1 mRNA CTD PMID:28542535 NCBI chr13:86,302,334...86,305,770
Ensembl chr13:86,298,387...86,305,770 		JBrowse link
G Nit2 nitrilase family, member 2 increases expression ISO trichostatin A results in increased expression of NIT2 mRNA CTD PMID:24935251 NCBI chr11:56,832,957...56,844,142
Ensembl chr11:56,832,558...56,844,141 		JBrowse link
G Nkain3 Sodium/potassium transporting ATPase interacting 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of NKAIN3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NKAIN3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:38,410,576...39,106,910
Ensembl chr 5:38,386,841...39,106,385 		JBrowse link
G Nkain4 Sodium/potassium transporting ATPase interacting 4 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of NKAIN4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NKAIN4 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 3:188,430,862...188,451,561
Ensembl chr 3:188,430,243...188,453,760 		JBrowse link
G Nkapd1 NKAP domain containing 1 decreases expression ISO trichostatin A results in decreased expression of NKAPD1 mRNA CTD PMID:24935251 NCBI chr 8:59,852,037...59,863,295
Ensembl chr 8:59,852,726...59,863,181 		JBrowse link
G Nkd1 NKD inhibitor of WNT signaling pathway 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of NKD1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NKD1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:34,649,803...34,722,846 JBrowse link
G Nkiras1 NFKB inhibitor interacting Ras-like 1 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of NKIRAS1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NKIRAS1 mRNA
trichostatin A affects the expression of NKIRAS1 mRNA 		CTD PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr15:9,924,316...9,934,538
Ensembl chr15:9,924,326...9,935,877 		JBrowse link
G Nle1 notchless homolog 1 affects expression ISO trichostatin A affects the expression of NLE1 mRNA CTD PMID:28542535 NCBI chr10:68,331,609...68,342,562
Ensembl chr10:68,331,609...68,340,386 		JBrowse link
G Nlgn1 neuroligin 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of NLGN1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:110,184,987...111,110,316
Ensembl chr 2:110,186,573...110,909,984 		JBrowse link
G Nlgn3 neuroligin 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of NLGN3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:70,469,251...70,497,380
Ensembl chr  X:70,469,457...70,497,379 		JBrowse link
G Nlk nemo like kinase decreases expression ISO trichostatin A results in decreased expression of NLK mRNA CTD PMID:24935251 PMID:26272509 NCBI chr10:63,965,432...64,089,006 JBrowse link
G Nln neurolysin increases expression
multiple interactions 		ISO trichostatin A results in increased expression of NLN mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NLN mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:36,867,436...36,966,749
Ensembl chr 2:36,853,551...36,966,680 		JBrowse link
G Nme1 NME/NM23 nucleoside diphosphate kinase 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of NME1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NME1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:79,403,939...79,426,620
Ensembl chr10:79,403,940...79,413,310 		JBrowse link
G Nme8 NME/NM23 family member 8 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of NME8 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NME8 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr17:49,932,861...50,000,610
Ensembl chr17:49,932,860...50,000,608 		JBrowse link
G Nmi N-myc (and STAT) interactor increases expression
multiple interactions
affects expression 		ISO trichostatin A results in increased expression of NMI mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMI mRNA
trichostatin A affects the expression of NMI mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 3:56,824,778...56,848,891
Ensembl chr 3:56,811,314...56,848,717 		JBrowse link
G Nmnat2 nicotinamide nucleotide adenylyltransferase 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of NMNAT2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMNAT2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr13:67,655,794...67,831,609
Ensembl chr13:67,655,807...67,831,608 		JBrowse link
G Nmrk1 nicotinamide riboside kinase 1 increases expression ISO trichostatin A results in increased expression of NMRK1 mRNA CTD PMID:24935251 PMID:26705709 NCBI chr 1:225,475,975...225,503,414
Ensembl chr 1:225,475,830...225,503,602 		JBrowse link
G Nmt2 N-myristoyltransferase 2 increases expression ISO trichostatin A results in increased expression of NMT2 mRNA CTD PMID:24935251 NCBI chr17:79,826,999...79,874,088
Ensembl chr17:79,826,999...79,870,259 		JBrowse link
G Nmu neuromedin U increases expression ISO trichostatin A results in increased expression of NMU mRNA CTD PMID:24935251 PMID:27188386 NCBI chr14:32,198,789...32,226,397
Ensembl chr14:32,198,943...32,226,632 		JBrowse link
G Noct nocturnin increases expression ISO trichostatin A results in increased expression of NOCT mRNA CTD PMID:24935251 NCBI chr 2:137,422,074...137,442,282
Ensembl chr 2:137,422,074...137,442,282 		JBrowse link
G Nog noggin increases expression
multiple interactions 		ISO trichostatin A results in increased expression of NOG mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] affects the expression of ADAM12 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] affects the expression of SCAF4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] affects the expression of SLAIN2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABCA5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABHD13 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABHD6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABRAXAS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABTB3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ACTN3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAMTS9 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADSS2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AFDN mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AFDN-DT mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AGBL1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AGBL2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AGBL3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AHSA2P mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AIG1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AJUBA mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AKAP12 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AKAP9 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AKT3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ALAD mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ALDH2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ALDH3A2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ALPK3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AMPH mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKMY2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKRD12 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKRD50 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKRD6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANO5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANOS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AP1S2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AP4S1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of APC mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of APPBP2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of APPL2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AR mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARB2A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARFGAP3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARFIP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARG2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARGLU1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGAP15 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGAP19 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGAP5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGEF4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARID2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARL4C mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARMC8 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARMH4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARNT2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARX mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASB1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASPHD2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASPM mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASTN1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATAD2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATAD5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATF1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATF2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATL1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATOSB mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP9A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATRX mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATXN7 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of B3GALNT1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of B4GALT4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BAALC mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BAIAP2-DT mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BASP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BBIP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BBS10 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCO1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCOR mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BDP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEND4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEND5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEND7 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEX2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BLCAP mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BLVRA mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BMERB1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BPTF mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BTBD8 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C12ORF57 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C12ORF60 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C12ORF75 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C12ORF76 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C15ORF61 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C16ORF87 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C17ORF100 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1ORF21 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1ORF226 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1ORF53 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1QTNF4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C22ORF39 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2CD2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2ORF68 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C3ORF38 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C5ORF24 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C6ORF141 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C8ORF76 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C9ORF72 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CA4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACHD1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNA2D4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CADM4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CADPS2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAMK1D mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAMK2N1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAMK4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAPN6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAPS2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAVIN3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CBLB mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CBX2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CBX5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC136 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC144NL-AS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC177 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC18 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC181 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC50 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC80 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC88A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCKBR mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNE2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNG2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNT2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNYL1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDC14A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDC25C mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDC27 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDC40 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDC42EP3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDC5L mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDC7 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDCA2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH8 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDK19 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDK8 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CECR2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CELF5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CEMIP2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CENPH mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CENPQ mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CENPU mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CENPV mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CEP112 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CEP350 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CEP57 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CEP68 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CEP70 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CEP89 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CERK mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP91 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFL2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CGRRF1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CHD2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CHRDL1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CHRNA5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CKB mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLCN3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLGN mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLIP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLIP3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLN5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLTRN mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNKSR2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNOT4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTN2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTNAP2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTNAP3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTRL mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COCH mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COPS8 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CPAP mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CPD mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CPNE2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CPNE3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CPSF2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CPT1C mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CREBZF mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CREM mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CROT mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSNK2A2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSRNP3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSRP2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSTF2T mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTBS mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTDSPL2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTPS2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUL3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUL4B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUX1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUX2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CWC22 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CXADR mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CXCR4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CYB5B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CYFIP2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAB1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DACH1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAZAP2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCAF16 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCAF7 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCBLD2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCK mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCUN1D4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DDAH1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DDAH2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DDB2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DDIT4L mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DDR1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DDX17 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DDX39B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DDX3X mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DDX6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND11 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND2A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DEPDC1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DESI2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKQ mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DHX30 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DHX9 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DIABLO mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DIPK1A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLG3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLK1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLL1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DMKN mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DMRT3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DNAJB9 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DNAJC24 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DNALI1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DPM3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DPY19L2P2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DPYSL2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DPYSL5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DRD4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DST mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DTNBP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DUSP4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DYNC1LI1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ECT2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EFHC1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EFNA5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGF mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGLN3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EHBP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EID2B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EIF3J-DT mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EIF4E3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELAVL1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELOVL2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELOVL4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELP4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EMSY mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EMX2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EMX2OS mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ENAH mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ENO2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ENO3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ENPP4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ENTPD4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ENY2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPB41L5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPC2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHA3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHA4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHA7 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERAP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERC2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERCC6L2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERO1B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERRFI1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ESCO1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ESCO2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ETFRF1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ETV1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ETV5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ETV6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EWSR1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EXOC5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EXOC6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EXT1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of F2RL2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM107A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM107B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM117A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM124A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM131B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM149A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM168A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM171B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM200B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM200C mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM221A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM226B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM76B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FANK1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN7 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBN1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXL14 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO16 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FCHSD2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZ1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZF2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF12 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF13 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF14-AS2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF8 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FHOD3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FIG4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FJX1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FLRT2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FMC1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FMN2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FMNL2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FNDC3A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FNDC5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FOXK1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRMD5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRY mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRZB mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FSD1L mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FST mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FUBP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FUT8 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FUT8-AS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FUT9 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FYB2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD8 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of G2E3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of G3BP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of G3BP2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GABPA mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GALNT10 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GALNT16 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GALP mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GARIN1B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GATAD2B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GATM mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GCNT1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GDPD1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GGA2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GHRH mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GK5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GKAP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLCCI1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLI2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLT1D1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLUD2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNAI2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNB5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNG10 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNG12 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GOLGA8A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPATCH2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR153 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR161 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR19 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR27 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPRASP2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPRC5B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIK3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRM3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GSDME mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GSPT2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GTF2I mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GTF2IRD1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GTF2IRD2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GUSBP4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GYG2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H1-2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H1-4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2AC6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC12 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC12L mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BW4P mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H3-3B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HAUS6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HDAC4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HDAC9 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HEATR1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HECTD1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HERPUD2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HESX1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HFM1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HIF3A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HINT3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HIP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HMGCLL1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HNRNPC mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HNRNPLL mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HS3ST3A1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HS3ST3B1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HSBP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HSF2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HTATSF1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HYMAI mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IFT74 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGDCC4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGF2BP3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGFBP5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL17RD mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL1RAPL1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ILDR2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ILF3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IMMP1L mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of INAVA mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ING4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of INTS6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IPO5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IPO9 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IPP mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IPW mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IRAK1BP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IST1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ITGA6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ITGB5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JADE1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JAG1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JKAMP mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JPT2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT2B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT6B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT7 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KBTBD11 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KBTBD2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCMF1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCND2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNG3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ13 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNS3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIAA1671 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIAA1958 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIF13A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIF18A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIF21A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIF26A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIZ mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHDC8A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHL13 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHL14 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHL2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHL23 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHL24 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHL7 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KMT2A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KNL1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KPNA5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of L3MBTL1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LARS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LATS2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LCA5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LCTL mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LDLRAD3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LEMD1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LFNG mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LGR4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LHX2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIM2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LINC00467 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LINC00515 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LINC00623 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LINC00847 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LINC02210 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIX1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LLGL1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LLGL2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMAN1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LPAR1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LPAR4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRATD2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRIG1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRIG3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP12 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC34 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC3B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC49 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC8B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC8C mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRN1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRTM4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LSM14B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LSM8 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LSR mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LTN1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LUZP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LYRM2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAB21L2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACF1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROD2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROH2A1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAGEL2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAK mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MALAT1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAMDC2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAN2A1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP2K6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP3K9 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP4K5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP7 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP9 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAPK10 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAPK12 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAPK8 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MATR3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MBD5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MBIP mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MBTD1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MCF2L mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MCM3AP-AS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MCUB mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ME3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MECOM mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MED30 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MEG3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MEIOC mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MEIS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of METTL21A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MEX3B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFAP3L mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFHAS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFNG mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MGAT4A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIAT mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MICAL1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MICU3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIDN mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIER3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIR124-2HG mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIS18BP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MKRN1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MND1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MOB1A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MOB3B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MOSMO mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MOV10 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MRPL50 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MSANTD3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MSL1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MSL3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MSRB3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MST1L mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MTURN mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MXRA7 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYC mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYCL mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYEF2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYO3B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of N4BP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NAA16 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NAALAD2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NADK2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NALF1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NANOS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NAT8L mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NAV1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NBPF1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCALD mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCAN mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCAPD2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCOA3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDC80 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NELL2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NES mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEURL1B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEXMIF mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NF1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NFATC4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NFYB mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NIN mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NIPA1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NIPBL mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NIPSNAP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NKAIN3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NKAIN4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NKIRAS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NNT-AS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NOVA1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY2R mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR1D2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2C1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2C2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2E1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2F1-AS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2F2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRG1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRIP3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRTN mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRXN2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NSD2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NSUN7 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NT5DC1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NTN4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NUCB2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NUDCD1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NUDT12 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NUDT21 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NUDT5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NUDT7 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NUP210 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NUP58 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NXPE3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NXT2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OLA1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OPRK1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ORAI2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OSBPL2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OSBPL6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OTUD4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OTX2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAFAH1B1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAIP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAK3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PALLD mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PALS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAMR1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAN3-AS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAPLN mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAPOLA mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAPSS2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAQR9 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PARD6B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PARP8 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PATZ1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAX6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAXIP1-DT mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCBD1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCDH18 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCDH19 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCDHB10 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCDHB14 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCDHB16 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCDHB7 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCM1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCMTD1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCSK5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE7A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE9A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDLIM5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDS5A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PEX13 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PEX2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PEX39 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PGAP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PGRMC2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PHACTR2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PHF13 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PHF20L1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PHF3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PHF6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PHOSPHO2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PHYH mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PIAS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PIP5K1B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PITPNC1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PITPNM3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PKIA mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLAGL1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLAGL2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLCH1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLCXD2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLEKHA1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLEKHA3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLEKHG4B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLPP5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLXDC2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLXNC1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PM20D2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PMEL mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PNCK mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PNMA2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PNMA8A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POPDC3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POU3F1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POU3F2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPM1A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP1R9A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP2R2B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP4R3B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP4R4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRDM16 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRDM2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRICKLE1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRKACB mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PROK2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRORSD1P mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRR14L mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRRC2C mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRRT2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRSS23 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRUNE2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRXL2A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PSTK mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTAR1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTCH1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTGR2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTGR3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPN12 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPN13 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPN5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPRD mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPRN2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPRS mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTX3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PURG mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PURPL mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PWWP2A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PWWP3A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PXK mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PXYLP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB33B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB39B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB3B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RABEP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAD21 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAD54B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RALB mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RALGPS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RASA2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RASD1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RASSF10 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RASSF2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RASSF4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAVER2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAX mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBAK mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBBP6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBM12B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBM24 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBM25 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBM26 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBM34 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBM8A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RCAN2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RCN2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RFFL mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RFK mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RFX3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RFX7 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RFXAP mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RGMA mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RHNO1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RHOU mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RIMKLB mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RIT1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RLN2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RMST mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RND1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RND2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RNF130 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RNF175 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RNF182 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RNFT2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RNPC3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RPAP3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RPL31 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RPRD2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RPS23 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RPS6KA6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RRAGD mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RSF1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RSPO2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RTKN2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RTN1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RTN3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RUFY3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RWDD2A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RYR3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of S1PR3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SALL1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SALL2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SALL3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SALL4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SAMTOR mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SAT2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SBNO1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCCPDH mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCD5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCHIP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCUBE2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SDC2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEC62 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SELENOM mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SELENOT mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEMA3A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEMA4D mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SENP8 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEPTIN10 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEPTIN4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SERGEF mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SERINC5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SERPINF1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SESTD1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SETBP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SETD2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SF3B1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SFRP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SFRP2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SGCB mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SH3D19 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SH3RF1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHISA2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHROOM3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SINHCAF mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SIX3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SIX3-AS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SKA2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SKIDA1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SKIL mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLAIN1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC16A14 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC16A9 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC1A6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC25A21-AS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC25A29 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC25A36 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC2A12 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC35G1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC38A4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC39A6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC6A8 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC7A3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC7A8 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLF1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMAD1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMAD2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMARCE1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMC3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMC5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMCHD1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMCO4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMIM14 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMOC1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNAP91 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNHG10 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNX16 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNX25 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOBP mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOCS3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOCS5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOCS6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORL1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX11 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX2-OT mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SP4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SP8 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SPA17 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SPAG5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SPAG9 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SPAST mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SPATA7 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SPON1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SPOP mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SPRED1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SPRED2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SPRY1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SREK1IP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SS18L2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SSBP2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SSX2IP mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ST6GALNAC5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STAT5B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STC2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STK32A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STK32C mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STON1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STON2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STOX1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STRIP2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STYX mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SUGP2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SULF1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SUMO3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SUPT16H mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SUSD6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SV2A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SVIP mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYNCRIP mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYNE2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYT1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYT11 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYTL2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TAB2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TADA1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TAOK1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TARDBP mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TARS3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TBC1D30 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TBC1D9 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TBL1X mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TBL1XR1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TCEAL7 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TCF3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TCF4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TCF7L2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TCIM mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TENT5A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TET2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TFDP2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TGIF1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of THAP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of THAP2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of THAP9 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of THNSL1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of THYN1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TIA1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TIGD1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TIGD2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TIMP3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TJP3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TK2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TLE4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TLK1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TLK2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM158 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM170B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM178A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM209 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM237 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM255A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM35A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM47 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM74 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM88 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM98 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMPO mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMPO-AS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMSB15A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMTC1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMTC2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMTC4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TNNI3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TNRC6C mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TOP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TOX3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TP53TG1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TPBG mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TPD52 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TPM1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TPM4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TPR mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TPST2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRAF3IP2-AS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRDMT1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRERF1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRIB1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRIM23 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRIM36 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRIM59 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRMT1L mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRPC4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSC22D1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSHZ3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSPAN12 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSPAN13 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSPAN18 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSPAN2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSPAN33 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSPAN5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TTBK2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TTC28-AS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TTC32 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TTK mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TTLL6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TTYH1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TUT4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TVP23A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TYRO3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UBE2E1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UBE2E2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UBE2I mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UBE2J1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UBE2W mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UBR5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UHMK1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UMAD1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UNC5D mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UPP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of USP34 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of USP42 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of USP44 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of USP49 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VAMP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VAPB mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VAT1L mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VEZT mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VOPP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VPS37A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VPS37D mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VPS50 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VSNL1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WAC mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WASF1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WASF3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WDFY1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WDHD1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WDR76 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WIPF1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WNK1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WNK3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WNT5B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WSCD1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of XYLT1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of YEATS4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of YPEL1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of YPEL2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZBED6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZBTB16 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZBTB21 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZBTB26 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZBTB46 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZC3H12C mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZDHHC2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZEB1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZEB1-AS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZFHX4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZFP14 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZFP2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZFP30 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZFP37 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZFP69B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZFR mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZFYVE16 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZIC2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZKSCAN5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZMYM5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZMYM6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZMYND11 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF101 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF214 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF219 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF22 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF226 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF254 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF287 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF385B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF385D mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF397 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF415 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF43 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF436 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF436-AS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF439 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF441 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF503 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF518B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF521 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF529 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF532 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF555 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF564 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF567 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF569 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF608 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF638 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF655 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF658 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF660 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF706 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF718 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF763 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF776 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF93 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZRANB2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZSCAN16 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZSCAN23 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AAK1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABAT mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABCG2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACKR3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACOX1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSL4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSM3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACTA2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS15 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS17 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS19 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCY9 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADGRG6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AFAP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AFF4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AGPAT3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AHNAK mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AK2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1C1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1C2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALCAM mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1A3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALKAL2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALX1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMER2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMIGO2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANK3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKH mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANTXR1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2P1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2P2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2P3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AOPEP mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AP2B1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARAP2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP18 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGEF3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARID5B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARPC1B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARRB1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASAP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASAP1-IT1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASCL1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASNS mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASXL3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATF3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATF7IP mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP1A2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP23 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP2B4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP6V0D2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AXIN2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of B2M mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of B3GNT2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BACE2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAMBI mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAZ1A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BBX mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCAR3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCHE mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCL11A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BEAN1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BGN mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BHLHE40 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BIRC3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BIVM mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP7 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMPER mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNIPL mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF52 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF96 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C12ORF56 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C14ORF132 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C3ORF52 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C8ORF34 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C8ORF34-AS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CACNA2D1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CALCA mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CASP8 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAV1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CBS mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC91 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCM2L mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCND1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD24 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD9 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD99 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDC42EP5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDCA7 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDCA7L mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH9 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDK5R1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDK6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDKN1C mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDON mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPB mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPD mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CELF2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP126 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP15 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP85L mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CGNL1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHCHD4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHL1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHMP3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHN2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHPT1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRM3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHST15 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHSY1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLASP2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLCN5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN23 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN7 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLEC11A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLIC6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLSTN2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CMTM7 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNKSR3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNMD mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNOT6L mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNPY2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNRIP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNTLN mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COBL mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COBLL1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL11A2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL13A1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL21A1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL23A1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL27A1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL5A1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL5A2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL5A3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COLEC12 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CORO2A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPE mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPEB2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPED1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPVL mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPXM2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CR1L mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRABP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRABP2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CREB3L2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRIM1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRIP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRISPLD1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRTAP mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CSRP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTHRC1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTNNB1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTSC mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTSV mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTSZ mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL12 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL14 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXXC5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYB5A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1B1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYTL1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DAAM2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DACT1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DAG1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCAF4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCBLD1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCC mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DDIT4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DECR1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPDC7 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DHTKD1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DISP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLC1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLEU2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNAJC1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNAJC12 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNER mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK9 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOK5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPPA5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPY19L1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPYD mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DSC2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DSP mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DTD2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DYNC1I1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EBF1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ECI2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDN1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRA mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EEF2K mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFNA1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGFR mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EIF4EBP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EIF5A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELK3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELMOD1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EML4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EMP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENC1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENO1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENOSF1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENPEP mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENPP2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EOGT mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPAS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPCAM mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPOP mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPPK1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPSTI1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERBB3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERMP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERP27 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERVH48-1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRG mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRP2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESYT2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETNK1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EYA4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EZR mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F2RL1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FABP5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FABP7 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM110B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM13C mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM162A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM162B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM210B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM3C mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM43A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM89A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAS mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBLN1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FER mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FERMT1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGD5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGFBP3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGFR3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FH mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FIGN mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FKBP11 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FKBP14 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLNB mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLRT1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLT1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FMO1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FN1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FNIP2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXD3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXH1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXO1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FRAS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FREM1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FREM2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FTL mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FTX mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FUS mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FXYD5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FYN mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAD1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAP43 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAS5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GFRA1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GFRA3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GJA3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLRX2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLS mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLT8D2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLUL mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNAS mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNG11 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNGT1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNL3L mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GOLGA4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPATCH2L mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPATCH4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPD1L mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPM6A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPM6B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR37 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GREM1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRIA2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GSN mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GSTO1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GXYLT2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GYPC mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HACD1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HACD4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAPLN1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAS2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HERC5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HGF mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HHIP mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HIRA mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HK1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HK2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-DMA mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMCN1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMGA2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HNMT mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HOPX mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPDL mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSD17B6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPG2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDS mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IER3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IER5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFI16 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFI6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFIT3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFITM1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGDCC3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGFBP7 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL13RA1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL27RA mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP4B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INSC mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IQGAP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRF2BP2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRF6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRS2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA8 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA9 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITPKB mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITPR1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITPR2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITPRID2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITPRIPL2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IVNS1ABP mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JCAD mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KANK4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNA2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNG1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNK1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNK5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNV1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD12 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KDELR2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA1755 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIFAP3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIT mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KITLG mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLHL21 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT18 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT8 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of L1CAM mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of L1TD1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACC1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACTB mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMA4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMC2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMP2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAYN mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LDB2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LDHA mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LDLRAP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LEF1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHFPL6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHX8 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIFR mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIMA1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC00673 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC01003 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC01128 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LITAF mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LMO4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNPEP mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LPAR3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LPAR6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LPCAT1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LPP mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRCH1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRP10 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRP4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRC17 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRC4C mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRN3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LTB mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LTBP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYN mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYPD1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYST mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LZTS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MACC1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MACIR mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAFB mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAFF mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAL2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAML2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAN1A1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP3K20 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP3K4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP4K4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBNL1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBNL2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBNL3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCC mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCOLN3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MDFIC mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MDH1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MED13L mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEF2C mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEIS2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEOX1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of METRNL mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of METTL8 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MFSD6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MGST1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIA mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MICALL1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MICB mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MID1IP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIDEAS mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR17HG mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR205HG mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR22HG mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR30C2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MITF mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MKLN1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MMP16 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MMP2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MMRN1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MNS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MPRIP mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MPZ mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTAP mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTDH mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTHFD1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTHFD1L mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTHFD2L mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC15 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUSTN1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYCBP2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYCN mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYCT1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO10 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYOF mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NABP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANOG mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANS mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NAP1L5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NAV3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NBPF10 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NCAM1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NCBP2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NCOA7 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEAT1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEDD4L mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEFL mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFAT5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFE2L2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NGFR mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NID1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NIFK mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NKD1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NLN mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NME1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NME8 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMI mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMNAT2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOG mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOP16 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOTCH2NLA mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPNT mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPPB mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPR3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPTX2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPY mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NQO1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NR2F1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRIP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRP2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NTM mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NUDT4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLFML3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OPCML mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OPN3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OSBPL10 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of P4HA2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PADI2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PALM2AKAP2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PATJ mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX7 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCBP4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH10 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH7 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH8 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH9 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCOLCE2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE3A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4D mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4DIP mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFA mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFC mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFRA mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDIA5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDK1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDLIM1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDPN mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDYN mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDZRN3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PELI1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PERP mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PFKP mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PFN2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PGM1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PGM2L1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHF11 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDA1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDA2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIM1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PITX2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKDCC mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKIB mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKM mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKP2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G2A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G4A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G7 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAAT1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAT mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAU mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLCE1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLCXD3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLEKHA8 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLK2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLOD2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLPP2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLS3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLSCR1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLXNA2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POLR3G mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POSTN mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU5F1B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU5F1P3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU5F1P4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPARGC1B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPIB mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPIC mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPM1H mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPM1K mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R3B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R3D mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP2R1B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP2R2A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP2R5C mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRAG1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRCP mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRELP mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PREX1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKAR1A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKCA mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKCE mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKCH mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRNP mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRRC2C mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRRG1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRSS12 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRSS8 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PTEN mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PTN mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PTPRE mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PWWP2B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PYGL mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of QKI mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB11FIP4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB13 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB20 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB25 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB31 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB3C mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB3GAP2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RABGAP1L mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RADX mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASA3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASEF mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASGRP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASL12 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASSF3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBFOX1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBMS3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBPMS2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RCAN1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of REEP5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RELL1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RELN mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RFTN2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RFX4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RGS5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHBDF1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHOB mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHOBTB3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHOJ mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHOQ mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RIMS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RIMS2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RIOX2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RIPK4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RND3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF43 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ROR1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ROR2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPL22L1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPS24 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPS27 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPS6KA5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RRBP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RREB1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RRS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX1T1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A10 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A11 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SAMD4A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SAR1B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SAT1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SBF2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCFD2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCGB3A2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCML1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCN1A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCN4B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCNN1A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCRG1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SDC4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEC24D mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SELENOP mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEMA3C mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEMA3E mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEPTIN6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINB9 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SETD5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SETD7 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEZ6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFMBT2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFN mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGK1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGK3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGMS2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGPP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SH3KBP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SH3PXD2A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SH3YL1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SHANK2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SHC1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SIX1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SKAP2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC16A1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC16A3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC16A4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC16A7 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC18B1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC1A3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC22A15 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC23A2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC27A6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC2A13 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC2A3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC30A10 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35F2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC39A8 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC40A1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC44A5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC5A3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC6A6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A11 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLCO4C1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLCO6A1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLF2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLFN12 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLFN5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLITRK6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMAD4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMAD7 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMARCA2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMG1P5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMIM8 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMPDL3A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMYD2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAP25 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNHG4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNHG8 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNORA21 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNRPA1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNRPN mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNX18 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNX24 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SORCS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX10 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX8 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX9 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP140L mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPHK1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPIN4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPSB4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SRGAP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SRPX mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SRRM4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SSUH2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ST14 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ST3GAL6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STAT6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STAU2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STC1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STEAP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STMN2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STRA6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STT3B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STXBP5 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1C2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SV2C mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYBU mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNCRIP mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNE1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYTL4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAC1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACC1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACSTD2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAF1D mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAGLN mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAGLN2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TANC2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TARS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TASOR2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAX1BP3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TBX2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TCAF1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TCERG1L mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TDRP mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TENM2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TENM4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TENT2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TENT5B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TENT5C mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TES mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2C mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFPI mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THBS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THRB mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TIFA mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TKTL1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMC6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM144 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM154 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM30B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM64 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMOD2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNC mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFRSF11B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFRSF12A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFRSF21 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNIK mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TOX mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TPD52L1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRAPPC10 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIL mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM14 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM25 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM38 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM6 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM9 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRMT9B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRNP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRPS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TSC22D2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TSPO mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TTC3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TWIST1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UBE2B mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UBE2D3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UBL3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UCHL3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGGT2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT8 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UNC5C mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP25 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP28 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UTRN mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VAMP8 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VASH2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VCAN mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VDAC1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VGLL1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VGLL3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VHRT mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WFDC2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT4 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT5A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WWC1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WWTR1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of YAP1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZC3HAV1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZC3HAV1L mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZCCHC17 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZCCHC24 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZCCHC7 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFAS1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFHX3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP36L2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP42 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZHX2 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZIC1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZIC3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZMAT3 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF124 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF165 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF600 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF703 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF750 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNG1A mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZYG11A mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr10:74,625,874...74,627,501
Ensembl chr10:74,625,875...74,628,103 		JBrowse link
G Nol11 nucleolar protein 11 affects expression ISO trichostatin A affects the expression of NOL11 mRNA CTD PMID:28542535 NCBI chr10:92,621,482...92,641,394
Ensembl chr10:92,621,498...92,641,394 		JBrowse link
G Nol12 nucleolar protein 12 affects expression ISO trichostatin A affects the expression of NOL12 mRNA CTD PMID:28542535 NCBI chr 7:112,373,749...112,379,362
Ensembl chr 7:112,373,845...112,380,357 		JBrowse link
G Nol4 nucleolar protein 4 increases expression ISO trichostatin A results in increased expression of NOL4 mRNA CTD PMID:24935251 NCBI chr18:14,207,303...14,569,697
Ensembl chr18:14,207,303...14,569,677 		JBrowse link
G Nol4l nucleolar protein 4-like increases expression ISO trichostatin A results in increased expression of NOL4L mRNA CTD PMID:24935251 NCBI chr 3:162,345,059...162,467,849
Ensembl chr 3:162,348,211...162,468,048 		JBrowse link
G Nono non-POU domain containing, octamer-binding affects expression ISO trichostatin A affects the expression of NONO mRNA CTD PMID:28542535 NCBI chr  X:70,594,116...70,611,976
Ensembl chr  X:70,593,888...70,611,979 		JBrowse link
G Nop16 NOP16 nucleolar protein increases expression
multiple interactions
affects expression 		ISO trichostatin A results in increased expression of NOP16 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOP16 mRNA
trichostatin A affects the expression of NOP16 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr17:10,028,058...10,032,975
Ensembl chr17:10,028,034...10,033,038 		JBrowse link
G Nos2 nitric oxide synthase 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of NOS2 mRNA
trichostatin A promotes the reaction [[bisphenol A affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of NOS2 mRNA] 		CTD PMID:24935251 PMID:26272509 PMID:29718165 NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880 		JBrowse link
G Nosip nitric oxide synthase interacting protein affects expression ISO trichostatin A affects the expression of NOSIP mRNA CTD PMID:28542535 NCBI chr 1:104,679,783...104,695,570
Ensembl chr 1:104,679,882...104,695,119 		JBrowse link
G Notch1 notch receptor 1 multiple interactions ISO [Decitabine co-treated with trichostatin A] results in decreased expression of NOTCH1 mRNA; trichostatin A inhibits the reaction [Arsenic results in increased expression of NOTCH1 protein]; trichostatin A inhibits the reaction [Folic Acid results in increased expression of NOTCH1 protein] CTD PMID:17185465 PMID:39617304 NCBI chr 3:29,676,040...29,721,613
Ensembl chr 3:29,676,171...29,721,613 		JBrowse link
G Notch2 notch receptor 2 multiple interactions EXP trichostatin A inhibits the reaction [Lead results in decreased expression of NOTCH2 mRNA] CTD PMID:29301062 NCBI chr 2:188,299,336...188,432,823
Ensembl chr 2:188,299,336...188,432,823 		JBrowse link
G Nova1 NOVA alternative splicing regulator 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of NOVA1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NOVA1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 6:69,506,983...69,632,437
Ensembl chr 6:69,506,983...69,632,437 		JBrowse link
G Nova2 NOVA alternative splicing regulator 2 decreases expression ISO trichostatin A results in decreased expression of NOVA2 mRNA CTD PMID:26272509 NCBI chr 1:87,700,328...87,741,755
Ensembl chr 1:87,700,328...87,778,669 		JBrowse link
G Npat nuclear protein, co-activator of histone transcription affects expression ISO trichostatin A affects the expression of NPAT mRNA CTD PMID:28542535 NCBI chr 8:62,829,141...62,867,065
Ensembl chr 8:62,829,185...62,867,065 		JBrowse link
G Npc1 NPC intracellular cholesterol transporter 1 affects expression ISO trichostatin A affects the expression of NPC1 mRNA CTD PMID:28542535 NCBI chr18:3,654,237...3,699,853
Ensembl chr18:3,654,237...3,699,800 		JBrowse link
G Npffr2 neuropeptide FF receptor 2 increases expression ISO trichostatin A results in increased expression of NPFFR2 mRNA CTD PMID:24935251 NCBI chr14:18,794,868...18,842,186
Ensembl chr14:18,797,234...18,842,186 		JBrowse link
G Nphp1 nephrocystin 1 affects expression ISO trichostatin A affects the expression of NPHP1 mRNA CTD PMID:28542535 NCBI chr 3:135,413,927...135,469,505
Ensembl chr 3:135,413,927...135,469,505 		JBrowse link
G Nphs1 NPHS1 adhesion molecule, nephrin multiple interactions EXP trichostatin A inhibits the reaction [Corticosterone results in decreased expression of NPHS1 mRNA]; trichostatin A inhibits the reaction [Corticosterone results in decreased expression of NPHS1 protein] CTD PMID:31306741 NCBI chr 1:94,848,261...94,876,522
Ensembl chr 1:94,848,261...94,876,521 		JBrowse link
G Npl N-acetylneuraminate pyruvate lyase increases expression ISO trichostatin A results in increased expression of NPL mRNA CTD PMID:24935251 NCBI chr13:68,205,602...68,247,940
Ensembl chr13:68,205,603...68,247,999 		JBrowse link
G Npnt nephronectin increases expression
multiple interactions 		ISO trichostatin A results in increased expression of NPNT mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPNT mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:224,065,191...224,133,567
Ensembl chr 2:224,065,191...224,133,435 		JBrowse link
G Nppa natriuretic peptide A affects expression
multiple interactions 		EXP trichostatin A affects the expression of NPPA mRNA
trichostatin A inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA] 		CTD PMID:19729022 PMID:25341891 NCBI chr 5:163,712,184...163,713,493
Ensembl chr 5:163,712,184...163,713,493 		JBrowse link
G Nppb natriuretic peptide B increases expression
multiple interactions 		ISO trichostatin A results in increased expression of NPPB mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPPB mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 5:163,699,955...163,701,314
Ensembl chr 5:163,699,839...163,701,310 		JBrowse link
G Npr1 natriuretic peptide receptor 1 multiple interactions ISO trichostatin A inhibits the reaction [Nickel affects the expression of NPR1 mRNA] CTD PMID:14575637 NCBI chr 2:178,231,766...178,247,591
Ensembl chr 2:178,231,766...178,247,088 		JBrowse link
G Npr2 natriuretic peptide receptor 2 decreases expression ISO trichostatin A results in decreased expression of NPR2 mRNA CTD PMID:24935251 NCBI chr 5:62,678,197...62,697,360
Ensembl chr 5:62,678,367...62,697,343 		JBrowse link
G Npr3 natriuretic peptide receptor 3 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of NPR3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPR3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:26705709 PMID:27188386 NCBI chr 2:62,592,557...62,660,497
Ensembl chr 2:62,597,668...62,660,066 		JBrowse link
G Nptx2 neuronal pentraxin 2 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of NPTX2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPTX2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr12:15,151,136...15,162,045
Ensembl chr12:15,151,136...15,162,045 		JBrowse link
G Npy neuropeptide Y increases expression
multiple interactions 		ISO
EXP 		trichostatin A results in increased expression of NPY mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPY mRNA
trichostatin A inhibits the reaction [Dexamethasone results in increased expression of NPY mRNA] 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:31778773 NCBI chr 4:80,212,111...80,219,310
Ensembl chr 4:80,212,111...80,219,310 		JBrowse link
G Npy1r neuropeptide Y receptor Y1 increases expression
decreases expression 		ISO trichostatin A results in increased expression of NPY1R mRNA
trichostatin A results in decreased expression of NPY1R mRNA 		CTD PMID:24935251 NCBI chr16:27,804,416...27,814,070
Ensembl chr16:27,804,416...27,813,387 		JBrowse link
G Npy2r neuropeptide Y receptor Y2 increases expression
decreases expression
multiple interactions 		ISO trichostatin A results in increased expression of NPY2R mRNA
trichostatin A results in decreased expression of NPY2R mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY2R mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:170,200,027...170,210,286
Ensembl chr 2:170,200,027...170,210,448 		JBrowse link
G Npy5r neuropeptide Y receptor Y5 increases expression
decreases expression 		ISO trichostatin A results in increased expression of NPY5R mRNA
trichostatin A results in decreased expression of NPY5R mRNA 		CTD PMID:24935251 NCBI chr16:27,822,055...27,830,012
Ensembl chr16:27,816,065...27,830,290 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions
decreases expression
increases expression 		ISO [Fenretinide co-treated with trichostatin A] results in decreased expression of NQO1 mRNA; [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NQO1 mRNA; trichostatin A inhibits the reaction [Benzo(a)pyrene results in increased expression of NQO1 mRNA]
trichostatin A results in decreased expression of NQO1 mRNA
trichostatin A results in increased expression of NQO1 mRNA 		CTD PMID:21319187 PMID:24935251 PMID:24973648 PMID:26272509 PMID:27188386 More... NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260 		JBrowse link
G Nqo2 N-ribosyldihydronicotinamide:quinone dehydrogenase 2 increases expression
affects expression 		ISO trichostatin A results in increased expression of NQO2 mRNA
trichostatin A affects the expression of NQO2 mRNA 		CTD PMID:24935251 PMID:28542535 NCBI chr17:31,114,825...31,144,062
Ensembl chr17:31,114,529...31,143,662 		JBrowse link
G Nr1d2 nuclear receptor subfamily 1, group D, member 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of NR1D2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR1D2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:9,955,034...9,981,329
Ensembl chr15:9,954,906...9,981,330 		JBrowse link
G Nr1h2 nuclear receptor subfamily 1, group H, member 2 affects expression ISO trichostatin A affects the expression of NR1H2 mRNA CTD PMID:28542535 NCBI chr 1:104,178,483...104,183,863
Ensembl chr 1:104,178,234...104,183,863 		JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions
decreases ubiquitination
increases acetylation
affects localization 		ISO Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]; Rifampin inhibits the reaction [trichostatin A results in increased acetylation of NR1I2 protein]; trichostatin A affects the reaction [Rifampin affects the localization of NR1I2 protein]; trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]; trichostatin A promotes the reaction [[PIAS1 protein co-treated with SUMO3 protein] results in increased sumoylation of NR1I2 protein]
trichostatin A results in decreased ubiquitination of NR1I2 protein
trichostatin A affects the localization of NR1I2 protein 		CTD PMID:26883953 NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380 		JBrowse link
G Nr2c1 nuclear receptor subfamily 2, group C, member 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of NR2C1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2C1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:30,602,338...30,655,610
Ensembl chr 7:30,603,018...30,658,349 		JBrowse link
G Nr2c2 nuclear receptor subfamily 2, group C, member 2 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of NR2C2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2C2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:126,167,350...126,223,942
Ensembl chr 4:126,168,085...126,223,942 		JBrowse link
G Nr2e1 nuclear receptor subfamily 2, group E, member 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of NR2E1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2E1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr20:47,632,347...47,653,464
Ensembl chr20:47,632,347...47,653,464 		JBrowse link
G Nr2f1 nuclear receptor subfamily 2, group F, member 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of NR2F1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NR2F1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 2:9,776,179...9,785,924
Ensembl chr 2:9,776,179...9,785,924 		JBrowse link
G Nr2f2 nuclear receptor subfamily 2, group F, member 2 decreases expression
multiple interactions
affects expression 		ISO trichostatin A results in decreased expression of NR2F2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2F2 mRNA
trichostatin A affects the expression of NR2F2 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr 1:133,419,161...133,434,290
Ensembl chr 1:133,420,227...133,431,975 		JBrowse link
G Nr3c1 nuclear receptor subfamily 3, group C, member 1 decreases expression
increases expression
affects expression
multiple interactions 		ISO
EXP 		trichostatin A results in decreased expression of NR3C1 mRNA alternative form; trichostatin A results in decreased expression of NR3C1 protein alternative form
trichostatin A results in increased expression of NR3C1 mRNA; trichostatin A results in increased expression of NR3C1 mRNA alternative form; trichostatin A results in increased expression of NR3C1 protein alternative form
trichostatin A affects the expression of NR3C1 mRNA
trichostatin A inhibits the reaction [Dexamethasone affects the localization of NR3C1 protein]; trichostatin A inhibits the reaction [HSP90AA1 protein binds to NR3C1 protein] 		CTD PMID:17498915 PMID:24935251 PMID:28542535 PMID:31778773 NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843 		JBrowse link
G Nr4a1 nuclear receptor subfamily 4, group A, member 1 multiple interactions
affects localization
increases expression 		ISO [Fenretinide co-treated with trichostatin A] affects the localization of NR4A1 protein; Fenretinide promotes the reaction [trichostatin A results in increased expression of NR4A1 mRNA]; Fenretinide promotes the reaction [trichostatin A results in increased expression of NR4A1 protein]; NR4A1 protein promotes the reaction [trichostatin A results in increased cleavage of CASP3 protein]; RARB protein promotes the reaction [Fenretinide promotes the reaction [trichostatin A results in increased expression of NR4A1 protein]]; RARB protein promotes the reaction [trichostatin A results in increased expression of NR4A1 protein]; trichostatin A promotes the reaction [Fenretinide results in increased expression of NR4A1 mRNA]
trichostatin A affects the localization of NR4A1 protein
trichostatin A results in increased expression of NR4A1 mRNA; trichostatin A results in increased expression of NR4A1 protein 		CTD PMID:21319187 NCBI chr 7:134,247,153...134,268,044
Ensembl chr 7:134,247,192...134,268,041 		JBrowse link
G Nr4a2 nuclear receptor subfamily 4, group A, member 2 increases expression ISO trichostatin A results in increased expression of NR4A2 mRNA CTD PMID:24935251 NCBI chr 3:62,098,739...62,115,926
Ensembl chr 3:62,098,743...62,106,769 		JBrowse link
G Nr5a1 nuclear receptor subfamily 5, group A, member 1 increases expression
multiple interactions 		ISO trichostatin A results in increased expression of NR5A1 mRNA
trichostatin A inhibits the reaction [Nicotine results in decreased expression of NR5A1 mRNA] 		CTD PMID:24709674 NCBI chr 3:42,874,505...42,896,109
Ensembl chr 3:42,875,221...42,896,046 		JBrowse link
G Nr6a1 nuclear receptor subfamily 6, group A, member 1 affects expression ISO trichostatin A affects the expression of NR6A1 mRNA CTD PMID:28542535 NCBI chr 3:42,904,832...43,094,622
Ensembl chr 3:42,904,832...43,092,951 		JBrowse link
G Nrarp Notch-regulated ankyrin repeat protein increases expression ISO trichostatin A results in increased expression of NRARP mRNA CTD PMID:24935251 NCBI chr 3:28,390,745...28,393,299
Ensembl chr 3:28,390,733...28,393,453 		JBrowse link
G Nrcam neuronal cell adhesion molecule decreases expression
increases expression 		ISO trichostatin A results in decreased expression of NRCAM mRNA
trichostatin A results in increased expression of NRCAM mRNA 		CTD PMID:24935251 NCBI chr 6:67,129,723...67,425,510
Ensembl chr 6:67,129,801...67,430,539 		JBrowse link
G Nrde2 NRDE-2, necessary for RNA interference, domain containing affects expression ISO trichostatin A affects the expression of NRDE2 mRNA CTD PMID:28542535 NCBI chr 6:125,137,121...125,177,689
Ensembl chr 6:125,136,635...125,198,616 		JBrowse link
G Nrg1 neuregulin 1 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of NRG1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRG1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr16:65,954,084...67,007,484
Ensembl chr16:65,953,865...66,999,849 		JBrowse link
G Nrg3 neuregulin 3 increases expression ISO trichostatin A results in increased expression of NRG3 mRNA CTD PMID:24935251 NCBI chr16:14,256,540...15,374,107
Ensembl chr16:14,257,148...15,374,147 		JBrowse link
G Nrgn neurogranin affects expression ISO trichostatin A affects the expression of NRGN mRNA CTD PMID:28542535 NCBI chr 8:45,444,223...45,452,417
Ensembl chr 8:45,444,223...45,452,417 		JBrowse link
G Nrip1 nuclear receptor interacting protein 1 increases expression
multiple interactions
affects expression 		ISO trichostatin A results in increased expression of NRIP1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRIP1 mRNA
trichostatin A affects the expression of NRIP1 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 PMID:28542535 NCBI chr11:28,382,835...28,466,483
Ensembl chr11:28,378,878...28,467,353 		JBrowse link
G Nrip3 nuclear receptor interacting protein 3 decreases expression
multiple interactions 		ISO trichostatin A results in decreased expression of NRIP3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRIP3 mRNA 		CTD PMID:24935251 PMID:26272509 PMID:27188386 NCBI chr 1:173,224,532...173,249,829
Ensembl chr 1:173,224,532...173,251,769